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Abstract 
 
Aim: To explore medicine quality and perception among the stakeholders in the 
Ministry of Interior Medical Services (MOI-MSD) clinical settings in Saudi Arabia 
using glibenclamide as an indicator.   
 
Method: A mixed method approach was used in two phases. Phase one involved 
chemical analysis for identity and quantity of the active pharmaceutical ingredient 
(API), visual analysis and authentication of source of a popular diabetes medicine 
(glibenclamide) collected from MOI-MSD general warehouse in Riyadh, Saudi Arabia. 
Phase two contained a focus group discussion, self-completed survey questionnaires and 
semi-structured interviews to explore the perceptions of various stakeholders including 
commissioners, physicians, pharmacists and patients in the MOI-MSD settings in Saudi 
Arabia about medicine quality and related problems.  
 
Data analysis: Phase one collected quantitative data of API quantity from the chemical 
analysis of glibenclamide samples using a high performance liquid chromatography 
apparatus (HPLC) based on United States Pharmacopoeia (USP 36) method. The visual 
inspection of glibenclamide samples was performed using tool kit developed by The 
World Health Professions Alliance (WHPA) and The International Pharmaceutical 
Federation (FIP). The authentication of glibenclamide source was performed by on-site 
comparison of available samples in the general MOI-MSD warehouse with the available 
official reception documents. Phase two collected quantitative and qualitative data 
regarding perceptions about medicine quality and related problems and subsequently 
analysed them using SPSS for descriptive statistics and NVivo version 10 for thematic 
analysis following data coding and the development of themes and sub-themes. 
Subsequently, stakeholders’ data were triangulated to establish common and specific 
themes and sub-themes among MOI-MSD stakeholders. 
 
Findings: Phase one of the study found that all glibenclamide samples were within 
acceptable USP limits in terms of identity and quantity between 90-110%. It was also 
found that all available glibenclamide batch numbers were present in the official 
reception documents and the visual analysis of samples revealed no visible errors on the 
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medicine samples or its packaging. Phase two of the study found that most stakeholders, 
particularly commissioners and physicians, believed that medicine quality was good or 
excellent in Saudi Arabia. However, the commissioners, physicians and pharmacists 
believed that the quality of medicines in the MOI-MSD was less than what is available 
in Saudi Arabia but patients mostly disagreed with these views. Most patients believed 
that the quality of medicines was high in both the Saudi Arabian market and in the 
MOI-MSD settings. Limited knowledge about good quality medicines and counterfeit 
medicines was found among most stakeholders where the quality of medicines was 
commonly associated with the effect rather than technical attributes of medicines 
including content, appearance and source. The stakeholders in this study reported a 
wide range of behaviour when in doubt about medicine quality such as reporting these 
doubts to authorities, finding alternative medicines, stopping the medicine use and 
taking no further action regarding these doubts. Furthermore, all stakeholders have 
identified medicine procurement focusing on price rather than quality, difficulty in 
reporting medicine quality problems and medicine storage conditions as challenges to 
medicine quality in the MOI-MSD. Patients, particularly chronic patients from Jeddah 
city, have complained about medicine non-availability in their local MOI-MSD primary 
clinic and expensive medicine prices.  
 
Conclusions: Glibenclamide quality in the MOI-MSD settings was found to be 
acceptable in terms of API identity and quantity, source and visual appearance. The 
perception about medicine quality in these settings seems to be low particularly from 
commissioners and pharmacists but not the patients. There is an urgent need to 
implement quality assurance steps to increase the commissioners and pharmacists trust 
in the quality of their medicines at the medicine selection, procurement, storage and 
transportation stages in addition to improving the accessibility to report medicine 
quality problems to all stakeholders. Subsequently, future research is needed to measure 
and evaluate the impact of these quality assurance steps on the confidence of 
commissioners and pharmacists trust in the quality of the MOI-MSD medicines. 
Furthermore, patients’ issues about medicine non-availability need to be addressed 
rapidly as it could result in patients’ acquiring medicines from unknown sources and/or 
cause additional financial burdens.  
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1 Chapter 1: Introduction 
1.1 History of medicine quality and related problems 
Concerns about medicine quality can be traced back to the innovation of the medicines 
themselves. Warning writings about adulterated medicines were found in the 4th 
Century BC. Dioscorides identified such dubious medicines and advised on their 
detection in the 1st Century AD (WHO, 1999a). Cases of fake cinchona bark and 
quinine were reported in the 19th Century (Newton, Green & Fernandez, 2010; Clift, 
2010). In more recent times, concerns about medicine quality resurfaced in 1951 briefly 
following the establishment of the World Health Organisation (WHO) in 1948. 
Consequently, the WHO adapted Resolution EB7.R.79 to establish methods that unify 
the control of medicines on a global scale in order to facilitate health and commercial 
requirements (WHO, 1999a). In the 20th Century AD, further international attention has 
been focused on fake medicines. The International Medical Products Anti-
Counterfeiting Taskforce (IMPACT) was established following the WHO meeting in 
Rome in 2006 (WHO, 2011; Edwards, 2011; WHO, 2012a). The aim of IMPACT was 
to combat the trade in fake medicines by combining the efforts of health regulatory 
agencies, international organisations, pharmaceutical companies, healthcare 
professionals and law enforcement experts (Edwards, 2011). However, some countries 
were sceptical of IMPACT’s role and duties, as it was perceived as a waste of scarce 
resources. Such opinions concluded that resources should be allocated towards 
combatting other more serious health-related threats from narcotics or the tobacco 
industry (IMPACT, 2011). The limited availability of up to date information about 
IMPACT’s current role, activities and cooperation with governmental agencies in the 
public domain does not allow for any estimation of attitude change towards IMPACT 
nor does it allow for evaluation of its success. 
1.2 Definition and views about medicine quality and related problems 
It is widely accepted that a high quality medicine is defined in terms of fulfillment of 
technical pharmacopoeial specification concerned with the medicine’s identity, purity, 
potency, dosage form uniformity, bioavailability and stability (Quick, Rankin, Liang & 
O'Connor, 1997; Patel, Norris, Gauld & Rades, 2009). According to the WHO, 
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standards of medicine quality would also include that the medicine is effective without 
severe side effects and maintains its appearance and therapeutic ability throughout its 
claimed shelf life (WHO, 1997).  A high quality medicine should also be registered with 
healthcare regulators in the intended market and have a correct label that clearly 
identifies the name of the medicine, the strength, lot number, expiry date, instructions 
for use and the manufacturer’s address (WHO, 1997; Syhakhang, Freudenthal, Tomson 
& Wahlstrom, 2004). Furthermore, the WHO has extended the description of quality 
assurance to include all related activities and services that could affect the quality of 
medicines (WHO, 2004). It is thought that such a broad view of medicine quality 
assurance from the development stage through manufacturing, storage, distribution and 
dispensing would minimise the chance of patients receiving medicines with doubtful 
quality (Patel et al., 2009). Moreover, other quality indicators have been proposed such 
as patients’ acceptance of their medication. This is particularly important in the case of 
generic medicines where patients’ acceptance can offer real cost savings (Asiri & Al-
Yamani, 2006). It can be concluded that medicine quality has a broad definition among 
different stakeholders with specific emphasis on technical specifications of medicines 
that can be established via laboratory testing of samples. 
 
Medicines with poor quality could be either counterfeit or substandard (Newton et al., 
2009; Newton et al., 2011). Substandard medicines or out of specification products 
(OOS) are defined by the WHO as products that do not meet the required specification 
in terms of content and ingredients (WHO, 2003a; WHO, 2012a). They are legally 
manufactured but do not conform to specifications as a result of inadequate 
manufacturing or poor storage conditions (Heyman & Williams, 2011; Yankus & 
Marks, 2009; Wertheimer & Norris, 2009; Clift, 2010). In contrast, the counterfeit 
medicines definition has a less globally accepted definition when compared to 
substandard medicines. The WHO definition of counterfeit medicines emphasises the 
act of deliberate and fraudulent mislabeling of medicines in terms of identity and/or 
source, indicating that counterfeit medicines could be either generic or brand (WHO, 
1999a). However, other well-respected organisations, such as the U.S. Food and Drug 
Administration (FDA)’s definition of a counterfeit medicine, indicates that generic 
medicines do not fall within this scope (FDA, 2001; Alfadl, Hassali & Ibrahim, 2013). 
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Recently, the term Substandard/Spurious/Falsely-labeled/Falsified/Counterfeit 
medicines (SSFFC) was used by the WHO to describe counterfeit and substandard 
medicines (WHO, 2012a). This joint definition could highlight the importance of 
addressing both counterfeit and substandard medicines equally when medicine quality is 
in question. 
 
Some researchers argue that it is necessary to distinguish between counterfeit and 
substandard medicines to facilitate appropriate strategies to combat each problem as it 
occurs (Newton et al., 2009; Newton et al., 2011). Others do not make such a distinction 
since both counterfeit and substandard medicines claim to be something, which in 
reality they are not (Amin & Kokwaro, 2007). Similarly, some view the issue of 
counterfeit medicines as being primarily a legal concern, while others insist that it is 
part of a larger medicine quality platform (Kontnik, 2006; Senior, 2008). In current 
times, it is important to focus the attention of the international arena on public health 
risks associated with substandard and counterfeit medicines rather than on debate about 
the terminology associated with it, in order to protect patient safety. 
 
For the purpose of this study, the widely accepted WHO definition of counterfeit 
medicines was used, which defines them as “one which is deliberately and fraudulently 
mislabeled with respect to identity and/or source. Counterfeiting can apply to both 
branded and generic products and counterfeit products may include products with the 
correct ingredients or with the wrong ingredients, without active ingredients, with 
insufficient active ingredient, or with fake packaging” (WHO, 1999a). Similarly, the 
WHO definition of substandard medicines as medicines that do not conform to the 
required specifications (WHO, 2003a) was adopted. Both substandard and counterfeit 
medicines were collectively referred to as medicine quality problems or SSFFC 
medicines, in accordance with the WHO’s most recent terminology.  
1.3 Causes of medicine quality problems 
The reasons for the existence of medicines with quality problems are highly dependent 
on the type of medicine problem, whether it is counterfeit or substandard. Typically, 
counterfeit medicines are associated with criminal activity and therefore are driven by 
high profit margins, cheap labour, mobility and low penalties for offenders, which has 
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attracted many to this activity in the past two decades (Ziance, 2008; Reynolds & 
McKee, 2010; Cheng, 2009; Shepherd, 2010; Siva, 2010). Medicines are considered 
attractive for illegal activity as they are easily transported, have high value per unit and 
are not easily distinguished from genuine samples based on visual inspection alone 
(Seiter, 2005). Additionally, some suggest that pharmaceutical companies, attempting to 
mitigate research and manufacturing costs by deploying overseas sites in weaker 
regulated countries, may have added additional pharmaceutical counterfeit threats 
(Shepherd, 2010). In contrast, substandard medicines could be a result of poor 
compliance to Good Manufacturing Practices (GMP), no quality demands by medicine 
purchasers, a declining number of quality manufacturers of essential medicines and 
limited awareness of healthcare professionals about the issue and the necessity to report 
it (Caudron et al., 2008). Other factors may also contribute to the existence of 
substandard medicines such as human error, limited resources and inadequate medicine 
regulation (WHO, 2003a). Furthermore, some suggest that low quality raw material for 
the active pharmaceutical ingredients (API) that are imported from developing countries 
such as China and India could be the reason for the existence of substandard medicines 
(Wilkinson, 2009). 
1.4 Impact of medicine quality problems 
It has been difficult to link clinical outcomes with SSFFC medicines since outcomes are 
routinely associated with the disease progression itself rather than suspecting SSFFC 
medicines (deKieffer, 2006; Liang, 2006; Newton et al., 2008; Feldschreiber, 2009; 
Davison, 2011). Nevertheless, it is estimated that more than 700,000 global deaths from 
Tuberculosis (TB) and Malaria were strongly associated with SSFFC medicines 
(Cockburn, Newton, Agyarko, Akunyili & White, 2005; Mackey & Liang, 2011). Other 
mortality incidents include contaminated heparin in the USA and sexual enhancement 
drugs adulterated with a large content of hypoglycemic drugs in Singapore (Kao et al, 
2009; Luhn, Schiemann & Alban, 2010; Holzgrabe & Malet-Martino, 2011). 
Furthermore, SSFFC medicines have been related to morbidity, drug resistance, 
therapeutic failure and toxicity (Cockburn et al., 2005; Amin & Kokwaro, 2007; 
Wertheimer & Norris, 2009; Mackey & Liang, 2011; Kyriacos, Mrouch, Chahine & 
Khouzam, 2008). Toxicity could be a result of the presence of toxic material in some 
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medicines including boric acid, leaded paint, floor polish, shoe polish, talcum powder, 
cement powder, chalk and brick dust, nickel and arsenic (Jackson, 2009). 
 
The economic and social impact of SSFFC medicines has also been briefly discussed in 
the literature. SSFFC medicines could lead to loss of productivity, inability to work and 
wasting limited resources, which could cause a macroeconomic burden to countries 
(Wertheimer & Norris, 2009). Furthermore, SSFFC medicines could decrease the 
profits of leading pharmaceutical manufacturers and therefore limit investment into 
research and drug development (Moken, 2003). Moreover, SSFFC medicines may affect 
society by other means: notably, loss of confidence in healthcare professionals and/or 
services (Cockburn et al., 2005; Amin & Kokwaro, 2007; Wertheimer & Norris, 2009; 
Mackey & Liang, 2011; Kyriacos et al., 2008).   
1.5 Prevalence rate of substandard and counterfeit medicines 
Estimating the prevalence of SSFFC medicines in a specific region or on a global scale 
is considered to be a difficult task. The limited amount of scientific research, variable 
existing definitions, limited number of reports sent to authorities, lack of resources and 
skills, and inadequate regulations all contribute to the complexity of the task (Amon, 
2008; Newton et al., 2010; Ziance, 2008; WHO, 2010). Moreover, evidence of 
suspected medicines are usually destroyed, either ingested or package discarded, which 
complicates the estimation of the true extent of the problem even further (deKieffer, 
2006; Liang, 2006). However, the WHO estimates that around 10% of all global 
pharmaceutical supply is SSFFC, which could reach up to 50% in developing countries 
and as low as 1% in the developed world (Cockburn et al., 2005; Heyman et al., 2011; 
Ziance, 2008). Evidence from medicine quality surveys suggests that the majority of 
reported SSFFC medicines were substandard rather than counterfeit, yet they receive 
less attention (Caudron et al., 2008; Fried, 2011). However, the United States Food and 
Drug Administration (US FDA) and the European Customs statistics both report a 
fourfold increase in investigations and seizures of counterfeit medicines in 2003 and 
2006 respectively (Cockburn et al., 2005). The Pharmaceutical Security Institute (PSI), 
a coalition of global pharmaceutical companies to monitor and combat counterfeit 
medicines, reports 2,003 incidents in 2009 compared with 781 incidents in 2005 and 
557 cases in 2004 (Kontnik, 2006; Davison, 2011). More recent PSI global reports 
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about counterfeit medicines are summarised in Figure 1.1 and the geographical location 
of these PSI reports is included in Figure 1.2. 
 
 
Figure 1.1 Number of counterfeit medicine seizures up to date (PSI, 2014a) 
 
 
Figure 1.2 Location of counterfeit medicine seizures up to date (PSI, 2014b) 
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1.6 Types of substandard and counterfeit medicine problems 
Several types of SSFFC medicine problems can be identified within the available 
medicine quality surveys in the literature. Two systematic reviews on medicine quality 
surveys found that the predominant types of SSFFC problems are associated with the 
API of the medicine itself (Almuzaini, Choonara & Sammons, 2013; Alghannam, 
Aslanpour, Evans & Schifano, 2014). Such problems could include unacceptable 
amounts of API concentration, no API or the wrong API in the medicine sample. Other 
less frequent types of SSFFC problems such as dissolution/disintegration failures or the 
presence of impurities in the medicine samples were also found within these two 
systematic reviews (Almuzaini et al., 2013; Alghannam et al., 2014). It is possible that 
these findings reflect the current predetermined objectives of such studies to focus on 
API rather than physical properties or medicine excipients. Further details about types 
of SSFFC problems in the existing literature on prospective field medicine quality 
surveys are found in Chapter 3.  
1.7 Analysis of substandard and counterfeit medicines 
The detection of SSFFC medicines is of the utmost importance to safeguard public 
health by a variety of different techniques. Chemical analysis techniques have been used 
to assess the pharmaceutical quality of samples in many medicines from different 
origins and settings. These analytical tools vary from well-established to fast growing 
emerging techniques.  The combination of simple visual, chemical and physical analysis 
of medicines appears to be widely used in SSFFC medicine studies, and has been 
adopted by many developing countries for medicine screening in their markets (Lon et 
al., 2006; Tipke et al., 2008; Risha et al., 2008; Bate, Coticelli, Tren & Attaran, 2008). 
In particular, thin layer chromatography (TLC) and colorimetric tests have been widely 
used and described in the literature (Minzi et al., 2003; Basco, 2004, Rodomonte et al., 
2010). However, these methods only confirm the presence of the API and present only 
semi-quantitative data, with no upper limits. Consequently, these simple, traditional 
methods are likely to detect unskillfully manufactured SSFFC medicines only. 
 
Recently, the SSFCC medicine manufacturers have arguably become more 
sophisticated, which in turn demands equally sophisticated, analytical techniques to 
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detect and possibly combat their activity. Chemical analysis techniques such as Near-
infrared (NIR) spectroscopy, Raman Spectroscopy and High Performance Liquid 
Chromatography (HPLC) are capable of detecting such sophisticated SSFFC medicines. 
None of the existing techniques are perfect and the study objectives, available resources 
and the researcher’s own experience might influence the choice of method. Appendix 1 
compares some of the advantages and drawbacks of a cross-section of these common 
analytical techniques. 
1.7.1 HPLC coupled with Ultraviolet (UV) or Mass Spectrometer (MS) 
High Performance Liquid Chromatography (HPLC) is a chromatographic method that 
has been widely used since the 1960s. The apparatus is based on a mobile phase that is 
pumped under pressure through a column. The column contains a stationary phase over 
which the analytes are carried by the mobile phase. The output of the HPLC system can 
be coupled with MS or UV detector (Davison, 2011; Hansen, Pedersen-Bjergaard & 
Rasmussen, 2012). 
 
Several studies described the use of HPLC-UV in identification and quantification of 
SSFFC medicines. Shi et al. (2008) developed HPLC-UV methods to separate nine 
different steroidal drugs quantitatively following their identification. Sacré et al. 
(2011a) used impurity profiles to distinguish between counterfeit and imitation Viagra® 
and Cialis® using the HPLC-UV system. Further, Sacré et al. (2011b) described the 
development and validation of method used to detect and quantify three licensed 
medicines (Viagra®, Cialis® and Levitra®) and their analogues using HPLC-UV. Debrus 
et al. (2011) reported the development of a method that can screen nineteen different 
antimalarial medicines using HPLC-UV. Other studies described using HPLC-MS in 
SSFFC medicine analysis. Wolff, Thomson & Eckers (2003) reported the use of LC-MS 
in identifying the wrong API in samples of Halfan® syrup. Arthur, Wolff & Carrier 
(2004) found one sample that contained only lactose and lacked the stated 
betamethasone and dexamethasone ingredients using LC-MS. Panusa & Gagliardi 
(2008) developed a method for simultaneous detection and quantification of six 
preservatives in homeopathic syrups. Panusa, Multari, Incarnato & Gagliardi (2007) 
coupled HPLC with MS and UV to detect seven pharmaceuticals in counterfeit 
homeopathic preparations. Venhuis, Zomer, Vredenbregt & de Kaste (2010) identified 
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the presence of the wrong active ingredient in four counterfeit Cialis® samples using 
HPLC-MS following Near-Infra Red (NIR) analysis. Schad, Allanson, Mackay, 
Cannavan & Tettey (2008) developed a method to detect potential quality problems in 
isometamidium veterinary products using HPLC-MS. Further, Dorlo, Eggelte, Schoone, 
de Vries & Beijnen (2012) used LC-MS to confirm the absence of any miltefosine in 
suspected samples in Bangladesh, when blood plasma samples were collected from 
patients. In recent times, HPLC-MSD was successfully used to differentiate between 
counterfeit and genuine Cialis® tablets (Custers et al., 2016). 
1.7.2 NIR spectroscopy 
NIR was not a popular analytical method until the 1960s, when Karl Norris recognised 
its potential in analysis for a variety of industries (Hart, Norris & Golumbic, 1962; 
Jamrógiewicz, 2012). In the 1970s, NIR started to be used extensively in several 
industries around the world. At the end of 1990s, NIR gained the pharmaceutical 
industry’s acceptance and has been included in the European Pharmacopeia since 1997 
(Rodionova & Pomerantsev, 2010). The NIR instrument mainly consists of a laser and a 
detector. The infrared spectrum is divided into 3 sub-regions: near, mid and far, 
according to proximity from the visible region (Davison, 2011). The NIR region covers 
the wavelengths between 700 nm to 2,500 nm (Scafi & Pasquine, 2001; Cui, Zhang, 
Ren, Liu & Harrington Pde, 2004). In this region, it is possible to observe C-H, N-H 
and O-H bonds present in organic molecules, represented by overtones and the 
combination of absorption bands in the mid-IR region (Scafi & Pasquine, 2001; Cui et 
al., 2004; Rodionova & Pomerantsev, 2010). The light from the laser would interact 
with a given sample and would be absorbed at specific frequencies, according to the 
molecular properties of the sample itself. Thus, forming a chemical fingerprint of the 
sample, which can be cross-referenced with spectra databases and can thus generate 
useful information (Davison, 2011). This generated chemical fingerprint or spectra is 
characteristic of each pharmaceutical formulation and, therefore, samples from different 
manufacturers may give rise to different spectra (Scafi & Pasquine, 2001). NIR is useful 
in identification and/or quantification of an active pharmaceutical ingredient and 
excipient, and in determining physical attributes of a drug such as particle size, 
crystalline form, polymorphism, hardness, dissolution behaviour, disintegration pattern 
(Hansen et al., 2012; Jamrógiewicz, 2012). In short, NIR application can be useful 
 10 
throughout the lifetime of a medicine from the manufacturing process up to the post-
marketing surveillance step of the final product. 
 
NIR has been used in the literature for the detection of SSFFC medicines in some 
international markets. Storme-Paris et al. (2010) tested the discriminating powers of 
NIR using various samples of fluoxetine and ciprofloxacin in France. Said, Gibbons, 
Moffat & Zloh (2010) compared NIR spectra of different paracetamol batches obtained 
from Malaysia and UK. Polli, Hoag & Flank (2009) tested eight suspected samples 
purchased from Hong Kong using handheld NIR. Fernandes, da Costa, Valderrama, 
Marco & de Lima (2012) used NIR to differentiate brand and generic glibenclamide 
tablets in Brazil. The Chinese experience with handheld NIR for detection of counterfeit 
medicines and tracking movement of drugs in the supply chain should also be 
highlighted (Feng, Yang, Yang & Hu, 2011). It can be concluded that NIR is a powerful 
analytical tool for identification and quantification of medicines, and provides both 
chemical and physical information for better assessment of samples. However, it is 
mostly used as a screening tool, as it cannot identify unknown samples, so other 
complementary techniques are needed for identification such as HPLC, Nuclear 
Magnetic Resonance (NMR) or Liquid Chromatography-Mass Spectrometry 
(Vredenbregt, Blok-Tip, Hoogerbrugge, Barends & de Kaste, 2006). 
1.7.3 Raman spectroscopy 
Raman Spectroscopy is based on light scattering phenomena, unlike NIR that is based 
on absorption. When light from a high-powered laser beam interacts with a sample, 
most of the light retains the same frequency, except around one in a million of the 
scattered photons that change frequency, to create what is called a Raman effect 
(Davison, 2011; Martino, Malet-Martino, Gilard & Balayssac, 2010). In recent years, 
Raman techniques have been increasingly utilised to screen for medicine quality 
problems. De Veij, Deneckere, Vandenabeele, de Kaste & Moens (2008) used Raman 
for the detection of 18 different Viagra® tablets, which were all found to contain the 
correct API but with different excipients. Furthermore, de Peinder, Vredenbregt & de 
Kaste (2008) successfully used Raman in discriminating between authentic and 
counterfeit Lipitor® obtained from different sources. It has also been shown that Raman 
techniques were able to detect early chemical changes caused by inappropriate storage 
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conditions for acetylsalicylic acid tablets (Neuberger & Neusüß, 2015). 
1.7.4 Visual, physical and authentication of source of medicine samples 
Chemical testing is not the only type of analysis that can be performed on suspected 
SSFFC medicine samples. Physical analysis can be performed to complement chemical 
analysis particularly disintegration and dissolution tests for solid dosage forms. This can 
be attributed to the availability of specific physical tests in different pharmacopoeias in 
addition to the use of physical information about the medicinal product to predict the 
bioavailability of medicines (Rookkapan et al., 2005; Amin, Snow & Kokwaro, 2005; 
Gaudiano et al., 2007). However, this could only be used as an indicator and cannot 
substitute bioavailability studies that can be lengthy and expensive (Kenyon et al., 1999; 
Kayumba et al., 2004).  
 
Package inspection is another type of medicine analysis, which can be found in 
medicine quality surveys in the literature. Problems with medicine packaging could 
include signs of obvious spelling errors, suspicious holograms when compared with 
known genuine samples, peculiar medicine taste and/or odour and also basic label 
information such as the medicine name, dosage, manufacturer details, expiry date and 
lot number. The WHO definition of counterfeit medicines (WHO, 1999a) signifies 
packaging information as a source of information to detect counterfeit medicines. The 
World Health Professions Alliance (WHPA) and The International Pharmaceutical 
Federation (FIP) had developed a tool for visual inspection of medicines that can be 
utilised for a systematic package inspection in medicine quality surveys (FIP, 2013).  
 
The authentication of medicine source through contact with manufacturers or authorities 
is another mode of inspection for medicine quality that could be less popular than the 
previously mentioned methods. Limited communication and feedback towards such 
queries could be a reason for its limited use (Khan et al., 2010; Nair, Strauch, Lauwo, 
Jahnke & Dressman, 2011). It could also be possible that the scope of a study did not 
consider the possibility of counterfeiting and focused only on substandard medicine 
issues.  
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1.8 Perception about medicine quality and related problems 
The research on medicine quality has been largely focused on laboratory testing of the 
actual medicine quality worldwide (Patel, Gauld, Norris & Rades, 2010). Few 
researches have investigated the perceptions about medicine quality and related 
problems from the perspective of different stakeholders. This could be a reflection of 
the complexity of such projects as different points are at stake. Failure of treatment 
because of wrong diagnosis, inappropriate medicine or dosage selection, patients’ non-
adherence, medication errors or adverse drug reactions, could be easily confused with 
poor quality medicines (Quick et al., 1997). Further, medicines can be regarded as 
different from other products since their quality cannot be determined visually in the 
absence of sophisticated laboratory methods for the confirmation of quality results 
(Quick et al. 1997; Patel et al., 2010).  
 
Of the limited available research articles investigating medicine quality without the 
laboratory testing of medicine samples, some have used a general approach about 
medicine quality from the perspective of medicine sellers, manufacturers, distributors, 
consumers and healthcare providers in Laos and South Africa respectively (Syhakhang, 
Freudenthal, Tomson & Wahlstrom, 2004; Patel et al., 2009; Patel et al., 2010; Patel, 
Gauld, Norris & Rades, 2012). The majority, however, investigated counterfeit 
medicines specifically in terms of risk, convenience of obtaining such products, 
knowledge, barriers, perception, practices, attitudes, related factors, difference in 
opinion between healthcare providers and patients, in addition to reviewing court 
sentences on offenders (Sugita & Miyakawa, 2010; Law & Youmans, 2011; Khan et al., 
2011; Alfadl et al., 2012; Shahverdi et al., 2012; Alfadl et al., 2013; Binkowska-Bury et 
al., 2012a; Lai & Chan, 2013). Other studies have focused on measuring responses of 
the public towards local and governmental campaigns against counterfeit medicines in 
Africa (Abdoulaye, Chastanier, Azondekon, Dansou & Bruneton, 2006; Cuchet-
Chosseler, Bocoum, Camara, Abad & Yamani, 2011; Oladepo, Brieger, Adeoye, Lawal 
& Peters, 2011). The majority of these studies have been conducted in developing 
countries and only some in developed areas of the globe such as Japan (Sugita & 
Miyakawa, 2010) and the USA (Law & Youmans, 2011).  
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There were some interesting findings from these studies and other related investigations 
examining the issue of medicine quality without laboratory analysis of samples. 
Counterfeit and substandard medicines have been shown to be confused with other 
issues such as generic medicines by some patients (Sarradon-Eck, Blanc & Faure, 2007; 
Håkonsen & Toverud, 2011). Some evidence in developing countries suggests that 
patients and healthcare providers are dubious about healthcare services and medicines 
that are available free of charge and consider them to be of inferior quality (Lo¨nnroth, 
Tran, Thuong, Quy & Diwan, 2001; Patel et al., 2010). Medicine quality has been 
previously described in terms of effect on felt symptoms by healthcare providers and 
patients in Laos and South Africa (Syhakhang et al., 2004; Patel et al., 2010; Patel et al., 
2012). Executive medicine wholesalers have described medicine quality in terms of the 
product itself and the process involved in the manufacturing and handling of the 
medicine (Patel et al., 2009). Counterfeit medicines were defined as a product without 
local registration in Cambodia by wholesale managers (Khan et al., 2011). In Poland, 
lay people have shown a higher level of knowledge about the scale of counterfeit 
medicines and the associated threats when compared to local physicians and nurses 
(Binkowska-Bury et al., 2012a). Pharmacists in Iran have shown high awareness of 
counterfeit medicines but low levels of knowledge and practices related to the subject 
(Shahverdi et al., 2012).  Moreover, a clear difference between low perception about 
medicine quality and the actual good medicine quality following laboratory analysis has 
been reported in South Africa (Patel et al., 2012). 
1.9 Generic medicines 
A generic medicine is defined by the WHO as “a pharmaceutical product, usually 
intended to be interchangeable with an innovator product that is manufactured without a 
license from the innovator company and marketed after the expiry date of the patent or 
other exclusive rights” (WHO, 2015). The generic medicine should be identical to the 
innovator product in terms of use, quality, safety, efficacy, dosage form, strength and 
route of administration (FDA, 2015a; EGA, 2015). However, generics can differ from 
the innovator product in terms of inactive ingredients, shape, colour and packaging 
(FDA, 2015a; FDA, 2015b; EGA, 2015). Generic medicines should also demonstrate 
bioequivalence to the innovator product in order to obtain market authorisation from 
different regulatory systems (Davit, Braddy, Conner & Yu, 2013). The bioequivalence 
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tests ensure that no significant differences are present between an innovator and a 
generic medicine in rate and extent of absorption (King & Kanavos, 2002; Hassali et al., 
2014). Occasionally, the bioequivalence study requirement may be waived if a given 
product demonstrates high solubility and high permeability for example (FDA, 2015b; 
Hassali et al., 2014). 
 
Generic substitution and generic prescribing are strategies adopted by many healthcare 
regulators in the world to promote generic medicines (Vogler, 2012). The possible 
explanation is that generic medicines offer a substantial reduction in the cost of 
medicine in a healthcare industry where medicines are considered the second largest 
source of expenditure, second only to healthcare workers’ wages (Matin, 1999; Shafie 
& Hassali, 2008; Marchildon & DiMatteo, 2011). The generic substitution can be 
described as the act of substituting a prescribed brand medicine with an equivalent 
generic when dispensed and the generic prescribing is the act of prescribing the 
medicine by its International Non-Proprietary Name (INN) of the medicine (Ferner, 
Lenney & Marriott, 2010). It has been suggested that generic substation should not be 
considered a simple task but rather a complex task that involves many considerations 
such as the patient preference, patient consent, prescriber’s approval, patient’s 
understanding of the difference between the medicine brands to prevent any confusion, 
the assessment of allergy history to any inactive ingredients and the healthcare 
professional’s own judgment for patient suitability for generic substitution (Duerden & 
Hughes, 2010; Alrasheedy, Hassali, Aljadhey, Ibrahim & Al-Tamimi, 2013). 
Furthermore, it is important to recognise that not all medicines may be suitable for 
generic substitution. For example, Narrow Therapeutic Index (NTI) medicines, 
modified release preparations of medicines, medicines containing more than one active 
ingredient and products using different salts to form the active ingredients could not be 
interchanged routinely (Ferner et al., 2010; Duerden & Hughes, 2010; Lewek & Kardas, 
2010). 
 
The perception about generic medicines has been explored in some studies. Some 
patients believe that generic medicines have inferior quality, safety or effectiveness 
when compared with brand medicines (Sansgiry, Bhosle & Pope, 2005; Shrank, Cox, 
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Fischer, Mehta & Choudhry, 2009; Albadr & Khan, 2014; Kjoenniksen, Lindbaek & 
Granas, 2006; Babar et al., 2010; Albarraq, 2013). However, other studies have reported 
that some patients do not believe that generic medicines have any safety risks (Heikkilä, 
Mäntyselkä & Ahonen, 2010). Negative views about generic medicines have also been 
associated in the literature with some healthcare professionals. There were some 
physicians that expressed such opinions regardless of whether the medical regulatory 
authorities were strict in their countries (Hassali et al., 2014).  Several reasons were 
suggested to contribute to such negative perception about generics medicines from 
different stakeholders. Lack of awareness about generic medicine registration and 
bioequivalence testing could be a factor from the healthcare professionals’ view (Shrank 
et al., 2011; Chua, Hassali, Shafie & Awaisu, 2010). 
1.10 Saudi Arabia 
1.10.1 Country profile 
Saudi Arabia is one of the largest countries in the Middle East with a population of 
around 27 million people according to the 2010 National Census and this has been 
expected to rise up to 29 million in 2012. According to the latest population estimation, 
The Central Department of Statistics and Information (CDSI) in Saudi Arabia predicts 
that 19 million of the whole population are Saudi nationals while the remaining 10 
million are expatriates (CDSI, 2013).  
 
Geographically, the country can be divided into five distinctive regions: Central, 
Western, Eastern, Southern and Northern region. Both Central and Western region 
account for approximately two thirds (64%) of the whole population, which is evenly 
divided between them. The Eastern and Southern regions accommodate 15% of the 
whole population within each. The remaining 6% of the population occupy the Northern 
region (CDSI, 2013). 
 
Administratively, the country is divided into thirteen different provinces, each with its 
own governor. The majority of the population (65%) resides in three provinces: Riyadh 
(25%), Mecca (25%) and The Eastern province (15%). The remaining 35% of the 
population are distributed among the remaining ten provinces. Four cities (Riyadh, 
Jeddah, Mecca and Medina) have a population of more than one million in each city. 
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Another four cities (Dammam, Hafouf, Taif and Tabouk) have a population of more 
than 500,000 people. Furthermore, there are nineteen other cities with a population of 
more than 100,000 in each city (CDSI, 2013). Appendix 2 illustrates the population 
figures of provinces and cities according to their geographical locations, based on the 
latest 2010 national census in the country.  
1.10.2 Chronic disease in Saudi Arabia 
Diabetes Mellitus is one of the most common chronic diseases in Saudi Arabia, with an 
estimated prevalence rate of 24% among the adult population, and is considered one of 
the highest figures worldwide (Salman & Al-Rubeaan, 2009; Eledrisi et al., 2007). 
Chronic diseases are among the leading mortality causes worldwide and are responsible 
for 71% of reported deaths in Saudi Arabia according to the WHO. Cardiovascular 
diseases, cancer and diabetes are responsible for 42%, 9% and 6% respectively for all 
mortality rates reported in the country. The WHO estimates a high percentage of risk 
factors present in the adult Saudi Arabian population, such as high blood pressure 
(33%), high blood sugar (18%), obesity (33%), smoking tobacco (24%) and high 
cholesterol levels (36%), which could further add to possible comorbidities associated 
with these chronic diseases (WHO, 2013a). Interestingly, high blood sugar and obesity 
are the only metabolic risk factors that have been constantly rising in Saudi Arabia since 
1980 according to the WHO data and therefore could require particular attention.  
 
Glycemic control has been shown to improve health outcomes of diabetic patients and 
prevent serious long-term complications (Salman & Al-Rubeaan, 2009; Eledrisi et al., 
2007). However, in a cross-sectional study set in Saudi Arabia, a significant 28.5% of 
diabetic patients were presented with poor glycemic control (Eledrisi et al., 2007). It is 
therefore essential to maintain acceptable glycemic levels among diabetic patients by all 
possible means, which could also include prevention of medicine quality problems. 
1.10.3 Healthcare system in Saudi Arabia 
Healthcare services started in Saudi Arabia with the establishment of a public health 
department in Mecca in 1925 to serve both the population and pilgrims. The 
establishment of the Ministry of Health (MOH) in 1950 followed to extend healthcare 
services in the country. In 1970, a governmental five-year plan was proposed to 
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improve all public sectors including healthcare services (Almalki, Fitzgerald and Clark, 
2011). 
 
The Saudi healthcare system is currently undergoing continuous improvements 
accompanied by annual increases of the budget allocated to the MOH by the 
government of Saudi Arabia (MOH, 2011; Alsultan et al., 2012; Bawazir, 2004).  
 
The MOH is the primary governmental healthcare provider in the country. It currently 
operates 251/420 (60%) of all hospitals in the country. Further, it established 2,109 
primary health care clinics distributed throughout Saudi Arabia (Almalki et al., 2011; 
MOH, 2011). However, the MOH is not the only government healthcare provider in 
Saudi Arabia, as other Ministries such as the Ministry of Defense, Ministry of Interior 
and the Ministry of National Guard offer healthcare services to their employees and 
their dependents at a primary, secondary and tertiary care level, and may refer clinical 
cases between them according to their area of expertise (Asiri & Al-Arifi, 2011; Al-
Shammari, Jarallah & Felimban, 1997; MOH, 2011). Additionally, it is estimated that 
70% of all hospital visits by patients were to government healthcare providers, 
predominantly influenced by free of charge health care services including prescription 
medicines (MOH, 2011; Abou-Auda, 2002; AbuYassin et al., 2011; Bawazir, 2004). An 
overview of the healthcare system structure in Saudi Arabia can be found in Figure 1.3. 
 
Private healthcare is also provided in Saudi Arabia through private hospitals, polyclinics 
and private clinics. However, unlike governmental healthcare facilities, fees must be 
paid for using private healthcare services including prescription medicines. The fees 
paid can either be directly by the patients or via medical insurance provided by some 
employers, or in certain circumstances patients may want to purchase health insurance 
for themselves. Currently, there are 130 private hospitals, 2,185 polyclinics and 198 
private clinics operating in the country (MOH, 2011). Interestingly, more than 50% of 
all private healthcare facilities in the country are located in the cities of Riyadh and 
Jeddah alone. 
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Figure 1.3 Overview of the healthcare system structure in Saudi Arabia 
 
1.10.4 MOI-MSD 
The Ministry of Interior Medical Supply Department (MOI-MSD) is one of the major 
governmental healthcare providers to their staff and families in Saudi Arabia 
(MOIMSD, 2015). It currently operates three secondary care hospitals in Riyadh, 
Dammam and Makkah. The hospital in Riyadh has an inpatient capacity of more than 
500 beds and had been in service for more than forty years. The hospitals in Makkah 
and Dammam have between 100 and 200 beds respectively as they have both been 
recently established less than four years ago.  
 
However, the majority of annual patient visits in the MOI-MSD, estimated to be around 
two million visits each year, are focused on the primary care clinics. The MOI-MSD 
operates 18 regional primary clinics located in different cities in the country in addition 
to 3 major primary clinics in the capital city of Riyadh. The majority of these primary 
clinics have been established for more than 20 years with some exceptions such as the 
primary clinics in Bisha and Alkharj. Furthermore, all of these previously mentioned 
primary clinics have clinics for the major types of medical care including 
cardiovascular, gastrointestinal, obstetric gynecology, respiratory, dermatology and 
Healthcare system in Saudi Arabia 
Private 
(subject to charge) 
Governmental 
(free of charge) 
Employees and their 
families 
Public for all individuals 
in the country 
Ministry of Interior 
(MOI) 
Ministry of Defense 
(MODA) 
Ministry of National Guard 
(NGH) 
Major oil companies 
Ministry of Health 
(MOH) 
Ministry of Education 
(MOE) 
Referral specialist 
hospitals 
Red Crescent 
 19 
neurological clinics.  
 
According to the latest available MOI-MSD statistical report (currently in publication), 
there are 293 physicians and 71 pharmacists working in the MOI-MSD primary clinics. 
In addition, there are more than 400 other members of staff in the MOI-MSD primary 
clinics including laboratory technicians, x-ray technicians, nurses and other 
administrative staff.     
1.10.5 Medicine supply chain in Saudi Arabia 
In recent times the pharmaceutical industry in Saudi Arabia has significantly changed 
with the establishment of The Saudi Food and Drug Authority (SFDA) in 2003 and The 
National Unified Procurement Company for Medical Supplies (NUPCO) in 2010 
(SFDA, 2015a; NUPCO, 2015). Although both organisations may require some time to 
achieve their full potential, they are predicted to be major stakeholders in the near 
future.  The SFDA is now the independent body responsible for regulating, pricing, 
ensuring safety, security, efficacy and analysis of all imported and locally produced 
food, medical devices and medicines in Saudi Arabia. SFDA employees are working in 
collaboration with Customs Clearance at all major Saudi ports to track and clear 
imported food and drug supplies (SFDA, 2015a). Conversely, NUPCO is the 
government-funded logistics company which will be responsible for all medical and 
pharmaceutical logistic operations in the country, once fully operational. The logistic 
operation of NUPCO will include procurement, warehousing and distribution of all 
pharmaceutical and medical equipment on behalf of all government healthcare 
providers in Saudi Arabia. 
 
Medicines in governmental healthcare providers are now mainly procured through a 
tendering system in order to lower medication costs. Tender systems can be through a 
group tendering system such as the Group Purchasing Program for the Gulf Countries 
(GPP) and/or local tenders in each governmental institute. The Gulf Countries GPP 
includes pharmaceutical and medical equipment annual tenders, in which governmental 
institutes from all seven Gulf countries (Saudi Arabia, United Arab Emirates (UAE), 
Kuwait, Qatar, Oman, Bahrain and Yemen) are eligible to participate (SGH, 2014). 
Saudi Arabia participates in this Gulf GPP with representatives from all government 
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agencies which provide healthcare services as described earlier. Therefore, medicines 
procured from the Gulf GPP by all governmental institution in Saudi Arabia and 
neighboring Gulf countries are mostly similar, which highlights the impact of medicine 
quality studies on a large population. Figure 1.4 briefly describes the Gulf Countries 
GPP annual tender cycle for medicine procurement. 
Figure 1.4 Annual GPP tender cycle (DeRoeck et al., 2006; SGH, 2014) 
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In contrast, government healthcare providers may require direct procurement from 
medicine suppliers in certain circumstances, particularly when medicines are urgently 
needed. Typically, the required items are sent in the form of quotation requests to a list 
of manufacturers and/or wholesalers. The vendors will then prepare quotations to be 
sent either by fax or directly to the procurement department in a given institution. 
Consequently, one quotation will be accepted and a single manufacturer will be 
awarded a purchase order to deliver the items within the specified time limits to avoid 
financial penalties. However, direct purchase of medicines is strongly regulated and 
discouraged, and can only be acceptable in the event of emergencies, unavailability of a 
required medication in the medicine formulary or in the absence of tender quantities of 
a specific medication. Furthermore, in rare cases a required medicine may not be 
available through a tender system, which eliminates the options available to the 
procurement department in any governmental organisation and using the direct purchase 
scheme becomes inevitable. In such cases, the responsibility of the SFDA remains in 
allowing these medicines to enter the country by providing portal clearance letters and 
ensuring the quality of these medicines through appropriate documentation and/or 
laboratory analysis.  
 
The medicine supply chain in the Saudi Arabian private sector is somewhat different 
than the governmental sector. Major private hospitals could procure their medicines via 
a tender system, but are not obligated to choose this route of procurement in contrast to 
public healthcare organisations in Saudi Arabia. Similarly, community pharmacies 
routinely procure medicines directly from the manufacturers in the country as their 
required medicine quantities and available staff may not support a decision to procure 
medicines via a tender system. The responsibility of the SFDA remains in this case to 
ensure the quality of medicines available in these settings and their adherence to the 
available pharmaceutical laws that govern the appropriate location of pharmacies; staff 
authorised to dispense medicines and types of medicines available for sale for example. 
 
1.10.6 Substandard and counterfeit medicine in Saudi Arabia 
In Saudi Arabia, official reports on SSFFC medicines are limited. The predominant 
source of information appears to be newspaper articles, similar to many countries 
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(Cockburn et al., 2005). However, the country is thought to have a lucrative market for 
all counterfeit materials, having an estimated 4 billion US dollar market of counterfeits 
and piracy trade (Havocscope, 2011).  
 
The SFDA has issued some warnings regarding counterfeit medical products and 
pharmaceuticals in the past. In 2011, a warning about one batch of the oral antibiotic 
Augmentin 1g was released, which was found to contain the wrong active ingredient 
following analysis in the SFDA laboratories (SFDA, 2011a). Moreover, warnings about 
counterfeit medical products such as aerosol chamber devices and counterfeit herbal and 
cosmetic agents were also issued (SFDA, 2011b; SFDA, 2011c). However, no recent 
information was available in the SFDA public domain regarding counterfeit medicine 
seizures in Saudi Arabia.  
 
Pharmaceutical companies in Saudi Arabia estimate that 30-40% of circulating 
medicines in pharmacies and hospitals in the country are counterfeit (Saudi Gazette, 
2008). In contrast, the SFDA insists that only 0.5% of medicines in the country are 
counterfeit (Arabnews, 2010). Additionally, there has been no reported prevalence of 
the level of substandard medicines in the country. The recent growing public concern 
about substandard and counterfeit medicines might have triggered the local councils to 
recommend amendments in the country’s pharmaceutical laws, to increase sentences 
and penalties for offenders (Arabnews, 2011). 
 
A limited number of research articles investigated SSFFC medicines in Saudi Arabia. 
Kyriacos et al., (2008) analysed four Amoxicillin samples from Saudi Arabia and found 
that 2/4 (50%) of samples did not meet USP API% limits. Afifi & Ahmadeen (2012) 
evaluated several Metformin brands marketed in the country and all were found to 
contain acceptable API% according to USP. Other studies found failure of 
disintegration among marketed vitamins in Saudi Arabia (Maswadeh & Al-Jarbou, 
2011). A recent study found that amoxicillin samples sold in nine community 
pharmacies in Riyadh did not contain the acceptable pharmacopoeial quantities of the 
active pharmaceutical ingredient (Khoja et al., 2013a). 
 23 
1.11 Scope and focus of thesis 
A literature review on the subject of counterfeit and substandard medicines has shown 
that a systematic detail of prospective medicine quality studies was not available. The 
major focus of the current literature, particularly in the developed world, was on the 
development of laboratory based and field detection methods for counterfeit medicines. 
There were fewer published research studies focusing on substandard and counterfeit 
medicine prevalence rates, particularly in some areas of the developing world, such as 
the Middle East. Furthermore, the issue of perception about medicine quality and 
related problems was rarely addressed in the literature worldwide. No study has been 
identified to address these issues simultaneously in Saudi Arabia. The findings of this 
study would support decision makers and the interested population in increasing the 
understanding about the issue of substandard and counterfeit medicines from a 
laboratory-based perspective and the stakeholders’ perspective. This approach would be 
beneficial in gaining a comprehensive understanding about laboratory-based facts 
versus the perceptions of different stakeholders with regard to medicine quality and 
their problems. Such an approach could be invaluable for making investment decisions 
towards laboratory analysis or towards public health campaigns, particularly in limited 
resource settings. Furthermore, this study could be used as a template for future studies 
regarding the issue of medicine quality and related problems in different countries and 
healthcare settings.  
 
This thesis will generally focus on medicine quality and SSFFC problems in the MOI-
MSD healthcare settings in Saudi Arabia from a laboratory and stakeholders’ 
perspective.  The thesis will include two systematic reviews (Chapters 3 and 5) of the 
relevant literature, laboratory analysis of glibenclamide (Chapter 4), a qualitative study 
investigating the stakeholders’ perceptions of the related issues (Chapters 6 and 7) and a 
final discussion regarding the research study. More specifically, the first systematic 
review (Chapter 3) assisted in identifying common SFFCC problems; the precise type 
of analysis performed; and to identify knowledge gaps to consider in the later parts of 
the study.  The analytical part (Chapter 4) has focused on the chemical analysis of one 
selected diabetes medicine (glibenclamide) in terms of API quantities within the 
acceptable USP pharmacopoeial limits using HPLC, in addition to authentication of 
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source and visual analysis. A second systematic review (Chapter 5) assisted in 
identifying the existing literature about knowledge and perceptions of stakeholders 
regarding medicine quality and their problems. The qualitative side of the study 
(Chapters 6 and 7) included in-depth exploration of various MOI-MSD stakeholders 
including commissioners’, patients’, pharmacists’ and physicians’ perceptions about 
medicine quality and its related problems. This thesis has not examined glibenclamide 
samples by physical analysis; examined other medicine constituents such as excipients 
or attempted to develop novel methods for SSFFC laboratory analysis, as it was not part 
of the study objectives. Furthermore, the findings of the qualitative part and the 
analytical part of the study are limited by the location and time of the data collection 
period, from August 2013 till December 2014.  
1.12 Aim of the study and research questions 
The overall aim of this study is to explore medicine quality and perception among the 
stakeholders in the MOI-MSD clinical settings in Saudi Arabia using glibenclamide as 
an indicator. The main objectives of this study include: 
1) Using glibenclamide as an indicator, to establish whether the randomly selected 
samples meet the quality control criteria of API quantity through chemical tests, 
visual tests and verification of source where possible. 
2) Describe the nature of any glibenclamide failed samples, if found. 
3) Establish commissioner, patient and healthcare providers’ beliefs about the 
quality of medicines available at MOI-MSD in Saudi Arabia and any related 
problems. 
4) Explore the knowledge and behaviour of MOI-MSD commissioners, healthcare 
providers and patients about medicine quality and related problems. 
The research questions that will be addressed in this thesis are as follows: 
1) Are there any SSFFC medicines in the glibenclamide samples collected from 
MOI-MSD healthcare services in Saudi Arabia in terms API quantity, 
appearance and source?  
2) What are the characteristics and nature of SSFFC glibenclamide samples in 
MOI-MSD in Saudi Arabia if found?  
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3) What are the perceptions of commissioners, healthcare providers and patients in 
MOI-MSD about the medicine quality and related problems? 
4) What is the knowledge about medicine quality and behaviour associated with 
doubtful quality medicines among commissioners, healthcare providers and 
patients in MOI-MSD healthcare services?  
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2 Chapter 2: Research context and methodology 
This chapter will contain information about the research context and methodologies 
used in this study. It will explain the theoretical framework and justify the use of 
methods. Furthermore, it will describe the research design and methods used in order to 
answer the research questions and fulfill the research objectives.  
2.1 Theoretical framework 
The theoretical framework provides a set of justifications for the research on different 
levels. It justifies the philosophical assumptions of the researchers themselves through 
the views they hold on epistemology and ontology (Creswell, Plano Clark, Gutmann & 
Hanson, 2003; Bryman, 2012), theoretical paradigms/perspectives held and choice of 
methodology/methods in the study (Crotty, 1998). On a practical level, the theoretical 
framework would influence and justify the study design, settings, sampling, data 
analysis and interpretation (Gerhard, 2008). 
2.1.1 Epistemology and ontology  
Epistemology entails the nature of knowledge, possibility, scope and basis (Hamlyn, 
1995). It can be associated with what is considered appropriate knowledge about the 
social world (Bryman, 2012). Therefore, it gives a philosophical ground to the type of 
knowledge possible and how we can ensure its adequacy (Maynard, 1994). 
Epistemological positions could include objectivism (presumes all knowledge is out 
there and humans only need to discover it), constructivism (rejects objectivism and 
considers knowledge to be a product of social engagements between subject and object) 
and subjectivism (meaning is imposed on the object by the subject) according to some 
researchers (Crotty, 1998). Ontology is concerned with whether the social world is 
regarded as something external to social factors or something that people are perceiving 
or constructing now (Bryman, 2012). Therefore, ontological positions could be either 
objectivism (social phenomena and their meaning have an independent existence from 
social factors) or constructivism (social phenomena and their meaning continue to be 
constructed by social factors) according to some researchers (Bryman, 2012). Within 
the context of this study, objectivism was adopted in the analytical part of the study and 
constructivism was adopted in the qualitative part of the study.   
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2.1.2 Theoretical paradigms 
Theoretical paradigms or perspectives entail a philosophical stance to inform 
methodology and provide context for process, explains its logic and criteria (Crotty, 
1998). Others have described it as a set of clusters and beliefs about what should be 
studied, how it should be studied and how results should be interpreted (Kuhn, 1996; 
Bryman, 1988; Bryman, 2012). In a sense, theoretical paradigms or perspectives can 
describe the ways in which we look at the world. Often, they are not addressed by the 
researchers and remain largely hidden in the research context (Slife & Williams, 1995). 
Four common types of world views exist and will be further discussed namely 
positivist, constructivist, emancipatory and pragmatist. In healthcare research including 
pharmacy practice, two paradigms often come into conflict namely the biomedical and 
social model (Jesson & Pocock, 2001).  
 
The biomedical model can be regarded as the principle model in healthcare research. 
The theoretical framework that follows this model is called positivism which 
emphasises objective and numeric measures to generate knowledge by establishing 
cause and effect relationships. Research in pharmacy has long been based on a positivist 
philosophical approach to science and the world, while limited attention has been given 
to the social world which would require a social science approach (Jesson & Pocock, 
2001; Creswell, 2009). In contrast, the social model emphasises the social action where 
some believe that not all diseases or phenomena can be detected by biochemical means, 
particularly where subjective feelings and perceptions of a disease or phenomena is 
present in a theoretical framework that can be described as constructivist. Social science 
often uses different methods to explore a single phenomenon in a similar approach to 
their paradigm (Jesson & Pocock, 2001; Creswell, 2009). Furthermore, emancipatory or 
advocacy/participatory paradigm is another school of thought that demands change 
through creation of political debates and actions (Creswell, 2009). On the other hand, 
pragmatism focuses on the problem itself rather than the philosophical background in 
order to liberate the researcher to use a single or multiple approach(es) in order to 
investigate phenomena based on what works at that point in time, which may be best 
suited with a mixed method approach as a research strategy of inquiry (Creswell, 2009).   
 
 28 
The framework of this research was formulated based on consideration of how to 
answer the research questions and meet research objectives in a suitable manner. In one 
phase of the study, glibenclamide samples were the subject of enquiry for possible 
quality problems mainly in laboratory settings to establish facts about medicine quality. 
In another phase of the study, the perceptions of stakeholders in MOI-MSD in Saudi 
Arabia about medicine quality and its related problems were the subject of inquiry in 
order to clearly establish their beliefs and views regarding this phenomena. Therefore, 
in order to answer the research questions and meet the research objectives of the study, 
a pragmatic paradigm using a mixed-method approach as a strategy of enquiry was 
adopted in order to facilitate answering the variety of research questions in this study. 
Within this context, a quantitative study was used to identify any common medicine 
quality problems associated with the API quantity in the laboratory, authentication of 
source and packaging information in glibenclamide samples collected from the MOI-
MSD in Saudi Arabia. On the other hand, a qualitative study was used to explore the 
perceptions of MOI-MSD stakeholders (i.e. commissioners, physicians, pharmacists and 
patients) about medicine quality and related problems such as counterfeit medicines 
through a focus group discussion, semi-structured interviews and self-completed survey 
questionnaires.    
2.1.3 Mixed method approach  
Mixed methods research is a type of research strategy that is often referred to as a third 
paradigm of research enquiry (Johnson & Onwuebuzie, 2004; Abdul Hadi, Alldred, 
Closs & Briggs, 2013). This strategy is arguably the most emerging research strategy 
and is closely related to the pragmatism paradigm of worldview (Creswell, 2009). 
Although mixed methods research has been increasingly used by researchers, its 
adaptation in pharmacy practice research remains limited possibly because of lack of 
clear understanding of what it is and the benefits of its use (Abdul Hadi et al., 2013). 
Mixed method approach can be described as a process where the investigator collects 
and analyses data, integrates the findings, and draws inferences using both qualitative 
and quantitative approaches or methods in a single study (Tashakkori & Creswell, 
2007).  
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Greene, Caracelli & Graham (1989) identified five reasons for adopting mixed methods 
research including: triangulation of data to enrich the description about the problem and 
validate findings, expanding the understanding of the research problem, overcoming the 
limitations of using a single method, clarification of results from one method by using 
the results from the other method and to find paradox or contradiction of questions or 
results from one method with questions or results from another method for the purpose 
of highlighting new areas for investigation and/or reshaping the research question. 
Bryman (2006) added more possible reasons to conduct mixed methods research such 
as instrument development, to facilitate sampling for another study, uncovering 
relationships between variables through quantitative methods and then discovering their 
meaning through qualitative methods. In practice, there is typically more than one 
reason for the researcher to justify their choice of mixed method approach in their study 
(Abdul Hadi et al., 2013). 
 
The selection of mixed methods approach for a study entails a range of advantages and 
shortcoming of both the qualitative and quantitative phases of the study. Evidence has 
shown that by mixing methods, the qualitative data was able to save quantitative data 
from being inaccurate or with limited value as it can highlight inconsistencies and could 
identify major issues that were not statistically significant (Weinholtz, Kacer & Rocklin, 
1995; Smith, 1999). Using mixed methods could overcome the limitations of using 
qualitative or quantitative methods alone, provides more evidence about a research 
problem, helps answer questions that cannot be answered by a single method and gives 
the researcher more freedom in the use of all research methods available to address a 
research problem (Creswell & Plano Clark, 2011). However, the use of mixed methods 
was also associated with some criticism within the literature. Some have concerns about 
combining methods from different philosophical assumptions (i.e. positivist and realist) 
within the conceptual framework of a single study, particularly with qualitative and 
quantitative approaches (Smith, 1999). Mixed methods are a relatively new 
methodology and therefore may be challenging to enlighten and convince others of their 
usefulness (Creswell & Plano Clark, 2011). They have a wide range of designs, which 
could confuse new researchers in the field when they want to select the optimal design 
for their study (Leech & Onwuegbuzie, 2007). The previous studies associated with 
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mixed methods could also be difficult to locate within the literature because researchers 
only recently started to use the term mixed methods in their titles or in their methods 
section (Creswell & Plano Clark, 2011). On a practice level, mixed method studies 
could require more skill from both the qualitative and quantitative components of the 
study, more time and resources to use, and may require more researchers to conduct it 
when compared with using qualitative or quantitative studies alone (Abdul Hadi, 
Alldred, Closs & Briggs, 2014; Creswell & Plano Clark, 2011; Johnson & 
Onwuegbuzie, 2004; Doyle, Brady & Byrne, 2009). 
 
Therefore, a mixed method design was chosen for this study in order to investigate 
medicine quality and their problems between the available facts and stakeholders’ 
perceptions in two main phases within this study. The first phase involved a quantitative 
study to examine the possibility of medicine quality problems in terms of API quantity, 
authenticity of source and visual inspection of package regarding one popular 
antidiabetic medicine (glibenclamide) within a chosen healthcare sector (MOI-MSD) in 
Saudi Arabia. The second phase of the study explored the stakeholders’ (i.e. 
commissioners, physicians, pharmacists and patients) perceptions about medicine 
quality and their problems within the same settings in the MOI-MSD in Saudi Arabia.  
2.1.4 Quantitative phase of the study 
The overall purpose of the quantitative approach is to generate reproducible findings 
that can be generalised to a wider population. The quantitative approach includes two 
major types of research known as survey and experimental research. The survey 
research provides a numeric description of trends, attitudes or opinions of a population 
by studying a large sample that is statistically significant. Experimental research is 
particularly useful for projects conducted in laboratory settings (Smith, 1999; Smith, 
2005; Jesson & Pocock, 2001; Creswell, 2009). 
 
The advantages in using a quantitative approach for research studies is in 
generalisability of findings, identifying factors associated with outcome, utility of an 
intervention and to understand the best predictors for an outcome. However, the 
limitation of this approach is the lack of flexibility to provide a true reflection of reality 
from different angles in a given situation. Furthermore, the quantitative approach does 
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not answer the “why?” and “how?” questions in contrast to the qualitative approach. 
This would therefore be of limited use in areas of research with an insufficient pre-
existing body of knowledge on a given phenomena (Smith, 1999; Smith, 2005; Jesson 
& Pocock, 2001; Creswell, 2009). 
 
Therefore, within the overall mixed method approach chosen for this study, the first 
phase adopted a quantitative approach since laboratory testing was based on recognised 
pharmacopoeial specifications that was required to answer the first research question. 
As shown in the first systematic review of the literature (Chapter 3), there were a large 
number of similar studies on a global scale that met the chosen inclusion criteria of 
focusing on prospective medicine field surveys of medicines. In addition to reinforcing 
the choice of approach for this phase of the study, the first systematic review (Chapter 
3) had influenced the choice of variables to be examined, the type of instruments to be 
used and the gaps in current knowledge regarding therapeutic categories and 
geographical locations where little is known about the actual medicine quality and their 
problems.       
2.1.5 Qualitative phase of the study 
The qualitative approach is essentially related to the constructivist paradigm where it is 
exploratory in nature and aims to generate rather than test a hypothesis. Qualitative 
strategies explore and attempt to understand the meaning people ascribe to a social or 
human phenomena or problem. The number of samples and statistical significance is of 
limited use in this type of approach. Qualitative research is particularly useful when we 
do not know the variables to examine; the topic is new, if the topic has never been 
addressed in this population or when the existing theories do not apply to a specific 
population (Smith, 2005; Creswell, 2009). 
 
Several types of research following the qualitative strategies can be identified including 
ethnography, grounded theory, case studies, phenomenology, narrative research and 
others. Ethnography is concerned with the study of culture groups in their natural 
settings in a flexible and evolving process over a prolonged period of time, collecting 
mostly observational and interview data. In grounded theory, the researcher develops a 
theory from participants’ views by collecting data on multiple occasions and comparing 
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the data with emerging categories and theoretical sampling in an attempt to view 
similarities and differences between groups. Case studies explore in detail an activity, 
program, event, process or people by using various data collection tools over a sustained 
period of time. Phenomenology, which can be considered as a philosophy as well as a 
method, identifies a human experience about phenomena as described by a participant 
over a prolonged engagement time to develop patterns and relationships. Narrative 
research asks one or more people about their life stories, which is then retold by the 
researcher and combined with their own life story (Smith, 2005; Creswell, 2009). 
Within the context of this phase of the study, a case study strategy was employed to 
gather information from different MOI-MSD stakeholders within a limited time by 
using a variety of data collection tools.  
 
The analysis of qualitative data follows similar steps to quantitative data analysis where 
both approaches start with organising raw data, entering and coding data, searching for 
the meaning of data through analysis, interpreting meaning and drawing conclusions. 
The main difference is that qualitative data analysis searches for meaning through 
thematic analysis while quantitative data analysis searches for meaning through 
statistical analysis. In addition, the steps of entering and coding data, data analysis and 
interpretation is much more close in qualitative data analysis while being distinctive 
steps in quantitative data analysis. The analysis of qualitative data could be inductive or 
deductive depending on the aim/objectives of the study and the available pre-existing 
knowledge on the subject  (O’Leary, 2010; Kumar, 2011). 
 
Therefore, within the overall mixed method approach chosen for this study, the second 
phase that was concerned with the stakeholders’ perceptions about medicine quality and 
their problems, a qualitative approach was selected in order to explore these issues in-
depth where little evidence is available in the pre-existing body of knowledge as was 
shown in the second systematic review of the literature in this study (Chapter 5). 
Moreover, a survey questionnaire was distributed to healthcare providers in the MOI-
MSD settings as a part of this study to examine the issue through a wider range of 
healthcare providers.   
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Qualitative data can be collected through several methods including individual 
interviews, focus groups, direct observation and analysis of textual or visual data 
(Silverman, 2014). The interview research method could either be structured, semi-
structured or unstructured. The structured interview method can be highly associated 
with quantitative strategies while semi-structured and unstructured interviews are 
associated with qualitative research strategies. The semi-structured interviews would 
have a number of questions within the interview schedule as a base for the study and 
allow probing and prompting answers from the participants in order to follow up on 
their interesting replies and clarify questions if needed (Bryman, 2012). The focus 
group allows for attitudes, opinions or perceptions about phenomena to be investigated 
through free and open discussions among a homogeneous group of no more than twelve 
participants. The researcher in a focus group discussion starts the process by raising 
issues or asking questions to stimulate the group discussion. It can be regarded as an 
inexpensive, easily designed and rapid source of valuable information. However, the 
drawbacks of using focus groups in a study needs careful attention from the researcher 
such as possible opinion domination of some individuals in the study and its 
incapability to find the magnitude of opinion diversity on a given issue (Krueger & 
Casey, 2009; Kumar, 2011). Furthermore, the direct observation of participants can be 
used to collect data in their natural settings (Mays & Pope, 1995). The analysis of texts 
or visual data can be performed by examining their content, coding of data and 
arranging them in themes or categories.  
 
Consequently, a variety of qualitative methods including focus group, semi-structured 
interviews and survey questionnaires that included open-ended questions were used in 
the second phase of the study in order to explore the stakeholders’ perceptions about 
medicine quality and their problems in the MOI-MSD in Saudi Arabia.   
2.1.6 Framework of thesis 
The framework of this thesis was a pragmatic framework and adopted a mixed method 
approach to investigate the perceived central research problem in order to address it in 
this study.  
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2.1.7 Thesis structure 
The thesis includes eight chapters in total as shown in Figure 2.1.  
 
 
.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     Figure 2.1 Overall methodology of the study 
2.1.8 Phase one of the study 
The first phase of the study started with a systematic review of the literature to 
determine existing gaps in knowledge about prospective field quality surveys which 
investigated the issue of counterfeit and substandard medicines. Based on the findings 
of this systematic review, limited studies have addressed these issues with chronic 
medicines worldwide, only a few studies were identified in the Middle East and none in 
Saudi Arabia. Therefore, it became evident that a study was needed to explore the 
possibility of counterfeit and substandard medicines in Saudi Arabia by focusing on 
specific variables and analysis types that were extracted from the systematic review 
results. Subsequently, chemical analysis of glibenclamide samples collected from the 
MOI-MSD in Saudi Arabia were analysed in the laboratory to examine the amount of 
API in comparison with USP specification and samples from community pharmacies in 
Najran, in addition to authentication of source, and the visual inspection of packaging 
information. 
Systematic review of counterfeit and substandard medicines in 
prospective field quality surveys 
Glibenclamide API, source and package analysis (n=19) 
MOI-MSD samples (n=15) Najran samples (n=4)   
Systematic review of stakeholders’ perceptions about medicine quality 
and their problems  
Focus group with Saudi pharmacists studying in UK to identify scope of 
perceptions and translate technical terms (n=5) 
Semi-structured interviews with MOI-MSD commissioners in Saudi 
(n=6) 
Semi-structured interviews with MOI-MSD patients in Saudi (n=53) 
Survey questionnaire to  MOI-MSD pharmacists and physicians (n=121) 
Semi-structured interviews with MOI-MSD pharmacists and physicians 
(n=16) 
Thematic analysis and triangulate results 
P
hase 1 
P
h
ase 2
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2.1.9 Phase two of the study 
The second phase of the study was also initiated with a systematic review of the 
literature to examine existing studies on stakeholders’ perception about medicine 
quality and related problems. The findings from this systematic review demonstrated 
the scarcity of research studies that addressed these issues worldwide and the absence of 
such studies in Saudi Arabia. Furthermore, it was found that none of the studies 
explored the perceptions of commissioners, healthcare providers and patients in a single 
setting and none explored perceptions about medicine quality and related problems in 
one study. Therefore, it was necessary to address these gaps in knowledge by 
conducting a study to explore these issues. The first phase of this study included a focus 
group study with Saudi Arabian pharmacists in the United Kingdom (UK) to generate 
ideas regarding the development of questions and Arabic translation of technical terms 
such as counterfeit medicines to be implemented in the following phases of this study. 
The second and third phases of this study explored the perceptions of commissioners 
and patients respectively in MOI-MSD in Saudi Arabia through semi-structured 
interviews. The fourth phase of this study investigated the perceptions of pharmacists 
and physicians in MOI-MSD by distributing a survey questionnaire that included open 
and closed-ended questions. This was followed by the fifth and final phase that 
confirmed the answers obtained from the survey questionnaires and further explored 
some issues raised by the pharmacists and physicians. Subsequently, common and 
specific themes were identified from all stakeholders’ groups and their results were 
discussed.     
2.1.10 Summary 
A summary of the research questions, methodology, rationale and methods used in the 
thesis can be found in Table 2.1.  
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Table 2.1 Summary of research questions, methodology, rationale and methods in the 
study 
 First phase   
Research questions Methodology Rationale Methods 
Are there any SSFFC medicines in the 
glibenclamide samples collected from 
MOI-MSD in Saudi Arabia? 
 
Quantitative Determine API quantity, 
source authenticity and 
package information of 
glibenclamide samples 
HPLC (USP standards) 
 
WHPA/FIP checklist for 
visual inspection 
 
Official reception documents 
comparison with available 
medicines 
What are the characteristics and nature 
of SSFFC Glibenclamide samples in 
MOI-MSD Saudi Arabia, if found? 
 
Quantitative Report any problems found 
in API quantity, source 
authenticity or packaging 
information 
HPLC (USP standards) 
 
WHPA/FIP checklist for 
visual inspection 
 
Official reception documents 
comparison with available 
medicines 
 Second phase   
What are the perceptions of 
commissioners, healthcare professionals 
and patients in MOI healthcare services 
about the medicine quality and related 
problems? 
 
Qualitative Explore evidence and 
triangulate findings regarding 
medicine quality and 
counterfeit medicines from 
different stakeholders’ 
perspectives 
Focus group 
Semi-structured interviews 
Survey questionnaire 
 
Thematic analysis 
Descriptive analysis 
What is the knowledge and behaviour 
associated with medicine quality and 
related problems among healthcare 
employees and patients in MOI health 
services? 
Qualitative Explore evidence and 
triangulate findings regarding 
medicine quality and 
counterfeit medicines from 
different stakeholders’ 
perspectives 
Focus group 
Semi-structured interviews 
Survey questionnaire 
 
Thematic analysis 
Descriptive analysis 
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2.2 Methodology 
2.2.1 General method 
This study used a mixed method approach and was carried out in two phases as 
previously discussed. The first phase started with a systematic review about counterfeit 
and substandard medicines in field quality surveys and was then followed by the 
analysis of glibenclamide samples. The second part of the study started with a 
systematic review regarding stakeholders’ perceptions about medicine quality and 
substandard or counterfeit medicines and was then followed by investigation of the 
perceptions of MOI-MSD stakeholders by using a series of methods including focus 
group discussion, semi-structured interviews and questionnaire survey in Saudi Arabia.    
2.2.2 Phase one 
2.2.2.1 Study design 
A quantitative research approach using a cross-sectional survey method was adopted in 
this phase of the study. The researcher collected fifteen glibenclamide samples overtly 
from MOI-MSD general warehouse in Riyadh and a research assistant collected four 
glibenclamide samples covertly from community pharmacies in Najran for comparison. 
All samples were kept in plastic bags arranged in a box where they were kept at room 
temperature and away from light for one week before being sent via a logistics company 
to the United Kingdom for analysis.  
2.2.2.2 Study settings 
The glibenclamide samples from MOI-MSD were collected prospectively from the 
general warehouse by the researcher in August 2013. A research assistant collected 
samples from Najran community pharmacies prospectively in September 2014.  
2.2.2.3 Study sample 
A total of 19 glibenclamide samples were available for analysis in this phase of the 
study. Glibenclamide was selected for the purpose of this phase of the study since 
diabetes affects a large proportion of the Saudi Arabian population (Salman & Al-
Rubeaan, 2009; Eledrisi et al., 2007) and had the largest volume of demand in MOI-
MSD at the time of the study design as discussed in Chapter 4. The number of samples 
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required was estimated to be five samples from each available batch in the MOI-MSD 
general warehouse based on previous literature to account for natural variations between 
medicine packages of the same batch (Phanouvong & Blum, 2004) and the WHO 
guidelines for sampling medicines (WHO, 2005). It was found that three different batch 
numbers from the same supplier were available at the time of sample collection and 
therefore fifteen samples in total were collected from MOI-MSD settings. Furthermore, 
four more samples from Najran community pharmacies were conveniently available for 
comparison purposes in this phase of the study. These samples were from four different 
manufacturers in order to obtain a snapshot about the quality of glibenclamide 
commercially available to MOI-MSD patients in case of glibenclamide non-availability 
in the MOI-MSD clinics.  
2.2.2.4 Data collection 
A random sampling strategy based on a systematic approach was employed to collect 
the required samples from MOI-MSD general warehouse in order to collect five 
samples from each available batch number at one point in time. Moreover, the research 
assistant collected samples from Najran conveniently from one community pharmacy in 
each area of the city at first sight.    
2.2.2.5 Data analysis 
The analysis process started with the authentication of source performed by the 
researcher for samples collected from MOI-MSD by on-site inspection of official 
reception documents with what was physically available in the warehouse. Following 
the shipment of glibenclamide samples to the UK, visual inspection of samples was 
performed using a tool kit developed by The World Health Professions Alliance 
(WHPA) and The International Pharmaceutical Federation (FIP) for visual inspection of 
medicines (FIP, 2013). Subsequently, chemical analysis of glibenclamide samples for 
API quantity was conducted in the laboratory using HPLC, according to USP 
specifications.   
2.2.2.6 Validity and reliability 
The chemical and visual data analysis of glibenclamide was based on recognised 
methods of the USP and WHPA/FIP respectively. Furthermore, in order to increase the 
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reliability of API concentration results, samples were injected in duplicates into the 
HPLC system and the mean of the results was reported. 
2.2.3 Phase two 
2.2.3.1 Study design 
This phase of the study was further divided into five phases. The first phase was a focus 
group discussion with Saudi Arabian pharmacists studying in the UK in order to explore 
the scope of perceptions about medicine quality and related problems to compose the 
question design of the study in addition to translating technical terms such as counterfeit 
medicines into Arabic for subsequent parts of the study. The second and third phases of 
the study explored the perceptions of MOI-MSD commissioners and patients 
respectively about medicine quality and related problems through semi-structured and 
face-to-face interviews with open-ended questions. The fourth phase of this study 
investigated the MOI-MSD primary clinic physicians’ and pharmacists’ perceptions 
about medicine quality and related problems through a survey questionnaire that was 
distributed electronically and manually to healthcare providers and included open-ended 
and closed-ended questions. The fifth phase of the study validated and further explored 
in-depth the results from the fourth phase of the study through semi-structured 
interviews with pharmacists and physicians in the MOI-MSD, being conducted via 
recorded telephone calls with the participants. Subsequently, results from all phases 
were triangulated and discussed to identify similarities and differences in perceptions 
about medicine quality and their problems from the different stakeholders’ perspectives 
in MOI-MSD settings in Saudi Arabia.   
2.2.3.2 Study settings 
The focus group phase of the study was conducted in the University of Hertfordshire 
settings in the UK. The semi-structured interviews with the commissioners were 
conducted in their offices at the MOI-MSD general administration in Riyadh, Saudi 
Arabia. The interviews with patients were conducted in two MOI-MSD primary clinics 
in Riyadh and one primary clinic in Jeddah, Saudi Arabia. The survey questionnaire was 
distributed to all MOI-MSD pharmacists and physicians in primary care clinics in the 
country, as well as to pharmacists working in the Medical Supply Department at the 
MOI-MSD General Administration in Riyadh, Saudi Arabia. Furthermore, the 
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telephone interviews with MOI-MSD healthcare providers were conducted with 
pharmacists and physicians working in different cities in Saudi Arabia.  
2.2.3.3 Study sample 
The focus group phase of the study included Saudi Arabian pharmacists, studying for 
post-graduate qualification during the academic year 2013/2014 at the University of 
Hertfordshire in the UK, who agreed to participate in the study. Convenient sampling 
was used to recruit pharmacists in this phase of the study in order to achieve the study 
objectives. Although this sampling approach could be bias, it was necessary to map the 
scope of pharmacists’ perceptions about medicine quality and their problems since it 
was not possible to identify other Saudi Arabian stakeholders in the UK at the time of 
the study. The commissioners of MOI-MSD were individually identified and 
approached in this study based on their professional role as decision makers in the 
pharmaceutical supply chain in MOI-MSD settings. Patients were randomly approached 
for recruitment in three MOI-MSD primary clinics, as they are the ultimate users of 
medicines with the only exception being younger patients under the age of 18 years old. 
Pharmacists and physicians in MOI-MSD primary clinics were recruited for the survey 
questionnaire and the following interviews via the commissioner of their department at 
the MOI-MSD general administration in Riyadh, Saudi Arabia, as they are responsible 
for medicine dispensing and prescribing respectively.       
2.2.3.4 Data collection 
The collection of data at the different phases of the study followed receipt of the 
participant information leaflet, signature of an informed consent form, and provision of 
their demographic details. The focus group part of the study was conducted in 
December 2013 and was completed in 93 minutes. The interviews with MOI-MSD 
commissioners were performed in their offices in March 2014 and none lasted more 
than 30 minutes. Interviews with MOI-MSD patients were conducted in vacant 
physicians’ offices in each setting to protect their privacy in the period between March 
to April 2014 and none lasted more than 30 minutes. The survey questionnaire was 
distributed to MOI-MSD physicians and pharmacists in March 2014 and the web-based 
version was available online for eight weeks. The telephone interviews with MOI-MSD 
pharmacists and physicians were conducted in December 2014 and none lasted more 
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than 50 minutes. Furthermore, with the exception of survey questionnaire completion 
and telephone interviews with MOI-MSD physicians and pharmacists, data was 
collected within normal working hours between 8 am and 2 pm in Saudi Arabia, and  9 
am and 5 pm in the UK on the previously discussed dates.    
2.2.3.5 Translation 
The focus group and the survey questionnaire phases of the study were conducted in 
English while interviews with commissioners, patients, physicians and pharmacists 
were conducted in Arabic. At the start of this study, the focus group participants 
translated technical terms such as counterfeit medicines into Arabic for the subsequent 
parts of the study. Survey questionnaires were distributed in English since they were 
aimed at healthcare providers only and therefore they would have sufficient English 
proficiency to complete these questionnaires. Commissioners were considered 
knowledgeable individuals in this study and therefore the interviews with them were 
conducted in Arabic to allow for more in-depth exploration of their perceptions. In 
contrast, patients could have low literacy levels and, therefore, interviews were 
conducted in Arabic in an attempt to simplify the process of exploring their perceptions. 
The follow-up telephone interviews with pharmacists and physicians were performed in 
Arabic to allow the participants to express their opinions freely by minimising any 
possible language barriers resulting from using English in the previous questionnaire 
phases of the study with the same stakeholders.  
 
The process of translating questions and transcripts into English, when Arabic was used, 
followed the same principle of back translation at the different phases of the study. The 
questions were translated to Arabic by the principal researcher; then translated to 
English and back to Arabic by two different bilingual native Arabic speaking members 
of staff at the University of Hertfordshire and the two versions of the Arabic questions 
in the interview guide were compared. Furthermore, following the transcription and 
translation of the Arabic interviews, two bilingual native Arabic speaking members of 
staff at the University of Hertfordshire assisted the principal researcher in validating the 
accuracy of translation from two randomly chosen interview transcripts. 
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2.2.3.6 Data analysis 
The data analysis for the focus group and the interview phases of the study started with 
the transcription of data into a Microsoft Word document, assigning a unique 
identifying code for each participant, the translation of data into English and the 
validation of translation, when required, before conducting thematic analysis. The 
thematic analysis of data was conducted using NVivo, version 10, where codes were 
developed in order to generate themes and sub-themes. The researcher extracted the 
themes and sub-themes and his supervisor performed trustworthiness checks at the end 
of each phase of the study.  
 
For the questionnaire survey part of the study, data was analysed using Microsoft Excel 
and SPSS version 21 software. The responses to open-ended questions were analysed 
using Microsoft Excel through a content analysis approach, and their results shown as 
numbers and percentages. The responses to closed-ended questions were descriptively 
analysed using SPSS for both categorical and continuous data, where association 
between some variables was examined, and the findings reported as numbers and 
percentages.  
2.2.3.7 Reliability 
The reliability of findings was addressed in this phase of the study by having a 
structured and documented process of data collection and analysis. Furthermore, the 
research supervisor independently coded at least two interviews from each part of the 
study and then met with the researcher to compare sets of codes and resolve any 
disagreement in coding by discussion of the issues.  
2.2.3.8 Validity 
The validity was addressed through a series of steps at different stages of this phase of 
the study. The questions design was based on findings of the systemic review about 
stakeholders’ perceptions on medicine quality and their problems in addition to findings 
from the focus group study. Subsequently, questions for the following phases of the 
study were designed and checked for face validity by three members of academic staff 
at the University of Hertfordshire. Before collecting data at each part of the study, the 
questions were piloted with at least two individuals, who were not part of the study 
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sample, to ensure the questions’ content, clarity, order and time required to complete. 
The interview transcripts were sent back to participants for their review where possible, 
excluding patients who only provided telephone numbers for contact in order to receive 
their comments and feedback. Moreover, the themes and sub-themes extracted from the 
different phases of the study were triangulated and the researcher’s supervisor reviewed 
and verified the interview coding and results to address the internal validity.  
2.2.3.9 Generalisability 
This phase of the study was exploratory in nature and therefore did not seek 
generalisability of findings for the Saudi Arabian population. Nevertheless, this phase of 
the study did explore the perception of six commissioners and more than fifty 
individuals from each group of pharmacists, physicians and patients in MOI-MSD 
settings in Saudi Arabia. Future research could address the issue of generalisability, 
based on the findings from this phase of the study.  
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3 Chapter 3: A systematic review of counterfeit and 
substandard medicines in field quality surveys 
3.1 Introduction 
 
Medicine safety, efficacy, and quality are the most important criteria in ensuring 
optimal treatment from medicines and are currently receiving increased attention in an 
era of globalisation and generic manufacturing (Waller, 2001; Amin et al., 2005). 
Medicines with questionable quality could either be counterfeit or substandard, 
according to the World Health Organisation (WHO). A counterfeit medicine is defined 
by the WHO as “one which is deliberately and fraudulently mislabeled with respect to 
identity and/or source.” Counterfeiting could include both branded and generic products 
and may include products with the correct ingredients or with the wrong ingredients, 
without active ingredients, with insufficient active ingredient, or with fake packaging 
(WHO, 1999a). Substandard medicines, also referred to as out-of-specification products, 
are defined by the WHO as “products that do not meet the required specification in 
terms of content and ingredients” (WHO, 2003a; WHO, 2014). They are legally 
manufactured but do not conform to specifications as a result of inadequate 
manufacturing or poor storage conditions (Heyman et al., 2011; Yankus & Marks, 
2009; Wertheimer & Norris, 2009; Clift, 2010). Recently, the term 
substandard/spurious/falsely labeled/falsified/counterfeit medicines (SSFFC) was used 
by the WHO to simultaneously describe both counterfeit and substandard medicines 
(Deats & Bourdillon-Esteve, 2013).  This joint definition highlights the importance of 
identifying both counterfeit and substandard medicines in any proposed medicine 
quality survey. 
 
The distinction between counterfeit and substandard medicines is imperative when 
applying appropriate strategies to combat potential threats of either quality problem 
(Newton et al., 2009; Newton et al., 2011). However, some dismiss this notion and 
argue that both counterfeit and substandard medicines are similar because they both 
claim to be something that in reality they are not (Amin & Kokwaro, 2007).  
Nevertheless, correctly identifying the type of medicine quality problem could aid 
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governments and responsible bodies in determining the need to involve local or interna-
tional law enforcement, particularly when scarce economic resources are present. 
Counterfeit medicines are strongly linked with organised crime and would most likely 
require criminal experts to aid health care professionals to combat this problem, as 
demonstrated by the establishment of the International Medical Products Anti-
Counterfeiting Taskforce to support the WHO efforts to combat counterfeit medicines 
globally (WHO, 2011). 
 
Medicine quality problems could be fatal in extreme clinical outcomes and have also 
been associated with severe economic consequences. More than 700,000 deaths from 
tuberculosis and malaria have been strongly linked with ineffective counterfeit and 
substandard medicines worldwide (Cockburn et al., 2005; Mackey & Liang, 2011). 
Mortality has also been reported after heparin contamination in the United States and 
sexual enhancement drugs adulterated with large contents of hypoglycemic drugs in 
Singapore (Kao et al., 2009; Lühn et al., 2011; Davison, 2011; Holzgrabe & Malet-
Martino, 2011). Moreover, substandard and counterfeit medicines have been related to 
morbidity, drug resistance, therapeutic failure, and toxicity (Wertheimer & Norris, 
2009; Amin & Kokwaro, 2007; Cockburn et al., 2005; Mackey & Liang, 2011). 
Economically, substandard and counterfeit medicines have been suggested to cause 
macroeconomic burdens worldwide by wasting limited resources, causing loss of 
productivity, and limiting investment of major pharmaceutical companies into medicine 
research and development (Yankus & Marks, 2009; Wertheimer & Norris, 2009; 
Moken, 2003). Furthermore, consequences of substandard and counterfeit medicines 
could result in loss of confidence in health care professionals and/or services 
(Wertheimer & Norris, 2009; Amin & Kokwaro, 2007; Cockburn et al., 2005; Mackey 
& Liang, 2011). 
 
The WHO estimates that around 10% of all global pharmaceutical supply is counterfeit 
and substandard, reaching up to 50% of the supply in developing countries and as low 
as 1% in the developed world (Heyman et al., 2011; Cockburn et al., 2005; Ziance, 
2008). These estimates cannot be a reliable estimate of the true extent of the problem 
since the available literature on the subject is limited; the existing studies used different 
methodologies and sampling techniques. Therefore, it is imperative to interpret any 
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estimates of SSFFC medicines prevalence rate with extreme caution. Moreover, it has 
been suggested that the majority of reported SSFFC medicines were substandard, rather 
than counterfeit, yet they receive far less attention within the media and the scientific 
community (Caudron et al., 2008; Fried, 2011).  
 
The aim of this systematic review is to broadly explore the evidence of substandard and 
counterfeit medicines in scientific reports to identify current knowledge limitations and 
provide an overview report of the current situation. Previously, some reviews have 
focused on specific medicine categories or problems (Amin & Kokwaro, 2007; Caudron 
et al., 2008; Newton, Green, Fernández, Day & White, 2006; Nayyar, Breman, Newton 
& Herrington, 2012). Only one review comprehensively searched for substandard and 
counterfeit medicine articles covering the period from 1966 to 2006 without specifying 
a therapeutic medicine category (Kelesidis, Kelesidis, Rafailidis & Falagas, 2007). 
Recently, the first systematic review on the subject of counterfeit and substandard 
medicines was published (Almuzaini et al., 2013).  However, Almuzaini et al have only 
reviewed some articles from a single therapeutic class that demonstrated high-quality 
reporting, which could be useful in the determination of SSFFC prevalence rates but 
may not be comprehensive enough to describe the broad scope and nature of SSFFC 
medicines available in other reports. Further, the previous systematic review did not 
discuss the types of analysis performed in the included studies, nor did it identify 
therapeutic classes or global regions in which the quality of medicines remains largely 
unknown. This review attempts to cover these issues broadly to encourage future 
researchers on medicine quality to focus their attention on neglected medicines and 
neglected parts of the globe. Furthermore, this review discusses types of analysis 
currently performed in medicine quality surveys to identify areas of concern and to 
promote the consideration of counterfeit as well as substandard medicines when 
conducting any medicine quality survey. 
 
3.2 Methods 
3.2.1 Searching the literature 
Scopus, PubMed, and ISI Web of Knowledge databases have been searched for relevant 
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research articles. The search covered the period from 1997, the year the first relevant 
citation was found, up to December 31, 2013. There was no language restriction applied 
on our search results. 
 
The following key search terms were used in conjunction, using (AND) to identify 
related articles: substandard(s) or counterfeit(s); medicine(s) or drug(s) or 
pharmaceutical(s). The choice of key search terms was based on key search terms used 
in five previous literature reviews (Amin & Kokwaro, 2007; Caudron et al., 2008; 
Newton et al., 2006; Nayyar et al., 2012; Kelesidis et al., 2007). The main distinction of 
our present review compared with most previously published reviews is its systematic 
nature and broader scope, as no medicine groups or settings were specifically chosen in 
the search terms and inclusion criteria used. 
 
The definitions and criteria used to describe counterfeit and substandard medicines in 
this review are based on the widely accepted WHO definitions of each phenomenon, as 
cited earlier (WHO, 1999a; WHO, 2003a; WHO, 2014). On the basis of the WHO 
criteria, a counterfeit medicine could be determined by chemical analysis methods if 
medicine samples contained no, or the wrong, active ingredient. A counterfeit medicine 
could also be identified via medicine package analysis by visual comparison to a known 
genuine package. Other means of detecting counterfeit medicines include authenticating 
its source through official consignment documents or communication with the stated 
manufacturer and regulatory organisations. In addition, deliberately manufactured 
substandard medicines are considered counterfeit, although this would be difficult to 
demonstrate without legal and criminal investigation by authorities. In contrast, a 
substandard medicine should always contain the correct active pharmaceutical 
ingredient (API), be produced from a legitimate source, and be without packaging 
defaults. Substandard medicines are present when the amount of API is outside the 
acceptable pharmacopoeial limits, the sample does not meet other standards set by the 
pharmacopoeias, or medicines are past their expiry dates. Collectively, we refer to both 
counterfeit and substandard medicines as SSFFC medicines, in accordance with the 
latest WHO joint definition (Deats & Bourdillon-Esteve, 2013). 
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3.2.2 Inclusion and exclusion criteria for articles in this review 
Studies included in this review were original research articles that reported prospective 
medicine sample collection from their natural settings; these medicines were presumed 
to be readily available to patients. Further, all included articles must have reported 
conducting chemical tests for the identification and/or quantification of the API. 
Without performing chemical analysis, it would not be possible to determine whether a 
medicine sample was counterfeit or not, as no information on the API would be present. 
In addition, relevant studies would include medicine samples from a wide range of 
different therapeutic categories and dosage forms without any restrictions. 
 
In contrast, the exclusion criteria of articles would include studies that did not report 
primary collection of medicine samples or medicines procured from the Internet or 
retrospectively collected through authority or innovator company seizures. Furthermore, 
studies that reported only physical or packaging testing without chemical analysis were 
excluded. Duplicate results and nonrelevant articles were also identified and excluded 
from this review. 
3.2.3 Data presentation of articles in this review 
This systematic review has been performed in accordance with Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses guidelines for systematic reviews 
(Moher et al., 2009). All percentages of SSFFC medicines available in this review are 
reported as cited from their primary source. Therefore, caution is advised, as 
methodological differences exist between articles. The data presented here do not allow 
for any estimation of the SSFFC prevalence rate worldwide. 
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3.3 Results 
3.3.1 Data extraction 
The use of the selected search terms resulted in a total of 3,861 hits from all databases. 
An initial screening of titles/abstracts followed this, excluding nonrelevant and 
duplicate results to reduce the number of results to 1,288 research articles. 
Subsequently, a full review of articles was performed that further excluded articles 
without primary data collection, such as reviews and opinions, articles containing 
retrospective sample collection of medicines (either donated or seized by authorities), 
medicines acquired through the Internet, nonrelated articles, studies without medicine 
sample collection, and studies that did not perform chemical analysis of samples. This 
strategy reduced the final number of the included articles to 66. A flowchart illustrating 
the method used for article selection in this review and different exclusion categories is 
shown in Figure 3.1. 
 
Figure 3.1 Flow chart for articles inclusion in the first systematic review 
 
Key search terms:  
Substandard(s) or Counterfeit(s) AND  
Medicine(s) or Drug(s) or Pharmaceutical(s) 
Potentially relevant 
articles (n=1288)  
Studies included (n=66)  
All identified hits 
(n=3861)  
PubMed database: 890 hits 
Scopus database: 1607 hits 
ISI Web of knowledge database: 1364 hits 
• Review title, abstract and keywords 
• Exclude duplicates (n=1439) 
• Exclude non-relevant titles (n=1134)  
• Full review of articles 
• Exclude opinion, letters, debates etc. (n=663) 
• Exclude reviews (n=159) 
• Exclude internet source (n=27) 
• Exclude perception articles (n=23) 
• Exclude retrospective collection or method 
development articles (n=236) 
• Exclude articles on package security or track and 
trace technology (n=49) 
• Exclude articles with no medicine collection or no 
laboratory analysis (n=46) 
• Exclude further non-related articles (n=22) 
• Add articles from bibliography (n=3) 
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3.3.2 Location of included studies 
The majority of reported studies prospectively examining SSFFC medicines were 
conducted in the African continent (31/66; 47%). Nigeria and Ghana alone were 
selected for more than 50% (17/31) of the studies in Africa (Tables 3.1, 3.2 and 3.4). In 
Asia, 23/66 (35%) of the SSFFC medicine quality surveys were conducted, mostly in 
the South Eastern part of Asia (Tables 3.1-3.4). Eight research articles were performed 
in the southern parts of the continent in Pakistan, Bangladesh, and India (Tables 3.1, 3.2 
and 3.4). Overall, only two studies (3%) were published that addressed SSFFC 
medicines in the western part of Asia, also known to be part of the Middle East (Table 
3.4). Elsewhere, 6/66 (9%) of studies were conducted in more than one continent 
simultaneously (Tables 3.1, 3.2 and 3.4). Moreover, three studies were performed in 
North/South America (4%) and two in Eastern Europe (3%) (Table 3.4). Only one study 
was located in the borderline area between Asia and Australia in Papua New Guinea 
(Table 3.1). 
 
3.3.3 Medicine therapeutic classes in included studies 
Substandard and counterfeit medicines were found from various therapeutic categories. 
However, most SSFFC studies 57/66 (86%) were focused on medicines that treat 
infectious diseases. Antimalarial, antibiotic, and antituberculosis medicines were 
examined in 30/66 (46%), 10/66 (15%), and 5/66 (8%) of the located studies, 
respectively (Tables 3.1, 3.2, and 3.4). The combination of more than one class of 
medicines to treat infectious diseases was found in 12/66 (18%) of the articles (Baratta 
et al., 2012; Nair et al., 2011; Bate et al., 2009b; Risha et al., 2008; Pouillot, Bilong, 
Boisier, Moumouni & Nabeth, 2008; Syhakhang et al., 2004; Taylor et al., 2001; 
Shakoor et al., 1997; Bate et al., 2011; Seear et al., 2011; Bate et al., 2009a; Kayumba et 
al., 2004). Other infectious diseases such as leishmaniasis medicines were investigated 
on one (2%) other occasion (Dorlo et al., 2012). In contrast, medicines for treatment of 
noncommunicable diseases were present in only 9/66 (14%) of the cited literature 
(Stanton et al., 2012; Baratta et al., 2012; Syhakhang et al., 2004; Said et al., 2011; 
Haruna, Adaku & Usifoh, 2013; Audu et al., 2012; Karlage et al., 2012; Twagirumukiza 
et al., 2009; Fotiou, Aravind, Wang & Nerapusee, 2009). The analgesic paracetamol 
was investigated on two separate occasions (Baratta et al., 2012; Said et al., 2011). 
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Similarly, antihypertensive medications were surveyed in only two studies (Haruna, et 
al., 2013; Twagirumukiza et al., 2009). Nonsteroidal anti-inflammatory agent aspirin 
was analysed in one further study (Syhakhang et al., 2004). The antihistamine medicine 
chlorpheniramine was only present in one survey (Audu et al., 2012). Narrow-
therapeutic index medicines also were the focus of only one published study (Karlage et 
al., 2012). Other types of medicines such as ergometrine, oxytocin, and erythropoietin 
appeared in only one study each (Stanton et al., 2012; Fotiou et al., 2009). A single 
study attempted to collect samples from various therapeutic categories simultaneously 
(Baratta et al., 2012). 
3.3.4 Evidence and nature of SSFFC medicines 
Overall, substandard medicines were found in the majority of prospective SSFFC 
medicine studies (60/66; 91%) (Tables 3.1 and 3.4). Counterfeit medicines were less 
evident in 29/66 (44%) of available studies (Tables 3.1 and 3.2). Counterfeit and 
substandard medicines were simultaneously found in 24/66 (36%) articles (Table 3.1). 
Few studies 5/66 (8%) reported only evidence of counterfeiting in the medicine samples 
collected (Table 3.2). Evidence of medicines being only substandard, rather than 
counterfeit, was found in 36/66 (55%) of the articles (Table 3.4). One study did not find 
evidence of counterfeit or substandard medicines in their sample (Table 3.3). 
 
Several types of SSFFC problems have been reported in the selected literature. It was 
noted that more than one medicine quality problem typically exists within each prospec-
tive medicine quality survey (Tables 3.1, 3.2, and 3.4). The most reported medicine 
quality problem was failure to comply with the specified API limits in 46/66 (70%) of 
cases (Tables 3.1 and 3.4). Failure of dissolution or disintegration tests has been 
reported in 24/66 (36%) of the articles (Tables 3.1 and 3.4). The presence of either no 
API (Newton et al., 2011; Stanton et al., 2012; Baratta et al., 2012; Nair et al., 2011; 
Ochekpe, Agbowuro & Attah, 2010; Bate et al., 2009a; Tipke et al., 2008; Pouillot et 
al., 2008; Atemnkeng, De Cock & Plaizier-Vercammen, 2007; Gaudiano et al., 2007; 
Syhakhang et al., 2004; Basco, 2004; Dondorp et al., 2004; Taylor et al., 2001; Stenson, 
Lindgren, Syhakhang & Tomson, 1998; Shakoor et al., 1997; Dorlo et al., 2012; 
Sengaloundeth et al., 2009; Newton et al., 2008)  or the wrong API (Newton et al., 2011; 
Onwujekwe et al., 2009; Prazuck et al., 2002; Sengaloundeth et al., 2009) was reported 
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in 20/66 (30%) and 4/66 (6%) cases, respectively. Other problems were also reported, 
including fake package (Ochekpe et al., 2010; Newton et al., 2001), fake hologram 
(Newton et al., 2011; Newton et al., 2008; Newton et al., 2001), manufacturer does not 
exist (Newton et al., 2011; Nair et al., 2011; Atemnkeng et al., 2007), manufacturer 
confirmed a nonauthentic batch (Khan et al., 2010; Newton et al., 2008), expired 
medicines (Stanton et al., 2012; Prazuck et al., 2002; Pribluda et al., 2012), no origin 
country stated (Taylor et al., 2001), no manufacturer address (Nair et al., 2011; Ali et al., 
2011; Ofori-Kwakye, Asantewaa & Gaye, 2008), no manufacturer stated (Atemnkeng et 
al., 2007), no expiry date (Ali et al, 2011; Bate et al., 2008; Prazuck et al., 2002), 
unusual interval between manufacturing and expiry date (Sengaloundeth et al., 2009), 
wrong name on package or leaflet (Newton et al., 2011), wrong spelling of “tablet” 
(Sengaloundeth et al., 2009; Newton et al., 2008), use of a different font (Newton et al., 
2008), different medicinal taste (Newton et al., 2001), heavier weight (Newton et al., 
2001), nonauthorised manufacturer (Lon et al., 2006), absence of trade name 
(Atemnkeng et al., 2007), signs of deterioration (Shakoor et al., 1997),  and diverted 
medicines (Gaudiano et al., 2007; Fotiou et al., 2009) intended for distribution in one 
location and found to be on sale in another market. 
3.3.5 Type of analysis identified in the included studies 
Four distinctive types of analysis can be used to distinguish between a genuine and 
SSFFC medicines; namely, authentication of the supplier, visual package inspection, 
and chemical and physical analysis (Tables 3.1–3.4). Authentication of the medicine 
source via contact with manufacturer, health regulatory agencies, or Internet search has 
been only attempted in 10/66 (15%) of the selected studies (Tables 3.1, 3.2, and 3.4). 
Package inspection was more popular than authentication, being reported in 39/66 
(59%) of studies, with the majority reporting obvious spelling errors and basic label 
information (medicine name, dosage, manufacturer, expiry date, and lot number), as 
shown in Tables 3.1, 3.2, and 3.4. As for the chemical analysis, high-performance liquid 
chromatography and thin-layer chromatography (TLC) were most widely used in 40/66 
(61%) and 19/66 (29%) of studies, respectively (Tables 3.1, 3.2, and 3.4). Other 
chemical analysis methods were reported such as color reaction tests, spectroscopic 
techniques and titration but remain less frequently used (Tables 3.1–3.4). 
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Moreover, physical analysis tests were performed in 39/66 (59%) of the studies (Tables 
3.1, 3.2 and 3.4). The most common physical tests reported were disintegration and/or 
dissolution tests in 36/39 (92%) cases (Tables 3.1, 3.2, and 3.4). Other less frequently 
used physical analysis tests include content uniformity (Tables 3.1 and 3.4), weight 
measurement (Tables 3.1, 3.2, and 3.4), hardness (Tables 3.1 and 3.4), and friability tests 
(Tables 3.1 and 3.4). Interestingly, only six studies (9%) reported all four types of 
analysis in an attempt to clearly identify and classify the type of SSFFC problem, where 
present, in any medicine sample (Tables 3.1 and 3.4). 
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Table 3.1 Research articles reporting both counterfeit and substandard medicines 
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Table 3.1 Continued 
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an
ti
th
el
m
en
ti
c 
A
n
ti
m
al
ar
ia
l 
ar
te
su
n
at
e 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
C
o
u
n
tr
y
 
N
ig
er
ia
 
T
an
za
n
ia
 
B
u
rk
in
a 
F
as
o
 
6
 A
fr
ic
an
 
co
u
n
tr
ie
s 
C
am
er
o
o
n
 
an
d
 N
ig
er
 
G
h
an
a 
C
o
n
g
o
 
C
o
n
g
o
, 
B
u
ru
n
d
i 
an
d
 
A
n
g
o
la
 
R
ef
er
en
ce
 
O
n
w
u
je
k
w
e 
et
 a
l.
 (
2
0
0
9
) 
R
is
h
a 
et
 a
l.
 
(2
0
0
8
) 
T
ip
k
e 
et
 a
l.
 
(2
0
0
8
) 
B
at
e 
et
 a
l.
 
(2
0
0
8
) 
P
o
u
il
lo
t 
et
 a
l.
 
(2
0
0
8
) 
O
fo
ri
-
K
w
ak
y
e 
et
 a
l.
 
(2
0
0
8
) 
A
te
m
n
k
en
g
 e
t 
al
. 
(2
0
0
7
) 
G
au
d
ia
n
o
 e
t 
al
. 
(2
0
0
7
) 
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Table 3.1 Continued 
 
T
y
p
e 
o
f 
S
S
F
F
C
 
p
ro
b
le
m
 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
 
N
o
n
-e
x
is
te
n
t 
m
an
u
fa
ct
u
re
r 
L
o
w
 o
r 
h
ig
h
 A
P
I%
 a
n
d
 
fa
il
ed
 w
ei
g
h
t 
v
ar
ia
ti
o
n
 t
 
N
o
 A
P
I 
L
o
w
 A
P
I%
 
 
N
o
 A
P
I 
N
o
 o
r 
tr
ac
e 
A
P
I 
an
d
 a
ll
 
w
er
e 
ar
te
su
n
at
e 
 
S
u
b
st
an
d
ar
d
 A
P
I 
%
 a
n
d
 
al
l 
w
er
e 
m
ef
lo
q
u
in
e 
 
L
o
w
, 
h
ig
h
 A
P
I%
 a
n
d
 
ex
p
ir
ed
 m
ed
ic
in
es
 
W
ro
n
g
 A
P
I 
an
d
 n
o
 
ex
p
ir
y
 d
at
e 
o
n
 p
ac
k
ag
e 
L
o
w
 A
P
I%
 
N
o
 A
P
I 
an
d
 n
o
 
o
ri
g
in
 c
o
u
n
tr
y
 o
n
 
p
ac
k
ag
e 
L
o
w
 o
r 
h
ig
h
 A
P
I%
 a
n
d
 
w
ei
g
h
t 
v
ar
ia
ti
o
n
 
 
N
o
 A
P
I 
 
L
o
w
 o
r 
h
ig
h
 A
P
I%
 a
n
d
 
si
g
n
s 
o
f 
d
ec
o
m
p
o
si
ti
o
n
 
 
N
o
 A
P
I 
 
R
es
u
lt
s 
9
/2
4
 (
3
8
%
) 
su
b
st
an
d
ar
d
 
 
3
/2
4
 (
1
2
.5
%
) 
co
u
n
te
rf
ei
t 
4
6
%
 a
n
d
 2
2
%
 s
u
b
st
an
d
ar
d
 
in
 1
9
9
7
 &
 1
9
9
9
 
1
%
 c
o
u
n
te
rf
ei
t 
5
3
/2
8
4
 (
1
8
%
) 
su
b
st
an
d
ar
d
 
 
5
9
/2
8
4
 (
2
0
%
) 
co
u
n
te
rf
ei
t 
9
9
/3
0
3
 (
3
3
%
) 
co
u
n
te
rf
ei
t 
  
4
/3
0
3
 (
1
%
) 
su
b
st
an
d
ar
d
 
1
0
/2
1
 (
4
8
%
) 
su
b
st
an
d
ar
d
 
 
3
/2
1
 (
1
4
%
) 
co
u
n
te
rf
ei
t 
2
7
9
/5
8
1
 (
4
8
%
) 
su
b
st
an
d
ar
d
 
 
4
3
/5
8
1
 (
7
%
) 
co
u
n
te
rf
ei
t 
t 
4
2
/3
6
6
  
(1
1
.5
%
) 
su
b
st
an
d
ar
d
 
 
1
2
/3
6
6
  
(3
.3
%
) 
co
u
n
te
rf
ei
t 
 
3
6
%
 f
ro
m
 N
ig
er
ia
 a
n
d
 4
0
%
 
fr
o
m
 T
h
ai
la
n
d
 s
u
b
st
an
d
ar
d
 
 
6
/9
6
 (
6
%
) 
co
u
n
te
rf
ei
t 
P
h
y
si
ca
l 
an
al
y
si
s 
N
R
 
W
ei
g
h
t 
v
ar
ia
ti
o
n
 a
n
d
 
d
is
in
te
g
ra
ti
o
n
 
N
R
 
N
R
 
N
R
 
N
R
 
M
ea
su
re
m
en
t 
o
f 
w
ei
g
h
t 
v
ar
ia
ti
o
n
 
N
R
 
C
h
em
ic
al
 
an
al
y
si
s 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
an
d
 t
it
ra
ti
o
n
  
C
o
lo
u
r 
te
st
 
an
d
 T
L
C
 
C
o
lo
u
r 
te
st
 
an
d
 H
P
L
C
 
w
it
h
 p
h
o
to
-
d
io
d
e 
ar
ra
y
 
U
V
, 
T
L
C
 a
n
d
 
ti
tr
im
et
ry
 
H
P
L
C
-U
V
 
C
o
lo
u
r 
te
st
, 
T
L
C
, 
H
P
L
C
-
U
V
 a
n
d
 
ti
tr
at
io
n
 
H
P
L
C
-U
V
 
V
is
u
al
 
an
al
y
si
s 
C
h
ec
k
 f
o
r 
il
le
g
al
 p
ri
n
ts
 
o
n
ly
 
N
R
 
N
R
 
P
ac
k
ag
e 
an
al
y
si
s 
o
f 
h
o
lo
g
ra
m
s 
N
R
 
B
as
ic
 
p
ac
k
ag
e 
in
fo
rm
at
io
n
 
o
n
 o
ri
g
in
 
B
as
ic
 v
is
u
al
 
an
al
y
si
s 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 f
o
r 
o
b
v
io
u
s 
er
ro
rs
 
A
u
th
en
ti
ca
te
 
so
u
rc
e 
C
h
ec
k
ed
 
so
u
rc
e 
o
f 
so
m
e 
co
m
p
an
ie
s 
 
N
R
 
N
R
  
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
S
am
p
le
 
si
ze
 
2
4
 
6
6
6
 
2
8
4
 
3
0
3
 
2
1
 
5
8
1
 
3
6
6
 
9
6
 
M
ed
ic
in
e(
s)
 
A
n
ti
m
al
ar
ia
l 
A
rt
em
is
in
in
-
d
er
iv
at
iv
e 
d
ru
g
s 
A
n
ti
b
io
ti
c,
 
an
ti
m
al
ar
ia
l 
an
d
 a
sp
ir
in
 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
ar
te
su
n
at
e 
d
er
iv
at
iv
es
 
an
d
 
m
ef
lo
q
u
in
e 
A
n
ti
b
io
ti
cs
 
A
n
ti
m
al
ar
ia
l,
 
an
ti
b
io
ti
c,
 
an
ti
 T
B
, 
an
ti
fu
n
g
al
 
A
n
ti
b
io
ti
cs
 
am
p
ic
il
li
n
 
an
d
 
te
tr
ac
y
cl
in
e 
A
n
ti
m
al
ar
ia
l 
an
d
 
an
ti
b
io
ti
cs
 
C
o
u
n
tr
y
 
K
en
y
a 
an
d
 
C
o
n
g
o
 
L
ao
s 
(t
w
o
 
st
u
d
ie
s 
in
 
1
9
9
7
 a
n
d
 
1
9
9
9
) 
C
am
er
o
o
n
 
T
h
ai
la
n
d
, 
V
ie
tn
am
, 
C
am
b
o
d
ia
, 
L
ao
s 
P
D
R
 
an
d
 M
y
an
m
ar
 
M
y
an
m
ar
 
N
ig
er
ia
 
L
ao
s 
N
ig
er
ia
 a
n
d
 
T
h
ai
la
n
d
 
R
ef
er
en
ce
 
A
te
m
n
k
en
g
 e
t 
al
. 
(2
0
0
7
) 
S
y
h
ak
h
an
g
 e
t 
al
. 
(2
0
0
4
) 
B
as
co
 (
2
0
0
4
) 
D
o
n
d
o
rp
 e
t 
al
. 
(2
0
0
4
) 
 
P
ra
zu
ck
 e
t 
al
. 
(2
0
0
2
) 
T
ay
lo
r 
et
 a
l.
 
(2
0
0
1
) 
S
te
n
so
n
 e
t 
al
. 
(1
9
9
8
) 
S
h
ak
o
o
r 
et
 a
l.
 
(1
9
9
7
) 
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Table 3.2 Research articles reporting counterfeit medicines only 
 
 
T
y
p
e 
o
f 
S
S
F
F
C
 
p
ro
b
le
m
 
N
o
 A
P
I 
W
ro
n
g
 A
P
I,
 n
o
n
-
ex
is
te
n
t 
m
an
u
fa
ct
u
re
r,
 n
o
 
A
P
I,
 h
o
lo
g
ra
m
 
d
if
fe
re
n
t 
fr
o
m
 
g
en
u
in
e 
p
ac
k
ag
e 
an
d
 w
ro
n
g
 n
am
e 
o
n
 
p
ac
k
ag
in
g
 o
r 
le
af
le
t 
N
o
 o
r 
w
ro
n
g
 A
P
I,
 
w
ro
n
g
 s
p
el
li
n
g
 o
f 
“t
ab
le
t”
 o
n
 p
ac
k
ag
e 
an
d
 u
n
u
su
al
 i
n
te
rv
al
 
b
et
w
ee
n
 
m
an
u
fa
ct
u
ri
n
g
 d
at
e 
an
d
 e
x
p
ir
y
 d
at
e 
o
f 
n
in
e 
y
ea
rs
 
F
ak
e 
h
o
lo
g
ra
m
, 
w
ro
n
g
 s
p
el
li
n
g
 o
n
 
p
ac
k
ag
in
g
, 
u
se
 o
f 
d
if
fe
re
n
t 
fo
n
t,
 
fa
il
u
re
 o
f 
au
th
en
ti
ca
ti
o
n
 w
h
en
 
m
an
u
fa
ct
u
re
r 
w
as
 
co
n
ta
ct
ed
 a
n
d
 n
o
 
A
P
I 
N
o
 A
P
I,
 d
if
fe
re
n
t 
ta
st
e 
o
f 
ta
b
le
ts
, 
h
ea
v
ie
r 
w
ei
g
h
t 
o
f 
ta
b
le
ts
 a
n
d
 
d
if
fe
re
n
t 
p
ac
k
ag
in
g
 a
n
d
 
h
o
lo
g
ra
m
s 
co
m
p
ar
ed
 t
o
 
g
en
u
in
e 
R
es
u
lt
s 
B
o
th
 (
1
0
0
%
) 
fa
il
ed
 a
ll
 
te
st
s 
an
d
 a
re
 c
o
u
n
te
rf
ei
t 
O
n
ly
 c
as
e 
re
p
o
rt
s 
o
f 
co
u
n
te
rf
ei
ts
 a
n
d
 d
o
 n
o
t 
al
lo
w
 f
o
r 
p
er
ce
n
ta
g
e 
es
ti
m
at
io
n
 
8
8
%
 f
ai
lu
re
 a
n
d
 
co
u
n
te
rf
ei
t 
1
9
5
/3
9
1
 (
5
0
%
) 
co
u
n
te
rf
ei
t 
O
v
er
al
l 
3
8
%
 a
re
 c
o
u
n
te
rf
ei
t 
fo
u
n
d
 i
n
 a
ll
 c
o
u
n
tr
ie
s 
P
h
y
si
ca
l 
an
al
y
si
s 
N
R
 
N
R
 
N
R
 
N
R
 
T
ab
le
t 
w
ei
g
h
t,
 
si
ze
 a
n
d
 c
o
lo
u
r 
C
h
em
ic
al
 
an
al
y
si
s 
L
C
-M
S
, 
F
T
-
IR
, 
N
IR
, 
co
lo
ri
m
et
ri
c 
te
st
 
H
P
L
C
 w
it
h
 
p
h
o
to
-d
io
d
e 
ar
ra
y
 a
n
d
 
o
th
er
 t
es
ts
 
C
o
lo
ri
m
et
ri
c 
te
st
s,
 H
P
L
C
-
m
as
s 
sp
ec
tr
o
sc
o
p
y
, 
p
o
ll
en
 
an
al
y
si
s,
 X
-
ra
y
 
d
if
fr
ac
ti
o
n
 
C
o
lo
ri
m
et
ri
c,
 
H
P
L
C
-m
as
s 
sp
ec
tr
o
m
et
ry
 
C
o
lo
u
r 
re
ac
ti
o
n
 t
es
t 
V
is
u
al
 
an
al
y
si
s 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 
P
ac
k
ag
e 
an
al
y
si
s 
P
ac
k
ag
e 
an
al
y
si
s 
in
cl
u
d
in
g
 
h
o
lo
g
ra
m
s 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 
an
d
 
h
o
lo
g
ra
m
s,
 
p
ri
n
ti
n
g
 a
n
d
 
b
ar
 c
o
d
es
 
A
u
th
en
ti
ca
te
 
so
u
rc
e 
N
R
 
C
o
n
ta
ct
 
m
an
u
fa
ct
u
re
r 
N
R
 
C
o
n
ta
ct
 w
it
h
 
o
n
e 
co
m
p
an
y
 
to
 
au
th
en
ti
ca
te
 
b
at
ch
 
n
u
m
b
er
s 
N
R
 
S
am
p
le
 
si
ze
 
2
 
5
9
 
3
0
 
3
9
1
 
1
0
4
 
M
ed
ic
in
e(
s)
 
M
il
te
fo
si
n
e 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
ar
te
su
n
at
e 
A
n
ti
m
al
ar
ia
l 
ar
te
su
n
at
e 
A
n
ti
m
al
ar
ia
l 
ar
te
su
n
at
e 
C
o
u
n
tr
y
 
B
an
g
la
d
es
h
 
M
u
lt
ip
le
 
co
u
n
tr
ie
s 
in
 
A
fr
ic
a 
L
ao
s 
V
ie
tn
am
, 
C
am
b
o
d
ia
, 
M
y
an
m
ar
, 
L
ao
s 
an
d
 
T
h
ai
la
n
d
 
M
y
an
m
ar
, 
C
am
b
o
d
ia
, 
V
ie
tn
am
, 
L
ao
s,
 a
n
d
 
w
es
te
rn
 
T
h
ai
la
n
d
 
R
ef
er
en
ce
 
D
o
rl
o
 e
t 
al
. 
(2
0
1
2
) 
N
ew
to
n
 e
t 
al
. 
(2
0
1
1
) 
S
en
g
al
o
u
n
d
et
h
 
et
 a
l.
 (
2
0
0
9
) 
N
ew
to
n
 e
t 
al
. 
(2
0
0
8
) 
N
ew
to
n
 e
t 
al
. 
(2
0
0
1
) 
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Table 3.3 Study with no report of substandard or counterfeit medicines  
 
R
es
u
lt
s 
A
ll
 s
am
p
le
s 
p
as
se
d
 b
u
t 
w
it
h
 v
ar
ia
b
le
 q
u
al
it
y
 
P
h
y
si
ca
l 
an
al
y
si
s 
N
R
 
C
h
em
ic
al
 
an
al
y
si
s 
N
IR
 
sp
ec
tr
o
sc
o
p
y
 
V
is
u
al
 
an
al
y
si
s 
N
R
 
A
u
th
en
ti
ca
te
 
so
u
rc
e 
N
R
 
S
am
p
le
 
si
ze
 
1
6
 
M
ed
ic
in
e(
s)
 
P
ar
ac
et
am
o
l 
C
o
u
n
tr
y
 
M
al
ay
si
a 
R
ef
er
en
ce
 
S
ai
d
 e
t 
al
. 
(2
0
1
1
) 
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Table 3.4 Research articles reporting only substandard medicines 
 
T
y
p
e 
o
f 
S
S
F
F
C
 
p
ro
b
le
m
 
L
o
w
 A
P
I%
 
L
o
w
 A
P
I%
 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
L
o
w
 A
P
I%
, 
fa
il
u
re
 
o
f 
co
n
te
n
t 
u
n
if
o
rm
it
y
 a
n
d
 
d
is
so
lu
ti
o
n
 t
es
ts
 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
m
o
st
ly
 a
rt
es
u
n
at
e 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
F
ai
li
n
g
 o
n
ly
 v
is
u
al
 
in
sp
ec
ti
o
n
 a
n
d
 
u
n
if
o
rm
it
y
 o
f 
w
ei
g
h
t 
L
o
w
 o
r 
h
ig
h
 A
P
I%
 a
n
d
 
fa
il
in
g
 p
h
y
si
ca
l 
te
st
s 
 
L
o
w
 A
P
I%
 
R
es
u
lt
s 
1
/4
 (
2
5
%
) 
su
b
st
an
d
ar
d
 
3
/1
0
 (
3
0
%
) 
su
b
st
an
d
ar
d
 
1
6
8
/1
9
4
8
 (
9
%
) 
su
b
st
an
d
ar
d
 
1
2
/5
9
 (
2
0
%
) 
su
b
st
an
d
ar
d
 
1
4
/3
2
 (
4
3
.7
5
%
) 
su
b
st
an
d
ar
d
 
1
9
/3
3
 (
5
8
%
) 
su
b
st
an
d
ar
d
 
4
/9
 (
4
4
%
) 
su
b
st
an
d
ar
d
 
1
3
/1
4
 (
9
3
%
) 
su
b
st
an
d
ar
d
 
  
5
/1
7
 (
3
0
%
) 
su
b
st
an
d
ar
d
 
P
h
y
si
ca
l 
an
al
y
si
s 
N
R
 
T
ab
le
t 
sh
ap
e,
 s
iz
e,
 
th
ic
k
n
es
s 
an
d
 w
ei
g
h
t.
 
D
is
in
te
g
ra
ti
o
n
 a
n
d
 
fr
ia
b
il
it
y
 t
es
ts
 
N
R
 
S
ta
b
il
it
y
 a
n
d
 
d
is
so
lu
ti
o
n
 
T
ab
le
t 
w
ei
g
h
t 
N
R
 
D
is
so
lu
ti
o
n
, 
d
is
in
te
g
ra
ti
o
n
, 
h
ar
d
n
es
s,
 u
n
if
o
rm
it
y
 
o
f 
w
ei
g
h
t 
an
d
 
fr
ia
b
il
it
y
 t
es
ts
 
U
n
if
o
rm
it
y
 o
f 
m
as
s,
 
cr
u
sh
in
g
 s
tr
en
g
th
 a
n
d
 
d
is
in
te
g
ra
ti
o
n
 
W
ei
g
h
t 
m
ea
su
re
m
en
t 
C
h
em
ic
al
 
an
al
y
si
s 
N
o
n
-a
q
u
eo
u
s 
ti
tr
at
io
n
 
H
P
L
C
-U
V
 
S
p
ec
tr
o
m
et
ry
 
H
P
L
C
-U
V
 
T
it
ri
m
et
ri
c 
an
d
 H
P
L
C
-
U
V
 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
C
o
lo
ri
m
et
ry
 
an
d
 T
L
C
 
H
P
L
C
-U
V
 
V
is
u
al
 
an
al
y
si
s 
N
R
 
N
R
 
N
R
 
B
as
ic
 v
is
u
al
 
an
al
y
si
s 
o
f 
p
ri
m
ar
y
 a
n
d
 
se
co
n
d
ar
y
 
p
ac
k
ag
in
g
 
B
as
ic
 v
is
u
al
 
an
al
y
si
s 
an
d
 
co
m
p
ar
ed
 t
o
 
g
en
u
in
e 
N
R
 
S
im
p
le
 
p
ac
k
ag
e 
an
al
y
si
s 
F
o
r 
il
le
g
al
 
p
ri
n
t 
er
ro
rs
 
N
R
 
A
u
th
en
ti
ca
te
 
so
u
rc
e 
N
R
 
N
R
 
N
R
 
C
o
n
ta
ct
 w
it
h
 
m
an
u
fa
ct
u
re
r 
an
d
 l
o
ca
l 
au
th
o
ri
ti
es
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
S
am
p
le
 
si
ze
 
4
 
1
0
 
1
9
4
8
 
ta
b
le
ts
 
5
9
 
3
2
 
b
li
st
er
s 
3
3
 
9
 
1
4
 
1
7
 
M
ed
ic
in
e(
s)
 
A
n
ti
h
y
p
er
te
n
si
v
e 
M
et
h
y
ld
o
p
a 
A
n
ti
h
is
ta
m
in
e 
ch
lo
rp
h
en
ir
am
in
e 
A
n
ti
-T
B
 
A
n
ti
b
io
ti
c 
am
o
x
ic
il
li
n
-
cl
av
u
la
n
ic
 a
ci
d
 
A
n
ti
m
al
ar
ia
l 
ar
te
su
n
at
e 
an
d
 
am
o
d
ia
q
u
in
e 
A
n
ti
b
io
ti
c 
ey
e 
d
ro
p
s 
A
n
ti
m
al
ar
ia
l 
m
ed
ic
in
es
 
A
n
ti
m
al
ar
ia
l 
ar
te
m
is
in
in
- 
m
ed
ic
in
es
 
A
n
ti
b
io
ti
cs
, 
w
ar
fa
ri
n
, 
le
v
o
th
y
ro
x
in
e 
an
d
 
si
ld
en
af
il
 
C
o
u
n
tr
y
 
N
ig
er
ia
 
C
o
n
g
o
 
In
d
ia
 
C
am
b
o
d
ia
 
G
h
an
a 
K
en
y
a 
an
d
 
C
o
n
g
o
 
B
ra
zi
l 
G
h
an
a 
M
ex
ic
o
 
R
ef
er
en
ce
 
H
ar
u
n
a 
et
 a
l.
 
(2
0
1
3
) 
A
u
d
u
 e
t 
al
. 
(2
0
1
3
) 
R
am
ac
h
an
d
ra
n
 
et
 a
l.
 (
2
0
1
3
) 
K
h
an
 e
t 
al
. 
(2
0
1
3
) 
A
ff
u
m
 e
t 
al
. 
(2
0
1
3
) 
B
ri
es
en
 e
t 
al
. 
(2
0
1
2
) 
N
o
g
u
ei
ra
 e
t 
al
. 
(2
0
1
2
) 
E
l-
D
u
ah
 &
 
O
fo
ri
-K
w
ak
y
e 
(2
0
1
2
) 
K
ar
la
g
e 
et
 a
l.
 
(2
0
1
2
) 
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Table 3.4 Continued 
 
T
y
p
e 
o
f 
S
S
F
F
C
 
p
ro
b
le
m
 
E
x
p
ir
ed
 m
ed
ic
in
es
 
m
o
st
ly
, 
lo
w
 A
P
I%
 
an
d
 f
ai
lu
re
 o
f 
d
is
in
te
g
ra
ti
o
n
 t
es
ts
 
L
o
w
 A
P
I%
 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
F
ai
lu
re
 o
f 
v
is
u
al
 
in
sp
ec
ti
o
n
, 
lo
w
 
A
P
I%
 a
n
d
 
d
is
so
lu
ti
o
n
 f
ai
lu
re
 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
L
o
w
 A
P
I%
, 
fa
il
u
re
 
o
f 
fr
ia
b
il
it
y
 a
n
d
 
d
is
so
lu
ti
o
n
 t
es
ts
 
L
o
w
 A
P
I%
 
F
ai
lu
re
 o
f 
v
is
u
al
 
in
sp
ec
ti
o
n
, 
lo
w
 A
P
I%
 
an
d
 d
is
so
lu
ti
o
n
 f
ai
lu
re
 
H
ig
h
 A
P
I%
 a
n
d
 
d
is
so
lu
ti
o
n
 f
ai
lu
re
 
R
es
u
lt
s 
1
9
3
/1
6
6
3
 (
1
1
%
) 
su
b
st
an
d
ar
d
 
1
/3
3
 (
3
%
) 
su
b
st
an
d
ar
d
 
1
1
/1
3
 (
8
5
%
) 
su
b
st
an
d
ar
d
 
1
5
%
 
su
b
st
an
d
ar
d
 
4
3
%
 
su
b
st
an
d
ar
d
 
1
/4
 (
2
5
%
) 
su
b
st
an
d
ar
d
 
1
8
%
 
su
b
st
an
d
ar
d
 
2
3
%
 s
u
b
st
an
d
ar
d
 
 
1
0
0
%
 s
u
b
st
an
d
ar
d
 
P
h
y
si
ca
l 
an
al
y
si
s 
D
is
in
te
g
ra
ti
o
n
 
N
R
 
N
R
 
D
is
in
te
g
ra
ti
o
n
 
N
R
 
U
n
if
o
rm
it
y
 o
f 
w
ei
g
h
t,
 
h
ar
d
n
es
s,
 
d
is
in
te
g
ra
ti
o
n
, 
d
is
so
lu
ti
o
n
 a
n
d
 
fr
ia
b
il
it
y
 
N
R
 
D
is
in
te
g
ra
ti
o
n
 
D
is
so
lu
ti
o
n
 
C
h
em
ic
al
 
an
al
y
si
s 
T
L
C
 
N
M
R
 
H
P
L
C
-U
V
 
T
L
C
 a
n
d
 
R
am
an
 
H
P
L
C
-M
S
 
T
it
ra
ti
o
n
 
H
P
L
C
-U
V
 
T
L
C
 a
n
d
 
R
am
an
 
H
P
L
C
-U
V
 
V
is
u
al
 
an
al
y
si
s 
P
ac
k
ag
e 
an
d
 
la
b
el
 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 o
f 
ex
p
ir
y
 d
at
e 
an
d
 
re
g
is
tr
at
io
n
 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 
N
R
 
N
R
 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 
P
ac
k
ag
e 
in
sp
ec
ti
o
n
 
N
R
 
A
u
th
en
ti
ca
te
 
so
u
rc
e 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
N
R
 
S
am
p
le
 
si
ze
 
1
6
6
3
 
3
3
 
1
3
 
8
9
9
 
3
0
0
 
4
 
1
0
4
 
3
3
9
 
9
 
M
ed
ic
in
e(
s)
 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
ar
te
su
n
at
e 
an
d
 
am
o
d
ia
q
u
in
e 
co
m
b
in
at
io
n
 
A
n
ti
m
al
ar
ia
l,
 
an
ti
b
io
ti
cs
 a
n
d
 
an
ti
-T
B
 
C
ip
ro
fl
o
x
ac
in
, 
A
rt
es
u
n
at
e 
an
d
 
R
if
am
p
ic
in
 
A
n
ti
b
io
ti
c 
ci
p
ro
fl
o
x
ac
in
 
5
 d
if
fe
re
n
t 
A
n
ti
b
io
ti
cs
 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
C
o
u
n
tr
y
 
S
ev
en
 
co
u
n
tr
ie
s 
in
 
S
o
u
th
 
A
m
er
ic
a 
G
h
an
a 
N
ig
er
ia
 
1
7
 
co
u
n
tr
ie
s 
fr
o
m
 a
ll
 
co
n
ti
n
en
ts
 
In
d
ia
 
N
ig
er
ia
 
In
d
o
n
es
ia
 
G
h
an
a 
an
d
 
N
ig
er
ia
 
P
ak
is
ta
n
 
R
ef
er
en
ce
 
P
ri
b
lu
d
a 
et
 a
l.
 
(2
0
1
2
) 
K
le
in
 e
t 
al
. 
(2
0
1
2
) 
E
h
ia
n
et
a 
et
 a
l.
 
(2
0
1
2
) 
B
at
e 
et
 a
l.
 
(2
0
1
1
) 
S
ee
ar
 e
t 
al
. 
(2
0
1
1
) 
A
k
p
ab
io
 e
t 
al
. 
(2
0
1
1
) 
H
ad
i 
et
 a
l.
 
(2
0
1
0
) 
B
at
e 
&
 H
es
s 
(2
0
1
0
) 
L
es
li
e 
et
 a
l.
 
(2
0
0
9
) 
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Table 3.4 Continued 
 
T
y
p
e 
o
f 
S
S
F
F
C
 
p
ro
b
le
m
 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
L
o
w
 a
n
d
 h
ig
h
 A
P
I%
 
L
o
w
 A
P
I%
 a
n
d
 
d
is
in
te
g
ra
ti
o
n
 
fa
il
u
re
 
E
x
ce
ed
ed
 s
p
ec
if
ic
 
co
n
te
n
t 
re
q
u
ir
em
en
t 
fo
r 
th
e 
p
ro
d
u
ct
 a
n
d
 
b
at
ch
 n
u
m
b
er
 
m
at
ch
es
 p
ro
d
u
ct
s 
so
ld
 o
u
ts
id
e 
th
e 
co
u
n
tr
y
 a
cc
o
rd
in
g
 t
o
 
th
e 
m
an
u
fa
ct
u
re
r 
L
o
w
 A
P
I%
 a
n
d
 
d
is
so
lu
ti
o
n
 f
ai
lu
re
 
L
o
w
 A
P
I%
 
L
o
w
 A
P
I%
 a
n
d
 
d
is
so
lu
ti
o
n
 f
ai
lu
re
 
R
es
u
lt
s 
2
/1
0
 (
2
0
%
) 
su
b
st
an
d
ar
d
 
1
5
/9
6
 (
1
6
%
) 
su
b
st
an
d
ar
d
 
4
0
/7
8
 (
5
1
%
) 
su
b
st
an
d
ar
d
 
3
2
/1
3
9
 (
2
3
%
) 
su
b
st
an
d
ar
d
 a
n
d
 
d
iv
er
te
d
 
1
2
.5
%
 
su
b
st
an
d
ar
d
 
5
6
%
 o
f 
ca
p
su
le
s 
su
b
st
an
d
ar
d
 
 
8
%
 o
f 
su
sp
en
si
o
n
s 
su
b
st
an
d
ar
d
 
2
/8
 (
2
5
%
) 
su
b
st
an
d
ar
d
 
P
h
y
si
ca
l 
an
al
y
si
s 
D
is
so
lu
ti
o
n
 
N
R
 
D
is
in
te
g
ra
ti
o
n
 
N
R
 
D
is
so
lu
ti
o
n
 
N
R
 
D
is
so
lu
ti
o
n
 
C
h
em
ic
al
 
an
al
y
si
s 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
T
L
C
, 
N
IR
 a
n
d
 
R
am
an
 
H
P
L
C
-U
V
 a
n
d
 
H
P
L
C
-M
S
 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
V
is
u
al
 
an
al
y
si
s 
N
R
 
N
R
 
N
R
 
P
ri
m
ar
y
 a
n
d
 
se
co
n
d
ar
y
 
p
ac
k
ag
e 
an
d
 
se
cu
ri
ty
 
fe
at
u
re
s 
N
R
 
N
R
 
B
as
ic
 
p
ac
k
ag
e 
in
sp
ec
ti
o
n
 
A
u
th
en
ti
ca
te
 
so
u
rc
e 
N
R
 
N
R
 
N
R
 
C
h
ec
k
ed
 
b
at
ch
 
n
u
m
b
er
s 
w
it
h
 
m
an
u
fa
ct
u
re
r 
N
R
 
N
R
 
N
R
 
S
am
p
le
 
si
ze
 
1
0
 
9
6
 
7
8
 
1
3
9
 
3
0
4
 
1
1
1
 
8
 
M
ed
ic
in
e(
s)
 
A
n
ti
h
y
p
er
te
n
si
v
e 
d
ru
g
s 
A
n
ti
b
io
ti
c 
ce
ft
ri
ax
o
n
e 
in
je
ct
io
n
 
A
n
ti
m
al
ar
ia
l,
 
an
ti
b
io
ti
c 
an
d
 
an
ti
m
y
co
b
ac
te
ri
al
 
E
p
o
et
in
 a
lf
a-
p
re
fi
ll
ed
 s
y
ri
n
g
es
 
A
n
ti
m
al
ar
ia
l 
A
m
o
x
ic
il
li
n
 
an
ti
b
io
ti
c 
in
 
d
if
fe
re
n
t 
fo
rm
u
la
ti
o
n
s 
A
n
ti
b
io
ti
c 
d
o
x
y
cy
cl
in
e 
C
o
u
n
tr
y
 
R
w
an
d
a 
P
ak
is
ta
n
 
G
h
an
a,
 
In
d
ia
, 
K
en
y
a,
 
N
ig
er
ia
, 
T
an
za
n
ia
, 
an
d
 
U
g
an
d
a 
T
h
ai
la
n
d
 
T
an
za
n
ia
 
L
eb
an
o
n
, 
S
y
ri
a,
 
Jo
rd
an
, 
E
g
y
p
t 
an
d
 
S
au
d
i 
A
ra
b
ia
 
E
st
o
n
ia
 a
n
d
 
R
u
ss
ia
 
R
ef
er
en
ce
 
T
w
ag
ir
u
m
u
k
iz
a 
et
 a
l.
 (
2
0
0
9
) 
O
b
ai
d
 (
2
0
0
9
) 
B
at
e 
et
 a
l.
 
(2
0
0
9
b
) 
F
o
ti
o
u
 e
t 
al
. 
(2
0
0
9
) 
K
au
r 
et
 a
l.
 
(2
0
0
8
) 
K
y
ri
ac
o
s 
et
 a
l.
 
(2
0
0
8
) 
M
o
es
 e
t 
al
. 
(2
0
0
8
) 
 
 62 
Table 3.4 Continued 
 
T
y
p
e 
o
f 
S
S
F
F
C
 
p
ro
b
le
m
 
D
is
so
lu
ti
o
n
 f
ai
lu
re
 
L
o
w
 A
P
I%
 a
n
d
 
d
is
in
te
g
ra
ti
o
n
 t
es
t 
fa
il
u
re
 
L
o
w
 A
P
I%
 a
n
d
 
d
is
in
te
g
ra
ti
o
n
 t
es
t 
fa
il
u
re
 
 
O
n
e 
il
le
g
al
 
m
an
u
fa
ct
u
re
r 
id
en
ti
fi
ed
 
L
o
w
 A
P
I%
 a
n
d
 
d
is
so
lu
ti
o
n
 f
ai
lu
re
 
L
o
w
 A
P
I%
, 
h
ig
h
 A
P
I%
 
an
d
 d
is
so
lu
ti
o
n
 f
ai
lu
re
 
F
ai
lu
re
 o
f 
v
is
u
al
 
in
sp
ec
ti
o
n
, 
lo
w
 
A
P
I%
 a
n
d
 
d
is
so
lu
ti
o
n
 f
ai
lu
re
 
D
is
so
lu
ti
o
n
 f
ai
lu
re
 
L
o
w
 A
P
I%
 a
n
d
 
d
is
so
lu
ti
o
n
 f
ai
lu
re
 
R
es
u
lt
s 
1
/6
 (
1
6
%
) 
su
b
st
an
d
ar
d
 
2
3
/3
6
9
 (
6
%
) 
su
b
st
an
d
ar
d
 
1
2
2
/4
5
1
 (
2
7
%
) 
su
b
st
an
d
ar
d
 
 
4
7
/1
1
6
 (
4
0
%
) 
su
b
st
an
d
ar
d
 
1
6
/5
0
 (
3
2
%
) 
su
b
st
an
d
ar
d
 
 
3
7
%
 s
u
b
st
an
d
ar
d
 
 
4
/3
3
 (
1
2
%
) 
su
b
st
an
d
ar
d
 
1
2
/3
3
 (
3
6
%
) 
su
b
st
an
d
ar
d
 
P
h
y
si
ca
l 
an
al
y
si
s 
D
is
so
lu
ti
o
n
 
D
is
in
te
g
ra
ti
o
n
 
D
is
in
te
g
ra
ti
o
n
 
D
is
so
lu
ti
o
n
 
D
is
so
lu
ti
o
n
 
D
is
so
lu
ti
o
n
 
D
is
so
lu
ti
o
n
 
D
is
so
lu
ti
o
n
 
C
h
em
ic
al
 
an
al
y
si
s 
H
P
L
C
-U
V
 
T
L
C
 a
n
d
 
H
P
L
C
-U
V
 
T
L
C
 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
H
P
L
C
-U
V
 
T
L
C
 a
n
d
 
H
P
L
C
-U
V
 
V
is
u
al
 
an
al
y
si
s 
B
as
ic
 
p
ac
k
ag
e 
in
sp
ec
ti
o
n
 
P
ac
k
ag
e 
an
d
 
la
b
el
 
V
is
u
al
 
in
sp
ec
ti
o
n
 
M
in
il
ab
®
 
P
ac
k
ag
e 
an
d
 
st
o
ra
g
e 
ar
ea
 
in
sp
ec
ti
o
n
 
N
R
 
T
ab
le
t 
in
sp
ec
ti
o
n
 
N
R
 
B
as
ic
 
p
ac
k
ag
e 
in
fo
rm
at
io
n
 
A
u
th
en
ti
ca
te
 
so
u
rc
e 
N
R
 
N
R
 
O
n
e 
co
m
p
an
y
 
w
as
 
in
v
es
ti
g
at
ed
 
b
y
 c
o
n
ta
ct
 
w
it
h
 l
o
ca
l 
au
th
o
ri
ti
es
 
N
R
 
N
R
 
O
n
e 
q
u
al
it
y
 
re
p
o
rt
 w
as
 
re
q
u
es
te
d
 
fr
o
m
 a
 
m
an
u
fa
ct
u
re
r 
N
R
 
N
R
 
S
am
p
le
 
si
ze
 
6
 
3
6
9
 
4
5
1
 
1
1
6
 
5
0
 
5
2
 
3
3
 
3
3
 
M
ed
ic
in
e(
s)
 
A
n
ti
b
io
ti
c 
am
o
x
ic
il
li
n
 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
A
n
ti
m
al
ar
ia
l 
ta
b
le
t 
an
d
 s
y
ru
p
 
A
n
ti
-T
B
 
A
n
ti
m
ic
ro
b
ia
l 
an
d
 
an
ti
m
al
ar
ia
l 
d
ru
g
s 
A
n
ti
m
al
ar
ia
l 
C
o
u
n
tr
y
 
E
st
o
n
ia
 a
n
d
 
R
u
ss
ia
 
T
h
ai
la
n
d
 
C
am
b
o
d
ia
 
K
en
y
a 
Y
em
en
 
T
h
ai
la
n
d
 
R
w
an
d
a 
an
d
 
T
an
za
n
ia
 
T
an
za
n
ia
 
 
R
ef
er
en
ce
 
B
ro
n
n
ik
o
v
a 
et
 
al
. 
(2
0
0
7
) 
V
ij
ay
k
ad
g
a 
et
 
al
. 
(2
0
0
6
) 
L
o
n
 e
t 
al
. 
(2
0
0
6
) 
A
m
in
 e
t 
al
. 
(2
0
0
5
) 
A
b
d
o
-r
ab
b
o
 e
t 
al
. 
(2
0
0
5
) 
 
R
o
o
k
k
ap
an
 e
t 
al
. 
(2
0
0
5
) 
K
ay
u
m
b
a 
et
 a
l.
 
(2
0
0
4
) 
M
in
zi
 e
t 
al
. 
(2
0
0
3
) 
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Table 3.4 Continued 
 
T
y
p
e 
o
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S
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F
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C
 
p
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b
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L
o
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n
d
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A
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L
o
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P
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L
o
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n
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A
P
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R
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u
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9
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2
 (
4
1
%
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b
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d
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d
 
1
0
%
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b
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d
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d
 
4
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3
 (
3
1
%
) 
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b
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d
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P
h
y
si
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y
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s 
N
R
 
N
R
 
N
R
 
C
h
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y
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H
P
L
C
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V
 
T
L
C
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n
d
  
L
C
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T
L
C
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L
C
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n
d
 
U
V
 
V
is
u
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y
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N
R
 
B
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ic
 
p
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k
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e 
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at
io
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N
R
  
A
u
th
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ti
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te
 
so
u
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e 
N
R
 
N
R
 
N
R
 
S
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p
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si
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2
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7
1
 
1
3
 
M
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A
n
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b
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c 
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d
if
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n
t 
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rm
u
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o
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A
n
ti
-T
B
 
A
n
ti
-T
B
 F
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ed
 
d
o
se
 c
o
m
b
in
at
io
n
 
(F
D
C
) 
C
o
u
n
tr
y
 
N
ig
er
ia
 
7
 d
if
fe
re
n
t 
co
u
n
tr
ie
s 
B
o
ts
w
an
a 
R
ef
er
en
ce
 
O
b
o
d
o
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e 
et
 a
l.
 
(2
0
0
3
) 
L
as
er
so
n
 e
t 
al
. 
(2
0
0
1
) 
K
en
y
o
n
 e
t 
al
. 
(1
9
9
9
) 
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Table 3.5 Prevalence of reported SSFFC problems in some studies 
Continent Country Reference 
Range of SSFFC 
reported problems 
(%) 
Africa Nigeria 
 
Ali et al. (2011) 
 
33%-50% 
  Ochekpe et al. (2010) 6%-38% 
  Onwujekwe et al. (2009)* 37% 
  Taylor et al. (2001)* 7%-48% 
  Shakoor et al. (1997)* 6%-36% 
  Haruna et al. (2013) 25% 
  Ehianeta et al. (2012) 85% 
  Akpabio et al. (2011) 25% 
  Obodozie et al. (2003) 41% 
 Ghana Stanton et al. (2012) 1%-9% 
  Ofori-Kwakye et al. (2008) 6%-65% 
  Affum et al. (2013) 43% 
  El-Duah & Ofori-Kwakye (2012) 93% 
  Klein et al. (2012) 3% 
 Tanzania Risha et al. (2008) 3% 
  Kaur et al. (2008)* 12% 
  Minzi et al. (2003) 36% 
 Burkina Faso Tipke et al. (2008) 1%-42% 
 Congo Atemnkeng et al. (2007) 14%-46% 
  Audu et al. (2013) 30% 
 Cameroon Basco (2004)* 18%-20% 
 Rwanda Twagirumukiza et al. (2009) 20% 
 Kenya Amin et al. (2005) 40% 
 Botswana Kenyon et al. (1999) 31% 
 Multiple countries Bate et al. (2008) 3%-35% 
  Pouillot et al. (2008) 3%-43% 
  Gaudiano et al. (2007) 3%-57% 
  Atemnkeng et al. (2007) 12%-38% 
  Bate & Hess (2010) 23% 
*High quality studies found in Almuzaini et al. (2013) 
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Table 3.5 Continued 
Continent Country Reference 
Range of SSFFC 
reported problems (%) 
Asia Papua New Guinea Nair et al. (2011) 11%-79% 
 
Cambodia Khan et al. (2010) 2%-4% 
  
Khan et al. (2013) 20% 
  
Lon et al. (2006)* 
27% 
 
India Bate et al. (2009a) 2%-8% 
  
Ramachandran et al. (2013) 9% 
  
Seear et al. (2011) 43% 
 
Laos Syhakhang et al. (2004)* 1%-46% 
  
Stenson et al. (1998) 11% 
  
Sengaloundeth et al. (2009) 88% 
 
Myanmar Prazuck et al. (2002) 14%-48% 
 
Thailand Shakoor et al. (1997)* 6%-40% 
  
Fotiou et al. (2009) 23% 
  
Vijaykadga et al. (2006) 6% 
  
Rookkapan et al. (2005) 37% 
 
Bangladesh Dorlo et al. (2012) 100% 
 
Malaysia Said et al. (2011) 0% 
 
Indonesia Hadi et al. (2010)* 18% 
 
Pakistan Leslie et al. (2009) 100% 
  
Obaid (2009) 16% 
 
Yemen Abdo-rabbo et al. (2005) 32% 
 
Multiple countries Dondorp et al. (2004)* 1%-33% 
  
Newton et al. (2001) 38% 
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Kyriacos et al. (2008) 56% 
South America Brazil Nogueira et al. (2012) 44% 
 
Multiple countries Pribluda et al. (2012) 11% 
North America Mexico Karlage et al. (2012) 30% 
Europe Estonia and Russia Moes et al. (2008) 25% 
 
Estonia and Russia Bronnikova et al. (2007) 16% 
*High quality studies found in Almuzaini et al. (2013) 
 
3.4 Discussion 
3.4.1 Neglected parts of the world in SSFFC surveys 
According to our findings, the vast majority of prospective medicine quality studies 
were conducted in small parts of Africa and Asia. These efforts can be attributed to an 
attempt to counteract nonexistent or lower levels of regulation in these pharmaceutical 
markets (WHO, 2010a). However, some parts of these two continents still have limited 
scientific research addressing the problem of SSFFC medicines, mainly in the Middle 
East and North Africa. In Yemen, 32% of selected antimalarial medicines failed 
analysis tests, and the majority of these were substandard, having lower than accepted 
API% limits and unacceptable dissolution rates (Abdo-Rabbo et al., 2005). Another 
study explored the API content of the antibiotic amoxicillin purchased from Egypt, 
Lebanon, Jordan, and Saudi Arabia and found that more than 50% of samples had lower 
API% than accepted by pharmacopeial limits, and therefore were considered 
substandard (Kyriacos et al., 2008). A multicountry medicine quality survey found that 
12% of samples collected from Egypt failed at least one medicine quality test and can 
be considered substandard (Bate et al., 2011). None of these studies reported an attempt 
to verify the source or analyse packages of the selected medicine samples to explore the 
possibility of counterfeiting activity. This may cause some concern, particularly with 
recent seizures of SSFFC medicines in this area. In addition, the currently unsettled 
political situation may be a catalyst for the increased prevalence of SSFFC medicines, 
as it allows them to escape immediate governmental attention (McGinnis, 2013). 
Reports of recent seizures of SSFFC medicines in this area can be mostly found in the 
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media, which remains the main source of information regarding SSFFC medicines in 
this region with limited published scientific reports (McGinnis, 2013). Moreover, a 
WHO report on questionnaire responses from a number of health organisations in the 
Eastern Mediterranean Regional Office regarding counterfeit medicines has confirmed 
counterfeit seizures in this region by some respondent countries (WHO, 2010b). In 
addition, this area could be of specific importance in terms of geographical location, as 
it separates two well-established regions of SSFFC medicine prevalence, according to 
our data, and is en route between potential counterfeit manufacturers in Asia (Newton et 
al., 2008) and their global targeted markets. It is therefore suggested that several pilot 
studies be conducted to survey the quality of medicines in the Middle East and North 
Africa to assess the current medicine quality situation before any countermeasures or 
large-scale medicine quality surveys can be recommended. Elsewhere, in developing 
countries such as India, Pakistan and Thailand, pilot studies have been shown to be 
instrumental in the assessment of the medicine quality situation in different countries 
and to have justified the need for further medicine quality surveys, where appropriate 
(Bate et al., 2013; Bate et al., 2009b; Newton et al., 2001; Obaid, 2009). 
 
Evidence from South America suggests that SSFFC medicines are available, but with 
only limited scientific research. A study found 11% of antimalarials to be substandard 
in seven South American countries using basic TLC chemical analysis (Pribluda et al., 
2012). The TLC analysis technique is limited by its inability to detect higher than 80% 
of API concentration in medicine samples (Bate et al., 2008) which has been evident to 
exist in previous studies (Stanton et al., 2012; Bate et al., 2008; Atemnkeng et al., 2007; 
Prazuck et al., 2002; Stenson et al., 1998; Shakoor et al., 1997; Ramachandran et al., 
2013; Affum et al., 2013; El-Duah & Ofori-Kwakye, 2012; Ehianeta et al., 2012). It is 
therefore possible that the prevalence of SSFFC medicines in South America could be 
higher than the reported figures if more sophisticated chemical techniques for the 
quantification of API% content were used, such as high-performance liquid 
chromatography. Another study reported problems with low API% on a range of 
medicines procured from Mexico; of particular importance are some narrow therapeutic 
index medicines such as warfarin and levothyroxine (Karlage et al., 2012). Two studies 
from Eastern Europe found some problems regarding low API% and dissolution failures 
when a limited number of antibiotics were analyzed in Estonia and Russia (Meos et al., 
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2008; Bronnikova et al., 2007). No studies could be identified that addressed medicine 
quality problems in the Australian continent. 
3.4.2 Neglected noncommunicable medicines in SSFFC surveys 
Most of the studies in this review were found to explore medicines used to treat 
infectious diseases such as malaria and tuberculosis. Medicines used to treat 
noninfectious diseases, also known as noncommunicable disease (NCD) medicines or 
chronic disease medicines, were only found in a few studies that presented some 
medicine quality problems (Stanton et al., 2012; Baratta et al., 2012; Syhakhang et al., 
2004; Said et al., 2011; Haruna et al., 2013; Audu et al., 2012; Karlage et al., 2012; 
Twagirumukiza et al., 2009; Fotiou et al., 2009). However, on a global scale, NCDs and 
their medicines must not be ignored. The WHO estimates that NCDs kill more than 36 
million people each year, of which 29 million deaths (80%) occur in low- and middle-
income countries (WHO, 2013b). The currently available literature on medicine quality 
does not reflect the wider use of NCDs and their medicines globally, including in lower-
income countries. This issue needs to be addressed rapidly, as recent evidence from 
Pakistan reported the death of more than 100 people after the administration of the 
antianginal medicine isosorbide mononitrate contaminated with large amounts of 
pyrimethamine (WHO, 2012b; Nishtar, 2012). Elsewhere, the US Food and Drug 
Administration recently issued warnings regarding counterfeit cancer medicines (FDA, 
2012a, FDA, 2012b). Furthermore, evidence of counterfeiting involving NCD 
medicines such as diabetes treatments were found in illicit or lifestyle drugs, which may 
have significant implications for the public health and could result in death (Kao et al., 
2009; WHO, 2012a; Lung, Gerona, Wu & Smollin, 2012). Therefore, it is 
recommended that we extend the attention of future medicine quality surveys globally 
beyond infectious diseases medicines and on to NCD medicines (and widely available 
treatments of diabetes and cardiovascular diseases in particular), in addition to cancer 
treatments and narrow therapeutics index medicines, as they could have severe health 
implications for the affected population. 
3.4.3 Type of analysis used in SSFFC surveys 
All studies included in this review performed chemical analysis for the identification 
and/or quantification of the API available in selected samples, in accordance with our 
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methodological approach. High-performance liquid chromatography and TLC were the 
most widely used chemical analytical techniques available in the selected articles, 
possibly because of their wide acceptance in the academic field and their application in 
many pharmacopoeial references. It is suggested that this would be a logical and 
possibly important consideration for future scholars interested in conducting medicine 
quality surveys to ensure the acceptance of their findings within the academic field. 
 
Physical analysis tests were performed to complement chemical analysis in 
approximately 2/3 of the selected studies particularly disintegration and dissolution tests 
for solid dosage forms. This can be attributed to the availability of specific physical 
tests in different pharmacopoeias in addition to the use of physical information about 
the medicinal product to predict the bioavailability of medicines (Amin et al., 2005; 
Gaudiano et al., 2007; Rookkapan et al., 2005). However, such physical analysis tests 
could only be used as a bioavailability indicator and cannot substitute lengthy and 
expensive bioavailability studies (Kayumba et al., 2004; Kenyon et al., 1999). 
Moreover, it is important to note that performing physical analysis only on medicinal 
samples can be considered inadequate if the objective of the study was to determine 
medicine quality issues since it cannot be determined if the correct API and its quantity 
is present in medicine samples as specified in the WHO definition of substandard and 
counterfeit medicines (WHO, 1999a; WHO, 2003a; WHO, 2014). 
 
Package inspection is another popular type of medicine analysis that was also found in 
nearly two-thirds of the medicine quality surveys in this review. On the basis of primary 
and secondary package information, the majority of reports seek obvious spelling errors, 
suspicious holograms compared with known genuine samples, and basic label 
misinformation such as medicine name, dosage, manufacturer details, expiry date, and 
lot number (Tables 3.1, 3.2, and 3.4). The WHO definition of counterfeit medicines 
highlights packaging information significance and could have influenced the wide use 
of package information among medicine quality surveys (WHO, 1999a). Furthermore, 
packaging information of medicines has been a valuable mode of analysis in the 
relevant literature and has revealed many counterfeit medicines that have passed 
chemical identification tests (Ali et al., 2011; Bate et al., 2008; Ofori-Kwakye et al., 
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2008). A tool kit developed by the World Health Professions Alliance and the 
International Pharmaceutical Federation for visual inspection of medicines can be used 
for a systematic package inspection by health care professionals and scholars both in 
practice and in future investigative projects (FIP, 2013). 
 
A less common level of analysis available in the literature is the authentication of 
medicine source via contact with the medicine manufacturer and local or international 
health authorities. This systematic review has identified only ten research articles that 
attempted to authenticate the source of the medicine samples (Nair et al., 2011; Khan et 
al., 2010; Tipke et al., 2008; Khan et al., 2013; Lon et al., 2006; Rookkapan et al., 2005; 
Newton et al., 2008; Atemnkeng et al., 2007; Newton et al., 2011; Fotiou et al., 2009). 
Perhaps researchers may not guarantee adequate responses to their queries from other 
parties, as some have suggested (Nair et al., 2011; Khan et al., 2010). It could also be 
possible that authenticating the source may not be within the scope of a particular 
medicine quality survey, as it could be only focused on substandard medicines issue 
(Taylor et al., 2001).  Nevertheless, the WHO definition of counterfeit medicines clearly 
describes the deliberate and fraudulent misrepresentation of the medicine source as a 
characteristic of a counterfeit medicine (WHO, 1999a). Moreover, according to the 
Pharmaceutical Security Institute, counterfeit medicines are currently increasing in 
terms of reported incidences worldwide and can no longer be ignored (PSI, 2014a). It is 
recognised that obtaining authentication confirmation of medicine sources could be 
difficult in studies collecting samples from street markets; however, this task could be 
less complex when samples are collected from pharmacies or hospitals, as official 
records and documentation of medicines are expected to exist. Furthermore, according 
to the limited studies that reported authentication analysis in this review, many 
counterfeit cases were found by confirmation from manufacturers or health authorities 
of a nonauthentic batch of medicines, even if samples contained the correct API when 
chemically analysed (Khan et al., 2010; Atemnkeng et al., 2007; Lon et al., 2006). 
 
Overall, there were very few research articles that performed all four levels of analysis: 
chemical, physical, package inspection, and authentication of source (Nair et al., 2011; 
Khan et al., 2010; Tipke et al., 2008; Khan et al., 2013; Lon et al., 2006; Rookkapan et 
al., 2005). Future medicine quality surveys are advised to consider performing all four 
 71 
types of analysis for a more holistic approach, and equally, to address the possibility of 
finding either counterfeit or substandard medicines during an investigation. Further, it 
was noted that none of the medicine quality surveys examined patient information 
leaflets within medicinal packages to check for accuracy and up-to-date information 
made available to patients. Some studies, particularly in the Middle East, have found 
disagreement between patient information leaflets in some medicine samples when 
compared with national formularies (Gebran & Al Haidari, 2006; Al-Aqeel, 2012). 
Therefore, the addition of patient information leaflets to examination of medicine 
samples in medicine quality survey studies is open for debate among the scientific 
community. 
3.4.4 Prevalence of SSFFC 
Our data suggest that reports of substandard medicines are more widely available in the 
literature, particularly medicines with incorrect API% and failure of 
dissolution/disintegration tests, than counterfeit medicine reports (Tables 3.1–3.4). 
These findings are in line with previous reports that suggested that substandard 
medicines are more prevalent than counterfeits and require more global attention 
(Caudron et al., 2008; Fried, 2011). This phenomenon might be attributed to poor 
manufacturing practices or extreme weather conditions in some countries, accompanied 
by inadequate storage conditions (WHO, 2003a; WHO, 2014; Kyriacos et al., 2008). 
However, because the majority of cited articles in this review did not conduct 
authentication processes via contact with manufacturers and/or health authorities, as 
previously mentioned, medicine counterfeiting remains a possibility that has not been 
largely explored. Hence, considering the available data, it cannot be determined whether 
substandard medicines are indeed more prevalent than counterfeit medicines at this 
time. Future medicine quality researchers are therefore encouraged to remain vigilant 
about counterfeiting possibility and conduct all types of analysis including chemical, 
physical, package inspection, and authentication efforts to determine the type of 
medicine quality problem more accurately. 
3.4.5 Limitations of this review 
This systematic review is not without limitations. Articles conducting chemical analysis 
were a prerequisite for inclusion in this review. It focused only on prospective field 
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quality surveys and excluded reporting of any studies with retrospective or previously 
seized SSFFC medicines in the literature. The rationale for excluding studies with 
retrospective medicine sampling is that they do not imitate natural settings of medicine 
procurement and typically aim to propose new methods of analysis rather than predict 
the prevalence rate of SSFFC in different markets. The Internet source of medicines was 
beyond the scope of our review. Relevant articles from the bibliographical list of 
available studies were only included on some occasions and cannot be considered 
exhaustive. The included articles were not assessed for the quality of their methodology, 
which was found to vary considerably among the selected articles. No attempt was 
made to calculate prevalence rates of SSFFC medicines or test for statistical 
significance, as it would have resulted in the exclusion of most articles from this review, 
as most reported studies used convenience sampling and/or with limited sample size 
(Newton et al., 2009). 
3.4.6 Strengths of this review 
This review has several strengths. To the researcher’s knowledge, it is only the second 
systematic review on the subject of SSFFC medicines. Evidence of SSFFC medicines in 
terms of nature and type of analysis were discussed. This information would most likely 
aid government agencies and health care authorities and scientists interested in the 
medicine quality issues in developing or improving current policies and practices. It was 
the intention of this review to help interested parties identify and describe SSFFC 
medicine problems with up-to-date scientific evidence. Further, this review highlighted 
neglected medicine types and neglected geographical location in terms of scientific 
research addressing SSFFC medicines. This could invite more research projects 
addressing these neglected medicines and geographical locations to improve current 
knowledge on the issue and maintain patient safety. Moreover, this review has 
identified the limited scientific research, conducting field quality surveys on SSFFC 
medicines, using all four levels of analysis, in an attempt to encourage future 
researchers to explore all possibilities when conducting a medicine quality survey in 
any settings. 
 73 
3.5 Conclusion 
The problem of SSFFC medicines is evident worldwide. Potential harm to patients’ 
health requires global collaboration exceeding the status quo. Limited research 
addressing SSFFCC medicines was noted in several parts of the world, including the 
Middle East, North Africa, and Australia. Similarly, more research is required to 
address SSFFC medicines from noncommunicable medicine classes, including narrow 
therapeutic index and chronic medicines, as current scientific knowledge regarding 
these medicines remains limited despite their popularity and media reports of the 
existence of SSFFC medicine problems in such therapeutic classes. Furthermore, the 
current focus of published research on chemical and physical analysis of medicine 
samples could overlook the possibility of counterfeiting if additional steps of analysis 
were performed, including package inspection and authentication of source via contact 
with manufacturers and health authorities. Future medicine quality surveys are 
encouraged to perform all four levels of analysis to explore all possibilities of 
substandard and counterfeit medicines that may be present in their selected sample of 
medicines. Such an approach would be beneficial in determining the type and 
prevalence rate of medicine quality problems in any setting and could consequently 
determine the most appropriate strategies to combat their threats. 
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4 Chapter 4: Glibenclamide quality analysis 
4.1 Background 
 
Poor quality medicines can be defined as medicine with quality problems such as 
counterfeit, substandard or degraded medicines (Newton et al., 2009; Newton et al., 
2011). For generic medicines, others propose that quality problems may also include 
medicines that are not bioequivalent, contain insufficient information in patient 
information leaflet, do not offer substantial price reduction and are not generally 
accepted by patients (Asiri & Al-Yamani, 2006).   
Glibenclamide, also known as glyburide in the United States, is a sulfonylurea oral 
hypoglycemic medicine that stimulates the beta cells’ release of endogenous insulin 
from the pancreas and has been used by Type two diabetic patients for generations 
(Luzi & Pozza, 1997). It has been described as the most extensively used medicine for 
type two diabetic patients in many parts of the globe (Nanovskaya, Nekhayeva, Hankins 
& Ahmed, 2006). 
Despite the perceived low price of glibenclamide, which might not be clearly attractive 
for counterfeiters in terms of price per unit, it could be a target in terms of mass volume 
since counterfeit glibenclamide has been found in Brazil (da Silva Fernandes, da Costa, 
Valderrama, Marco & de Lima, 2012). On other occasions, street drugs have been found 
to contain counterfeit glibenclamide, which resulted in severe health implications on 
some individuals and on extreme cases and may have resulted in their death (Lung et 
al., 2012; Lim et al., 2009). 
4.2 Aim and objectives 
 
The overall aim of this study is to evaluate the quality of glibenclamide medicine 
samples available in the MOI-MSD settings. 
The objectives of this study include: 
1) Establish whether any selected glibenclamide medicine samples fail API 
quantity chemical tests, visual tests and verification of source where possible. 
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2) To describe the nature of any glibenclamide failed samples, if found. 
4.3 Selection of glibenclamide for quality analysis 
 
The consideration was given to a medicine with the highest potential impact on a large 
population in Saudi Arabia. The prevalence of diabetes in Saudi Arabia is estimated to 
be 24% of the adult population, which presents a significant challenge for the 
government (Salman & Al-Rubeaan, 2009; Eledrisi et al., 2007). This is not only in 
provision of health care but also financially. Medicines for the treatment of chronic 
conditions such as diabetes and cardiovascular diseases have been shown to be of high 
volume and demand in MOI-MSD healthcare settings (Table 4.1). Moreover, findings 
of a recent study within MOI hospital found that 16% of diabetic patients receiving oral 
hypoglycemic medicines were unsatisfied with their treatment and 54% of them were 
interested in changing their medicine (Al-Aujan, Al-Aqeel, Al-Harbi & Al-Abdulltif, 
2012). Therefore, the choice of the oral hypoglycemic medicine glibenclamide, which 
had the highest amount of ordered quantities and potential use, was considered for the 
purpose of this study. 
Table 4.1 High-volume diabetes and CV medicines available from GPP tender in the 
MOI-MSD in Saudi Arabia 
Medicine Pharmacological 
Class 
Manufacturer Annual 
order 
(tablet) 
Price per 
tablet 
(USD) 
Total annual 
expenditure 
(USD) 
Glibenclamide 5 
mg tablet 
Sulfonylurea 
Hypoglycemic 
Kuwait Saudi 
(Kuwait) 
8,000,000 0.0062 49,600 
Acetyl Salicylic 
Acid 75-100 mg 
tablet 
NSAID Julphar (UAE) 6,400,000 0.0105 67,200 
Metformin 500 mg 
tablet 
Biguanide 
Hypoglycemic 
Gulf Pharm. 
Ind. (UAE) 
3,500,000 0.0103 36,050 
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Atenolol 50 mg 
tablet 
Beta Blocker National 
Pharm. (Oman) 
1,600,000 0.0065 10,400 
Amlodipine 5 mg 
capsule 
Calcium Channel 
Blocker 
Tabouk (KSA) 1,200,000 0.0065 7,800 
Lisinopril 10 mg 
tablet 
ACE inhibitor Pharma Intl. 
(Jordan) 
1,200,000 0.0093 11,160 
Atorvastatin 10 mg 
tablet 
Cholesterol 
lowering agent 
Tabouk (KSA) 1,100,000 0.0140 15,400 
*Based on MOI-MSD data for medicines available in the year 2013  
4.4 Context of this study (MOI-MSD) 
 
The setting chosen for this study is the MOI-MSD Primary Care Clinics (PCC). There 
are three major primary clinics in Riyadh and 18 PCC in other regions of the country 
that provide healthcare to approximately 2 million patient visits each year (Table 4.2). 
Employees of the MOI and their families are eligible to free healthcare services in these 
PCCs, including free prescription and over the counter medicines. Typically, these 
PCCs are the first point of contact with patients, and any critical cases that require 
further secondary care can be referred to MOI-MSD secondary care hospital in the 
capital city Riyadh. Although both the hospital and PCC serve the same patients, each 
has its own method of medicine procurement. The PCCs generally acquire their 
medicines from the GPP tender, particularly high volume medicine to utilise price 
reductions available through the programme. This joint programme involves 
participants from all ministries of health in the gulf countries and other governmental 
healthcare providers in Saudi Arabia as discussed earlier. Medicines are usually 
delivered from the awarded manufacturer or agent to the MOI-MSD general warehouse 
in Riyadh in two or three shipments throughout the year. It is then distributed to all 
PCCs around the country. Therefore, it was thought that the MOI-MSD general 
warehouse in Riyadh would be an ideal location for sample collection as it serves as the 
first point of receiving of medicines from the manufacturers before distribution to all 
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PCCs around the country. Table 4.2 lists all MOI-MSD PCC in Saudi Arabia according 
to their region and illustrates the number of annual patient visits at each site. Appendix 
3 further demonstrates the location of MOI-MSD PCC in different regions on the 
geographical map of Saudi Arabia. 
Table 4.2 MOI-MSD primary care clinics statistics (official 2014 statistical report 
currently in publishing) 
Location City or PCC name Annual number of 
patients 
Percentage of all PCC 
patients 
Riyadh city 
 
Riyadh Polyclinics 
Training City 
Security College 
 
13704 
23935 
100195 
0.7% 
1.2% 
5% 
Central Region Alkharj 34725 1.8% 
 Hail 69634 3.5% 
 Qassim 
 
111570 5.6% 
Northern Region Aljouf 101803 5.1% 
 Alqoriat 43656 2.1% 
 Northern Borders 99267 5% 
 Tabouk 
 
58340 3% 
Western Region Jeddah 137197 7% 
 Medina 153984 7.8% 
 Mecca 205771 10.3% 
 Taif 
 
99003 5% 
Eastern Region Ahsa 123971 6.2% 
 Dammam 
 
115444 5.9% 
Southern Region Albaha 87151 4.3% 
 Asir 93183 4.7% 
 Bisha 79433 4% 
 Jizan 159700 8% 
 Najran 76423 3.8% 
           Total                                    1988089              100% 
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4.5 Sample size 
 
Different sample sizes were used in the relevant literature, usually depending on the 
scope of each study and the resources available to the researchers (Appendix 4). 
Typically, countries with established scientific evidence of medicine quality problems 
require a larger sample size from different locations. Moreover, studies with the aim of 
quantifying the prevalence rate of substandard or counterfeit medicines would require 
an increased number of samples with an appropriate sampling method. Nevertheless, 
studies reporting randomised sampling are scarce while the vast majority of published 
articles employ sample selection based on convenience (Newton et al., 2009). 
The general warehouse in Riyadh is the primary point of receiving medicines from 
different manufacturers before they are distributed to all MOI primary care clinics in 
Saudi Arabia. For the purpose of this study, at least five different samples of each 
available batch number were collected from the MOI-MSD general warehouse in 
Riyadh. This will allow for any natural variation between different batches from the 
same manufacturer (Phanouvong & Blum, 2004). The WHO guidelines for sampling 
medicines states that collecting a single sample from a single batch would be adequate 
if they were from the same manufacturer, had the same batch number, had official 
documentation and were in sufficient quantities to conduct the required analytical tests 
(WHO, 2005). Furthermore, four additional glibenclamide samples from four different 
pharmaceutical manufacturers were conveniently collected from different community 
pharmacies in Najran for comparison purposes. 
4.6 Materials and Methods 
4.6.1 Chemical structure of glibenclamide 
 
 
Figure 4.1 Chemical structure of glibenclamide 
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4.6.2 Glibenclamide sampling  
 
To achieve these study objectives, a quantitative research approach using a cross-
sectional survey method was adopted.  Fifteen glibenclamide samples were collected 
overtly from the MOI-MSD general warehouse in Riyadh on one occasion only. 
Different brand names and batch numbers of glibenclamide available within the 
warehouse were identified electronically from available warehouse records and visually 
on site prior to data collection. Additionally, four different samples representing various 
batch numbers of four different glibenclamide manufacturers were conveniently 
obtained from community pharmacies in Najran in a two-month period between August 
and September 2014. The research collaborator was asked to covertly collect different 
samples from different community pharmacies in Najran. Four samples were collected 
from different community pharmacies that were selected at first sight from each area in 
Najran. Each community pharmacist was not aware of the purpose of the medicine 
purchase as the collaborator was instructed to ask to purchase the medicine for a relative 
without a prescription. None of the community pharmacists declined the purchase 
request. The covert collection of samples from community pharmacies using a mystery 
shopper technique was chosen based on similar studies widely available within the 
literature (Shakoor et al., 1997; Minzi et al., 2003; Atemnkeng et al., 2007; Bate et al., 
2008; Tipke et al., 2008; Bate et al., 2009). Thus, a total number of 19 glibenclamide 
samples were available for analysis in this study. 
Samples were collected from the MOI-MSD general warehouse on the 22nd August 
2013 on a hot summer afternoon (12.30 pm) where temperatures were reported to reach 
43 degrees Celsius. The researcher had previously contacted the MOI-MSD healthcare 
administration for this arrangement and agreed upon an appropriate time and date for 
the sample collection. Only one glibenclamide manufacturer was found in the 
warehouse with three different batch numbers available. Both electronic records as well 
as visual inspection confirmed this finding. The glibenclamide medicines were kept on 
fifteen different wooden pallets arranged in parallel positions. All the glibenclamide 
pallets were stored on the top shelves available in the warehouse. Hence, it was 
necessary for warehouse workers to assist the researcher with the collection of the 
required samples from the top shelves using a forklift truck (Appendix 5). This strategy 
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for sample collection was chosen to ensure the safety of the researcher in unfamiliar 
settings as well as minimising their selection bias. The warehouse workers were 
instructed by the researcher throughout the sampling procedure, except for the selection 
of the final medicine sample package from the medicine box row, where they were 
instructed to choose randomly at their preference. Each pallet contained 24 boxes while 
each box contained 144 sample units of medicines each containing 100 tablets/unit of 
package. Based on these calculations, the approximate number of glibenclamide sample 
units available for collection was 51,840 glibenclamide packages each containing 100 
tablets of 5 mg glibenclamide concentration.  
As previously mentioned, at least five different samples of each batch number were 
collected from the general MOI warehouse in Riyadh, in addition to the availability of 
at least 30 tablets/capsules in each sample to facilitate all necessary analysis tests 
similar to previous studies conducted by US pharmacopeia on medicine quality tests 
(Phanouvong & Blum, 2004). This allowed for any natural variation between different 
batches of the same manufacturer with a minimum number of sample size requirements 
and was in line with the WHO guidelines for medicine sampling (WHO, 2005).  
 
A random strategy based on a systematic approach was employed to collect the samples 
from MOI warehouse. Pallets with different batch numbers (batches number 77, 89 and 
90) were observed and recorded by the researcher. The objective was to collect five 
samples from each batch number for batch representation. When the batch number was 
represented by only one pallet (batch number 90), counting downwards each third row 
available in the pallet was selected for medicine box sampling. Also, counting from the 
left, each third medicine box was selected from the chosen pallet row. Each selected 
medicine box was then opened and the warehouse worker was instructed to select a 
medicine sample (package of 100 tablets) at his preference. Similarly, when batch 
numbers were represented by more than one pallet (batch number 77 had 3 pallets and 
batch number 89 had 11 pallets) a similar strategy was employed in addition to the 
selection of each third pallet counting from the left. When the count returned back to a 
previously chosen pallet and row, the third medicine box following our previously 
opened medicine box was chosen for sampling to include a wider representation of 
samples. The selected fifteen samples were then kept in plastic bags arranged in a box 
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where they were kept in room temperature and away from light for one week before 
being sent via a logistic company to the United Kingdom for analysis 60 days after 
collection. All sample documents were kept with the researcher at all times.  
4.6.3 Glibenclamide chemical analysis 
The chemical analysis for this study was performed using HPLC methods based on the 
findings from the systematic review (Chapter 3) and what the SFDA would routinely 
use to analyse medicines.  
4.6.3.1 Duration and time 
The chemical analysis process in this study started in November 2013 and the initial 
analysis was completed within three months for the samples collected from MOI-MSD 
general warehouse. The samples collected from Najran were analysed in a two-month 
period between September and October 2014.  
4.6.3.2 HPLC analysis process  
The HPLC analysis process for glibenclamide 5 mg (known as glyburide in the USA) 
was performed according to the latest United States Pharmacopoeial guidelines (USP 
36) at the time of analysis (Appendix 6). Each sample was divided into 3 HPLC vials 
and run against reference sample in duplicate. The mean API% of each sample was then 
calculated according to the following equation: 
Result = (rU/rS) × (CS/CU) × 100 
rU = peak response from the sample solution 
rS = peak response from the standard solution 
CS = concentration of USP glyburide RS in the standard solution (mg/mL) 
CU = nominal concentration of glyburide in the sample solution (mg/mL) 
The acceptance criteria was 90-110% according to USP limits. 
4.6.3.3 HPLC system 
Shimadzu Autosampler SIL-20A/20AC  
SIL-20AHT/20ACHT prominence High Performance Liquid Chromatograph  
4.6.3.4 Chromatographic system 
Mode: isocratic reversed phase LC 
Detector: UV 254 nm 
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Column: 3.0×50 mm XTerra® RP18 3.5µ  
Mobile phase: Ammonium dehydrate phosphate buffer (pH= 5.25)/acetonitrile (450:550 
% v/v) 
Flow rate: 0.25 mL/min 
Sample run time: 15 min 
Injection size: 10 µL  
4.6.3.5 Preparation of mobile phase 
Ammonium dihydrogen phosphate (2.6 g) was weighed and dissolved in 450 ml of 
deionised water. The solution was then transferred into a volumetric flask and shaking 
dissolved all powder. Then, 550 ml of acetonitrile was added to the solution, which was 
then filtered and degassed. The pH meter was used to measure the pH concentration 
prior to attachment to the HPLC system. The process was repeated twice throughout the 
experiment as required and on both occasions no pH adjustments were necessary as 
both readings fulfilled USP requirements of 5.25 ± 0.3 (5.29 and 5.46 respectively). 
4.6.3.6 Preparation of reference sample (standard solution) 
USP glyburide RS powder (10 mg, Sigma-Aldrich) was weighed and transferred into a 
25 ml volumetric flask. Then, 20 ml of acetonitrile were added into the volumetric flask 
and shaken to dissolve. Subsequently, 4 ml of deionised water were added to the 
solution and then transferred to a HPLC vial for analysis following completing up to 
flask volume with a proportional mixture (25 ml Acetonitrile/5 ml deionised water). 
4.6.3.7 Preparation of sample solution 
Twenty tablets from each sample (equivalent to 100 mg glibenclamide) were crushed, 
weighed and transferred to a 250 ml volumetric flask. Then, 40 ml (equivalent to 0.4 
mg/mL glibenclamide) of deionised water were added to the volumetric flask and the 
solution was swirled until complete dispersion. Subsequently, 200 ml (equivalent to 2 
mg/mL glibenclamide) was added then the solution was shaken for 30 minutes. The 
sample solution was then centrifuged (8000 RPM for 10 minutes) and the clear 
supernatant was transferred to 3 coded HPLC vials for analysis following completing up 
to flask volume with a proportional mixture (100 ml Acetonitrile/20 ml deionised 
water). This process was repeated for each sample in this study. 
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4.6.3.8 Selection of 20 tablets to be analysed in each sample 
Fifteen samples of glibenclamide 5 mg tablet (pack of 100 tablets) collected from MOI-
MSD warehouse were all from a single manufacturer and with 3 different batch 
numbers. Each batch number was therefore represented by 5 packs. Each glibenclamide 
sample package contained 10 blister packs and each pack containing 10 tablets. It was 
possible to code each blister pack with a batch number and a blister pack number in 
order to select 2 random blister pack (20 tablets) from each sample. The randomisation 
was performed through a software www.randomizer.org to generate two random 
numbers for each batch (Appendix 7). This process was also performed for the other 
four samples collected from Najran community pharmacies for comparative purposes. 
4.6.4 Glibenclamide visual analysis  
Visual inspection included medicine package checks for obvious errors and 
misspellings, missing package information (medicine name, dose, ingredients and 
manufacturer name and address) as well as the general appearance of medicine tablets. 
A draft data collection form adopted from two tool kits developed by The WHPA and 
FIP for visual inspection of medicines was utilised for this purpose (FIP, 2013). The 
tool included the sample code and name, package size, expiry date, collection date, 
package and tablet inspection, price, registration and results from the chemical test. 
4.6.5 Glibenclamide authentication of source 
Official records or communication with the manufacturer can determine the 
authentication of the source of each medicine sample. Since our study settings were 
mainly governmental primary care clinics, official medicine reception records were 
utilised to verify that each medicine sample has indeed been received from their 
manufacturers directly. Other authentication methods exist in the literature such as 
communicating with the manufacturer by telephone or e-mail, although the literature 
suggests that responses from companies cannot be always guaranteed (Khan et al., 
2010; Nair et al., 2011). For the purpose of this study, official documents of reception 
have been collected and considered as sufficient evidence of product authenticity 
(Appendix 8). Hence, contact with the pharmaceutical manufacturers to verify the 
source of medicines was not necessary. 
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4.7 Results 
 
The results of the chemical HPLC analysis of glibenclamide samples indicated the 
presence of the correct active pharmaceutical ingredient within the USP acceptance 
limits between 90-110% as shown in Table 4.3, when compared with the reference 
glibenclamide sample. An example of a sample and reference chromatograms can be 
found in Figures 4.2 and 4.3 respectively.  
 
Figure 4.2 Example of glibenclamide batch 90 sample one first run chromatogram 
 
Figure 4.3 Example of glibenclamide reference chromatogram 
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Table 4.3 Summary of API concentration found in glibenclamide samples 
 
Sample 
name 
Weight 
of 20 
tablets 
(g) 
Peak 
response 
from 
sample 
{Mean 
(SD)} 
Peak 
response 
from 
standard 
 {Mean 
(SD)} 
Sample 
concentration 
(mg/mL) 
Standard 
concentration 
(mg/mL) 
API 
concentration 
(%) 
Sample 
status 
B77S1 3.1532 7555123 
(23539.38) 
3342591 
(851.356) 
0.9041 0.4000 100.00% Accepted 
B77S2 3.1713 7570157 
(15436.64) 
3342591 
(851.356) 
0.9059 0.4000 99.99% Accepted 
B77S3 3.1423 7431540 
(63521.16) 
3342591 
(12822.6) 
0.8893 0.4000 100.00% Accepted 
B77S4 3.2164 7544297 
(31739.65) 
3376532 
(12822.6) 
0.8937 0.4000 99.99% Accepted 
B77S5 3.2345 7636824 
(74821.16) 
3376532 
(12822.6) 
0.9046 0.4000 99.99% Accepted 
B89S1 3.2321 7802229 
(30190.24) 
3376532 
(2174.35) 
0.9180 0.4000 99.99% Accepted 
B89S2 3.2380 7695240 
(14215.46) 
3358398 
(2174.35) 
0.9165 0.4000 100.00% Accepted 
B89S3 3.2153 7730118 
(13216.29) 
3358398 
(6827.82) 
0.9206 0.4000 99.99% Accepted 
B89S4 3.2361 7783437 
(7015.60) 
3358398 
(6827.82) 
0.9270 0.4000 100.00% Accepted 
B89S5 3.2932 7953606 
(10018.03) 
4660425 
(6827.82) 
0.6826 0.4000 99.99% Accepted 
B90S1 3.2736 7871610 
(18649.04) 
4660425 
(17134.6) 
0.6756 0.4000 100.00% Accepted 
B90S2 3.2203 7729021 
(9348.38) 
4660425 
(17134.6) 
0.6633 0.4000 100.00% Accepted 
B90S3 3.3022 7793337 
(5703.25) 
4638998 
(25065.5) 
0.6719 0.4000 100.00% Accepted 
B90S4 3.2720 7903040 
(1097.10) 
4638998 
(25065.5) 
0.6814 0.4000 100.00% Accepted 
B90S5 3.2586 7914560 
(6097.34) 
4638998 
(9157.03) 
0.6824 0.4000 100.00% Accepted 
B3KT90 3.2122 7880760 
(37668.13) 
4695007 
(6512.17) 
0.6714 0.4000 99.99% Accepted 
B5872 3.8239 7690646 
(81932.87) 
4695007 
(6512.17) 
0.6552 0.4000 99.99% Accepted 
B71231 3.2380 8117232 
(23138.97) 
4657379 
(32116.5) 
0.7604 0.4000 91.67% Accepted 
BCT412 3.2807 7957436 
(87868.17) 
4657379 
(32116.5) 
0.7461 0.4000 91.59% Accepted 
 
An example of the calculation of the API concentration in samples is shown below: 
USP Formula to calculate percentage of glyburide in samples: 
Sample Area/Standard Area x Standard Concentration/Sample Concentration x 100 
USP acceptance limit between 90-110% 
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Sample area: peak reading of API from the chromatogram  
Standard area: peak reading of API from the chromatogram 
Standard concentration: 10 mg of glyburide powder in 25 ml solution of water and 
acetonitrile that is equal to 0.4000 mg/ml 
Sample concentration: calculated by the formula: 
Sample Area/Standard Area x Standard Concentration 
 
Example Batch 77 sample number one: 
Sample area: 7546344 
Standard area: 3342591 
Standard concentration: 10 mg reference powder in 25 ml solution = 0.4000 mg/ml 
Sample concentration: = Sample Area/Standard Area x Standard Concentration 
                                     = 7546344/3342591 x 0.4000 mg/ml 
                                     = 2.2576 x 0.4000 mg/ml 
                                     = 0.9030 mg/ml 
 
Then by applying the USP acceptance formula: 
Sample Area/Standard Area x Standard Concentration/Sample Concentration x 100 
= 7546344/3342591 x 0.4000/0.9030 x 100 
= 2.2576 x 0.4429 x 100 
= 99.99% (accepted) 
 
Furthermore, the visual analysis of glibenclamide medicine packages and the tablets did 
not reveal any unacceptable features, when examined according to the WHPA/FIP tool. 
Moreover, when the official documents of receiving glibenclamide batches delivered to 
the MOI-MSD were compared with the actual batches available at the MOI-MSD 
general warehouse, no discrepancies were found and were thus considered authentic and 
from the original manufacturing source. 
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4.8 Discussion 
This study has identified the presence of the API in acceptable limits according to USP 
methods within glibenclamide medicine samples collected from MOI-MSD warehouse 
in Riyadh an community pharmacies in Najran in Saudi Arabia. Moreover, the visual 
analysis and authentication of source analysis were also performed and found to be 
acceptable in the MOI-MSD glibenclamide samples. These findings are reassuring, 
particularly with the growing evidence of global medicine problems, specifically with 
API quantity and identity as found in our systematic review of the literature (Chapter 3). 
Therefore, the subsequent parts of this study examined the perceptions of MOI-MSD 
stakeholders about medicine quality and their problem in order to explore the 
phenomena from a different and a social perspective.  
Within the context of Saudi Arabia, this study was the first to examine glibenclamide 
API in Saudi Arabia. It did not identify any unacceptable quantities of API, as was 
found in previous studies that found such problems with amoxicillin in community 
pharmacies in Riyadh in Saudi Arabia (Kyriacos et al., 2008; Khoja et al., 2013a). This 
could be attributed to the different settings between these studies or the different API 
examined. Furthermore, these encouraging findings were similar to pharmacopoeial 
analysis studies that were performed in Saudi Arabia on other medications such as 
metformin (Afifi & Ahmadeen, 2012) that found them to contain the correct amount of 
API according to USP pharmacopoeial specifications. 
There are several limitations that can be identified in this study. The cross-sectional 
survey design of the study would only permit relevance of the findings to a specific 
location and time. Further, glibenclamide was procured by the MOI-MSD healthcare 
services from a joint tender programme (GPP) which awards most medicines to 
different pharmaceutical companies each year, based on price competition. This would 
prove problematic if additional samples were required at a later time to confirm findings 
from this study.  
The sample size in this study was determined based on similar small-scale studies 
conducted by the USP convention to analyse medicines in the absence of solid scientific 
evidence that would suggest a medicine quality problem at a particular location 
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(Phanouvong & Blum, 2004) and the WHO guidelines for sampling of pharmaceutical 
products (WHO, 2005). Examples of the sample size used in similar studies can be 
found in Appendix 4. Therefore, the findings from this study may not be generalisable. 
However, it can be suggested that a larger scale study over few procurement cycles 
could validate findings of this study.  
Furthermore, the random strategy of sampling was mostly based on a systematic 
approach, where possible. However, for the final medicine selection from the medicine 
box, the warehouse worker performed the task, as it was not visible to the researcher 
from his standpoint. The time allowed for the medicine sample collection by the 
warehouse management would not permit for physical movement of pallets using a 
forklift truck to lower ground. Future medicine collection strategies could be performed 
in a systematic approach including the final medicine package selection particularly if 
present on lower shelves, where they can be visible to the principle researcher.  
Moreover, some limitations are associated with the HPLC chemical analysis method 
used to test the API itself and not other medicine components such as excipients. The 
HPLC tests were performed to measure the API quantity only based on the findings 
from the previous study (Chapter 3) and previous studies in Saudi Arabia that have only 
found problems with API quantity (Kyriacos et al., 2008; Khoja et al., 2013a). It was 
not possible to conduct chemical identification tests, physical analysis tests or to 
confirm the authentication of source in samples collected from the community 
pharmacies in Najran since it was not one of the objectives of the study and could have 
compromised the covert collection of these samples by simulating everyday costumers 
in these settings. 
The chromatograms obtained from the HPLC tests in this study (Figures 4.2 and 4.3) 
illustrated an unexpected peak in addition to the peak response from the sample and the 
reference chromatograms. It is possible that the second unexpected peak could be a 
result from degradation or deterioration of the samples used in the HPLC analysis. 
Existing literature supports this possibility as glibenclamide impurities such as related 
compound A (sulphonamide impurity) and related compound B (carbamate impurity) 
have been found in similar glibenclamide chromatograms (Sudha, Krishna & Kumar, 
2014). Additionally, degradation may have also affected the two samples from Najran 
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(samples B71231 and BCT412) as they were found to contain a borderline API 
percentage content when compared with the USP acceptance criteria.  
This phase of the study was considered a learning process for the principal researcher, 
as he is not a pharmaceutical analyst and his prior knowledge about such 
pharmaceutical analysis techniques was limited. Within this context, the laboratory 
examination of the samples in this phase of the study may have not been as rigorous as 
what is performed in the pharmaceutical industry. Additionally, system suitability tests 
were not performed in this phase of the study due to an oversight at the beginning of the 
analysis process and when it was addressed at later stages of the study, it was found to 
be associated with additional financial costs and therefore was not performed. However, 
although the system suitability tests were not performed, the resolution of the 
chromatograms was clear and the peaks obtained appeared to be sufficiently separated 
across all the results obtained from the chemical analysis. Moreover, only duplicate 
results were obtained from each sample and therefore the number of analysis 
replications may not be significant. However, the analysis of two samples from Najran 
were repeated with minimal differences in the results since they were found to contain 
less API than the other samples albeit within the accepted USP limits. It is possible that 
this finding could have been associated with unknown storage conditions of the samples 
collected from Najran as they were collected and sent to the UK by a research 
collaborator rather than the principal researcher.  
4.9 Conclusion 
Glibenclamide samples collected from MOI-MSD warehouse and community 
pharmacies in Najran in Saudi Arabia were found to be within acceptable USP API 
limits. The samples from MOI-MSD were found to be visually acceptable in terms of 
the medicine package itself and the tablets. Furthermore, it was possible to authenticate 
the source of the available glibenclamide samples at the MOI-MSD warehouse through 
cross-examination with the official consignment reception documents available. The 
finding of this study will be compared with other studies which explore the 
stakeholders’ perception about medicine quality and related issues within MOI-MSD 
settings in the next phase of the study. 
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4.10 Ethical considerations 
 
The medicine samples collected from all settings were coded and no 
brand/manufacturer name was revealed in the thesis in order to minimise the possibility 
of commercial use of the findings of this study. All official records and hardcopy data 
collected were in the possession of the researcher at all times or otherwise stored in a 
lockable storage area. With the possible exception of individual names appearing on 
official documents, no other people could be identified in this study. If medicine quality 
problems were detected after analysis, the MOI healthcare services would have been 
notified immediately of the findings of this study to protect patients from possible 
threats to their health. Since the medicine collection sites were mostly at a government 
setting, it was unlikely that the researcher would have been in any danger while 
collecting the samples.  The Ethics committee at the University of Hertfordshire, Health 
and Human Sciences ECDA in the United Kingdom has reviewed and approved this 
study (Appendix 9). 
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5 Chapter 5: A systematic review of perceptions about 
medicine quality and related problems 
5.1 Introduction  
Medicines with quality problems can be either counterfeit or substandard according to 
the World Health Organisation (WHO) classification (WHO, 2003a). A counterfeit 
medicine is charecterised by a deliberate and fraudulent mislabeling of the identity 
and/or source of the medicine itself or its packaging (WHO, 1999a). Substandard 
medicines, on the other hand, are legitimate medicines in terms of identity or source, but 
do not meet the required specification in terms of content and ingredients, as a result of 
poor manufacturing or storage conditions (WHO, 2003a; WHO, 2012a; Heyman & 
Williams, 2011; Yankus & Marks, 2009; Wertheimer & Norris, 2009; Clift, 2010). 
Collectively, both counterfeit and substandard medicines have been referred to as poor 
quality medicines by some researchers (Newton et al., 2010; Nayyar et al., 2012) and 
Substandard/Spurious/Falsely-labeled/falsified/counterfeit medicines (SSFFC) by the 
WHO (WHO, 2012a). 
 
The threat from counterfeit and substandard medicines to society could be on different 
levels. More than 700,000 deaths from TB and malaria worldwide have been associated 
with ineffective treatment from counterfeit or substandard medicines (Cockburn et al., 
2005; Mackey & Liang, 2011). Other examples of related fatal incidents include heparin 
contamination in the United States and adulterated life style drugs in Singapore (Kao et 
al, 2009; Luhn et al., 2011; Davison, 2011; Holzgrabe & Malet-Martino, 2011). 
Moreover, substandard and counterfeit medicines could lead to economic consequences 
such as loss of productivity, waste of limited resources and mitigating investments into 
pharmaceutical research and development (Moken, 2003; Yankus & Marks, 2009; 
Wertheimer & Norris, 2009). Furthermore, counterfeit and substandard medicines could 
lead to loss of confidence in healthcare organisations and their staff (Cockburn et al., 
2005; Amin & Kokwaro, 2007; Wertheimer & Norris, 2009; Mackey & Liang, 2011; 
Kyriacos et al., 2008).  
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The true extent of the problem of counterfeit and substandard medicines remains largely 
unknown. However, the WHO estimates that around 10% of the global pharmaceutical 
supply is counterfeit and/or substandard: a figure that could reach up to 50% in 
developing countries and as low as 1% in the developed countries (Cockburn et al., 
2005; Heyman & Williams, 2011; Ziance, 2008). Moreover, scientific research has 
addressed the problem of counterfeit and substandard medicines in the analysis of 
medicine samples collected from different countries. Detailed accounts of such studies 
can be found in systematic reviews elsewhere (Almuzaini, et al., 2013; Alghannam, et 
al., 2014). 
 
The research into medicine quality and related problems has been largely focused on the 
actual quality of the medicine itself, demonstrated by laboratory testing (Patel et al., 
2010). A detailed systematic review on non-laboratory research into counterfeit and 
substandard medicines is not available. The aim of this systematic review was to 
explore the existing scientific research on counterfeit and substandard medicines from a 
non-laboratory perspective. Specifically, the objective was to identify research articles 
addressing the views, perceptions and knowledge about counterfeit and substandard 
medicines from different stakeholders’ perspectives. The results obtained from this 
systematic review helped the researcher in identifying the knowledge gaps in 
perspectives of stakeholders on counterfeit and substandard medicines and designing 
the next stage of the study. 
5.2 Method 
Scopus, PubMed, CINAHL Plus and MEDLINE databases were searched for relevant 
research articles. Our search covered all available periods up to 31st August 2015 and no 
language restrictions were applied. The following key search terms were used in 
conjunction with (AND) to identify related articles: 
1- Substandard or counterfeit or “poor quality” 
2- Medicine or drug or pharmaceutical 
3- View or opinion or understanding or knowledge or experience or perception 
This systematic review was performed in accordance with Preferred Reporting Items for 
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Systematic Reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews 
(Moher et al., 2009). The inclusion criteria included articles that reported views, 
opinions or experiences of different stakeholders towards medicine quality and related 
problems such as counterfeit or substandard medicines from the selected databases and 
bibliography lists. In contrast, the exclusion criteria included articles investigating the 
actual quality of medicines through laboratory testing only, articles with no social 
contact with different stakeholders, duplicate and non-relevant articles.  One reviewer 
(AFG) initially searched the selected databases and screened the titles/abstracts to 
exclude irrelevant and duplicate studies. Then, two reviewers (AFG and ZA) 
independently evaluated the remaining abstracts for possible inclusion. Any 
disagreement was resolved by discussion with the remaining authors (SE and FS).  
The risk of bias in individual studies was addressed by performing a quality assessment 
on the selected studies. The quality of qualitative studies was assessed using 
Consolidated Criteria for reporting qualitative research (Tong, Sainsbury & Craig, 
2007) with the addition of four criteria from the critical appraisal skills programme tool 
(CASP, 2013), namely having a clear aim, appropriate methods for the aim, ethical 
considerations and contribution to knowledge and future research as demonstrated in 
Table 5.1. The qualitative studies that scored between 0 to 12 were considered poor 
quality, between 13 to 24 were considered medium quality and studies that scored 
between 25 to 36 were considered high quality studies. Moreover, the quality of 
quantitative studies was assessed using a tool adapted from the STROBE statement 
(STROBE, 2007) with the addition of one criterion concerning ethical considerations as 
demonstrated in Table 5.2. The quantitative studies that scored between 0 to 10 were 
considered poor quality studies, between 11 to 20 were considered medium quality and 
studies that scored between 21 to 30 were considered high quality quantitative studies. 
Furthermore, the quality of mixed-method studies was assessed independently 
corresponding to their qualitative and quantitative components since there is a lack of an 
agreed, valid and reliable quality instrument in such mixed methods studies (O’Cathain, 
Murphy & Nicholl, 2008). The scoring system for the mixed methods studies was 
similar to the qualitative and quantitative studies scoring systems as previously 
described.  
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Table 5.1 Criteria for quantitative studies based on STROBE statement 
Domain Item number Criterion 
Title and abstract 1 
Indicate the study’s design with a commonly used term in the title or the 
abstract 
 
2 
Provide in the abstract an informative and balanced summary of what was 
done and what was found 
Introduction 3 
Explain the scientific background and rationale for the investigation being 
reported 
 
4 State specific objectives, including any prespecified hypotheses 
Methods 5 Present key elements of study design early in the paper 
 
6 
Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
 
7 
Give the eligibility criteria, and the sources and methods of selection of 
participants 
 
8 
Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers.  
 
9 
For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if 
there is more than one group 
 
10 Describe any efforts to address potential sources of bias 
 
11 Explain how the study size was arrived at 
 
12 
Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
 
13 
Describe all statistical methods, including those used to control for 
confounding 
 
14 Describe any methods used to examine subgroups and interactions 
 
15 Explain how missing data were addressed 
 
16 
If applicable, describe analytical methods taking account of sampling 
strategy 
 
17 Describe any sensitivity analyses 
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Results 18 Report numbers of individuals at each stage of study 
 
19 Give reasons for non-participation at each stage 
 
20 Give characteristics of study participants 
 
21 
Indicate number of participants with missing data for each variable of 
interest 
 
22 Report numbers of outcome events or summary measures 
 
23 
Give unadjusted estimates and, if applicable, confounder-adjusted estimates 
and their precision 
 
24 Report other analyses done 
Discussion 25 Summarise key results with reference to study objectives 
 
26 
Discuss limitations of the study, taking into account sources of potential bias 
or imprecision. Discuss both direction and magnitude of any potential bias 
 
27 
Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
 
28 Discuss the generalisability (external validity) of the study results 
Other 
Information 
29 Give the source of funding and the role of the funders for the present study 
 
30 Discuss ethical approval of the study 
 
Table 5.2 Criteria for qualitative studies based on Consolidated Criteria for Reporting 
Qualitative Studies and CASP tool 
Domain Item 
number 
Criterion 
Researcher’s information 1 Specified who conducted the study 
 
2 Credentials 
 
3 Occupation 
 
4 Gender 
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5 Experience and training 
 
6 Relationship with participants 
 
7 Participants’ knowledge about the researcher 
 
8 Interviewer characteristics 
Study design and data 
collection 
9 Methodology orientation and theory described 
 
10 Sampling strategy described 
 
11 Approach described 
 
12 Sample size stated 
 
13 Non-participants described 
 
14 Clearly described data collection settings  
 
15 Presence of non-participants during data collection 
 
16 Description of sample 
 
17 Description of the interview guide 
 
18 Indicate if any interviews were repeated 
 
19 Describe type of recording of interviews 
 
20 Describe if field notes were used 
 
21 Indicate the duration of interviews 
 
22 Address data saturation 
 
23 Indicate if transcripts were returned to participants 
Data analysis 24 Indicate who coded the data 
 
25 Description of the coding process 
 
26 Describe the derived themes 
 
27 Software used in the analysis where possible 
 
28 Participants’ feedback on findings discussed 
 
29  Participants’ quotes present in the themes 
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30 Data and findings consistent 
 
31 Clear major themes 
 
32 Clear minor themes 
Other Information 33 Clear aim for the study 
 
34 Appropriate methods for the aim 
 
35 Discuss ethical approval of the study 
 
36 Contribution to knowledge and future research 
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5.3 Results 
5.3.1 Search results 
The use of the selected search terms resulted in a total of 1,598 hits from all databases. 
An initial screening of titles/abstracts followed this, excluding non-relevant and 
duplicate results to reduce the number of hits to 120 research articles. Non-relevant 
articles included research conducted on quality of care, quality of life as well as 
research on non-pharmaceuticals. Subsequently, a full review of articles was performed, 
which further excluded studies that performed chemical analysis of samples only, 
review articles and opinion or letters where no primary data were collected. 
Furthermore, a manual search of bibliography lists was performed to include any 
relevant studies. This strategy reduced the final number of the included articles to 
sixteen. Figure 5.1 represents a flowchart illustrating the method used for article 
selection in this review. 
 
 
 
Figure 5.1 Flowchart for article inclusion in the second systematic review 
Key search terms:  
Substandard or Counterfeit AND  
Medicine or Drug or Pharmaceutical AND 
View or opinion or understanding or knowledge 
or experience or perception 
 
Potentially relevant 
articles (n=120)  
Studies included (n=16)  
All identified hits 
(n=1598)  
PubMed database: 228 hits 
Scopus database: 705 hits 
CINAHL Plus database: 76 hits 
MEDLINE database: 589 hits 
• Review title, abstract and keywords 
• Exclude duplicates (n=94) 
• Exclude non-relevant titles (n=1384)  
• Full review of articles 
• Exclude opinion, letters, debates etc. (n=45) 
• Exclude reviews (n=16) 
• Exclude articles with only laboratory analysis (n=29) 
• Exclude further non-related articles (n=9) 
• Include article from bibliography search (n=2) 
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5.3.2 Description of studies included  
The search yielded a total of sixteen relevant articles. Seven studies (Dunne et al, 
2014a; Dunne et al, 2014b; Lai & Chan, 2013; Binkowska-Bury et al., 2012a; 
Binkowska-Bury et al., 2012b; Law & Youmans, 2011; Håkonsen & Toverud, 2011) 
were conducted in high-income countries according to the World Bank categorisation 
(The World Bank, 2015). Six studies (Shahverdi et al., 2012; García et al., 2011; Patel 
et al., 2010; Patel et al., 2009; Sharrad et al., 2011; Patel et al., 2012) were in upper-
middle income countries. Two studies were identified (Alfadl et al., 2013; Syhakhang et 
al., 2004) in lower-middle income countries and one study (Khan et al., 2011) in a low-
income country. Geographically, five studies (Dunne et al, 2014a; Dunne et al, 2014b; 
Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b; Håkonsen & Toverud, 
2011) were conducted in Europe. Five studies (Lai & Chan, 2013; Shahverdi et al., 
2012; Sharrad et al., 2011; Syhakhang et al., 2004; Khan et al., 2011) were located in 
Asia. Four studies (Alfadl et al., 2013; Patel et al., 2010; Patel et al., 2009; Patel et al., 
2012) were found in Africa. One study (Law & Youmans, 2011) was located in North 
America and one study (García et al., 2011) in South America. 
 
Studies included in this review were found to have different aims. Seven studies (Lai & 
Chan, 2013; Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b; Law & 
Youmans, 2011; Shahverdi et al., 2012; Alfadl et al., 2013; Khan et al., 2011) had 
counterfeit medicines as the aim of their research. Four studies (Patel et al., 2010; Patel 
et al., 2009; Patel et al., 2012; Syhakhang et al., 2004) were exploring medicine quality 
in general. Four studies (Dunne et al, 2014a; Dunne et al, 2014b; Håkonsen & Toverud, 
2011; Sharrad et al., 2011) were assessing generic medicine perceptions. One study 
(García et al., 2011) investigated antimicrobial resistance and prescribing. In terms of 
stakeholders involved, ten studies (Dunne et al, 2014b; Lai & Chan, 2013; Binkowska-
Bury et al., 2012a; Binkowska-Bury et al., 2012b; Håkonsen & Toverud, 2011; Patel et 
al., 2010; Patel et al., 2009; Sharrad et al., 2011; Patel et al., 2012; Syhakhang et al., 
2004) involved patients and/or medicine consumers. Five studies (Dunne et al, 2014a; 
Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b; García et al., 2011; Patel 
et al., 2012) were conducted with physicians. Five studies (Alfadl et al., 2013; 
Shahverdi et al., 2012; Law & Youmans, 2011; Syhakhang et al., 2004; Patel et al., 
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2012) involved pharmacists and three studies (Binkowska-Bury et al., 2012a; 
Binkowska-Bury et al., 2012b; Patel et al., 2012) involved nurses. Furthermore, some 
studies were conducted with other stakeholders such as a lawyer (Lai & Chan, 2013), 
health policy makers (Alfadl et al., 2013), a custom officer (Lai & Chan, 2013), 
pharmaceutical company representatives (Lai & Chan, 2013; Patel et al., 2009) and 
wholesalers and/or distributors (Khan et al., 2011; Patel et al., 2009). 
5.3.3 Quality assessment results 
Seven studies (Dunne et al, 2014a; Lai & Chan, 2013; Alfadl et al., 2013; Patel et al., 
2009; Patel et al., 2010; Sharrad et al., 2011; Patel et al., 2012) included in this review 
had a qualitative design. Of these, the majority used semi-structured interviews (Dunne 
et al, 2014a; Lai & Chan, 2013; Alfadl et al., 2013; Patel et al., 2009; Sharrad et al., 
2011; Patel et al., 2012) and some used focus group methods (Patel et al., 2010; Patel et 
al., 2012) to collect their data. The number of participants in these qualitative studies 
ranged from 5 to 73. Overall, the quality of the qualitative studies in this review was 
average. All qualitative studies were of medium quality with the exception of two high-
quality studies (Patel et al., 2009; Patel et al., 2010). The main shortcomings were 
identified within the research team and reflexivity domain, where two studies (Dunne et 
al, 2014a; Lai & Chan, 2013) did not identify the person who conducted the interviews 
and only one study (Patel et al., 2009) described the researcher’s experience and 
training in qualitative studies. For the research design domain, three studies (Lai & 
Chan, 2013; Patel et al., 2009; Patel et al., 2012) did not specify their methodological 
orientation and theory. All studies indicated the sampling procedure which was 
predominantly purposeful. Only three studies (Dunne et al, 2014a; Lai & Chan, 2013; 
Patel et al., 2009) disclosed information about non-participants and/or their reason for 
not taking part in the studies. The majority of qualitative studies clearly indicated the 
duration of data collection with the exception of two studies (Sharrad et al., 2011; Patel 
et al., 2012). Three studies (Dunne et al, 2014a; Alfadl et al., 2013; Sharrad et al., 2011) 
did not indicate whether the data transcripts/summaries were communicated back to the 
participants for comments and/or corrections. Only three studies (Dunne et al, 2014a; 
Alfadl et al., 2013; Sharrad et al., 2011) discussed data saturation in their studies. 
Moreover, within the analysis and findings domain, only two studies (Dunne et al, 
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2014a; Sharrad et al., 2011) clearly described the coding procedure and only one study 
(Patel et al., 2012) sought participant feedback on the study findings.  
 
There were five studies (Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b; 
Law & Youmans, 2011; Shahverdi et al., 2012; García et al., 2011) which adopted a 
quantitative cross-sectional design in this review. The quality of all these studies was 
found to be medium with only one high-quality study (García et al., 2011) excluded. 
The number of participants ranged from 155 to 1,455 in these studies. All studies 
indicated the study design and had a balanced summary of what had been done and 
found with the exception of one study (Law & Youmans, 2011). Similarly, all 
quantitative studies clearly described the participant eligibility criteria with one 
exception (Shahverdi et al., 2012). None of the studies discussed bias potential in their 
method section. Moreover, none of the studies explained how the sample size was 
calculated with only one exception (García et al., 2011). Missing data and participants’ 
reasons for non-participation were not discussed in any of the included studies. All 
studies discussed the limitations, interpretation, generalisability and ethical 
considerations with one exception  (Shahverdi et al., 2012). 
 
Four studies (Dunne et al., 2014b; Håkonsen & Toverud, 2011; Syhakhang et al., 2004; 
Khan et al., 2011) were found to have a mixed-method design. However, only two 
studies (Dunne et al., 2014b; Syhakhang et al., 2004) clearly stated a mixed-method 
design for their study and only one study (Dunne et al., 2014b) justified the selection of 
a mixed-method design for their research. The quality of these mixed method studies 
was varied. Only one study (Syhakhang et al., 2004) had high quality in both the 
qualitative and quantitative components of the study. Another study (Dunne et al., 
2014b) was found to be of medium quality in both the qualitative and quantitative parts. 
The remaining two studies were found to be of poor quality in the qualitative part 
(Håkonsen & Toverud, 2011; Khan et al., 2011) and ranged between medium quality 
(Håkonsen & Toverud) and high quality (Khan et al., 2011) in the quantitative part of 
the mixed method studies. Further details about these studies can be found in the Tables 
(5.3-5.5). 
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5.3.4 Knowledge about medicine quality 
Several criteria have been found to define medicines with good quality according to 
different stakeholders’ perceptions found in some studies. Having a good effect with 
minimal side effects was a key character of a good quality medicine according to 
patients in South Africa (Patel et al., 2010), patients and nurses in Lao PDR (Syhakhang 
et al., 2004) and both consumers and healthcare professionals in South Africa (Patel et 
al., 2012). Another reported perceived characteristic of a high quality medicine is that it 
should be a medicine that is expensive and from a well-known manufacturer, according 
to the opinion of urban customers and nurses in Lao PDR (Syhakhang et al., 2004). 
Additionally, medicine quality has been described in terms of the medicine itself and 
the manufacturing and handling processes involved with it in the opinion of different 
healthcare providers, pharmaceutical company representatives, wholesalers and 
distributers in South Africa (Patel et al., 2009). In contrast, the definition of counterfeit 
medicines has been reported in two studies (Alfadl et al. 2013; Khan et al., 2011). A 
counterfeit medicine has been described as a medicine entering the country from illegal 
channels and having different standards to the previously approved specifications, 
according to some healthcare commissioners in Sudan (Alfadl et al. 2013). Furthermore, 
managing executives of Cambodian wholesalers defined a counterfeit medicine as an 
unregistered product, fraudulently manufactured, containing less than stated active 
pharmaceutical ingredient, without batch or lot number, containing harmful substances 
and expired medicines (Khan et al., 2011). 
 
The knowledge and awareness about the scale of counterfeit medicines has been found 
in some studies (Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b; 
Shahverdi et al., 2012). One study found that the physicians and nurses in Poland had 
less awareness about the scale of counterfeit medicines and the threats they posed when 
compared to lay people (Binkowska-Bury et al., 2012a). A similar study found that lay 
people had slightly lower awareness about counterfeit medicines in comparison to 
physicians and nurses in Poland (Binkowska-Bury et al., 2012b). Pharmacists in Iran 
were also found to have low knowledge about counterfeit medicines (Shahverdi et al., 
2012). 
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5.3.5 Perceptions about medicine quality 
Two studies investigated the perception about medicine quality in general in South 
Africa (Patel et al., 2012) and Lao PDR (Syhakhang et al., 2004). All healthcare 
providers in the study conducted in South Africa thought that medicine quality was 
good in their country (Patel et al., 2012). Most nurses (80%) and customers (62%) held 
the belief that all medicines in Lao PDR were of a good quality (Syhakhang et al., 
2004). However, there were some results that suggested a degree of confusion between 
medicine quality problems and other pharmaceutical issues. For instance, 12% of the 
GPs (Dunne et al., 2014a) and 24% of patients (Dunne et al., 2014b) in Ireland held the 
view that generic medicines were of poor quality. Some consumers in South Africa 
shared similar views that generic medicines are of inferior quality (Patel et al., 2010; 
Patel et al., 2012). In Peru, one study (García et al., 2011) found that 57% of physicians 
who participated in the study were of the opinion that the generic antibacterial 
medicines in their own settings were of poor quality. Medicines from China and India 
were also perceived as poor quality medicines by some healthcare providers in South 
Africa (Patel et al., 2012). Furthermore, some studies reported the perception that 
generic medicines are counterfeit or fake. In one study 25% of recruited Pakistani 
participants living in Norway thought that generic medicines were counterfeit 
(Håkonsen & Toverud, 2011). Another study (Patel et al., 2012) found that some 
customers in South Africa believed that cheaper generics were fake medicines. 
5.3.6 Practice to ensure medicine quality 
Few studies (Patel et al, 2009; Khan et al., 2011) discussed specific strategies to ensure 
medicine quality in their settings. Patel et al (2009) identified procurement from 
licensed suppliers, use of standard operating procedures and audits as key strategies to 
ensure medicine quality. More than 50% of medicine wholesalers in a Cambodian study 
(Khan et al., 2011) indicated that they would consider the local registration status, 
credibility of the product and reputation of the manufacturer during procurement. They 
would also consider intactness of medicines, their specification, local registration, batch 
and/or lot number and the name of the manufacturer during the reception of medicine 
consignments.  
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Barriers to practices to ensure medicine quality and associated challenges were also 
identified in some studies. Lack of communication with authorities regarding medicine 
quality problems and appropriate feedback were reported in two studies (Law & 
Youmans, 2011; Patel et al., 2009). Lack of resources and the use of online pharmacies 
were identified in one study (Law & Youmans, 2011). In another study, Shahverdi et al. 
(2012) found a low practice level in Iranian pharmacists towards counterfeit medicines, 
particularly in attending educational courses about them. Furthermore, two studies in 
Poland (Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b) found that the 
majority of their responding physicians and nurses did not know the procedure to report 
suspicious medicines. However, Law & Youmans (2011) report that 52% of Californian 
pharmacists in the United States who responded to their questionnaire indicated that 
they would report encountering a counterfeit medicine to the FDA, board of pharmacy 
or their headquarters. Lenient penalties for medicine counterfeiters were also identified 
as a challenge to ensuring medicine quality (Lai & Chan, 2013). 
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Table 5.3 Characteristics of studies that used thematic analysis of data 
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Table 5.4 Characteristics of studies that used monovariate and bivariate analysis of data 
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Table 5.5 Characteristics studies that used combination of thematic analysis and 
monovariate or bivariate analysis of data 
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Table 5.6 Unifying themes and contributing subthemes from stakeholders’ papers 
 
 
Theme Subtheme Reference 
Definition of a good quality 
medicine 
Registered by authorities Patel et al. (2009) 
Syhakhang et al. (2004) 
 Has good effect Syhakhang et al. (2004) 
Patel et al. (2009) 
Patel et al. (2010) 
Patel et al. (2012) 
 Has original colour Syhakhang et al. (2004) 
 Expensive medicines Syhakhang et al. (2004) 
Definition of a counterfeit 
medicine 
A medicine from illegal source Alfadl et al. (2013b) 
Khan et al. (2011) 
 Has different standards to registered products Alfadl et al. (2013b) 
Khan et al. (2011) 
 Non-registered medicine Khan et al. (2011) 
 Expired medicines Khan et al. (2011) 
Strategies to ensure medicine 
quality 
Procurement from licensed suppliers Patel et al. (2009) 
 Use of standard operating procedures Patel et al. (2009) 
 Audits between manufacturers and providers Patel et al. (2009) 
 Check medicine registration status Khan et al. (2011) 
 Consider manufacturer’s reputation Khan et al. (2011) 
 Visual check of labeling information Khan et al. (2011) 
 Check analytical certificates Khan et al. (2011) 
Barriers  and concerns to 
medicine quality 
Communication and reporting Patel et al. (2009) 
Patel et al. (2012) 
Binkowska-Bury et al. 
(2012a) 
Binkowska-Bury et al. 
(2012b) 
Law & Youmans (2011) 
 Generic and free medicines perceived as inferior 
in quality 
Patel et al. (2010) 
Patel et al. (2012) 
Dunne et al. (2014b) 
Dunne et al. (2014a) 
Garcia et al. (2011) 
Håkonsen & Toverud 
(2011) 
Sharrad et al. (2011) 
Syhakhang et al. (2004) 
 Generic medicines perceived as counterfeit Håkonsen & Toverud 
(2011) 
Patel et al. (2010) 
 Developing countries perceived as manufacturing 
inferior quality medicines 
Patel et al. (2012) 
 Generic medicines perceived as less monitored 
than brand medicines 
Patel et al. (2012) 
 Lack of education about counterfeit medicines Alfadl et al. (2013b) 
Shahverdi et al. (2012) 
Binkowska-Bury et al. 
(2012a) 
Binkowska-Bury et al. 
(2012b) 
Law & Youmans (2011) 
 Penalties to counterfeiters are lenient Lai & Chan (2013) 
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5.4 Discussion 
Research articles were found from twelve different countries including South Africa 
(Patel et al., 2009; Patel et al., 2010; Patel et al., 2012), Poland (Binkowska-Bury et al., 
2012a; Binkowska-Bury et al., 2012b), Ireland (Dunne et al., 2014a; Dunne et al., 
2014b), Hong Kong (Lai & Chan, 2013), Sudan (Alfadl et al., 2013), Iraq (Sharrad et 
al., 2011), Iran (Shahverdi et al., 2012), Peru (García et al., 2011), USA (Law & 
Youmans, 2011), Norway (Håkonsen & Toverud, 2011), Lao PDR (Syhakhang et al., 
2004) and Cambodia (Khan et al., 2011). However, no studies were found in higher 
income countries in the western parts of Asia, Australia and South America. Similarly, 
no studies were found in European countries from the middle and low-income group. 
Evidence from Africa was only found in the middle-income group and no African 
studies were found in the high or low-income groups. Furthermore, the included studies 
were found to have different aims and objectives. The majority of included studies (Lai 
& Chan, 2013; Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b; Law & 
Youmans, 2011; Shahverdi et al., 2012; Alfadl et al., 2013; Khan et al., 2011) focused 
their research on counterfeit medicines. Some studies (Patel et al., 2010; Patel et al., 
2009; Patel et al., 2012; Syhakhang et al., 2004) had a general explorative aim of the 
understanding of medicine quality. Interestingly, we found few articles with other aims 
and objectives such as perceptions of generic medicines (Dunne et al, 2014a; Dunne et 
al, 2014b; Håkonsen & Toverud, 2011; Sharrad et al., 2011) and one study (García et 
al., 2011) explored antimicrobial resistance and prescribing. This finding suggests that a 
degree of confusion between such subjects and medicine quality problems is possible 
from the perspective of different stakeholders. Furthermore, it was possible to arrange 
the outcomes from this systematic review into three categories concerned with 
knowledge and awareness of medicine quality and their problems, perceptions about 
medicine quality and practices to ensure medicine quality. 
 
Knowledge about medicine quality appears to be limited when considered in terms of 
the number of cited studies in literature, exploring the issue and their results. It appears 
that medicine quality is commonly comprehended by its perceived effect for both 
patients (Patel et al., 2010; Patel et al., 2012) and healthcare professionals (Patel et al., 
2009; Patel et al., 2012; Syhakhang et al., 2004). A high quality medicine was also 
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linked with having a higher price according to other findings (Syhakhang et al., 2004; 
Alfadl et al., 2013). However, it is widely accepted that a high quality medicine should 
be defined according to its fulfillment of pharmacopoeial specifications (Quick et al., 
1997; Patel et al., 2009). This view can also be extended to include all related activities 
and services that could affect the quality of medicines (WHO, 2004). Examples of such 
criteria include: that the medicine is registered with healthcare regulators and has a 
correct label that clearly identifies the name of the medicine, the strength, lot number, 
expiry date, instructions for use and the manufacturer’s address (WHO, 1997; 
Syhakhang et al., 2004). 
 
Counterfeit medicines have also been described as medicines without registration and 
entering the market illegally (Alfadl et al., 2013; Khan et al., 2011). Other descriptors of 
counterfeit medicines found include fraudulent manufacturing, having less than stated 
active pharmaceutical ingredient, containing harmful substances and missing some 
packaging details (Khan et al., 2011). These views closely resemble the WHO definition 
of counterfeit medicines which highlights issues of packaging and product identity 
and/or source (WHO, 1999). However, both studies (Alfadl et al., 2013; Khan et al., 
2011) were conducted with healthcare commissioners and wholesaler executives. No 
study was found that explored the understanding of counterfeit medicines within 
healthcare professional staff and the members of the community.   
 
Evidence from some of the cited studies suggests a possible confusion between generic 
medicines and poor quality medicines, or even counterfeits. Some healthcare 
professionals, physicians in particular, have been reported to have a perception that 
generic medicines are of poor quality (Dunne et al., 2014a; García et al., 2011; Patel et 
al., 2012). Patients could also share some of these views of the inferior quality of 
generic medicines according to some studies (Dunne et al., 2014b; Patel et al., 2010). 
Furthermore, it has been reported that some patients could have the perception that 
generic medicines are counterfeit or fake (Håkonsen & Toverud, 2011; Patel et al., 
2012). Such perceptions could have a negative impact on generic medicine prescription 
and use for all different stakeholders. Therefore, it is imperative to extend the research 
into understanding the perceptions about medicine quality problems to gain more 
insight about the scale of confusion between generic medicines and poor quality or 
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counterfeit medicines in various contexts. Furthermore, it is possible to use public 
health campaigns as a means of educating the healthcare professionals and public about 
medicine quality and their problems in order to minimise the magnitude and effect of 
such confusion (Po, 2001; Syhakhang, 2004). 
 
There were a limited number of cited articles that addressed specific practices 
implemented to ensure medicine quality. Practices in the medicine procurement phase 
were found to emphasise the reliability of source and the registration status of the 
medicines as key strategies to ensure the quality of a medicine (Patel et al., 2009; Khan 
et al., 2011). Other considerations during medicine procurement included the use of 
standard operating procedures and audits (Patel et al., 2009). The practices during the 
reception of medicine consignments focused on the investigation of the medicine 
package in terms of appearance and the information included (Khan et al., 2011). It has 
been established that medicine quality should be ensured throughout the medicine cycle 
starting from manufacturing, procurement, storage and distribution (WHO, 2007). 
However, none of the cited articles explored the practices during the manufacturing, 
storage and distribution phases of the medicine cycle. It could be interesting to explore 
such reports about practices in future research and compare it with the actual practice in 
an observational study. 
 
This systematic review has several strengths. To the researcher’s knowledge, this was 
the first systematic review examining the stakeholders’ perception about medicine 
quality and related problems such as counterfeit and substandard medicines. A 
comprehensive literature search, use of stringent inclusion and exclusion criteria, and 
the use of recognised methods from the literature to assess the quality of included 
studies was followed to locate relevant studies and extract the necessary data. The 
extracted information from this systematic review could be beneficial in raising the 
awareness of healthcare authorities, industries and interested researchers about the 
perception of medicine quality and related problems such as counterfeit and substandard 
medicines in order to design appropriate strategies to enhance medicine safety, 
accessibility and use. 
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Findings from this systematic review should not be interpreted without considering its 
limitations. The systematic review nature of this study would only allow for observation 
of trends rather than their causes from the available data. There was a diverse range of 
study designs in the included studies that could introduce the possibility of bias. The 
search process was limited by the search strategy used in this review in terms of the 
selected databases, keywords, and inclusion and exclusion criteria. This review was 
limited to the available data found in studies from only twelve countries, which could 
limit the generalisability of findings. However, the limited number of identified studies 
would suggest that further research is needed on the subject. Furthermore, it was found 
that there was some degree of integration between the perceptions of medicine quality 
problems with the perception of generic medicines in some of the studies included. 
However, the aim was to focus the search on perceptions of medicine quality and their 
problems and, therefore, the findings do not claim to include all perceptions regarding 
generic medicines particularly the bibliographic lists from the relevant research articles. 
Furthermore, there was a degree of difficulty in the quality assessment of studies using a 
mixed-method design. It has been suggested that there is an absence of an agreed, valid 
and reliable measure for the quality assessment of mixed methods studies (O’Cathain et 
al., 2008; Twyman, Bonevski, Paul & Bryant, 2014). Hence, recognised methods to 
evaluate the quantitative and qualitative components independently for each included 
mixed methods study was used in an attempt to evaluate their quality overall.  
 
 
 113 
5.5 Conclusion 
Evidence about perceptions, practices and knowledge of medicine quality and their 
problems remains limited. The quality of the available research articles was mostly 
moderate. A high quality medicine was commonly defined in terms of perceived effect 
by healthcare professionals and patients. Other reported criteria of a high quality 
medicine included expensive price, manufacturing and handling of the medicine itself. 
Counterfeit medicines were defined as medicines from illegal sources, non-registered 
and with inaccurate product specifications. Some confusion was found between the 
issues of generic medicines and poor quality medicines including counterfeits. The 
reported practices to ensure medicine quality focused on the procurement and the 
reception of consignment phases. Further in-depth research into the subject of 
perceptions, practices and knowledge of medicine quality and their problems is required 
in order to gain further insight into the phenomenon and their prevalence in different 
contexts. Such insights could be helpful in identifying gaps in knowledge about the 
issue and help in designing appropriate strategies to increase the stakeholders’ 
knowledge and awareness about medicine quality problems and to minimise confusion 
with other issues such as generic or cheaper medications that could affect their 
availability and use. 
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6 Chapter 6: Stakeholders’ perception about medicine quality 
and related issues in the MOI-MSD in Saudi Arabia 
This chapter consists of five phases. Phase 1 explores the scope of stakeholders’ 
perceptions and developing questions about medicine quality and related problems for 
subsequent phases of the study through conducting a focus group. Phase 2 explores the 
MOI-MSD commissioners’ perceptions about medicine quality and related problems 
through interviews. Phase three examines the MOI-MSD patients’ perceptions about 
these issues by interviews. Phases 4 and 5 explores the MOI-MSD pharmacists’ and 
physicians’ perceptions about these issue by a questionnaire survey and interviews. A 
flowchart (Figure 6.1) illustrates an overall view of this chapter.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Flowchart illustrating phases of stakeholders’ perception about medicine 
quality and their problems study in MOI-MSD in Saudi Arabia 
Stakeholders’ perceptions about medicine quality and 
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6.1 Introduction to stakeholders’ perceptions about medicine quality 
Medicine quality problems can either be counterfeit or substandard according to the 
WHO (WHO, 2003a). A counterfeit medicine is defined as a medicine that is 
deliberately and fraudulently mislabeled in terms of identity and/or source according to 
the WHO definition (WHO, 1999a). Substandard medicine can be defined as a 
legitimate medicine from a legitimate source that demonstrates a degree of unacceptable 
standards when compared with the required specifications (WHO, 2003a; WHO, 2014). 
Both types of medicine quality problems could lead to undesired effects on the public 
health, the economy and damage trust between healthcare providers and beneficiaries. 
For example, more than 700,000 deaths from TB and Malaria around the world were 
strongly associated with poor quality medicines (Cockburn et al., 2005; Mackey & 
Liang, 2011). Counterfeit and substandard medicines were also responsible for several 
reported deaths in the USA and Singapore (Kao et al, 2009; Luhn et al., 2011; Davison, 
2011; Holzgrabe & Malet-Martino, 2011). Economically, counterfeit and substandard 
medicine could result in wasting limited resources and causing unnecessary financial 
burdens associated with inadequate treatment and patient hospitalisations (Yankus & 
Marks, 2009; Wertheimer & Norris, 2009). Furthermore, counterfeit and substandard 
medicines may cause loss of faith and trust in healthcare providers in a degree that 
exceeds the medicines themselves to include other healthcare practices (Cockburn et al., 
2005; Amin & Kokwaro, 2007; Wertheimer & Norris, 2009; Mackey & Liang, 2011; 
Kyriacos et al., 2008). 
 
Traditionally, the quality of medicines has been established through laboratory testing 
of medicine samples in comparison with various pharmacopoeial requirements (Patel et 
al., 2010). The findings from a systematic review conducted previously (Chapter 5) 
suggested that limited research has been conducted to understand medicine quality and 
their problems from the perspectives of different stakeholders and in non-laboratory 
settings.  
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6.2 Overall aim of stakeholders’ perception study 
The overall aim of this chapter was to explore the commissioners’, healthcare providers’ 
and patients’ perspectives on medicine quality and related issues such as counterfeit and 
substandard medicines in the MOI-MSD in Saudi Arabia.  
6.3 Objectives of stakeholders’ perception study 
The specific objectives of this study included the following: 
 Establishing stakeholders’ beliefs and views about medicine quality and their 
problems. 
 Explore the stakeholders’ knowledge and behaviour about medicine quality and 
any related problems. 
 Investigate potential improvements to the existing policies and procedures to 
address the issue of medicine quality problems in Saudi Arabia within the 
context of the global market.  
6.4 Methods used in stakeholders’ perception study 
A mixed-method approach was adopted in this study. Triangulation by the use of 
different techniques for data collection and analysis to examine a single research 
problem was implemented in different phases in this study (Strauss & Corbin, 1990). 
Qualitative interviews helped to achieve an in-depth exploration of answers to the 
research questions from the perspective of healthcare professionals and patients. 
Quantitative survey questionnaires were useful in the estimation of the extent of such 
beliefs, views, knowledge and behaviour among healthcare professionals in MOI-MSD. 
Collectively, the use of both qualitative interviews and quantitative survey 
questionnaires increased the understanding of the patients’ and healthcare professionals’ 
perceptions about medicine quality and their problems in the MOI-MSD in Saudi 
Arabia. The sampling techniques used in this study included convenience sampling in 
the Saudi Arabian pharmacists’ focus group and healthcare providers’ interview phases, 
purposeful sampling in the commissioners’ interview phase and random sampling in the 
health care providers’ survey questionnaire phase. 
 
The qualitative data analysis was based on thematic approaches in this study. In the 
focus group phase, themes were generated using a method adopted from Krueger & 
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Casey’s (2009) steps for focus group data analysis. It involved data transcription, 
familiarisation and arrangement of participants’ quotes in a specific order based on pre-
determined questions to categorise data into themes. The analysis of interview data in 
this study was based on Strauss & Corbin’s (1990) steps for interview data analysis. 
This approach involved data transcription, translation, familiarisation, assignment of 
initial codes, establishing connections between the codes and identifying themes and 
sub-themes after cross-examination of codes across all interviews.  
6.5 Ethical approval for stakeholders’ perception study 
The Ethics committee at the University of Hertfordshire, Health and Human Sciences 
ECDA in the United Kingdom has reviewed and approved this study (Appendix 9). The 
MOI-MSD has also issued similar letters of permission to conduct this study with their 
staff and patients (Appendices 10 and 11). All participants in this study were provided 
with participant information sheet to explain the purpose of the study and their 
confidentiality and/or anonymity rights, where applicable, prior to their recruitment 
(Appendices 12, 13 and 14). Furthermore, participants were reminded of their right to 
withdraw from the study at any time without the necessity to provide any explanation. 
All participants in the focus group and subsequent interview phases of the study were 
provided with consent forms (Appendices 15 and 16) entailing the previously 
mentioned conditions in order to obtain their signature for agreement to participate in 
this study prior to the start of the data collection process at each phase.  
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6.6 Phase 1: Scope of stakeholders’ perceptions about medicine quality 
and their problems in Saudi Arabia 
6.6.1 Introduction 
Based on the findings from a previous systematic review (Chapter 5), limited research 
has addressed the issue of medicine quality and their problems from the perspectives of 
different stakeholders worldwide. It has also been found that some studies have 
addressed the issue of perspectives about medicine quality in general while other studies 
have focused on the perspectives about counterfeit medicines problem. However, none 
of the studies examined the perspectives of stakeholders about medicine quality in 
general and medicine quality problems such as counterfeit medicines concurrently. 
Furthermore, no studies were identified that explored the perspectives of any 
stakeholders about medicine quality and their problems in Saudi Arabia.  
6.6.2 Aim  
The overall aim of this study was to explore the scope of stakeholders’ perceptions on 
medicine quality and related issues such as counterfeit and substandard medicines in 
Saudi Arabia in order to inform subsequent survey questionnaire and interview studies.  
6.6.3 Objectives 
The specific objectives of this study included the following:  
 Establish pharmacists’ beliefs and views about medicine quality and their 
problems.  
 Explore their knowledge and behaviour about medicine quality and any related 
problems. 
 Seek pharmacists’ views on potential improvements that can be made to the 
existing policies and procedures to address the issue of counterfeit and 
substandard medicines in Saudi Arabia within the context of the global market. 
 Identify Arabic words used to describe counterfeit and substandard medicines.  
 The addition and deletion of questions for the survey questionnaire and 
interview studies to be used in the next phases of the study. 
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6.6.4 Methods 
6.6.4.1 Recruitment of participants 
The initial sample frame for this phase of the study consisted of twelve qualified Saudi 
Arabian pharmacists conducting postgraduate MSc and PhD studies during the 
academic year 2013/2014 at the University of Hertfordshire. No more than twelve 
invitations in total were sent for participant recruitment to address the possibility of 
attendance of all invited participants in this single group discussion and also the 
possibility of a low response rate. As a prerequisite for student acceptance on the MSc 
programme, candidates were required to have a minimum of one-year’s practical 
experience. Similar requirements of practical experience were also obligated by Saudi 
Arabian governmental employers before sponsoring their staff to pursue postgraduate 
studies. However, it should be highlighted that the sampling approach in this phase of 
the study was based on convenience and therefore could be bias towards the opinions of 
the participants who agreed to participate in this phase of the study.    
6.6.4.2 Question design and order 
The questions for this phase of the study were exclusively open-ended and were 
developed following the systematic review (Chapter 5) and a specific literature research 
of interview guides and questionnaire samples found in relevant articles (Syhakhang et 
al., 2004; Patel et al., 2009; Khan et al., 2011; Law & Youmans, 2011; Alfadl et al., 
2012; Patel et al., 2012; Binkowska-Bury et al., 2012a; Shahverdi et al., 2012) with the 
addition of some questions to address the aim and objectives of this phase of the study. 
Two academic members of staff at the University of Hertfordshire tested the questions 
for face validity. Appendix (17) contains the focus group schedule that includes the 
questions used for this phase of the study and Appendix (18) includes the demographic 
information sheet collected from the participants. 
6.6.4.3 Data collection and study setting 
A single focus group session was conducted in English in December 2013 and was 
completed within 93 minutes. Demographic and consent forms were completed by 
participants before the group discussion started. The group discussion was conducted 
within the Pharmacy Department at the University of Hertfordshire. This specific 
location was selected based on it is familiarity and accessibility to all participants. In 
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addition, the selected meeting room was equipped with video/audio recording 
equipment to facilitate data collection. The round table discussion was conducted with 
the use of a projector and a flipchart where the assistant moderator, also the supervisor 
of this study, recorded key points. The group meeting started with the research team 
introduction, appreciation of attendance and participants’ round of introduction. 
Questions were asked to facilitate the group discussion regarding the topic of this 
research (Appendix 17). Then, the researcher delivered a short presentation to the 
participants in order to describe the phenomena of counterfeit and substandard 
medicines, as well as to outline the aim and objectives of the overall research study at 
the end of the meeting. This was followed by two questions asking the participants to 
translate the words “counterfeit” and “substandard” into Arabic. The meeting was then 
concluded with the appreciation for participants’ involvement in this study. 
6.6.4.4 Data analysis 
A systematic strategy based on Krueger & Casey’s (2009) steps to analyse focus group 
studies was adopted. The researcher transcribed the entire focus group session verbatim, 
then watched the videotape of the session while reading the written transcript for 
assertion and familiarisation with data. Multiple Microsoft Word documents were 
created to keep the original transcription, including a cut and paste document and an 
analysis document where similar quotes were collected together. Each quote was 
arranged in a suitable category, based on a specific decision-making process, by 
answering some questions. Subsequently, a summary of answers to each question was 
made without any interpretation at this stage. A scan of the summary of answers was 
followed to identify emerging themes to be used to report the findings regardless of the 
questions initial order. The data was left for a couple of days and then revisited in order 
to obtain an insight into the bigger picture of the findings and to conclude the analysis. 
The written report was then completed by adding no more than three quotes per theme 
as evidence of what had been said in the focus group session. The addition of the 
researcher’s interpretation to the findings of the study was added at this stage and 
comparison of data made with the available literature to conclude the data analysis. 
Figure 6.2 illustrates the process of data analysis in this phase of the study. 
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Figure 6.2 Strategy for data analysis for the scope of stakeholders’ perceptions about 
medicine quality and problems in Saudi Arabia adopted from Krueger and Casey (2009) 
6.6.5 Results 
6.6.5.1 Participants’ characteristics 
Five participants attended the focus group discussion phase of this study. The overall 
response rate was 42.6 % (5 participants from 12 invited individuals). The participants 
were all Saudi Arabian pharmacists and included three male and two female 
participants. One participant was between the age of 26 to 30 while the remaining four 
participants were between the age of 31 and 35. Two participants had between 1 and 4 
years of practical experience while the remaining three participants had between 5 and 
10 years of work experience. The participants in this phase of the study worked in 
different regions in Saudi Arabia including the Central region (n=3), Northern region 
(n=1) and Southern region (n=1). Furthermore, the participants had worked in various 
governmental ministries in Saudi Arabia including the Ministry of Health (n=3) and 
other ministries (n=2). Further details about the participants’ characteristics in this 
phase of the study can be found in Table 6.1. 
Transcribe verbatim 
Conduct Focus Group session 
Familiarise with data 
Categorise and arrange quotes 
Data left for days then revisited 
• Two hour session with five participants 
• Discussion in English and Videotaped 
 
While watching video tape 
Reading through the whole transcript 
By answering questions for each quote: 
1) Did it answer the question? 
2) Did it answer another question? 
3) Does it say something important? 
4) Is it similar to what has been said? 
 
To obtain a new perspective on data 
Write report according to 
emerging themes 
• No more than three quotes per theme 
• Compare to similar studies   
• Add our own interpretation 
 122 
Table 6.1 Focus group participants’ demographic table 
Participant 
code 
Gender Age 
(years) 
Education Governmental 
Ministry 
Region 
of 
practice 
Work 
experience 
(years) 
Participant 1 Male 31-35 MSc 
Ministry of 
Health 
 
Central 
region 
5-10 
Participant 2 Male 31-35 MSc 
Ministry of 
Health 
 
Southern 
region 
1-4 
Participant 3 Male 31-35 BSc 
Ministry of 
Defense 
 
Northern 
region 
5-10 
Participant 4 Female 31-35 BSc 
Ministry of 
Health 
 
Central 
region 
5-10 
Participant 5 Female 26-30 BSc 
Ministry of 
Defense 
 
Central 
region 
1-4 
 
6.6.5.2 Themes 
Eight themes emerged from the focus group discussion as follows: 
 
Theme one: Definition of a good quality medicine 
Most participants (4/5) indicated that a good quality medicine is a medicine that should 
have a good effect, where it would have a rapid effect with a minimum of side effects.  
 
“I think for me it is the effect. If I was the patient and the effect of the medicine was 
okay, then that is a good quality medicine.” (Participant 2) 
 
Some participants (3/5) indicated that a good quality medicine should be available in 
different formulations and doses, to facilitate different requirements for different 
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patients. Others (2/5) believed that a good quality medicine should be affordable and 
have a good appearance in an attractive package. There were other individual (1/5) 
characteristics of a good quality medicine according to the participants, such as being 
previously used and accepted by the patient, present in a well regulated market and 
originating from a reliable source. 
 
Theme two: Perceptions about medicine quality in Saudi Arabia 
The majority of participants (4/5) believed that the quality of medicines in Saudi Arabia 
is high, that developed countries produce high quality medicine and that patients prefer 
brand name medicine manufactured in developed countries. 
 
“Most people in Saudi Arabia think that medicines that come from developed countries 
like America or Europe has good quality more than medicines from Arab countries…” 
(Participant 4) 
 
Some participants (2/5) indicated that physicians may share some of these negative 
views about the quality of generic medicines and advise their patients to procure brand 
medicines. There was one answer (1/5) where a participant indicated that some patients 
complained about some medicines not containing the active ingredient or with less than 
stated quantity of the active ingredient.  
 
“Many patients complained about the active ingredient it not the same quantity as the 
British brand… they keep saying they don’t have any active ingredient it is just powder 
you give us…it has less active ingredient” (Participant 5) 
 
Theme three: Challenges to medicine quality in Saudi Arabia 
The participants in the focus group discussion identified several challenges to the 
quality of medicines in Saudi Arabia on individual bases (1/5). There was no agreement 
among participants to each challenge identified in this theme. Examples of challenges to 
medicine quality in Saudi Arabia included poor storage conditions, extreme weather 
conditions, poor transport conditions, the presence of a single laboratory for medicine 
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clearance in the country and that hospitals from different organisations use different 
procurement practices to acquire their medicines.  
 
“Sometimes I worry about how do you store it because sometimes in the summer it gets 
very warm” (Participant 1) 
 
Theme four: Experiences with questionable quality medicines 
Some participants (2/5) shared their experiences with medicine quality defects that were 
visually noticed. 
 
“I also remember one IV injection … there was rubber inside…” (Participant 5) 
 
There was one answer (1/5) where one participant recalled a previous encounter with 
counterfeit medicines while working in Hajj (Muslim pilgrimage season). 
 
“I worked in the Hajj season…there is a lot of samples that are copied like the brand 
name but is different from the brand name when you compare the two boxes” 
(Participant 1) 
 
 
 
Theme five: Price and quality relationship in medicines 
All participants (5/5) in this phase study agreed that there was a relationship between 
price and quality of medicines. Some (2/5) indicated that expensive medicines had 
higher quality than cheaper alternatives.  
 
“As a general impression with all the products not just medicines, you associate good 
quality with high price” (Participant 2) 
 
There was one participant (1/5) who did not agree with the opinion that higher prices 
would always guarantee a high quality medicine. 
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“The government supports local manufacturers and for that reason the price of local 
products is cheaper than from other countries” (Participant 1) 
 
Theme six: Assurance of medicine quality 
Some participants (2/5) indicated that they check medicine expiry dates and storage 
conditions to ensure medicine quality. Other practices were reported on individual bases 
(1/5) such as dispensing medicines with ice bags if needed, visual check of medicine 
containers and on some occasions communicating with the regulatory authority 
laboratory to ensure that specific medicines were analysed and cleared for distribution. 
 
“We check the temperature of medicines, we check for any crystals or particles or 
precipitation checked by more than one person” (Participant 4) 
 
Theme seven: Knowledge about causes and impact of medicine quality problems 
There was a clear understanding among all participants (5/5) in this study regarding the 
possible causes of medicine quality problems and their potential impact on health, 
economy and on trust between healthcare providers and patients. 
 
“The other thing that it could break the trust of the patient, if that happens once to a 
patient, he will never trust anything again from this hospital” (Participant 2) 
 
Theme eight: Recommendations to improve medicine quality in Saudi Arabia 
Some participants (2/5) suggested that laboratory analysis of medicine samples would 
be helpful in order to improve the quality of medicines in Saudi Arabia.  
 
“Select random samples to test in the lab…especially if that is the first time, also if 
some cases or reports coming it should be sent to the lab for testing” (Participant 1) 
 
Other individual recommendations (1/5) included the improvement of the national 
reporting system for medicine quality problems, conducting more research on the topic, 
establishing appropriate punishments for individuals responsible for poor quality 
medicines, the rapid resolution of any poor quality medicine incident, the assessment of 
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the current registration process in the healthcare regulatory authority and for 
manufacturers to establish good practices and monitor the quality of their medicines.  
 
6.6.5.3 Translation of counterfeit and substandard medicines into Arabic 
All participants (5/5) in this phase of the study agreed that the term “maghshoosh” in 
Arabic was the most appropriate translation of the term counterfeit. However, none of 
the participants was able to translate the term substandard medicines into Arabic. 
6.6.6 Discussion 
The majority of participants in this focus group study defined a good quality medicine 
in terms of its perceived effect on the patient. This result is in line with other findings 
from the perspective of nurses in Laos (Syhakhang et al., 2004), healthcare 
professionals in South Africa (Patel et al., 2009; Patel et al., 2012) and patients in South 
Africa (Patel et al., 2010; Patel et al., 2012). However, such a definition of a good 
quality medicine does not take into account that a medicine may not generate the 
desired effect for other reasons besides its quality, such as incorrect diagnosis, wrong 
selection of medicine or dosage form, medicine non-adherence or medication errors 
(Quick et al., 1997; Patel et al., 2009). Therefore, it becomes imperative that healthcare 
professionals in particular and the public in general become aware of the possibility of 
such treatment failures, in order to avoid confusion between medicine quality problems 
and other medicine-related issues. Furthermore, some participants in this study provided 
new insights into the definition of medicine quality from different perspectives. Such 
insights included that a good quality medicine should be available in different dosage 
forms and doses to address different patients’ requirements; be available in an attractive 
package; have been previously used and accepted by patients; is present in a well 
regulated market and procured from a reliable source. These new insights were not 
found in the results of similar studies (Syhakhang et al., 2004; Patel et al., 2009; Patel et 
al., 2010; Patel et al., 2012). 
 
Most participants felt that the quality of medicines in Saudi Arabia was high to indicate 
their faith in the medicine regulators in the country. This could be due to the healthcare 
professionals’ confidence in the health care system they work in, including the 
medication supply chain, as was reported in other studies conducted in developing 
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countries, and as found with nurses and patients in Laos (Syhakhang et al., 2004) and 
healthcare professionals in South Africa (Patel et al., 2009; Patel et al., 2012). 
Moreover, most participants believed that higher priced branded medicines 
manufactured in developed countries available in the Saudi Arabian market were better 
in quality than other alternatives and are, therefore, preferred by patients. This is in line 
with other studies conducted in developing countries. One such study found that nurses 
selling medicines in Laos believed that expensive medicines from a reputable 
manufacturer were of higher quality and advised patients to procure these medicines 
(Syhakhang et al., 2004). Healthcare policy makers in Sudan believed that consumers 
linked high price with high quality medicines (Alfadl et al., 2013). Patients in South 
Africa treated cheaper medicines with suspicion and also thought they were fake (Patel 
et al., 2010; Patel et al., 2012). Holloway, Gautam, Harpham & Takey (2002) found that 
patients in rural Nepal were more likely to select the more expensive brand of 
paracetamol.   
 
Some participants indicated several practices associated with ensuring the quality of 
medicines in their settings. Such practices include checking the medicine expiry dates 
and storage conditions, dispensing medicines with ice bags if required, visual checks of 
medicine containers and communicating with the regulatory authority laboratory to 
ensure that specific medicines’ batch numbers were analysed and cleared for patient 
administration. These findings did not mirror similar studies found in the literature to a 
large extent. Patel et al. (2009) found that healthcare professionals in South Africa 
identified medicine procurement from licensed suppliers, use of standard operating 
procedures and audits as key strategies to ensure medicine quality in South Africa. 
Khan et al. (2011) found that managing executives of pharmaceutical wholesalers 
identified local registration status, credibility of the product and reputation of the 
manufacturer during procurement and also considered intactness of medicines, their 
specification, local registration, batch and/or lot number and the name of the 
manufacturer during the reception of medicine consignments. 
 
The participants in this study have discussed challenges to medicine quality in Saudi 
Arabia. Poor storage conditions, extreme weather conditions, poor transport conditions, 
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the presence of a single laboratory for medicine clearance in the country, as well as that 
hospitals from different organisations use different procurement practices to acquire 
their medicines, have all been highlighted by different participants. Such concerns about 
the effect of the hot weather conditions on medicine quality in Saudi Arabia might be 
shared with other researchers who investigated the storage conditions of community 
pharmacies in Saudi Arabia and found medicines stored in temperatures above the 
accepted standards in some community pharmacies in Riyadh (Khojah et al., 2013a). 
However, several recommendations were made by participants to improve the quality of 
medicines in Saudi Arabia. Such recommendations included laboratory analysis of 
medicine samples, the improvement of the national reporting system for medicine 
quality problems, conducting further research on the topic of medicine quality, 
establishing appropriate legislation for poor quality medicines, the rapid resolution of 
any poor quality medicine incident, the assessment of the current medicine registration 
process in the healthcare regulatory authority and for manufacturers to establish good 
practices and monitor the quality of their medicines within the market. 
 
The results from Phase 1 of this study, in conjunction with the systematic literature 
review (Chapter 5), directed the development of the questions in the survey 
questionnaire and interview guides used for the subsequent phases. The questions about 
knowledge of possible causes and the impact of medicine quality problems 
demonstrated a clear understanding by all participants and were, therefore, deleted from 
future phases of the study. The participants did not comprehend the term “substandard 
medicines” and they were unable to translate it into Arabic. Hence, questions about 
substandard medicines were deleted from future phases of this study. Counterfeit 
medicines were successfully translated into the term “maghshoosh” in Arabic and 
therefore were added to the questions for the future phases of the study. Moreover, 
several issues emerged in the discussion about the type of medicine formulation for 
quality concern, the type of medicine therapeutic class of quality concerns and the 
number of annual incidents of suspicion of poor quality medicines in their practice. 
Hence, questions about these emerging issues were developed and added for the 
following phases of this study.  
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Limitations and strengths of this phase of the study 
The findings from this study must be considered within their limitations. It was only a 
single focus group discussion with a limited number of participants and therefore 
findings cannot be generalised. All the participants in this study were pharmacists, 
which might suggest a different possible outcome if other perceptions of alternative 
healthcare professionals were explored. The use of a focus group method could limit in-
depth understanding of various opinions, particularly from some shy participants in a 
group dynamic. However, the researcher attempted to minimise this effect by ensuring 
that individuals shared their opinion on topics equally, where possible. Nevertheless, 
this study had successfully achieved its objectives. It was the first study to explore 
perceptions about medicine quality and their related issued in Saudi Arabia. Findings 
from this study could be helpful for future studies about perceptions of medicine quality 
and their related issues in different settings, particularly in Arabic-speaking countries. 
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6.7 Phase 2: Commissioners’ perceptions about medicine quality and 
their problems within the MOI-MSD in Saudi Arabia 
6.7.1 Introduction 
Conventionally, counterfeit and substandard medicines have been mainly determined 
through laboratory testing of medicine samples (Patel et al., 2010). There have been 
multiple studies conducted to confirm their existence in some parts of the world 
(Chapter 3). However, limited studies have been conducted to understand medicine 
quality and their problems from a non-laboratory perspective (Chapter 5) particularly in 
Saudi Arabia (Chapter 6 phase 1).  
6.7.2 Aim  
The overall aim of this phase of the study was to investigate the commissioners’ 
perspectives on medicine quality and related issues at MOI-MSD healthcare settings in 
Saudi Arabia.  
6.7.3 Objectives 
The specific objectives of this study includes the following: 
 Explore MOI-MSD commissioners’ beliefs and views about medicine quality 
and their problems. 
 Investigate MOI-MSD commissioners’ knowledge and behaviour towards 
medicine quality and any related problems.  
 Explore commissioners’ views on the potential improvements to existing 
policies and procedures to address the issue of medicine quality in Saudi Arabia 
in the context of the global market. 
6.7.4 Methods 
To achieve the objectives of this phase, a qualitative approach using semi-structured 
interviews as a method for data collection was considered appropriate. This approach 
allowed for flexible collection of data and achieved a greater in-depth understanding of 
this social phenomena (Smith, 2002; Morse & Field, 1995). 
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6.7.4.1 Selection of participants and study settings  
The participants selected for this phase of the study were commissioners within the 
MOI-MSD who were purposefully selected based on having an active decision-making  
role in the medicine supply chain from the point of medicine selection from different 
manufacturers until such time as it reaches the dispensing pharmacy in any MOI-MSD 
primary care clinics in these settings. These participants were considered to be 
knowledgeable individuals who require deeper insight into their experiences regarding 
medicine quality and any related problems. Respondents were approached personally 
and recruited by the principal researcher, who explained the aim of this study, before 
receiving a verbal consent from them to participate at a later date convenient to them. 
All potential respondents agreed to participate in this study. The commissioner’ 
interviews were conducted in their offices within familiar settings to them in an attempt 
to ensure the respondents’ privacy and comfort before answering any questions. A 
commissioner information sheet (Appendix 14) was handed to all respondents prior to 
the interview beginning. 
6.7.4.2 Development of interview guide 
The semi-structured interview guide was developed based on the findings from a 
previous systematic literature review (Chapter 5) and a focus group study (Chapter 6 
phase 1). Table 6.2 highlights the key questions in the commissioners’ interview guide. 
 
Table 6.2 Commissioners’ interview guide questions in chronological order regarding 
their perception about medicine quality and their problem in MOI-MSD in Saudi Arabia 
1. In your opinion, what is a high quality medicine? 
 
2. What do you think of the quality of medicines available in Saudi in general? 
 
3. What do you think of the quality of medicines available in MOI in general? 
 
4. Have you ever experienced a medicine with doubtful quality? If yes when and how? 
 
5. How many times a year do you come across medicines with doubtful quality? 
 
6. If you had concerns about the quality of a medicine what would you do? 
 
7. What medicine therapeutic class are you mostly concerned with in terms of quality? 
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8. What type of medicine formulation are you mostly concerned with in terms of 
quality? 
 
9. What are the attributes required for a medicine to be available to your patients? 
 
10. In your opinion, what is the relationship between price and quality of medicines? 
 
11. In your opinion, what is the relationship between medicine quality and health 
outcomes? 
 
12. In your opinion, what is a counterfeit medicine? 
 
13. What in your opinion is the percentage of counterfeit medicines globally? 
 
14. What in your opinion is the percentage of counterfeit medicines in Saudi Arabia? 
 
15. What changes would you recommend to ensure the high quality of medicines? 
 
16. What other concerns about medicines in your settings that you may have that we did 
not discuss? 
 
 
6.7.4.3 Validity and reliability checks 
Three academic members of staff at the University of Hertfordshire reviewed the 
interview guide questions for face validity. The interview was piloted with two post-
graduate Saudi Arabian pharmacists studying at the University of Hertfordshire, who 
were not members of the previous phase of the study (Chapter 6 phase 1) and were 
asked to provide feedback on the question content, order and clarity. The outcomes 
from the previous phase of the study (Chapter 6 phase 1), expert feedback and pilot tests 
resulted in minor amendments in the wording of the final interview guide (Table 6.2). 
6.7.4.4 Data collection 
The period for data collection in this phase was during March 2014. All interviews were 
tape-recorded and conducted in the Arabic language, native to both the researcher and 
the respondents. Probing and follow-up questions were frequently posed to respondents 
to ask for further clarification and information regarding their answers. The order of 
questions was similar for all participants to allow for data comparability where possible 
and to minimise possible effects of variation in the questions order on the results 
(Patton, 1987; Alfadl, 2012). Demographic information of commissioners was collected 
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prior to the start of interviews. All interviews were conducted following an informed 
consent and none lasted longer than 30 minutes in this phase. 
6.7.4.5 Questions and transcript translation 
Interview guide questions were delivered to the commissioners in Arabic in an attempt 
to maximise their ability to express their thoughts freely. The questions were translated 
into Arabic by the principal researcher; then translated into English and back to Arabic 
by two bilingual native Arabic-speaking members of staff at the University of 
Hertfordshire and the two versions of the Arabic questions in the interview guide were 
compared and found to have minimal differences in some phrases. All participants were 
sent a copy of the interview transcripts via e-mail to ensure the accuracy of their 
statements and none proposed any changes. Furthermore, following the transcription 
and translation of the interviews, two bilingual native Arabic-speaking members of staff 
at the University of Hertfordshire assisted the principal researcher in validating the 
accuracy of translation from two randomly chosen interview transcripts and the two 
versions were found to be similar, with the exception of some minor differences in some 
of the phrases used. 
6.7.4.6 Data analysis 
Interview data were thematically analysed following transcription verbatim in Arabic 
and translation of data into English using the qualitative data analysis software NVivo, 
version 10 to generate major themes. The data analysis process followed a method 
adopted from Strauss & Corbin (1990) in five steps, as follows: 
1) Interview transcripts were read and re-read to increase familiarisation with data, 
while taking initial notes. 
2)  Preliminary description and interpretation of notes was performed and codes 
assigned based on these interpretations. 
3) The connection between the codes was identified and the pattern in the codes 
was developed. 
4) Themes and sub-themes were determined by examining the different cluster of 
codes available. 
5) The themes and sub-themes were examined across all interviews and 
predominant themes were assigned. 
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The principle researcher independently analysed the interview data and assigned the 
initial codes. The supervisor of this study coded two random interviews and reviewed 
the final results with minimal discrepancies in the coding and interpretation of data. 
6.7.5 Results 
6.7.5.1 Participants’ characteristics 
All commissioners (6/6) who were approached for recruitment had agreed to participate 
in this phase of the study (100% response rate). All commissioners were pharmacists 
working in the MOI-MSD. Table 6.3 presents the demographic details collected from 
the commissioner group in this phase of the study. 
 
Table 6.3 Commissioners’ demographic details 
Participant code Gender Age Education Position title 
Commissioner 1 Male 35 BSc  Manager 
Commissioner 2 Male 40 BSc Manager 
Commissioner 3 Male 42 BSc Manager 
Commissioner 4 Male 43 BSc 
Assistant 
Director 
Commissioner 5 Male 42 MSc 
Assistant 
Director 
Commissioner 6 Male 50 PhD Director 
 
6.7.5.2 Themes 
The interviews with the MOI-MSD commissioners generated seven themes as follows:  
 
Theme 1: Knowledge and belief about medicines and their quality 
All commissioners (6/6) believed that a good quality medicine was a medicine that 
generated a good effect. 
 
“The one which gives you 100% desired effect within the desired time” 
(Commissioner 3) 
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The majority of commissioners (4/6) also described a good quality medicine, in their 
opinion, as the brand medicine from the innovator company since they have a high 
reputation, more experience and have run trial studies on their products accordingly. 
 
“The first thing is quality which is attached with brand companies because such 
companies are prestigious, well-known in the market, preserve their reputation, comply 
with GMP, market their products in their own countries…” (Commissioner 2) 
 
The commissioners also described other characteristics of a good quality medicine less 
frequently, such as having a good bioavailability (3/6), good packaging (2/6), having an 
affordable price (1/6), being a registered product (1/6), with good stock movement 
(1/6), accepted by patients (1/6) and with additives from a reliable source (1/6). 
 
The commissioners identified several sources of information regarding medicine 
quality. Most commissioners (4/6) identified actual experiences with medicines whether 
this was their personal experience, a family or friend’s experience, the experience of 
primary care representatives, physicians or patients from the primary care clinics. Other 
commissioners (3/6) have identified memos or letters of product recalls distributed by 
the SFDA or MOH as a primary source of information about medicine quality. 
 
“We usually know about the quality of medicines from the memos and letters we receive 
from SFDA and MOH” (Commissioner 3) 
 
Theme 2: Experiences and behaviour with questionable quality medicines 
The majority of commissioners’ (4/6) experiences with questionable quality medicines 
involved a past experience of a generic medicine that did not have an effect, which was 
followed by a successful treatment following a switch to a brand product of the same 
medicine. 
 
“I had a chest infection so I used the product… not the mother company’s product … 
but it felt like I haven’t used a medicine…it was like taking a placebo...”    
(Commissioner 1) 
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Some commissioners (2/6) specifically recalled receiving a letter from the medicine 
regulatory authority in Saudi Arabia regarding generic paracetamol syrup that did not 
contain any active ingredient. 
 
“The paracetamol syrup not containing any active ingredient like an empty syrup” 
(Commissioner 3) 
 
The commissioners did not agree on the frequency of poor medicine quality reports they 
received. Some (3/6) believed that such reports are common and are easily more than 
ten reports each year. Others (3/6) said that it was not common and they might receive 
one poor medicine quality report every one or two years. 
When the commissioners were asked about their behaviour, when in doubt about the 
quality of any medicine, most commissioners had different answers according to the 
settings where such doubts occurred. In their work settings, some commissioners (3/6) 
would report the incident to SFDA and their higher administration. Other actions were 
also mentioned on single occasions (1/6), such as evaluating the medicine’s stock 
movement and summoning the manufacturing company for discussion. On a personal 
level, some commissioners (2/6) would look for alternative medicines or pharmacies if 
necessary. Only one commissioner considered reporting the matter to the SFDA or 
MOH, if in doubt about a poor quality medicine outside their work settings. Moreover, 
one commissioner suggested that patients might not know where to report poor 
medicine quality incidences. 
Theme 3: Perceptions about medicine quality 
Most commissioners (5/6) generally perceived the quality of medicines available in the 
Saudi Arabian market as good or excellent. When asked to rate the quality of medicines 
available in the market on a scale of 10, where 10 was the best quality, the majority of 
commissioners (5/6) responded with answers ranging from 7 up to 10 out of 10.  Some 
justification was provided by the commissioners for their rating, based on individual 
factors such as the high control of the market by the SFDA, having an open market 
where you could find both generic or brand medicines and the low incidences of fake 
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medicine in the country. However, there was one commissioner (1/6) who perceived the 
quality of medicines in Saudi Arabia as average with 6 out of 10 in rating, and none of 
the commissioners rated them poorly. Moreover, some commissioners (2/6) had a 
perception that medicine quality of brand medicines comes first, followed by Saudi 
Arabian manufactured generics, and then all other manufactured generics. 
“…If you want them in order I think that the mother company is the best followed by the 
Saudi product and then the Arabic products…” (Commissioner 1) 
The majority of commissioners (4/6) perceived the quality of medicines available in the 
MOI-MSD as average. When asked to rate the quality of medicines available in the 
MOI-MSD on a scale of 10, where 10 was the best quality, the majority of 
commissioners (4/6) responded with 5 up to 6 out of 10. Only one commissioner 
thought it was of a good quality, rating it between 7 up to 8 on a scale, where 10 is the 
best, and only one commissioner believed that the quality of medicines in the MOI-
MSD was poor, rating it between 3 to 4 on a scale of 10. For the majority of 
commissioners (4/6), who thought that the quality of medicines available in the MOI-
MSD was average, some justification was noted which mainly concentrates on the fact 
that the majority of available medicines were generics, procured from a tender system 
which is commonly associated with selection based on the cheapest price rather than 
quality, unsatisfactory reports from physicians and patients on their efficacy, and the 
number of product recall memos or letters they appear in, according to some 
commissioners. 
“90-95% of letters from SFDA about failed products are generics which causes distrust 
of physicians and pharmacists because these letters are sent to them” (Commissioner 6) 
 
Some commissioners (4/6) offered their perspectives on patients’ perception about 
medicine quality. Patients could complain and reject their generic medicines and ask for 
brand medicines according to some (3/6) commissioners. One commissioner was of the 
opinion that patients always complained and that, when they did, their complaint is 
taken seriously. Additionally, one commissioner suggested that patients could confuse 
manufacturing errors with counterfeit medicines.  
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“I remember once that a company’s suspension… stuck to the bottle…we cannot say 
that this is counterfeiting but manufacturing errors, although the patient would perceive 
that as counterfeiting” (Commissioner 5) 
Theme 4: Price, health outcome and quality relationship in medicines 
The majority of commissioners (4/6) believed that there was a relationship between 
medicine quality and price, where the higher the medicine price, the higher the quality 
of medicine you received. One commissioner stated that they did not believe such a 
relationship existed between medicine quality and price. One other commissioner did 
not know what the relationship between medicine quality and price was. 
 
“There is a common understanding among people that high price means high quality, 
and a common understanding among specialists that high quality must be expensive” 
(Commissioner 5) 
 
Most commissioners (5/6) believed that there was a relationship between medicine 
quality and health outcomes, where the higher the medicine quality, the better the health 
outcomes. One commissioner did not believe that such a relationship existed between 
medicine quality and health outcomes.  
 
Theme 5: Counterfeit medicines 
The majority of commissioners (5/6) described counterfeit medicine in terms of 
problems associated with the active pharmaceutical ingredient. Some commissioners 
(3/6) emphasised that a counterfeit medicine was a medicine that had no active 
pharmaceutical ingredient, while other commissioners (4/6) described it as a change in 
the percentage of the active pharmaceutical ingredient and presence of undeclared 
additives (1/6). On several occasions, counterfeit medicines have been described by 
some commissioners (3/6) as not complying with the physical attributes required for the 
medication such as disintegration problems, change in colour or change in odour, 
highlighting problems with weather and storage conditions.  
“A counterfeit medicine could be stored in poor conditions although the manufacturing 
was of good quality but the poor storage could lead to certain precipitations or odour” 
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(Commissioner 2) 
Some commissioners (3/6) described a counterfeit medicine in terms of effect, such as 
lack of effect, toxic effect or different effect than that which is described on the 
medicine package or desired by the patient. 
“As I see it, it wouldn’t give me its effect. As you know, what is written or desired I 
didn’t feel so you feel that this medication is fake or bogus…” (Commissioner 4) 
Few commissioners (2/6) described counterfeit medicines in terms of packaging 
problems such as a deliberate change in expiry date and fake packaging. One 
commissioner described the term counterfeiting by emphasising that it must be 
intentional and should not be confused with manufacturing errors. Furthermore, one 
commissioner described the process of companies keeping their medications in 
unsuitable containers as counterfeiting, since it employs the deception of the 
uninformed consumer. 
“A medicine that should be stored in glass containers…then you find it in plastic 
containers this is also counterfeiting…” (Commissioner 1) 
 
When commissioners were asked about their estimation of the prevalence of counterfeit 
medicines on a global scale, mixed responses were given. Some commissioners (2/6) 
estimated that it could reach 20-40%. Some commissioners (2/6) believed that the 
counterfeit medicine prevalence rate is between 0-10% globally. Other commissioners 
(2/6) believed that 50% or more of global medicines were counterfeit.  
 
Similarly, when commissioners were asked about their estimation of the prevalence of 
counterfeit medicines in Saudi Arabia, mixed responses were also obtained. Some 
commissioners (2/6) estimated that it could reach 20-40%. Some commissioners (2/6) 
believed it was between 0 to 10% in Saudi Arabia. Other commissioners (2/6) estimated 
that 50% or more of the medicines available in Saudi Arabia were counterfeit.  
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Theme 6: Challenges to medicine quality 
Most commissioners (4/6) identified the tender-based medicine procurement system as 
a challenge to medicine quality in their setting since it was largely focused on the 
cheapest price rather than the medicine quality. 
 
“… The procurement system does not support me in the selection of medicines; there 
should be a section about quality” (Commissioner 2) 
 
Several commissioners (3/6) identified limited reports about medicine quality problems 
they received from MOI-MSD staff as a challenge to medicine quality in their settings. 
 
“If there were concerns, it matters to me that there would be forms for example post 
marketing surveillance, which is completed by specialists. This is our biggest support 
however the feedback is really not positive…they do not write to us although the forms 
are available to them…” (Commissioner 6) 
 
Some commissioners (2/6) described the limited budget available for medicine 
procurement in the MOI-MSD as a challenge in these settings as it would minimise 
their ability to procure higher quality brand medicines in their opinion. 
 
“The problem is that you are restricted with a limited budget that is the problem” 
(Commissioner 4) 
 
There were other less common challenges to medicine quality that were identified by 
commissioners, such as the unknown storage conditions of medicines received from 
companies, lack of post-marketing analysis of medicines, absence of quality guidelines 
to follow, generic company representatives only discussing medicine prices with local 
MOI-MSD staff and the outdated MOI-MSD medicine formulary: all were highlighted 
by commissioners on an individual basis. 
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Theme 7: Recommendations to ensure high medicine quality 
Participants in this phase of the study had a wide range of recommendations to ensure 
medicine quality in Saudi Arabia. The major recommendations from the 
commissioners’ group included activating the role of the SFDA in monitoring and 
analysing medicines (2/6) and implementing changes to the current medicine 
procurement system (2/6).  
 
“The patients’ daily bed cost today is much more expensive than payment for a good 
medicine…when you are procuring a good medicine you are actually saving money” 
(Commissioner 1) 
 
Other individual recommendations by commissioners included increasing the medicine 
procurement allocated budget, the establishment of independent laboratories for 
medicine analysis, sending MOI-MSD staff to inspect GMP compliance of 
pharmaceutical manufacturers and the establishment of an awareness programme or 
advertisement about medicine quality problems (2/6). 
6.7.6 Discussion 
All commissioners in this phase of the study believed that a good quality medicine was 
a medicine that resulted in a good effect for the patient. This result is in line with 
findings from other studies conducted with nurses in Laos (Syhakhang et al., 2004), 
healthcare professionals in South Africa (Patel et al., 2009; Patel et al., 2012) and the 
findings from a study with Saudi Arabian pharmacists in the UK (Chapter 6 phase 1). 
Most commissioners indicated that a good quality medicine was a brand medicine from 
an innovator company. This finding mirrors other opinions regarding brand medicines’ 
superiority over generic medicines, held by some pharmacists within the literature 
(Babar et al., 2011; Basak & Sathyanarayana, 2012) and the findings from the previous 
phase of this study (Chapter 6 phase 1). In one study, 65% of pharmacists in New 
Zealand stated that the original brands had higher quality than their generic substitutes 
(Babar et al., 2011). Patients had mixed views about generics in the literature. Some 
reported accepting it (Heikkilä et al., 2011) while others believed they were inferior in 
quality (Kjoenniksen I, Lindbaek M, Granas, 2006; Babar et al., 2008; Albarraq, 2013). 
Physicians were also reported to have mixed views where some were supportive of the 
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quality of generic medicines (Kersnik & Peklar, 2006; Alghasham, 2009; Heikkilä et 
al., 2007; Tsiantou et al., 2009) and others were concerned about the quality of generic 
medicines to some degree (Hassali et al., 2006; Shrank et al., 2011; Chua et al., 2010). 
 
Most commissioners in this study believed that the medicine quality in Saudi Arabia 
was high. This result is in line with findings from other studies conducted in developing 
countries where nurses, pharmacists and physicians believed that the quality of 
medicines was high in their own countries (Syhakhang et al., 2004; Patel et al., 2009; 
Patel et al., 2012) and the findings from the previous phase of this study (Chapter 6 
phase 1). However, most commissioners believed that the quality of medicines in the 
MOI-MSD was less than what is available in the Saudi Arabian market generally. Some 
commissioners justified these views as resulting from the tender-based system for 
medicine procurement which favours cheaper generic medicines, which in turn receive 
the highest numbers of product-recall memos from the healthcare regulators in Saudi 
Arabia, and physician or patient complaints.  
 
Counterfeit medicines were defined by most commissioners in this study in terms of 
problems associated with the active pharmaceutical ingredient. This finding does not 
mirror results from other studies, for example, where the commissioners in Sudan 
predominantly described a counterfeit medicine as one that entered the country illegally 
(Alfadl et al., 2013). Although the commissioners in this study clearly understood that a 
counterfeit medicine could mean the absence of the active pharmaceutical ingredient or 
the presence of the wrong active ingredient, there was less emphasis in their answers on 
the deliberate nature of the act, the importance of medicine package details and the 
authentication of medicine source, when compared with the widely accepted WHO 
definition of counterfeit medicines (WHO, 1999a). It was found that the majority of 
commissioners in this study predicted that the counterfeit medicine prevalence rate on a 
global scale was considerably higher than the WHO estimation of 10% (Cockburn et al., 
2005; Heyman & Williams, 2011; Ziance, 2008). Moreover, when asked about their 
estimation of the counterfeit medicine prevalence rate in Saudi Arabia, mixed opinions 
were evident. Around one third of the commissioners agreed with the SFDA estimation 
that counterfeit medicines were almost non-existent in the country, with a prevalence 
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rate between 0 to 10% (Arabnews, 2010). One third of the commissioners estimated that 
counterfeit medicines were 20 to 40% prevalent in Saudi Arabia, in agreement with 
media prediction in the country (Saudi Gazette, 2011). Furthermore, one third of 
commissioners predicted that 50% or more of medicines in Saudi Arabia were 
counterfeit, to exceed any previous estimation. It remains a possibility that the limited 
understanding of what a counterfeit medicine was could have resulted in the higher 
estimation of their prevalence in this study. 
 
Commissioners in this phase of the study identified several challenges to medicine 
quality. Most commissioners highlighted the tender-based system for medicine 
procurement as a challenge to medicine quality in their settings, as it favoured lowest 
price rather than quality, in their opinion. Perhaps the wide belief shared among the 
participants in this study about their preference for brand innovator products and their 
perception of their superior quality could have influenced such perceptions about 
challenges to medicine quality. However, the tender system for medicine procurement 
was not identified as a challenge to medicine quality in the results obtained from the 
previous phase of this study (Chapter 6 phase 1). Moreover, limited reporting of 
medicine quality problems by healthcare staff was another major challenge identified by 
half of the commissioners in this phase of the study. Similar results concerning poor 
communication among healthcare staff regarding medicine quality reports have been 
found in other studies (Patel et al., 2009). In response to these medicine quality 
concerns, the participants in this phase of the study have shared some recommendations 
to ensure and improve medicine quality in the MOI-MSD. It has been suggested that the 
improvement of medicine monitoring, particularly within SFDA and improvements to 
the current tender-based system, which was predominantly based on cheapest price and 
did not include a quality element, would have improved the quality of the medicines 
available to patients.  
 
Limitations and strengths of this phase of the study 
This present interview phase of the study has several limitations. The findings from this 
study cannot be generalised to all MOI-MSD healthcare staff, considering the small 
number of the sample frame and sample size. However, generalisibility has not been the 
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aim of this phase of the study as we aimed to explore different opinions and conduct in-
depth analysis of the available information from the executives responsible for medicine 
supply in the MOI-MSD. Another limitation of this study could be the absence of 
female participants in this phase of the study. This limitation was not avoidable since 
the entire sample frame in this phase of the study was male. Furthermore, some 
questions required answers from the respondents’ past experiences and could be subject 
to recall bias. Moreover, other questions asked respondents about their practices 
regarding medicine quality issues that cannot be verified in the absence of an 
observational study. The small number of the sample frame available for this phase of 
the study has prevented seeking data saturation. Nevertheless, this study was among the 
very few studies that examined medicine quality issues from the perspective of different 
stakeholders. To the researcher’s knowledge, it was the first study exploring such issues 
in Saudi Arabia and MOI-MSD settings. The next phase of this study examined the 
MOI-MSD patients’ perception about medicine quality and any related problems, in 
order to improve the understanding of the phenomena. 
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6.8 Phase 3: Patients’ perceptions about medicine quality and their 
related issues within the MOI-MSD in Saudi Arabia 
6.8.1 Introduction 
It has been previously established that studies addressing perceptions about medicine 
quality and their problems are severely lacking worldwide (Chapter 5). Stakeholders’ 
perceptions about medicine quality and their problems have been found to be non-
existent in Saudi Arabia (Chapter 5). The previous phases of this study have resulted in 
exploration of the scope of stakeholders perceptions about medicine quality and any 
related problems in Saudi Arabia, the development of questions for interview guides 
and survey questionnaires (Chapter 6 phase 1) and examined the perceptions of MOI-
MSD commissioners (Chapter 6 phase 2) regarding medicine quality and any related 
issue. 
6.8.2 Aim  
The overall aim of this phase of the study was to investigate the patients’ perspectives 
on medicine quality and related issues at MOI-MSD healthcare settings in Saudi Arabia.  
6.8.3 Objectives 
The specific objectives of this study includes the following: 
 Explore patients’ beliefs and views about medicine quality and any related 
issues. 
 Investigate the patients’ knowledge and behaviour towards medicine quality 
and any related issues. 
 Explore potential improvements to existing policies and procedures to address 
the issue of medicine quality in Saudi Arabia in the context of the global 
market. 
6.8.4 Methods 
A qualitative approach using semi-structured interviews as a method for data collection 
was used in this phase of the study in order to obtain a greater in-depth understanding of 
the research problem (Smith, 2002; Morse & Field, 1995). Furthermore, using an 
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interview method for data collection would allow for the inclusion illiterate patients into 
the sample frame. 
6.8.4.1 Selection of participants and study settings  
As previously mentioned in the introduction part of this thesis (Chapter 1), the MOI-
MSD operates 18 primary clinics outside the capital city of Riyadh, in addition to 3 
specialist primary care clinics in Riyadh. The sample frame for this interview phase of 
the study included MOI-MSD patients from two specialist primary care clinics in 
Riyadh and one in Jeddah city, which are the two most populated cities in Saudi Arabia 
(Appendix 2). Patients were conveniently selected based on their actual visits to the 
selected primary care clinics during the data collection period. The only exclusion 
criteria applied for recruitment in this phase of the study were patients below the age of 
18 years old. Both male and female participants were recruited in this study in order to 
enhance patient representation from both genders in the final results.  
 
Patient recruitment was carried out by several means. The principal researcher 
personally approached some, whilst collaborating physicians and pharmacists initially 
approached others. The principal researcher explained the aim of the study to all 
respondents and they were handed a hard copy of the participant information sheet 
(Appendix 14). Interviews were conducted in vacant physicians’ offices in each setting, 
in order to be in close proximity to collaborating physicians to ensure patients’ privacy 
and also to minimise the patients’ effort to reach the interview site. The principal 
researcher introduced himself as a scholar from the University of Hertfordshire in the 
United Kingdom to all respondents and explained that this work was for academic 
purposes only, in an attempt to achieve honest answers. All respondents were 
encouraged to speak freely without fear, as there will be no action based on their 
answers and they were reminded that the results would be anonymised. All interviews 
were conducted immediately following the respondent’s agreement to participate by 
signing an informed consent (Appendix 16).  
6.8.4.2 Development of interview guide 
The semi-structured interview guide was developed based on the findings from a 
previous systematic literature review (Chapter 5) and a focus group study (Chapter 6 
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phase 1). The interview guide used in this phase of the study was mostly similar to the 
interview guide used with the commissioners’ group (Chapter 6 phase 2).  A few 
questions were added to the patient interview guide in order to identify patients’ 
expectations from their medicine, the source of their medicines, the type of medicines 
they were using and the source of information regarding their medicines. Furthermore, 
some questions were only available for the commissioner’s interview guide and not in 
the patient’s interview guide since they were irrelevant to this sample frame. Examples 
of such deleted questions included questions about the frequency of annual doubts about 
the quality of medicines, the therapeutic classes and formulations of most quality 
concerns. 
6.8.4.3 Data collection 
The interviews were conducted in the period between March 2014 and April 2014. All 
interviews were tape-recorded and conducted in the Arabic language, native to both the 
researcher and the patients. Probing and follow-up questions were frequently posed to 
respondents to ask for further clarification and information regarding their answers. The 
question order was similar for all participants, to allow for data comparability where 
possible and to minimise the possible effects of variation of question order on the 
results (Patton, 1987; Alfadl, 2012). Demographic information was collected prior to 
the start of the interviews. All interviews were conducted following the signature of a 
patient informed consent form and none lasted more than 30 minutes in this phase. The 
recruitment of participants in this phase continued until no new themes emerged with 
the final three interviews.  
6.8.4.4 Validity and reliability checks 
The validity and reliability check were conducted using a similar method to the previous 
interviews with the commissioners in the MOI-MSD (Chapter 6 phase 2). In addition, 
the interview guide was piloted with two patients in Saudi Arabia, who were not 
members of the sample frame, through Skype (www.skype.com) internet-based 
video/audio recording method and they were requested to provide feedback on the 
question content, order and clarity. 
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6.8.4.5 Questions and transcript translation 
The interview guide was developed in Arabic since patients in these settings cannot be 
assumed to have adequate proficiency in the English language. The process of 
translation and validation of the accuracy of translation was conducted with a similar 
approach to a previous phase of this study (Chapter 6 phase 2).  
6.8.4.6 Data analysis 
Interview data were thematically analysed following transcription verbatim in Arabic 
and translation of data into English using the qualitative data analysis software NVivo, 
version 10 to generate major themes. The data analysis and coding of themes was 
similar to that reported in a previous phase of the study (Chapter 6 phase 2). 
 
Furthermore, the relationship between the patients’ perceptions about medicine quality 
in the MOI-MSD and some sociodemographic variables such as age, gender, education, 
occupation and types of medicines used was statistically examined. The Chi-square and 
Fishers’s exact tests were conducted using SPSS version 21 where 95% confidence 
interval (CI) was considered statistically significant. 
 
6.8.5 Results 
6.8.5.1 Participant characteristics 
In total, 53 patient interviews were conducted in this phase of the study to achieve a 
response rate of 66% from the total number of patients approached for recruitment. A 
description of the recruited patients’ characteristics can be found in Table 6.4. 
 
Table 6.4 Patients’ characteristics in the interview phase of the study 
Category Subcategory Number (%) 
Location of interview Riyadh 
Jeddah 
 
44 (83%) 
9 (17%) 
Gender Male 
Female 
 
35 (66%) 
18 (34%) 
Age 18-19 
20-29 
30-39 
40-49 
50-59 
60 or more 
 
3 (6%) 
17 (32%) 
12 (23%) 
11 (21%) 
5 (9%) 
5 (9%) 
Education None 6 (11%) 
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Primary 
Intermediate 
Secondary 
Diploma 
BSc 
MSc 
 
3 (6%) 
5 (9%) 
23 (43%) 
3 (6%) 
12 (23%) 
1 (2%) 
Occupation Unemployed 
Retired 
Civilian employee 
Military employee 
Student 
 
10 (19%) 
6 (11%) 
7 (14%) 
24 (45%) 
6 (11%) 
Type of medicines used now Chronic disease medicines 
Acute disease medicines 
Not using medicines now 
 
22 (42%) 
27 (51%) 
4 (7%) 
Source of patients’ medicines MOI-MSD only 
MOI-MSD and other public hospitals 
MOI-MSD and private pharmacies 
Private pharmacies only 
Public or private hospitals 
 
11 (21%) 
12 (23%) 
16 (30%) 
9 (17%) 
5 (9%) 
6.8.5.2 Themes 
The interviews with MOI-MSD patients generated eight themes as follows: 
Theme 1: Knowledge and belief about medicines and their quality 
A significant number of patients (14/53) did not know the name of their medicines. 
Male patients, in particular, (11/35) showed less knowledge about their medicine names 
when compared with female patient (3/18). Moreover, patients with no or lower 
educational levels were found to have lower knowledge about their medicine names 
(6/14) compared with patients with higher educational levels (8/36). Furthermore, a 
considerable number of chronic patients (7/22) did not know the names of their 
medicines when compared with patients taking medicines for acute conditions (6/27). 
 
Most patients (29/53) described a good quality medicine in terms of its effect, which 
should be ideally rapid with minimal side effects in their opinion.  
 
“That means that is fast in effect for the disease…” (Patient 43) 
 
Patients identified other characteristics of good quality medicines. Some patients (7/53) 
indicated that a good quality medicine was the one recommended by their physician. 
This understanding of high quality medicines was particularly noted with patients aged 
50 years or older (5/10) and patients with no education (3/6). Other patients (7/53) 
believed that a good quality medicine has good manufacturing status. There were other 
answers reported by patients such as not manufactured locally (2/53), having a previous 
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successful experience with it (2/53), was appropriate for the disease (2/53), has a high 
price (1/53), accepted by their body (1/53), had strong dose (1/53), diabetes medicines 
(1/53) and medicines recommended by the pharmacist (1/53). Furthermore, there were 
some patients (5/53) who did not know what a good quality medicine was. 
 
“It depends on the company…I would ask the advice of the doctor most importantly” 
(Patient 5) 
 
Patients also shared some of their beliefs about medicines in general and medicine 
quality in particular. Some patients (6/53) expressed their opinion that medicines did 
not work similarly for all patients. A number of patients (11/53) believed that the 
quality of medicines was different between different hospitals in Saudi Arabia and other 
patients (12/53) indicated that the quality of medicines differs according to their 
manufacturers. There were some patients (3/53) who believed that the higher the 
strength of a medicine, the more likely that it had better quality and generated better 
effect.  
 
“Every hospital is different…some of my relatives get treatment in the National Guard 
hospital and Ministry of Defense hospital and they are dispensed better and more 
effective medicines that would heal your condition rapidly” (Patient 2) 
 
Theme 2: Experiences and behaviour with questionable quality medicines 
Some patients (13/53) shared some experiences with medicines which did not give them 
the desired effect and therefore they questioned their quality. 
 
“In the governmental hospital, I took medicines that were not that good ... I then went 
to a private clinic and got treatment on my expense …and I felt better” (Patient 26) 
 
The majority of patients (23/53), however, did not have any past experiences with 
questionable quality medicines, specifically patients with no or lower educational levels 
(9/14). A few patients (3/53) did not recall such experiences with doubtful quality 
 151 
medicines. Some patients (8/53) shared their experiences with medicine side effects to 
describe their encounters with medicines with questionable quality.  
 
“Once I was getting treatment from a psychiatric hospital and the psychiatry medicines 
would worsen your case so I didn’t use it. I would take the medicine bag from here and 
throw it from here because I felt very tired and sleepy when I took them and I have 
children so I need to keep moving” (Patient 16) 
 
Patients reported a wide range of behaviour when in doubt about the quality of a 
medicine. The majority of patients (37/53) reported that they would stop taking the 
medicine immediately. Some patients (22/53) said that they would ask their physician 
for advice before taking any action, which was specifically found in patients aged 50 
years or older (7/10) and patients with no or lower levels of education (9/14). Other 
patients (12/53) indicated that they would look for an alternative medicine. There were 
a number of patients (6/53) who would not take any action and a similar number (6/53) 
who would inform other medicine users to warn them about their experience. There 
were also less common types of patient behaviour when in doubt about the quality of 
medicines, such as informing the Authority (4/53), throwing the medicine away (4/53), 
asking the pharmacist for advice (3/53), reading the medicine leaflet for information 
(1/53) and not accepting to receive a medicine from the pharmacy, if they had any doubt 
about its quality. 
 
“I would go back to the doctor and stop the medicine and inform the doctor…”  
(Patient 1) 
 
Theme 3: Perceptions about medicine quality 
Most patients (31/53) generally perceived the quality of medicines available in the 
Saudi Arabian market as good or high. They rated the quality of medicines available in 
the market between 7 up to 10, on a scale of 10 where 10 was the best quality. Female 
patients in particular (14/18) and patients with no education or limited education (8/14) 
had mostly rated the quality of medicines in Saudi Arabia as good or excellent. Some 
patients (15/53) rated the quality of medicines as average between 5 up to 6 on the same 
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scale. Only a few patients (5/53) rated the quality of medicines in Saudi Arabia as poor 
or unacceptable, ranging from 1 to 4 on a similar scale. There were also a few patients 
(2/53) who did not know how to rate the quality of medicines in Saudi Arabia. 
 
“In the Security Forces, they are excellent and also in Saudi” (Patient 48) 
 
Similarly, most patients (38/53) perceived the quality of medicines available in the 
MOI-MSD as good or high, rating them between 7 up to 10, on a scale of 10 where 10 
was the best quality. Female patients in particular (15/18) and patients with no 
education or limited education (9/14) have favourably rated the quality of medicines in 
the MOI-MSD as good or excellent. Some patients (6/53) perceived the quality of 
medicines available in the MOI-MSD as average with ratings from 5 to 6 on the same 
scale. A few patients (5/53) believed that the quality of medicines in the MOI-MSD was 
poor or unacceptable by rating it from 1 to 4 on the scale. There were also a few patients 
(4/53) who did not know how to rate the quality of medicines in the MOI-MSD. 
 
“The medicines in the Ministry of Interior and some outside primary clinics do not 
depend on quality of the medicine but rather on the cheap medicine price” (Patient 2) 
 
When patients were asked about their perceptions about the quality of the medicines 
they were using, the majority (34/53) rated them as good or high, ranging from 7 to 10 
on a scale where 10 was the best. Some patients (11/53) rated them as average, ranging 
from 5 to 6 on a scale where 10 was the best. Only two patients rated their medicine as 
poor, ranging from 1 to 4 on the scale, and six patients did not rate the quality of their 
medicines.  
“I would give it 7 because I have been using this medicine for a while with the same 
result and I am hoping for more” (Patient 38) 
Theme 4: Price, health outcome, disease and quality relationship in medicines 
The majority of patients (27/53) believed that there was a relationship between 
medicine quality and price where the higher the medicine price, the higher the quality of 
a medicine. Some patients (17/53) stated that they did not believe such a relationship 
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existed between medicine quality and price. Female patients (9/18), in particular, did 
not associate medicine price with its quality when compared with male patients (8/35).  
A few patients (8/53) did not know what the relationship between medicine quality and 
price was. 
 
“What is common among people is that the expensive medicine has higher quality…” 
(Patient 42) 
 
Most patients (35/53) believed that there was a relationship between medicine quality 
and health outcomes where the higher the medicine quality, the more likely health 
outcomes would be better. A few patients (5/53) did not believe that such a relationship 
existed. Several patients (13/53) indicated that they did not know if there was a 
relationship between medicine quality and health outcomes. 
 
“They have a relationship. If the quality increased, the recovery would be better and 
wouldn’t take long time” (Patient 53) 
 
There were a few patients (4/53) who perceived a relationship between medicine price 
and the severity of the disease. They believed the medicine price would be more 
expensive if the disease was more severe. 
 
“It depends on the type of disease. The most expensive medicines are for very sick 
people like cancer, blood pressure and diabetes and surely their cost is higher…” 
(Patient 19) 
 
A number of patients (14/53) have expressed their opinion that medicine prices were 
expensive. In particular, patients from Jeddah (5/9) who were using medicines to treat 
their chronic conditions (4/9) shared this view.  
 
Theme 5: Counterfeit medicines 
Some patients (14/53) described a counterfeit medicine in terms of effect such as lack of 
effect, toxic effect or different effect than what was described on the medicine package 
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or desired by the patient. Other patients (10/53) believed that a counterfeit medicine was 
a medicine with a problem in manufacturing with minimal description of the type of 
problem. Moreover, some patients (5/53) described counterfeit medicines as fake copies 
of the original medicine. Some patients (3/53) described a counterfeit medicine as one 
from an unreliable source. There were a few patients (2/53) who described them as non-
registered or non-authorised medicines. Furthermore, one patient described the process 
of companies keeping their medications in unsuitable containers as counterfeiting since 
it employed the deception of the uninformed consumer. 
“…If they have no benefit and cause harm then these are counterfeit…” (Patient 26) 
Notably, there were some answers in the patients’ group that would suggest a degree of 
confusion between their understanding of counterfeit medicines and other medicine 
related issues. Some patients (4/53) thought that cheaper generic medicines were 
counterfeit. Other patients (4/53) believed that expensive medicines were counterfeit. 
Expired medicines were perceived as counterfeit by some patients (5/53). There were a 
few patients (2/53) who described counterfeit medicines as medicines stored in poor 
conditions. One patient thought that counterfeit medicines were medicines with side 
effects. Furthermore, there were some patients (12/53) who did not know what a 
counterfeit medicine was. 
 
“It could be expired or it could be without benefit” (Patient 20) 
 
When patients were asked about their estimation of the prevalence of counterfeit 
medicines on a global scale, mixed responses were given. Some patients (12/53) 
believed that the counterfeit medicine prevalence rate was between 0 to 10% globally, 
in particular from the female patients’ perspective (7/18). Other patients (18/53) 
estimated that it could reach 20 to 40%. Several patients (15/53) believed that 50% or 
more of global medicines were counterfeit. Furthermore, there were a number of 
patients (8/53) who did not know what the prevalence of counterfeit medicine was on a 
global scale.  
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Similarly, when patients were asked about their estimation of the prevalence of 
counterfeit medicines in Saudi Arabia, mixed responses were also given. Some patients 
(17/53) believed it was between 0 to 10% in Saudi Arabia. Other patients (19/53) 
estimated that it could reach between 20 to 40%. Several patients (11/53) estimated that 
50% or more of the medicines available in Saudi Arabia were counterfeit. Additionally, 
there were a number of patients (6/53) who did not know how to answer this question. 
 
There were some additional patient comments regarding counterfeit medicines in Saudi 
Arabia. A few patients (4/53) indicated that the problem of counterfeit medicines had 
increased recently in the country. Other patients (4/53) believed that counterfeiting in 
the country was not in medicines but rather in cosmetic and herbal products. 
 
“In Jeddah they found a warehouse that has counterfeit medicines smuggled from 
abroad… It happened 2 or 3 times and it was on the television on the news”  
(Patient 26) 
 
Theme 6: Challenges to medicines and their quality 
The patients identified several challenges to medicine quality in this phase of the study. 
Some patients (11/53) highlighted medicine non-availability at the primary clinics as a 
challenge to medicine quality since it required them to buy medicines out of their own 
pocket elsewhere. This issue was raised by a higher number of patients in interviews 
conducted in Jeddah (4/9) than interviews conducted in Riyadh (7/44). Furthermore, 
chronic patients reported medicine non-availability more often (7/22) than patients 
taking medicines for acute conditions (4/27). 
 
“…Especially the diabetes tablet, I have been buying it for 3 months on my expense 
because it is not available” (Patient 14) 
 
Some patients (8/53) voiced concerns about the difficulty they found when they wanted 
to report medicine quality problems. 
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“If I went back to the pharmacy, they wouldn’t accept anything from me. If I went to the 
Ministry of Interior they wouldn’t respond to me. The only option I have is to throw it 
away” (Patient 18) 
 
Some patients in this study identified several barriers that might not be directly related 
to medicine quality within the MOI-MSD services. The majority of barriers identified 
by patients (12/53) focused on the distant locations of primary care clinics and their 
limited opening times. Other patients (3/53) believed that hospital appointments were 
taking too long. A few patients (2/53) believed that pharmacists in the MOI-MSD were 
dispensing more than the required amounts of medicines to patients. One patient 
indicated that the emergency first aid at the primary clinic was slow and another patient 
reported that there was no emergency reception at their clinic. 
 
“…The working hours also if I get here after a traffic jam at around 12 they would say 
we are closed go and come back in the afternoon…” (Patient 16) 
 
Theme 7: Recommendations to ensure high medicine quality 
There were several recommendations from the patient group to ensure medicine quality, 
although a considerable number of patients (11/53) did not have any recommendations. 
Improving medicine monitoring was recommended by some patients (13/53). Others 
(4/53) recommended the analysis of medicine samples and procurement from 
international pharmaceutical companies instead of local manufacturers. There were 
other less common recommendations, such as ensuring good storage conditions (2/53), 
ensuring date of expiry and product information was correct (2/53), that governmental 
medicines should have a unique identifying symbol on medicine packages (1/53), to 
have only one generic option to each brand medicine (1/53) and to improve supply and 
demand forecast to avoid having excess medicines or shortages (1/53). 
 
“There should be high monitoring in hospitals and particularly in primary clinics” 
(Patient 42) 
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“To have contracts with global pharmaceutical companies that are known would be 
better” (Patient 2) 
Theme 8: Patients’ trust  
The majority of patients (29/53) expressed their complete trust in their physicians at the 
MOI-MSD and (22/53) of them indicated that they would consider their advice before 
taking any medicines. Patients with chronic conditions, in particular, (16/22) expressed 
trust in their physicians on more occasions than patients taking medicines for acute 
conditions (11/27). However, only a small number of patients (4/53) expressed similar 
feelings of trust in their pharmacist and only two patients (2/53) highlighted that they 
would consider a pharmacist’s advice before taking their medicine. Patients in this study  
also considered personal experience (5/53) and a friend or family experience (4/53), as a 
source of information they trusted, before using medicines. 
 
“The doctor has better background knowledge about quality and price” (Patient 17) 
 
6.8.5.3 Statistical analysis 
The statistical analysis that explored the relationship between the patients’ perceptions 
about medicine quality and their sociodemographic data did not show any statistical 
significance. Further details can be found in Table 6.5. 
 
Table 6.5 Relationship between patients’ perception about medicine quality in the MOI-
MSD and their sociodemographic data 
 
Characteristic P-value 
Gender .138 
Age .720 
Education .258 
Occupation .702 
Type of medicines used 1.000 
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6.8.6 Discussion 
The majority of patients in this phase of the study understood medicine quality based on 
their effect. This finding was similar to other patient reports in developing countries 
(Patel et al., 2010; Patel et al., 2012) and our findings from previous phases of this study 
with Saudi Arabian pharmacists in the UK (Chapter 6 phase 1) and MOI-MSD 
commissioners  (Chapter 6 phase 2). However, only a few patients associated a good 
quality medicine with a brand innovative company, which is in contrast with our 
findings from a previous phase of this study with MOI-MSD commissioners (Chapter 6 
phase 2).  
 
Most patients believed that medicine quality in Saudi Arabia was good or high. This 
result is in line with findings from other studies conducted with nurses, pharmacists, 
physicians and patients in developing countries (Syhakhang et al., 2004; Patel et al., 
2009; Patel et al., 2010; Patel et al., 2012) and the findings from a previous phase of this 
study with Saudi Arabian pharmacists in the UK (Chapter 6 phase 1) and MOI-MSD 
commissioners (Chapter 6 phase 2). However, there was no agreement between the 
MOI-MSD commissioners (Chapter 6 phase 2) and patients regarding their perception 
about the quality of medicines in the MOI-MSD settings. Only a few patients believed 
that the quality of medicines in the MOI-MSD was less than what is available in the 
Saudi Arabian market when compared with the MOI-MSD commissioners’ group 
(Chapter 6 phase 2). Furthermore, the association between patients’ demographic 
information and their perception about medicine quality in the MOI-MSD was found to 
be statistically insignificant. Therefore, it was not possible to statistically relate such 
demographic information with their perception about medicine quality in this sample. 
 
Around half of the patient group believed that high quality medicines were the 
expensive options. Patients were reported to have similar beliefs about the relationship 
between medicine price and quality in other studies (Holloway et al., 2002; Syhakhang 
et al., 2004; Patel et al., 2010; Patel et al., 2012; Alfadl et al., 2013). However, this 
belief was found to be more prevalent in the MOI-MSD commissioner’ group (Chapter 
6 phase 2) when compared with the current patient phase of the study. 
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Most patients in this study described a counterfeit medicine in terms of medicine 
manufacturing problems and lack of or toxic effect. This result was similar to some 
degree to the findings from the interviews with MOI-MSD commissioners’ phase of the 
study (Chapter 6 phase 2). Although patients were not expected to have a correct and 
accurate definition of counterfeit medicines due to their technical nature, it was 
important for the purpose of this study to explore their understanding of counterfeit 
medicines before they were asked about their prediction of the counterfeit prevalence 
rate in Saudi Arabia and on a global scale. However, the patients’ estimations of the 
prevalence of counterfeit medicine globally and in Saudi Arabia were found to be 
similar to the commissioners’ estimation in the previous phase of the study (Chapter 6 
phase 2). Around one third of patients believed that the counterfeit medicine prevalence 
rate was minimal in the country: between 0 to 10%. One third of patients estimated that 
counterfeit medicines were 20 to 40% prevalent in Saudi Arabia. Furthermore, one third 
of the patients predicted that 50% or more of medicines in Saudi Arabia were 
counterfeit. 
 
The patients in this phase of the study identified several challenges to their medicine 
experience and to their medicines’ quality. Some patients reported non-availability of 
medicines that they were prescribed at the MOI-MSD settings. However, only one of 
the commissioners in the previous phase of the study (Chapter 6 phase 2) identified 
medicine availability as a challenge to medicine quality in their practice. This could be 
potentially dangerous, as it would probably mean extra financial burdens on patients to 
procure such medicines elsewhere or, in a worst case scenario, could mean that patients 
may be vulnerable to other medicines that cannot be verified in terms of quality. Similar 
to the findings from the commissioners’ interviews (Chapter 6 phase 2), concerns were 
raised by some patients about the difficulty of reporting medicine quality problems in 
MOI-MSD settings. Furthermore, other issues were raised by patients in this phase of 
the study and were not reported in the commissioners’ interviews (Chapter 6 phase 2), 
such as the inaccessibility of some primary care clinics in terms of distant locations and 
inconvenient opening times.  
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Patients’ trust in their physicians was clearly described by most patients in this phase of 
the study. However, only a small number of patients expressed much trust in their 
pharmacist’s competency and some clearly stated that they do not trust their 
pharmacists. A gap in the relationship between pharmacists and patients was noted and 
required that the next phases of this study to address possible reasons for such beliefs 
and possible changes to increase the patients’ trust in pharmacists working in the MOI-
MSD settings. 
 
Limitations and strengths of this phase of the study 
This present interview phase of the study has several limitations. The findings from this 
study cannot be generalised since patient recruitment was from only three primary care 
clinics in two major cities in Saudi Arabia. However, generalisibility has not been the 
aim of this study as we aimed to explore different opinions and conduct in-depth 
analysis of the available information.  
 
Moreover, it was noted from the patient interviews that most of them had been seeking 
treatment in other public healthcare providers in Saudi Arabia, which could enhance the 
generalisability of our finding. Furthermore, some female patients did not agree to 
participate in the study and some did not agree to tape recording and therefore the 
principal researcher took notes of their answers. Their refusal for the interview to be 
tape-recorded could be due to cultural barriers between genders in these settings since 
the principal researcher is male. The characteristics and reasons for female patients who 
declined participation in this study remain unknown to the researcher.  
 
Furthermore, some questions required answers from the respondents’ past experiences 
and could be subject to recall bias. It was not possible to send the interview transcripts 
back to patients since they have only provided telephone numbers in their contact 
details and some had little or no educational background which did not permit them to 
use the Internet. Our aim in this study was explorative and, therefore, we did not seek 
data saturation from these interviews.  
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Nevertheless, this study was among the very few studies that examined medicine quality 
issues from the perspective of different stakeholders. To the researchers’ knowledge, it 
was the first study exploring such issues in Saudi Arabia and MOI-MSD settings from 
the patient’s perspective. The next phases of this study explored the perspectives of 
pharmacists and physicians in the MOI-MSD regarding medicine quality and any 
related issues. 
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6.9 Phase 4: Pharmacists’ and physicians’ perceptions about medicine 
quality and their related issues within the MOI-MSD in Saudi Arabia 
6.9.1 Introduction 
Studies investigating the perceptions about medicine quality and any related issues are 
extremely scarce in the literature (Chapter 5). Previously, the perceptions of 
commissioners (Chapter 6 phase 2) and patients (Chapter 6 phase 3) have been explored 
within the MOI-MSD settings in Saudi Arabia. 
6.9.2 Aim  
The overall aim of this phase was to explore the pharmacists’ and physicians’ 
perspectives on medicine quality and related issues such as counterfeit medicines in the 
MOI-MSD in Saudi Arabia.  
6.9.3 Objectives 
The specific objectives of this study included the following: 
 Establishing the MOI-MSD pharmacists’ and physicians’ beliefs and views 
about medicine quality and their related issues. 
 Explore their knowledge and behaviour about medicine quality and any related 
problems. 
  Seek the pharmacists’ and physicians’ views on potential improvements to the 
existing policies and procedures to address the issue of medicine quality in 
Saudi Arabia in the context of the global market. 
6.9.4 Methods 
6.9.4.1 Sample selection and settings 
The total number of individuals in the sample frame available in the study was 293 
physicians and 89 pharmacists. All 293 physicians and 71 pharmacists worked in MOI-
MSD clinics according to the latest available MOI-MSD annual statistical report 
(Appendices 19 and 20). Eighteen additional pharmacists working in the Medical 
Supply Department at the MOI-MSD were added to the sample frame for their 
relevance to subject area of this study. The total number of pharmacists working in the 
Medical Supply Department was determined through personal communication with the 
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Department’s Director in the absence of such official records. There were no physicians 
working at the medical supply department at the time of study. 
6.9.4.2 Survey questionnaire design  
A cross-sectional survey design was selected for this study to facilitate the 
understanding of the phenomena from the perspective of a wide range of pharmacists 
and physicians within our sample frame in the country. Survey questionnaires 
addressing medicine quality and related issues were developed in English based on a 
systematic literature review of similar studies (Chapter 5) and the findings from a 
previous phase of this study (Chapter 6 phase 1). English was chosen as the primary 
language for the survey questionnaires since the members of the sample frame were 
healthcare professionals who have a minimum of a Bachelor Degree in their subject 
area, which was primarily taught in English in Saudi Arabia.  
The majority of questions in the questionnaire instrument were closed-ended and only a 
few were open-ended. A rating scale from 1 to 10, where 10 was the best or most likely, 
was used in some questions to measure perceptions in a similar approach to a Likert 
scale. The final physician questionnaire (Appendix 21) consisted of 27 questions, 
including 7 demographic questions, 5 questions to establish knowledge about medicine 
quality, 14 questions to explore perception and behaviour associated with medicine 
quality and one question to explore potential improvement to existing policies and 
procedures to address medicine quality. All respondents received every question as skip 
logic was not programmed in the survey. The pharmacists’ survey questionnaires 
(Appendix 22) were similar to their physician counterparts except on some demographic 
and practice-related questions, such as prescribing or dispensing, to allow for group 
comparability. 
6.9.4.3 Validity and reliability checks 
The validity and reliability checks were performed in a similar method to the approach 
in the previous phases of this study (Chapter 6 phases 1, 2 and 3). In addition, the 
survey questionnaire was piloted with four pharmacy students at the University of 
Hertfordshire, who did not participate in the previous phase of the study (Chapter 6 
phase 1). 
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6.9.4.4 Survey questionnaire distribution 
The survey questionnaire was distributed electronically using the electronic software 
Survey Monkey (Portland, Oregon USA; http://www.surveymonkey.com) via a web 
link in WhatsApp smartphone application (Santa Clara, California USA; 
http://www.whatsapp.com) to all pharmacists and physicians working in MOI-MSD 
primary care clinics. This choice of survey distribution method was based on 
consultation with the Healthcare Centers Department Commissioner to ensure a higher 
response rate from potential participants. The Commissioner of the Healthcare Centers 
Department in the MOI-MSD received the customised invitation letters and web links to 
each survey and then distributed it to potential participants. This choice of survey 
distribution was considered appropriate for this sample frame since they can be assumed 
to be literate, with sufficient English proficiency, and it ensured the anonymity of 
respondents. Furthermore, the choice of an online method of questionnaire distribution 
was an attempt to minimise interviewer bias and social desirability bias (Bowling, 
2011). The survey was available online for 8 weeks from March 2014 and required 10-
15 minutes to be completed by respondents. The researcher monitored the number of 
responses regularly while the survey was open and weekly reminders were sent to 
potential respondents by the same method. Moreover, the electronic method of survey 
distribution was not applied to pharmacists working within the Medical Supply 
Department. Following consultations with the Medical Supply Director, it was agreed 
that hard copy survey questionnaires would ensure a higher response rate since Internet 
access and smart phone applications may not be available to all eligible participants in 
this department. The researcher distributed hard copy survey questionnaires to each 
section staff and agreed a time for the collection of completed copies at their 
convenience. This approach was selected in order to minimise the effect on participants’ 
anonymity through multiple distribution and collection periods for hard copy self-
administered survey questionnaires. The completed hard-copy survey questionnaires 
were subsequently entered manually into the SurveyMonkey system by the researcher. 
Permissions were granted prior to the start of this study from the University of 
Hertfordshire Ethical Committee and the General Administration of the MOI-MSD in 
Saudi Arabia (Appendices 9, 10 and 11). 
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6.9.4.5 Data analysis 
Following the survey completion, results were downloaded into the latest available 
Microsoft Excel spread sheet and SPSS for the descriptive analysis of quantitative data. 
For open-ended questions, data was analysed using a content analysis approach and 
findings reported as numbers and percentages. 
 
An ordinal regression model was undertook to study the relationship between the 
pharmacists’ and physicians’ perceptions about medicine quality in the MOI-MSD and 
the explanatory categorical variables including their gender, age, education, region of 
practice and years of experience working in the MOI-MSD. Ordinal regression models 
were chosen since the perceptions about medicine quality were initially coded as ordinal 
variables. The purpose for this ordinal regression model was to examine the odds ratio 
(OR) between these explanatory variables and having poor perception about the quality 
of medicines in the MOI-MSD. For example, if the OR between male physicians and 
poor perception about medicine quality was four, this would indicate that male 
physicians were four times more likely to have negative perceptions about medicine 
quality in these settings. The statistical analysis for the ordinal regression tests was 
performed using SPSS and 95% confidence intervals were considered significant. 
6.9.4.6 Data coding 
For Likert style questions that asked the respondents to rate their answers on a scale of 
10, a five point system was used to categorically code the data as follows: ratings of 1 
and 2 were coded as unacceptable; ratings of 3 and 4 were coded as poor; ratings of 5 
and 6 were coded as average; ratings of 7 and 8 were coded as good and ratings of 9 and 
10 were coded as excellent. However, the perception data about the quality of medicines 
in the MOI-MSD was recoded into rating 1 to 5 as poor quality and rating 6 to 10 as 
good quality in order to facilitate the ordinal regression model.  
6.9.5 Results 
6.9.5.1 Rate of response 
A total of 58 pharmacists and 63 physicians responded to this survey questionnaire. The 
response rate was therefore 65% and 21.5% from pharmacists and physicians 
respectively. 
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6.9.5.2 Respondents’ characteristics 
Table 6.6 illustrates the demographic information of the participants in this phase of the 
study. 
 
Table 6.6 Characteristics of respondents to the survey phase of the study 
Category Subcategory Pharmacists (n=58) Physicians (n=63) 
Gender Male 
Female 
 
40 (69%) 
18 (31%) 
53 (84%) 
10 (16%) 
Age 20-29 
30-39 
40-49 
50-59 
60 or more 
 
15 (26%) 
32 (55%) 
7 (12%) 
3 (5%) 
1 (2%) 
4 (6%) 
23 (37%) 
23 (37%) 
11 (17%) 
2 (3%) 
Practice region Central region 
Western region 
Southern region 
Northern region 
Eastern region 
Not specified 
 
30 (52%) 
9 (16%) 
7 (12%) 
6 (10%) 
3 (5%) 
3 (5%) 
23 (37%) 
16 (25%) 
9 (14%) 
13 (21%) 
2 (3%) 
Education BSc 
MSc 
PhD 
Other higher education 
 
39 (67%) 
13 (22%) 
2 (4%) 
4 (7%) 
15 (24%) 
24 (38%) 
9 (14%) 
15 (24%) 
Work experience in 
MOI-MSD 
Less than one year 
1-4 years 
5-9 years 
10-14 years 
15 years or more 
 
1 (2%) 
16 (27%) 
12 (21%) 
16 (27%) 
13 (23%) 
4 (6%) 
14 (22%) 
12 (19%) 
15 (24%) 
18 (29%) 
 
6.9.5.3 Knowledge, beliefs and views about medicine quality and their problems 
The pharmacists and physicians in this study were asked to define what a high quality 
medicine was in an open-ended question. The majority of responses from pharmacists 
(n=22, 38%) and physicians (n=30, 47%) indicated that a high quality medicine was a 
medicine with good effect and minimal side effects. Some pharmacists (n=8, 13%) and 
physicians (n=1, 2%) believed that a good quality medicine was a medicine that was 
manufactured in optimal conditions. Several pharmacists (n=6, 10%) and physicians 
(n=1, 2%) considered brand medicines manufactured from innovative pharmaceutical 
companies as good quality medicines. Some pharmacists (n=4, 7%) and physicians 
(n=4, 6%) have highlighted reasonable medicine price as a key characteristic of a good 
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quality medicine. Furthermore, some pharmacists (n=2, 3%) and physicians (n=1, 2%) 
considered medicine availability as a characteristic of a good quality medicine. 
Respondents from the pharmacists’ group described a good quality medicine as a 
medicine with good appearance or packaging (n=4, 7%) and being registered with the 
authorities (n=2, 3%). Few respondents from the physicians’ group described a good 
quality medicine as a medicine that was accepted by the patient (n=2, 3%). Figure (6.3) 
illustrates the key characteristics of a good quality medicine in the opinion of 
pharmacists and physicians in this phase of the study. 
 
 
Figure 6.3 Definition of high quality medicine by pharmacists and physicians in the 
MOI-MSD 
6.9.5.4 Medicine attributes of importance 
Pharmacists and physicians were asked to rate the importance of 13 different medicine 
attributes on a scale from 1 to 10, where 10 was the most important. Both pharmacists 
and physicians believed that confidence in the medicine quality of production, SFDA 
registration, lot number and expiry date information, their personal experience with the 
medicine, clinical effectiveness and patient safety were important medicine attributes 
with an average score of more than 8 in both groups (Figure 6.4). Other medicine 
attributes such as manufacturing company details, patient information leaflet, 
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medicine’s price, the experience of a friend or family member, medicine’s availability 
and patient’s preference were found to be of less importance according to the 
pharmacists and physicians’ beliefs in this study, with an average score between 5 up to 
8 on the rating scale (Figure 6.4).  
 
 
Figure 6.4 Pharmacists’ and physicians’ average rating on medicine attributes  
 
6.9.5.5 Relationship between medicine price, health outcome and medicine quality 
The pharmacist’ and physicians’ beliefs about the relationships between expensive 
medicines and medicine quality and health outcomes were examined on a scale from 1 
to 10, where 10 was the most likely. On average, pharmacists were more likely to 
believe that expensive medicines resulted in a better medicine quality and better health 
outcomes, when compared with physicians in this study (Figure 6.5). In contrast, 
physicians rather than pharmacists were more likely to believe that medicine quality 
influenced their practice of prescribing on an average rating (Figure 6.5). Detailed 
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accounts for all pharmacists’ and physicians’ ratings on the relationships between 
medicine price, medicine quality, health outcomes and influence on practice can be 
found in (Figures 6.5, 6.6 and 6.7.)  
 
 
Figure 6.5 Price, health outcome, influence on practice and medicine quality 
relationships in physicians’ and pharmacists’ opinions 
 
 
Figure 6.6 Price, health outcome, influence on practice and medicine quality 
relationships in physicians’ opinions 
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Figure 6.7 Price, health outcome, influence on practice and medicine quality 
relationships in pharmacist’ opinions 
6.9.5.6 Counterfeit medicines 
Pharmacists and physicians were asked to define what a counterfeit medicine was. 
Some responses by the pharmacists (n=15, 26%) and most physicians (n=26, 41%) 
described a counterfeit medicine as one with minimal or harmful effect. Some 
pharmacists (n=6, 10%) and physicians (n=1, 2%) indicated that a counterfeit medicine 
has a manufacturing problem. Other characteristics of a counterfeit medicine were also 
described by the participants in this phase of the study such as no API, wrong API, 
wrong percentage of API, a medicine with an appearance problem, a fake copy of an 
original medicine, a medicine from an unreliable source or a non-registered medicine. 
Figure 6.8 lists all reported characteristics of a counterfeit medicine. 
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Figure 6.8 Definition of counterfeit medicines by pharmacists and physicians in the 
MOI-MSD 
 
The majority of pharmacists and physicians in this phase of the study estimated that the 
global prevalence rate of counterfeit medicines was more than 10% of the 
pharmaceutical supply chain. Figure 6.9 illustrates all the respondents’ estimations 
regarding the prevalence of counterfeit medicines globally.  
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Figure 6.9 Pharmacists’ and physicians’ estimations about prevalence of counterfeit 
medicines globally 
 
When asked about their estimation of the prevalence rate of counterfeit medicines in 
Saudi Arabia, mixed responses were obtained from both the pharmacists and physicians. 
Figure 6.10 contains a brief summary of the participants’ estimations about the 
prevalence rate of counterfeit medicines in Saudi Arabia. 
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Figure 6.10 Pharmacists’ and physicians’ estimations about prevalence of counterfeit 
medicines in Saudi Arabia 
 
6.9.5.7 Perception and behaviour regarding medicine quality and problems 
On a scale from 1 to 10 where 10 is the best, the pharmacists (55%) and physicians 
(71%) in this study had the perception that medicine quality available in the Saudi 
Arabian market was above average in general. Both the pharmacists (50%) and 
physicians (52%) believed that medicine quality in their own settings at the MOI-MSD 
was lower than what is available in the Saudi Arabian market as a whole. Furthermore, 
pharmacists had lower rating scores for medicine quality in Saudi Arabia, in the MOI-
MSD and in the medicines they dispensed on a scale from 1 to 10, where 10 was the 
best when compared to physicians (Figure 6.11). Detailed accounts for all pharmacists’ 
and physicians’ ratings on medicine quality in Saudi Arabia, the MOI-MSD and in the 
medicines they prescribed or dispensed can be found in Figure 6.12 and Figure 6.13. 
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Figure 6.11 Pharmacists’ and physicians’ views about medicine quality in Saudi Arabia 
and the MOI-MSD 
 
 
Figure 6.12 Physicians’ views about medicine quality in Saudi Arabia and the MOI-
MSD 
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Figure 6.13 Pharmacists’ views about medicine quality in Saudi Arabia and the MOI-
MSD 
 
Respondents were asked about the medicines therapeutic classes and formulations of 
concern in terms of quality. Both the pharmacists and physicians highlighted chronic 
disease and infectious disease medicines as the main therapeutic classes of medicine 
quality concerns. Furthermore, the pharmacists and physicians indicated that tablets and 
injections were the formulations of most quality concerns. Figures 6.14 and 6.15 
illustrate all the physicians’ and pharmacists’ responses to identify therapeutic classes 
and formulations they thought were of most concern with regard to medicine quality. 
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Figure 6.14 Therapeutic classes of concern to pharmacists and physicians regarding 
medicine quality 
 
 
Figure 6.15 Medicine formulation of quality concerns to pharmacists and physicians 
 
Some pharmacists (n=21, 36%) and physicians (n=13, 20%) reported experiences with 
medicines that had questionable quality within their practice in the MOI-MSD. The 
frequency of these encounters varied and can be found in Figure 6.16. When asked to 
describe these experiences, some descriptions were provided by the pharmacists and 
physicians in this study that can be summarised in Figures 6.17 and 6.18. 
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Figure 6.16 Frequency of pharmacists’ and physicians’ doubts about medicine quality in 
the MOI-MSD 
 
 
Figure 6.17 Pharmacists’ encounters with medicine quality problems 
 
0 10 20 30 40 50 60
Never
Once a year
2 to 4 times a year
5 to 10 times a year
More than 10 times a year
No answer
Percentage of medicine quality doubts
T
y
p
e 
o
f 
m
ed
ic
in
e 
q
u
a
li
ty
 d
o
u
b
t
Physician Pharmacist
0%
5%
10%
15%
20%
25%
P
er
ce
n
ta
g
e 
o
f 
a
n
sw
er
s
Type of medicine quality problem
 178 
 
Figure 6.18 Physicians’ encounters with medicine quality problems 
 
The pharmacists and physicians were asked about their behaviour when in doubt about 
the quality of a medicine. The majority of pharmacists (n=35, 60%) and physicians 
(n=31, 49%) indicated that they reported it to the Director of Pharmacy. Some 
pharmacists (n=15, 26%) and physicians (n=35, 56%) highlighted that they took action 
by stopping dispensing or prescribing the medicine. A number of pharmacists (n=30, 
52%) and physicians (n=14, 22%) considered reporting their doubts to the SFDA. 
Further details about the type of pharmacists’ and physicians’ behaviour reported when 
in doubt about the quality of medicines can be found in Figure 6.19. 
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Figure 6.19 Pharmacists’ and physicians’ behaviour following doubts about medicine 
quality 
*Multiple answers were allowed and hence percentages do not add up to 100% 
 
6.9.5.8 Challenges to medicine quality and recommendations for improvement 
Pharmacists and physicians were asked about their concerns about medicine issues at 
their settings in general, including quality. The most reported concerns were regarding 
medicine storage or transportation, medicine expiry dates, damaged medicine packages, 
patients’ acceptance of the available medicines and the visual appearance of available 
medicines. Other less reported concerns included doubts about the presence of the 
correct amount of active ingredient. Figure 6.20 illustrates all the respondents’ major 
concerns about medicines in this phase of the study. 
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Figure 6.20 Healthcare providers’ views on major challenges to medicine quality in the 
MOI-MSD 
*Multiple answers were allowed and hence percentages do not add up to 100% 
 
Pharmacists and physicians provided recommendations to enhance the medicine quality 
assurance in their settings. The majority of recommendations included the improvement 
of medicine practice at the warehouse and procurement level. Other recommendations 
were given at the Saudi Arabian regulatory and the MOI-MSD administrative level. 
Table 6.7 illustrates the recommendations of all pharmacists and physicians in this 
phase of the study. 
 
Table 6.7 Pharmacists’ and physicians’ recommendations to enhance quality of 
medicines 
Pharmacist (n=58) Physicians (n=63) 
No recommendation (12%) 
 
At regulatory level (14%) 
More effort from SFDA (5%) 
Improve monitoring of medicines (3%) 
Strengthen registration process (1%) 
Analysis of medicine samples (5%) 
 
 
At MOI-MSD administrative level (12%) 
Establish quality control section (8%) 
Establish policy and guidelines (4%) 
No recommendations (18%) 
 
At regulatory level (18%) 
More effort from SFDA (3%) 
Improve monitoring of medicines (9%) 
Analysis of medicine samples (6%) 
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At warehouse level (17%) 
Improve storage conditions (8%) 
Improve transport conditions (4%) 
Monitor expiry dates (1%) 
Visual check of medicine info. (4%) 
 
At procurement level (17%) 
Have more brand medicines (3%) 
 
Selection of medicines based on evidence and 
clinical experience (3%) 
Selection of medicines based on quality and less 
emphasis on price (5%) 
Buy from trustful suppliers or manufacturing 
companies (5%) 
 
Less procurement from tender systems (5%) 
 
 
Increase education (4%) 
 
Improve communication with other healthcare 
organisations (4%) 
 
Staff to improve their practice in dispensing, 
preparation and prescribing (5%) 
 
Stop dispensing doubtful quality medicines 
(3%) 
 
Update the medicine formulary (1%) 
 
Establish a reporting system (1%) 
 
Conduct more research (1%) 
 
 
At warehouse level (19%) 
Improve storage conditions (10%) 
Improve transport conditions (6%) 
Monitor expiry dates (3%) 
 
 
At procurement level (10%) 
Have more brand medicines (4%) 
 
Selection of medicines based on quality and less 
emphasis on price (n=3%) 
 
 
Buy from trustful suppliers or manufacturing 
companies (3%) 
 
 
 
 
Increase education (4%) 
 
Improve communication with pharmacists and 
staff (4%) 
 
Pharmacist to improve their practice and 
competency (3%) 
 
More control over OTC and antibiotics (1%) 
 
Classify drugs according to quality (1%) 
 
To have a good health information system (1%) 
 
To have good follow-up of cases and outcomes 
for patients (1%) 
 
6.9.5.9 Ordinal regression model 
The independent variables explored in this model were the pharmacists’ and physicians’ 
perception about medicine quality in the MOI-MSD settings based on their rating scores 
from 1 to 10 where 10 is the best. The dependent variables included the pharmacists’ 
and physicians’ age, gender, education, region of practice and years of experience 
working in the MOI-MSD. The ordinal regression model fitting information was 
positive for both the physicians’ and pharmacists’ models and indicated that these 
models fit the data significantly (Table 6.8).  
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Table 6.8: Model fitting information table for pharmacists and physicians data 
Model -2 Log 
Likelihood 
Chi-Square df Sig. 
Pharmacists 93.957 43.886 16 .000 
Physicians 111.226 33.247 16 .007 
 
In the pharmacists’ data, the Goodness-of-Fit table had inconclusive results as shown in 
Table (6.9). While one test resulted in rejecting the null hypothesis and considering the 
model as inadequate (Pearson), the other test resulted in accepting the null hypothesis 
and considered the model as adequate (Deviance). In contrast, within the physicians’ 
data, the Goodness-of-Fit table resulted in accepting the null hypothesis and considered 
the model as adequate. 
 
Table 6.9: Goodness-of-Fit table for pharmacists and physicians data 
Model Test Chi-Square df Sig. 
Pharmacists Pearson 
Deviance 
145.695 
74.313 
16 
16 
.032 
.999 
Physicians Pearson 
Deviance 
119.012 
99.796 
188 
188 
1.000 
1.000 
 
The results of Wald’s test in the parameter estimates table were mostly insignificant in 
the pharmacists’ data except two variables (Age 50-59) and (Central region of practice). 
This would suggest that pharmacists’ between the ages of 50 to 59 were three times 
more likely to have a poor perception about medicine quality in the MOI-MSD. It 
would also suggest that MOI-MSD pharmacists working in the central region in the 
country were 0.1 times more likely to have poor perceptions about medicine quality in 
their settings. Similarly, the results in the physicians’ data were mostly insignificant 
except two variables (MSc education) and (having 1 to 4 years of experience in the 
MOI-MSD) as shown in Table 6.10. This would suggest that physicians with MSc 
education and also physicians with an experience between 1 to 4 years in the MOI-MSD 
were almost one time more likely to have a poor perception about medicine quality in 
their settings.  
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Table 6.10 Parameter estimate table for pharmacists and physicians 
Model Variable Sig OR 95% C. I. 
Upper 
95% C. I. 
Lower 
Pharmacists Age 50-59 
Central region of practice 
.000 
.026 
3.04 
0.107 
12.650 
-4.190 
26.567 
-0.270 
Physicians Education MSc 
Experience between 1 to 
4 years in the MOI-MSD 
.025 
.015 
0.975 
0.985 
.250 
.492 
3.645 
4.654 
 
 
The test of parallel lines showed statistical significance for both the physicians’ and 
pharmacists’ models. This indicated that we have violated the assumption of the ordinal 
regression analysis and therefore caution is advised when interpreting the results (Table 
6.11). 
 
Table 6.11 Test of parallel lines for pharmacists and physicians 
Model -2 Log 
Likelihood 
Chi-Square df Sig. 
Pharmacists .000 93.957 48 .000 
Physicians .000 111.226 48 .000 
 
Additionally, a Chi-Square statistical test was performed and found no statistical 
significance between the pharmacists’ and physicians’ perceptions about medicine 
quality in Saudi Arabia and the MOI-MSD as shown in Table 6.12. 
 
Table 6.12 Chi-Square statistical significance between the MOI-MSD pharmacists’ and 
physicians’ perceptions about medicine quality 
Characteristic P-value 
Perceptions about medicine quality in Saudi Arabia 0.950 
Perceptions about medicine quality in the MOI-MSD 0.247 
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6.9.6 Discussion 
The pharmacists and physicians in this study defined high quality medicines mostly 
through their perceived effects. This perception is in line with findings from other 
studies (Haddad et al., 1998; Syhakhang et al., 2004; Patel et al., 2009; Patel et al., 
2010; Patel et al., 2012) conducted with patients and healthcare professionals in low and 
middle-income countries. However, findings from this study suggest that physicians 
(58%) associated medicine quality with medicine effects more frequently when 
compared with pharmacists (35%) in these settings. Pharmacists (24%) highlighted 
several medicine attributes such as manufacturing, source, expiry, storage and transport 
conditions to describe a high quality medicine compared to physicians (6%). This 
mirrors findings from other studies, for example, with nurses selling medicines in Laos 
(Syhakhang et al., 2004). Interestingly, few pharmacists (7%) and physicians (2%) used 
the term brand medicine to describe a high quality medicine, in line with similar studies 
(Syhakhang et al., 2004). In addition, pharmacists in this study held a stronger belief 
that more expensive medicines were associated with higher quality and better health 
outcomes when compared with physicians. These results are not without support from 
the existing literature (Tellis & Geath, 1990; Chapman & Wahlers, 1999; Syhakhang et 
al., 2004; Alfadl et al., 2012).  
 
The respondents in this study had a perception that the quality of medicine was above 
average in Saudi Arabia. They believed that the quality of medicines in their own 
settings at the MOI-MSD was lower than what is available in the Saudi Arabian market 
as a whole. It is possible that the respondents were dubious about medicines procured 
from tender systems that could generally favour cheaper and alternative generic 
medicines, where possible. Further exploration using in-depth interviews with members 
of this population is needed to determine the factors associated with this belief. 
 
Pharmacist in this study (59%) reported having doubts about medicine quality more 
frequently than physicians (44%). The experiences encountered by those reporting such 
doubts about medicine quality included not having an effect, expired, appearance 
problem, non-registration, bad odour, less than stated dosage quantity, patient 
complaints and information about product recalls issued by the SFDA. Moreover, their 
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practice when in doubt about medicine quality was mostly to report it to the Director of 
Pharmacy in their own settings. A total of 52% of pharmacists and only 22% of 
physicians have considered informing the SFDA of such doubts about medicine quality. 
This finding is alarming as it could hinder any efforts by the healthcare regulators in the 
country to collect and exchange information about suspicious medicines through 
pharmacovigilance programmes. Education and campaigns to facilitate nationwide 
reporting of medicine quality problems or suspicions are recommended in this 
population. 
 
The notions pharmacist and physicians have about counterfeit medicines were explored 
in this study. Most physicians (45%) and some pharmacists (25%) defined a counterfeit 
medicine as one with no effect, minimal effect or with a harmful effect. This finding 
supports the medicine effect and quality perception discussed earlier. The majority of 
pharmacists’ answers (48%) and some physicians (23%) described a counterfeit 
medicine as having problems in manufacturing, active ingredient, packaging, 
appearance and source. Only some pharmacists (13%) and physicians (7%) clearly 
specified that a counterfeit medicine was a fake copy of an original product that was 
intended for fraudulent deception. Similarly, only a few pharmacists (6%) and 
physicians (10%) defined a counterfeit medicine as unregistered or unauthorised by the 
SFDA. Interestingly, some physicians (4%) described a counterfeit medicine as one that 
has come from the Middle East. For the most part, the definition of counterfeit 
medicines provided by the respondents in this study does not reflect the WHO 
definition of counterfeit medicines which highlights the medicine identity, source, 
packaging and fraudulent activity as key features to determine a counterfeit medicine 
(WHO, 1999a). 
 
The estimation of counterfeit medicines prevalence on a global scale was thought to be 
between 20% to 50% by most pharmacists (53%) and physicians (62%). Only 9% of 
pharmacists and 11% of physicians predict similar estimations to the WHO on a global 
scale at 10%. Also, 30% of pharmacists and 21% of physicians believed that counterfeit 
medicines contributed to 60% or more of the global pharmaceutical supply. The 
respondents’ estimations of counterfeit medicines in Saudi Arabia were different. Most 
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pharmacists (38%) and some physicians (25%) agreed with the SFDA in that counterfeit 
medicine was non-existent or up to 10% of the Saudi Arabian market (Arabnews, 2010; 
Ameinfo, 2011). Further, 36% of pharmacists and 43% of physicians believed that it 
was between 20% to 40%, in line with local media reports in the country (Saudi 
Gazette, 2011). Moreover, 26% of pharmacists and 24% of physicians believed that the 
prevalence of counterfeit medicine in Saudi Arabia was 50% or more of the supply 
chain. It is possible that the limited understanding of what a counterfeit medicine was, 
which can be found in the literature (Jacobs, Coskun & Jedlik, 2001; Bosworth, 2006; 
Alfadl et al., 2012) and the results from this study could have contributed to such high 
estimations. There is a need for education about counterfeit medicine and strategies to 
enhance the healthcare professionals’ confidence in the quality of medicines available in 
these settings, for better utilisation of the available medicine resources. 
 
The majority of respondents believed that incorrect storage conditions, incorrect 
transport conditions and the presence of expired medicines were major challenges to 
medicine quality in these settings. Future observational studies could be employed to 
confirm or provide assurance for the concerned respondents. Some pharmacists and 
physicians had concerns about the presence and the correct percentages of the active 
ingredients in the available medicines. Chemical analysis tests on selected medicine 
samples from these settings could be performed according to international 
pharmacopeias in order to examine these concerns and to ensure that the results are 
widely published among the healthcare providers to support their knowledge in this 
regard. Interestingly, the results suggest that more pharmacists believed that patients’ 
non-acceptance of their medicines was a challenge in these settings when compared 
with physicians. This could highlight the fact that the pharmacists are the last healthcare 
professionals in the supply chain facing patients when medications are supplied to them 
experiencing “non-acceptance” behaviour of patients first hand. Future in-depth 
interviews with this population could examine fully the reasons for such discrepancies 
and assumptions. 
 
The pharmacists and physicians made several recommendations to enhance medicine 
quality in the MOI-MSD. The majority of recommendations included the improvement 
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of medicine practice at the warehouse and procurement level. Such recommendations 
could include improvement of the storage and transport conditions of medicines. In 
addition, more flexibility could be employed for the procurement of medicines through 
direct purchases in addition to tenders. However, such recommendations could be 
impractical particular with limited financial resources. Other recommendations were 
aimed at the Saudi Arabian regulatory and MOI-MSD administrative level to establish 
policy and guidelines, in addition to improving medicine monitoring in the country. 
 
Implications for future research 
This phase of the study has identified several areas that would require in-depth 
exploration using semi-structured interviews with a sample from the same sample 
frame. Firstly, it was unclear why some pharmacists and physicians in this phase of the 
study perceived a difference in medicine quality in the MOI-MSD and the medicines 
available in the Saudi Arabian market as a whole. Secondly, there were some negative 
comments regarding medicine procurement systems through tenders that required more 
understanding in terms of possible causes and recommendations to improve it. Thirdly, 
it was not clear how the participants in this study could make a clear judgment of 
whether a medicine was of good quality or not. Fourthly, difficulty in the reporting of 
suspected medicine quality problems has been noted from several comments made by 
the participants in response to open-ended questions and would require further 
exploration of those experiences and how to improve the reporting of such problems in 
these settings. Fifthly, it was found that physicians reported the behaviour of stopping 
prescribing a medicine with suspicious quality more often than pharmacist and, 
therefore, would require further insight for understanding the reasons for such 
differences. Furthermore, some medicine attributes were found to be of less importance 
than others in the opinions of the participants and therefore would require further 
exploration. Moreover, the participants made several recommendations that did not 
have sufficient details in order for them to be applied in these settings and hence the 
upcoming phase of this study is required to explore them in-depth.     
 
Strengths and limitations of the survey questionnaire phase of the study 
This present phase of the study had several limitations. The method of online self-
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completed survey administration was less reliable than other forms of survey 
administration since the identity of respondents cannot be verified and the physical 
absence of the researcher does not allow for any further clarification of questions. The 
nature of most questions required predetermined answers; however, using the “other” 
option was frequently applied to allow for different opinions, to minimise the effect of 
framing bias. Some questions required answers from the respondents’ past experiences 
and could be subject to recall bias. Moreover, some questions asked respondents about 
their practices regarding medicine quality issues and cannot be verified in the absence 
of an observational study. This survey has been designed and sent to members of the 
study sample frame and therefore findings are limited and cannot be extrapolated to 
other healthcare professionals within the same settings. Nevertheless, this study is 
among the very few studies that examined medicine quality issues from the perspective 
of different stakeholders. To the researcher’s knowledge, it is the first study exploring 
such issues with pharmacists and physicians in Saudi Arabia and the MOI-MSD 
settings.  
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6.10 Phase 5: Confirmatory interview study of pharmacists’ and 
physicians’ survey questionnaire findings 
6.10.1 Introduction 
Research into medicine quality and their problems from the stakeholders’ perspective is 
limited worldwide (Chapter 5). The perceptions about medicine quality and their 
problems have been previously explored from the different stakeholders’ perspective 
including commissioners (Chapter 6 phase 2), patients (Chapter 6 phase 3) and 
pharmacists and physicians (Chapter 6 phase 4) within the MOI-MSD settings in Saudi 
Arabia in this study. 
6.10.2 Aim  
The aim of this phase of the study was to explore in-depth some issues regarding 
medicine quality found from the previous survey questionnaire phase of the study 
(Chapter 6 phase 4) with pharmacists and physicians in the MOI-MSD settings in Saudi 
Arabia in order to validate and supplement the survey findings. 
6.10.3 Objectives 
The objectives of this phase of the study includes the following: 
 To explore in-depth the beliefs and views of pharmacists and physicians about 
medicine quality in the MOI-MSD 
 Seek the pharmacists’ and physicians’ recommendations to improve the 
pharmacist’s role, improve tender system for medicine procurement, improve 
reporting of medicine quality problems, quality assurance of medicines, 
medicine monitoring and analysis within the MOI-MSD 
 Explore the perceived effect of some medicine attributes on the supply of 
medicine from the pharmacists’ and physicians’ perspective 
6.10.4 Methods 
In order to achieve the objectives of this phase, a qualitative approach using semi-
structured interviews as a method for data collection was selected for flexible collection 
of data and achieved a greater in-depth understanding of this social phenomena (Smith, 
2002; Morse & Field, 1995). 
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6.10.4.1 Selection of participants and study settings  
The participants selected for this phase of the study were pharmacists and physicians 
working within the MOI-MSD settings. An invitation letter was sent from the 
Commissioner of Primary Care Clinics in the MOI-MSD on the researcher’s behalf to 
all pharmacists and physicians working in MOI-MSD primary clinics electronically 
using WhatsApp smartphone application (Santa Clara, California USA; 
http://www.whatsapp.com). All MOI-MSD pharmacists and physicians had been 
previously sent a similar invitation during the previous survey phase of the study 
(Chapter 6 phase 4) and, therefore, an explanation was provided within the invitation 
letter that these interviews would complement the survey phase of the study on the same 
topic. The Commissioner of the primary care clinics provided the researcher with the 
contact details of potential participants who agreed to be interviewed. Telephone calls 
were made to ensure their agreement by verbal consent and to set up an appropriate time 
for the interview for each individual. A commissioner information sheet (Appendix 14), 
consent form (Appendix 16) and a demographic information sheet (Appendix 23) were 
sent via e-mail to all respondents who agreed to be interviewed. 
6.10.4.2 Development of the interview guide 
The semi-structured interview guide was developed based on the findings from the 
previous phases of the study (Chapter 6 phase 3) and (Chapter 6 phase 4). Table 6.13 
highlights the key questions in the pharmacists’ and physicians’ interview guide. 
 
Table 6.13 Pharmacists’ and physicians’ interview guide questions  
1-In your opinion, what role does the pharmacist play in providing healthcare? How? 
Why? How can it be improved? 
 
2-What do you think about the quality of medicines available in Saudi in general? In 
MOI? If different why? 
 
3-What do you think about the tender system for medicine procurement? Why? How can 
it be improved? 
 
4-How would you judge the quality of a medicine? Why? 
 
5-What do you think about reporting of medicine quality problems? How? When? What 
happens after your report? How can it be improved? 
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6-What do you think about taking action (stop prescribing or stop dispensing a 
medicine) if you had doubt about its quality? Why? 
 
7-How would country of manufacturing affect your supply of the medicine? Why? 
 
8-How would the availability of a medicine affect your supply of the medicine? Why? 
 
9-How would the experience of a family member or a friend with a medicine affect your 
supply of the medicine? Why? 
 
10-How would price affect your supply of the medicine? Why? 
 
11-How would patient preference affect your supply of the medicine? Why? 
 
12-How would patient information leaflet affect your supply of the medicine? Why? 
 
13-What do you think about the medicine storage conditions in MOI? How? Why? How 
can we improve it? 
 
14-What do you think about the medicine transportation conditions in MOI? How? 
Why? How can we improve it? 
 
15-What do you think about the patient acceptance of their medicines in MOI? How? 
Why? How can we improve it? 
 
16-What do you think about the expired medicines in MOI? How? Why? How can we 
improve it? 
 
17-What do you think about the monitoring of medicines in MOI? How? Why? How 
can we improve it? 
 
18-What do you think about the analysis of medicines in MOI? How? Why? How can 
we improve it? 
 
19-What do you think about establishing of a medicine quality section or department? 
How? Why? What level would be appropriate? What could it do? 
 
20-What other recommendations do you have to ensure the supply of high quality 
medicines? 
 
 
 
6.10.4.3 Validity and reliability checks 
The validity and reliability checks were conducted in a similar method to the previous 
phases of the study (Chapter 6 phases 2 and 3). The interview guide was piloted with 
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two post-graduate Saudi Arabian pharmacists studying in the UH who were asked to 
provide feedback on the question content, order and clarity.  
6.10.4.4 Data collection 
All interviews were conducted via a telephone call with respondents in December 2014. 
The interviews were tape-recorded and conducted in the Arabic language, native to both 
the researcher and the respondents. The question order was similar for all participants to 
allow for data comparability where possible and to minimise the possible effects of 
variation of question order on the results (Patton, 1987; Alfadl, 2012). All interviews 
were conducted following the participant’s signature of an informed consent form and 
none lasted longer than 50 minutes in this phase. 
6.10.4.5 Questions and transcript translation 
Interview guide questions were asked in Arabic in an attempt to maximise the 
participants’ ability to express their thoughts freely. All participants were sent a copy of 
the interview transcripts via e-mail to ensure the accuracy of their statements and none 
proposed any changes. The validity of translation of questions and interview transcripts 
from Arabic to English was performed using a similar approach to previous phases of 
the study (Chapter 6 phases 2 and 3) using two random transcripts in the process.  
6.10.4.6 Data analysis 
Interview data were thematically analysed following transcription verbatim in Arabic 
and translation of data into English using the qualitative data analysis software NVivo, 
version 10 to generate major themes. The data analysis process followed a method 
adopted from Strauss & Corbin (1990) as previously discussed in other phases of the 
study (Chapter 6 phases 2 and 3). Coding and validation of coding were performed 
using a similar approach to previous phases of this study (Chapter 6 phases 2 and 3). 
6.10.5 Results 
6.10.5.1 Participant demographic characteristics 
There were 16 participants who agreed to take part in this phase of the study, including 
8 pharmacists and 8 physicians working in the MOI-MSD primary clinics. The 
characteristics of participants can be found in Table 6.14. 
 
 193 
Table 6.14 Physicians’ and pharmacists’ demographic characteristics in the interview 
phase of the study 
Category Subcategory Pharmacists (n=8) Physicians (n=8) 
Gender Male 
Female 
 
7 (88%) 
1 (12%) 
8 (100%) 
0 (0%) 
Age 20 – 29 
30-39 
40-49 
50-59 
60 or more 
 
1 (12%) 
7 (88%) 
0 (0%) 
0 (0%) 
0 (0%) 
1 (12%) 
3 (38%) 
3 (38%) 
1 (12%) 
0 (0%) 
Education BSc 
MSc 
PhD 
 
3 (38%) 
5 (62%) 
0 (0%) 
1 (12%) 
1 (12%) 
6 (75%) 
Region of practice Central region 
Western region 
Northern region 
Southern region 
 
5 (62%) 
1 (12%) 
1 (12%) 
1 (12%) 
2 (25%) 
5 (62%) 
0 (0%) 
1 (12%) 
Years of experience 
working in MOI-MSD 
settings 
Less than one year 
1 to 4 years  
5 to 9 years  
10 to 14 years  
15 years or more  
 
0 (0%) 
0 (0%) 
5 (62%) 
3 (38%) 
0 (0%)  
1 (12%) 
0 (0%) 
0 (0%) 
4 (50%) 
3 (38%) 
 
 
6.10.5.2 Themes 
Eight themes emerged from the pharmacists’ and physicians’ interviews as follows: 
 
Theme one: Pharmacists’ role in MOI-MSD primary clinics 
The majority of participants (11/16) believed that the pharmacist’s role was to educate 
the public, including other healthcare professionals, about their medicines. Several 
participants (7/16) held the opinion that the pharmacist’s role was to dispense the 
correct medicine in the correct dose. Some participants (4/16) believed that the 
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pharmacist’s role was comprehensive, starting from the medicine manufacture up to 
dispensing the medicine to patients. Other participants (4/16) specified the pharmacist’s 
role as discovering medication errors.  
 
“His importance in giving the correct doses to the patient, education to the patient, 
general medical advice, monitoring medicine movement in the body and raise 
awareness of the patient about the medicine” (Pharmacist 1) 
 
There were other less common opinions about the pharmacist’s role. A few participants 
(2/16) indicated that the pharmacist’s role was to ensure proper logistic conditions for 
the medicines and a similar number of participants (2/16) highlighted the pharmacist’s 
role in tracking the medicine movement in the body and in medicine formulation (2/16). 
Additionally, one participant believed that the pharmacist had a role in informatics 
coding of medicines and another participant reported that the pharmacist had a role in 
transferring the patient’s feelings about the healthcare services to their administration. 
 
“The pharmacist should be a checkpoint to convey the patients’ feelings about the 
service…I mean managers don’t know how the patient feels but they put plans that have 
results and we convey these results” (Pharmacist 6) 
 
The participants in this phase of the study had several recommendations to improve the 
pharmacist’s role within the MOI-MSD settings. Training and educational programmes 
aimed at the pharmacists in the MOI-MSD were suggested by half of the participants 
(8/16). Improving the communication between the pharmacists and other MOI-MSD 
staff, particularly physicians, was suggested by some participants (5/16). Some 
participants (3/16) suggested that a separate space should be allocated in each primary 
clinic for patient counselling. Other participants (3/16) believed that the pharmacist 
should have a more active role within the treatment team. There were some suggestions 
reported on an individual basis by the participants such as raising awareness about the 
comprehensive role the pharmacists play in healthcare, reviewing physician’s 
prescriptions and improving patient education. 
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“…The doctor will make the decision regarding the disease but for treatment and 
management the pharmacist should support him...to increase the quality for people in 
specialties by sending some to study specific subjects that we need instead of just 
sending them all to study Pharm D” (Physician 6) 
 
Theme two: Beliefs and views about medicine quality 
The majority of participants (12/16) in this phase of the study believed that the quality 
of medicines manufactured in developing countries was inferior to the quality of 
medicines manufactured in developed countries. On a few occasions (2/16), it has been 
indicated that some patients held the belief that generic medicines were inferior to brand 
medicines but this view was not shared by the healthcare professionals.  
 
“…When you take it from some companies and unfortunately they are local companies 
and take medicines from foreign companies you notice the difference in medicine results 
and effect…” (Pharmacist 4) 
 
Nearly half of the participants (7/16) described the quality of medicines in Saudi Arabia 
as excellent. Some (5/16) believed that it was average: that some medicines were of 
good quality and others were not. Only one participant described the quality of 
medicines in Saudi Arabia as poor and another participant did not know what the 
quality of medicine in the country was. One participant suggested that the quality of 
medicines has recently improved in the country. Moreover, half of the participants 
(8/16) in this phase of the study believed that the quality of medicines in the MOI-MSD 
was similar to the quality of medicines in Saudi Arabia as a whole. Some participants 
(3/16) explained these views by stating that the quality of medicines is similar to what is 
available in the local market because they are all supplied from the same source. 
 
“MOI-MSD is part of the healthcare services in Saudi Arabia so we have the same 
medicines to some extent” (Pharmacist 1) 
 
Several participants (5/16) believed that the quality of medicines in the MOI-MSD was 
less than what is available in the Saudi Arabian market. Others (4/16) indicated that the 
 196 
medicine quality available to them was less than the quality of medicines available in 
other Saudi Arabian hospitals including the MOI hospital. A few participants disagreed 
with these views by indicating that the medicine quality is now improving within the  
MOI-MSD (2/16) and that the quality of medicines in the MOI-MSD was better than 
what is available in the Saudi Arabian market (1/16). One participant held the opinion 
that the quality of medicines in the MOI-MSD was average: that there are medicines of 
good quality and others that are not.  There were several reasons provided by the 
participants to explain why they thought the quality of medicines in the MOI-MSD was 
different from what is available elsewhere in Saudi Arabia. Some participants (4/16) 
indicated that it would be a result of the difference in tenders and medicine prices. 
Others (4/16) indicated that the difference is in the medicine manufacturers used.  A few 
participants (3/16) believed that it is a result of outdated medicines available in the 
MOI-MSD formulary. One participant held the opinion that medicines in the MOI-MSD 
receive more attention than other healthcare providers such as the MOH. Furthermore, 
one participant believed that the difference in medicine quality could be attributed to the 
lack of efforts to improve medicine quality in the MOI-MSD settings. 
 
“I think there is a difference in financial abilities between hospitals in Saudi where 
there are hospitals with excellent financial abilities who have excellent medicines and 
that is why the patients like to be treated there because their medicines are good” 
(Physician 4) 
 
When the participants were asked how they determined the quality of medicines, a 
number of methods have been suggested. The majority of participants (12/16) involved 
the patient at the centre of their answers, particularly from the physician’s group (8/8). 
The quality of medicines could be determined by the patient’s reported effect (4/16), 
their acceptance of a medicine (5/16) and the degree of their compliance with the 
medicine (1/16). The patient experience with the medicine quality of any product could 
be achieved through the physician’s follow-up with the patient (4/16) and the 
pharmacist’s questions about their previous use of a medicine (2/16).  Other reported 
methods for determining the quality of a medicine included laboratory analysis of 
medicine samples (4/16) and visual checks of the medicine appearance (2/16), 
particularly from the pharmacist group (5/8). Published research articles have been 
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identified as a method to determine medicine quality (5/16) particularly from the 
physician’s group (4/8). Furthermore, the medicine manufacturers’ reputation (3/16) 
and the physicians’ experience from treating multiple patients (2/16) have also been 
identified as a method to determine the quality of a medicine exclusively by members 
from the physician’s group. 
 
Theme three: The tender system for medicine procurement 
Most participants (10/16) in this phase of the study stated that they do not have 
sufficient information about the tender system used for medicine procurement in the 
MOI-MSD. However, some (7/16) believed that it focused on the cheapest prices. 
Others (4/16) believed that it does not focus on the quality of medicine manufacturing. 
There were a few (3/16) participants who clearly stated that they were unhappy with the 
current tender system for medicine procurement within the MOI-MSD. There were 
some justifications provided by participants for their dissatisfaction with the current 
medicine procurement system, including their view that it would not be appropriate for 
medicine (2/16), that it would result in frequent changes to the available medicine trade 
names (2/16) and it would result in receiving medicines that were different from the 
medicinal products that have been experienced and studied in the literature (1/16). 
 
“The idea of governmental tenders where you buy the cheapest would be suitable if you 
were buying cars, typewriters or offices but not medicines … because you took the 
cheapest so you will settle for less. When they take the medicine because it is cheapest, 
it is cheaper but also worse” (Pharmacist 6) 
 
“…Most patients have a psychological factor for example if glibenclamide changed 
from one company to another or to the brand, so every change in 3 months in 
procurement causes problems with the patients when you try to convince them that it is 
the same medicine as the first one…” (Pharmacist 8) 
 
Several recommendations have been made by the participants to improve the current 
medicine procurement practice. Involving staff from different MOI-MSD departments 
in the medicine procurement process has been suggested by some (6/16). Finding other 
alternatives to the current tender system has been suggested by others (2/16). There 
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were other individual suggestions, such as procuring the same medicines for chronic 
patients, unifying the medicines available in MOI-MSD primary clinics and hospitals, 
conducting bioequivalence studies on all generic medicines, adding a quality criterion in 
the medicine selection process at tenders, learning from other Saudi Arabian healthcare 
providers’ experiences in medicine supply and to conduct cross-sectional studies about 
medicine quality and their problems in MOI-MSD settings and report their findings. 
 
“There should be a medical committee consisting of physicians and pharmacists who 
based on their experiences would know specific medicines that would be suitable 
regardless of the price because quality is more important than price” (Physician 5) 
 
Theme four: Reporting of medicine quality problems 
Several participants (5/16) believed that the reporting of medicine quality issues was an 
important subject. However, nearly half of the participants (7/16) held the opinion that 
reporting medicine quality problems was not active in the MOI-MSD and requires 
further improvements. Other limitations of the current situation of medicine quality 
problem reporting were also mentioned, such as not having a clear mechanism or 
responsible personnel for the collection of such data (4/16) and being currently 
performed manually using paper-based documents (4/16). Furthermore, other barriers to 
the reporting of medicine quality problems were also highlighted on an individual basis 
such as patients underreporting such problems, inability to find reporting forms, lack of 
incentives to the reporter and that reporting of such problems might be unnecessarily 
problematic for the reporter. 
 
“…If someone reports a medicine or bad things about a medicine then you will get 
questioned … you won’t get even a thank you…. Therefore, many pharmacists do not 
care about this issue …” (Pharmacist 5) 
 
The participants in this phase of the study provided several recommendations to 
improve the reporting of medicine quality problems within the MOI-MSD. Most 
participants (10/16) believed that it would be necessary to establish a department or a 
committee to collect data about medicine quality problems. Other suggestions included 
 199 
improving education about medicine quality problems (3/16), encouraging staff to 
report such problems by providing incentives (3/16), establishing an electronic reporting 
system (2/16), establishing patient counselling in pharmacies (1/16) and expressing 
appreciation for any suspected quality problem report, even if proven inaccurate (1/16). 
 
“There should be a committee that receives the reports of medicine complications or 
problems … and then this committee would report it to the SFDA…” (Physician 2) 
 
Theme five: Storage and transportation of medicines in the MOI-MSD 
The participants’ views about medicine storage within the MOI-MSD had mixed 
responses. Some believed they were good (3/16), others believed they were poor (2/16) 
and some (5/16) did not know what the storage conditions were. However, some 
participants (6/16), particularly from the physician group (5/8), indicated that the ideal 
storage conditions in the main store in Riyadh were different from the poor storage 
conditions in other MOI-MSD primary clinics.  
 
“I don’t know about Riyadh, but here in the primary clinic it is very poor. There isn’t 
appropriate temperature or air-conditioners supply and the location too, it used to be in 
the basement where you would even find cats and mice with the medicines…” 
(Physician 2) 
 
Several recommendations for improving storage condition in the MOI-MSD settings 
were provided by the participants. Some participants (5/16) suggested establishing new 
warehouses that are up to international standards. Others (3/16) suggested embracing 
technology such as the use of robots, forklift trucks and electronic shelves in order to 
facilitate medicine storage. Other less frequent suggestions included establishing a 
department to monitor medicine storage (2/16) and establishing one new main 
warehouse in each region of the country. 
 
The participants’ opinion on medicine transportation within the MOI-MSD also 
displayed mixed views. Some (6/16) believed the transport conditions were poor, 
particularly within the pharmacist group (5/8). Others (4/16) believed that the medicine 
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transportation conditions were good. There were some physicians who did not know 
what the medicine transportation conditions were (4/16). The main participants’ 
concerns about medicine transportation in these settings were that medicines were 
commonly transported in open-trunk cars (4/16) and therefore might be exposed to 
extreme weather conditions in the process (6/16).  
 
“This is the worst side of MOI-MSD … In the MOH, it is prohibited to transport 
medicines in open trunk cars. Unfortunately, we only have one or two cars that are 
specialist in medicine transportation…” (Pharmacist 5) 
 
Several recommendations were offered by the participants in order to improve the 
medicine transport conditions in the MOI-MSD. Transportation of medicines via 
airplane to distant primary clinics has been suggested (3/16). Others suggested that 
medicines could be distributed by a specialised distribution company (3/16) or 
adequately refrigerated cars (3/16). It has also been suggested to include thermometers 
with each medicine consignment distributed (2/16) and to establish a department to 
monitor distribution (2/16). Other individual recommendations included training of 
personnel responsible for medicine transportation and direct delivery of medicines from 
the supplier to regional primary clinics without the involvement of the general 
warehouse located in Riyadh.  
 
The issue of expired medicines within the MOI-MSD produced different views from the 
participants. Some (7/16) believed that it was a problem in these settings particularly 
within the physician’s group (5/8). Others (6/16) believed that it was not a problem 
particularly within the pharmacist’s group (4/8). Furthermore, some participants (7/16) 
raised an issue with nearly expired medicines that were delivered to MOI-MSD primary 
clinics as a challenge in these settings.  
 
“There is a problem here with the nearly expired here…they are not expired because I 
don’t think someone would receive expired medicines…” (Pharmacist 2) 
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Several recommendations have been proposed by the participants to address the issue of 
expired medicines in the MOI-MSD settings. Such recommendations included the 
collection of statistical data regarding the quantity of dispensed medications from all 
primary clinics (5/16), establishing a department to monitor expired medicines (4/16), 
use of computers in warehouses to dispense near expiry medicines first (4/16), medicine 
suppliers to deliver medicines with a minimum acceptable expiry date (3/16) and 
encouraging primary clinics to exchange nearly expired medicines between each other 
and with other healthcare organisations (3/16). 
 
“I think it needs precise calculations…Communicating through the system would be 
better to ask for exchange with colleagues…” (Pharmacist 6) 
 
Theme six: Patients’ acceptance of available medicines in MOI-MSD 
The participants expressed different opinions regarding the patient’s acceptance of their 
medicines in the MOI-MSD primary clinics. Some (7/16) believed that the patients did 
accept their medicines in these settings. Others (3/16) believed that they mostly 
accepted their medicines but with some issues on occasions. Furthermore, only a few 
participants (3/16) believed that patients had poor acceptance of their medicines in these 
setting. The most common barriers to patient acceptance of their medicines have been 
identified by some participants, including that some patients demanded brand medicines 
(5/16) and some patients preferred to have similar medicines to those available within 
the MOI-MSD hospitals (2/16). 
 
“Sometimes there are certain issues… if there were specific brand names other than 
what I give him and he tried them and was comfortable with them… in this situation I 
don’t try to talk to him. I would only talk to a patient if I saw something that has harm... 
I think it is his right to take the brand and I support him in that” (Physician 1) 
 
The participants provided some suggestions to improve the patients’ acceptance of their 
medicines. Improvement of medicine supply and selection has been suggested by 
several (7/16) participants. Staff reassurance about the quality of the medicines 
available in the MOI-MSD has been highlighted by a few (3/16) participants. Other 
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suggestions included patient education about their medicines (2/16) and supplying the 
same medicines as the MOI-MSD hospital (2/16). 
 
“I myself need to be sure that this medicine is the same as the other medicine before I 
talk…I don’t want to tell a patient that this medicine is similar to the other and then two 
months later a report is written about it. This would make my image not look good and I 
would have betrayed the patient in all honesty” (Pharmacist 6) 
 
Theme seven: Recommendations to enhance quality assurance 
The medicine monitoring issue has been perceived by some participants as excellent in 
the MOI-MSD (2/16) and as currently improving by others (3/16). However, there were 
some participants (3/16) who believed that medicine monitoring does not exist in the 
MOI-MSD and one participant who did not have sufficient knowledge about medicine 
monitoring in these settings. 
 
When asked about what medicine monitoring means in their opinion, some participants 
(4/16) believed that it means a comprehensive monitoring of medicines from the point 
of storage in the warehouse until the patient uses them. Other participants (4/16) 
specified monitoring medicines during storage and dispensing. A few participants (3/16) 
specified monitoring medicines during dispensing in order to adequately forecast future 
required quantities of different medicines. 
 
“…The monitoring from the warehouse to the pharmacy. The monitoring of quantities, 
expiry dates and dispensing…” (Physician 2) 
 
Several recommendations were provided in order to improve medicine monitoring. The 
establishment of a department or a committee to monitor and collect data about 
medicines has been suggested by nearly half of the participants (7/16). Other 
suggestions included the use of existing electronic systems to monitor medicines in all 
primary clinics (1/16), education and training of staff (1/16), in addition to the use of 
barcode technology to enable medicine monitoring.  
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Although the issue of medicine analysis has been perceived as an important issue by 
some participants (4/16), nearly half of the participants (7/16), particularly pharmacists 
(5/8), believed that it is essentially the responsibility of the SFDA and not the MOI-
MSD. The only role that the MOI-MSD staff can perform regarding medicine analysis 
is to actively send medicine samples to the SFDA and wait for analysis results, 
according to some opinions (3/16). It appears that a common belief among some 
participants (7/16) is that conducting medicine analysis within MOI-MSD settings 
would be wasteful of resources and staff efforts. 
 
“…You shouldn’t do someone else’s job, which is the SFDA and medical licenses…” 
(Pharmacist 8) 
 
Various suggestions to improve medicine analysis in the MOI-MSD settings have been 
proposed by participants. Such suggestions included requesting information regarding 
medicine analysis results and the registration status of medicines from the SFDA (2/16), 
encouraging the SFDA to send the MOI-MSD copies of medicine analysis results 
(2/16), establishing one SFDA analytical laboratory in each region of the country 
(1/16), routine and periodic collection of medicine samples to be sent to the SFDA for 
analysis (1/16) and for medicine suppliers to include an analysis certificate of each 
delivered batch of medicines to the MOI-MSD (1/16). 
 
The majority of participants in this phase of the study (14/16) believed that the 
establishment of a medicine quality department within the MOI-MSD settings would be 
important. They believed that the establishment of such a department would be helpful 
in the protection of public health (1/16), protect medicines which are the bases of MOI-
MSD medical services provided to patients (2/16) and would assist primary clinic 
pharmacists to focus on their daily work (2/16). 
 
“…I think it is important to have a section for medicine quality in MOI-MSD because 
medicine safety is very important … I know in the National Guard and the Defense 
Ministry, they do have a department for medicine quality” (Pharmacist 1) 
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There were a number of recommendations provided by the participants in order to 
achieve the best possible outcomes by establishing a medicine quality department in 
these settings. More than half of the participants (9/16) believed that this department 
should be located in the MOI-MSD headquarters and that it should have representatives 
in all primary care clinics (5/16). Other suggestions included having a sufficient number 
of staff in this department (4/16), with adequate training on the subject (2/16) and using 
electronic means of communication between the department and the stakeholders 
(3/16). 
 
The participants have also expressed their thoughts on the potential roles that this 
department could contribute to the MOI-MSD healthcare services. The majority of 
participants (10/16) held the opinion that this department could monitor medicine 
quality throughout all stages of the medicine cycle from the point of receiving the 
medicines in the warehouse until it is dispensed to the patient, particularly within the 
pharmacist group (6/8). The medicine quality department could also be responsible for 
conducting research on patient satisfaction and patient response to their medicines, 
according to some opinions (6/16). It could also act as a link between the SFDA and 
different stakeholders within the MOI-MSD regarding medicine quality problems in 
order to facilitate rapid information exchange (6/16). Furthermore, the medicine quality 
department could adopt an educational role by educating MOI-MSD staff about 
medicine quality problems according to the latest research worldwide (4/16). 
 
Theme eight: Medicine attributes affecting medicine supply 
The medicine country of manufacture was perceived as an important factor in the 
supply of medicines by half of the participants (8/16) particularly from within the 
pharmacist group (6/8). Other participants believed that it was not important (3/16), 
could be important on some occasion (2/16) or had no opinion on this topic (2/16). 
 
The participants had several reasons for considering country of manufacture as an 
important attribute in medicine supply. Different countries were perceived as having 
different medicine monitoring abilities (2/16), different reputations regarding the quality 
of their medicines (2/16) and different economic ability to ensure the safety of their 
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medicines (2/16). Furthermore, it has been suggested that importing medicines from 
distant countries could result in medicine shortages (2/16) and that political relations 
between two countries could be associated with the inability to supply medicines from 
pharmaceutical manufacturers in certain countries (2/16).  
 
“Medicines manufactured in America … are different than the medicines manufactured 
in Arabic countries…the manufacturing material, monitoring and reputation” 
(Pharmacist 5) 
 
The majority of participants (11/16) believed that medicine availability is an important 
factor in medicine supply. Other participants believed that the impact of medicine 
availability on medicine supply was either not important (1/16), occasionally important 
(2/16) or had no opinion on the subject (2/16).  
 
Most participants considered medicines that are readily available to be preferred by both 
the healthcare providers and patients (6/16), and that medicines that are not available in 
the market could raise suspicions about the reasons for their non-availability (2/16). 
Furthermore, the participants believed that a medicine’s non-availability could cause 
several undesired outcomes such as inability of primary clinics to provide any services 
to patients (1/16), patient non-compliance (1/16), deterioration in a patient’s health 
condition (1/16) and the patient taking the wrong alternative medicine (1/16). 
 
“…This would affect the compliance of the patient, create complications and maybe 
cause deterioration or morbidity and mortality increases…”  (Physician 6) 
 
Most participants did not consider the experience of a friend or a family member 
important in medicine supply (10/16). Some participants believed it was important 
(2/16), occasionally important (3/16) or had no answer (1/16). 
 
The participants justified their common belief about the insignificance of a family or 
friend member experience in medicine supply by indicating that such experiences were 
not based on sufficient evidence to be considered in supply decisions (5/16), patients 
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reacted differently to the same medicine (4/16), not all patients preferred the same 
medicine (2/16) and that supply decisions should be made by a professional committee 
within MOI-MSD settings (2/16). 
 
“…Experience of a friend or a family member is not evidence based for us to depend on 
to supply the medicine because for sure there is much variability between patients” 
(Physician 8) 
 
More than half of the participants (9/16) considered medicine price as an important 
attribute in the medicine supply decision. Other participants believed that medicine 
price was not important (4/16), sometimes important (2/16) or had no opinion regarding 
this topic (1/16). 
 
There was a common belief (4/16) that expensive medicine prices have resulted in 
patients’ acceptance of lesser quality and cheaper medicines, particularly from within 
the physicians’ group (4/8). Furthermore, some participants (2/16) suggested that higher 
medicine prices guaranteed a higher quality medicine. It has also been suggested that 
medicine price is an important attribute since it is highly emphasised in the 
governmental procurement tender systems (1/16). 
 
The impact of patient preference on the medicine supply decision had mixed responses 
from the participants in this phase of the study. Some believed it was important (3/16) 
or possibly important (3/16). Others did not believe it was important (6/16), particularly 
from within the physicians’ group (4/8), or had no opinion on the subject (4/16). 
 
The participants who believed that patient preference was important or possibly 
important in medicine supply justified their views by indicating that patients would not 
take their medicines if they were supplied without considering their preference (4/16) 
and that ethical issues may arise with the patient’s right to choose the medicines that 
they will take (1/16). In contrast, the participants who did not believe that patient 
preference would be important in the medicine supply decision have highlighted that 
patient preference would not make a difference in deciding which medicines were 
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available within the MOI-MSD (2/16) and that it would be impossible to please all 
patients (3/16). 
 
The participants had also mixed responses about the significance of the medicine 
information leaflet on the medicine supply decision. Some participants believed that it 
was important (5/16) or possibly important (2/16). Others held the opinion that it was 
not important (5/16) or did not have an answer (3/16). 
 
The participants who believed that the medicine information leaflet was important in the 
supply decision have indicated that the patient has the right to know everything about 
their medicine (3/16) and that the absence of the medicine leaflet would raise suspicion 
about the medicine (1/6). In contrast, the argument of views that did not consider that 
the medicine information leaflet important in the supply decision, involved reasons such 
as most patients do not read them (2/16), being scientifically invalid or bias towards the 
manufacturer (2/16), it includes unnecessary information about rare side effects (2/16) 
and is written in small font size that complicates the process of reading it (1/16). 
6.10.6 Discussion 
Most participants in this phase of the study perceived that the pharmacist’s role in MOI-
MSD settings is mainly as a provider of medicine-related information. Studies 
conducted in neighbouring Arab countries such as Kuwait, Jordan, Qatar and Iraq have 
shown that physicians perceive pharmacists as a reliable source of information 
regarding medicines (Matowe et al., 2006; Tahaineh, Wazaify, Albsoul-Younes, Khader 
& Zaidan, 2009; Zaidan, Singh, Wazaify & Tahaineh, 2011; Hamadi, Mohammed, 
Dizaye & Basheti, 2015). Nearly half of the participants perceived that the pharmacist’s 
role is as a medicine dispenser in these settings. This opinion is in line with the more 
traditional view of the role of pharmacists in the compounding and dispensing of 
medicines (Jones, Mackinnon & Tsuyuki, 2005). However, only one quarter of 
participants in this phase of the study recognised that a pharmacist can detect 
medication errors and be part of the medicine cycle, starting from medicine manufacture 
right through to medicine administration. Furthermore, the participants have suggested 
increasing pharmacists’ training and education, improving pharmacists’ communication 
skills and conducting patient counselling as key components in order to improve the 
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pharmacists’ role in the MOI-MSD settings. 
 
A large number of participants in this phase of the study believed that the quality of 
medicines manufactured in developed countries was better than the quality of medicines 
manufactured in developing countries. These views are in agreement with and could 
explain finding from previous phases of this study within the commissioner’s group 
(Chapter 6 phase 2) and the healthcare provider’s group (Chapter 6 phase 4), where a 
common belief was reported that medicines with higher prices, most likely imported 
from developing countries, were considered to be of better quality.  
 
Most participants had mixed views about the quality of medicines in Saudi Arabia, 
ranging from excellent to average. These results were similar to reports from all 
stakeholders in this study. Half of the participants believed that the quality of medicines 
in the MOI-MSD was similar to that available in the Saudi Arabian market, because the 
medicines are supplied from the same source. However, less than half of the participants 
believed that the quality of medicines in the MOI-MSD was less than that available in 
the Saudi Arabian market because of different tenders used to supply medicines in 
different healthcare sectors in the country, different manufacturers used to supply the 
medicines and outdated medicines available in the MOI-MSD medicine formulary.  
 
The majority of participants in this phase of the study used information related to 
patients in order to make a judgment about the quality of a medicine. Such information 
included patient’s reported effect and experience with the medicine used, patient’s 
acceptance of the medicine and patient’s compliance with the treatment regimen. This 
finding was in contrast with the current technical nature of determining medicine 
quality through laboratory testing according to pharmacopoeial specifications (Patel et 
al., 2010). Only one quarter of the participants referred back to the scientific literature 
or laboratory analysis results to determine the quality of a medicine. Furthermore, only 
a few participants considered the manufacturer’s reputation or visual examination of the 
pharmaceutical product as indicators of the quality of a medicine.      
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Nearly half of the participants in this phase of the study believed that the tender system 
used for medicine procurement in their settings focused on cheaper prices only. This 
was not surprising since reducing procurement costs is one of the key objectives of 
pharmaceutical tenders in any setting (WHO, 1999b). One quarter of the participants 
indicated that the current tender system did not consider the quality of the medicine 
manufacturers. It is possible that the participants may not be fully informed about the 
prequalification requirements of manufacturers to participate in the tender or they might 
believe that these prequalification requirements may not be adequate. Furthermore, a 
few participants highlighted that the current tender system caused frequent changes to 
the available medicines. This might be an area of concern particularly with chronic 
patients as it could lead to medicine non-adherence due to frequent changes to the 
medicines that they were comfortable using, as has also been reported as a concern by 
healthcare professionals in Germany and Denmark (Dylst, Vulto & Simoens, 2011). 
 
The participants in this phase of the study had mixed views about the state of the current 
medicine storage and transporting conditions in MOI-MSD settings. The physicians’ 
group, in particular, had more negative views about these conditions when compared 
with the pharmacists’ group. Examples of concerns about medicine storage conditions 
included storage in areas exposed to heat, humidity and water leakage in rainy weather, 
pests found in the medicine storage area, medicine boxes not immediately placed on the 
warehouse shelves and not having a separate area for medicine storage away from other 
departments. The participants have also shared concerns about transportation 
conditions, where they reported that medicines were not arranged appropriately in 
transportation vehicles, exposure of medicine to heat and humidity during 
transportation, distant locations in the country to transport medicines from the main 
store in Riyadh and medicines transported by drivers with limited knowledge about 
appropriate medicine transportation conditions. In response to these concerns about 
medicine storage conditions, the participants recommended the establishment of new up 
to date standard medicine warehouses, embracing technology to facilitate medicine 
storage, monitoring storage conditions and establishing a new main store in each region 
of the country. Furthermore, the participants in this phase of the study recommended 
transporting medicines by other means including airplanes, including thermometers 
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with each medicine consignment, the training of staff responsible for medicine 
transportation, monitoring medicine transportation conditions and direct delivery of 
medicines from suppliers to the primary clinic warehouses. However, international 
guidelines (WHO, 2003b; DELIVER, 2003; WHO, 2007) for appropriate medicine 
storage and transportation conditions are available that could be followed in order to 
improve any possible defects in storage or transportation of medicines in these settings.  
 
Nearly half of the participants in this phase of the study believed that expired medicines 
and nearly expired medicines are an issue of concern in MOI-MSD settings. The 
systematic review of literature (Chapter 3) had identified several studies that found 
expired medicines in their settings worldwide. These expired medicines could be a 
result of inappropriate quantification of required medicines during medicine 
procurement, suppliers delivering nearly expired medicines or poor distribution 
practices that could include dispensing a further expiry pharmaceutical product while a 
nearer expiry date product is available in stock. The participants had several 
recommendations to improve this situation, including the collection of accurate 
consumption data from all primary clinics, using computers to dispense medicine 
quantities according to the nearest available expiry product, monitoring expiry dates, 
suppliers to deliver only minimum acceptable expiry dates and to encourage medicine 
exchanges between MOI-MSD primary clinics and also other healthcare sectors in the 
country. 
         
The majority of participants believed that the reporting of medicine quality problems 
was not activated in MOI-MSD settings, which would suggest a degree of under-
reporting of such problems from different stakeholders at these settings. Some barriers 
to the reporting of medicine quality problem were identified in this study. A few 
participants indicated that the reporting mechanism was not clear to them: similar to 
other reports identified in the literature (Suyagh, Farah & Abu Farha, 2014; Toklu & 
Uysal, 2008; Bawazir, 2006; Khan, 2013). Other participants believed that the reporting 
method was paper-based and that there were no incentives to the reporter. It has been 
previously shown that electronic reporting systems and providing incentives to reporters 
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would contribute to an increase in the number of medicine-related problem reports such 
as adverse drug reactions (Pedrós et al., 2009; Linder et al., 2010; Cereza et al., 2010).  
 
Furthermore, most participants in this phase of the study recommended establishing a 
department within the MOI-MSD to handle reports of medicine quality problems. A 
previous study has shown that establishing a network of physicians has increased the 
number of medicine-related problem reports such as adverse drug reactions and also 
introduced new reporters (Goldstein, Berlin, Saliba, Elias & Berkovitch, 2013). Other 
suggestions included increasing education about medicine quality problems and 
encouraging staff to report problems by offering incentives. It has been shown in 
previous studies that the rate of reporting of medicine-related problems such as adverse 
drug reactions could be improved through educational intervention and advocacy 
(Clarkson, Ingleby, Choonara, Bryan & Arlett, 2001; Mehta et al., 2007).  
 
Several strategies to enhance quality assurance of medicines have been discussed in this 
phase of the study. Medicine monitoring divided opinion between participants, where 
some believed it was excellent, others believed it was improving, while some believed it 
was non-existent in these settings. The meaning of medicine monitoring also incited 
different opinions, where some believed it was comprehensive throughout the medicine 
cycle while others focused on medicine storage and/or dispensing to patients. The WHO 
has indicated that medicine monitoring can be achieved through all medicine stages, 
including manufacture, procurement, storage, transportation and, following use by the 
patient, for possible complaints (WHO, 2007).  
 
Medicine analysis was another strategy to enhance quality assurance that was discussed 
in this study. Nearly half of the participants in this study believed that the SFDA was 
responsible for conducting medicine analysis, since it would be demanding in terms of 
resources for it to be conducted within MOI-MSD settings.  Some specified the role of 
the MOI-MSD within this context to send samples to the SFDA and receive analysis 
reports. The participants recommended sending samples to the SFDA frequently, that 
the SFDA should establish at least one medicine laboratory in each region in the 
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country, and that suppliers should include batch analysis reports with each medicine 
consignment delivered to the MOI-MSD, as a means of improving medicine analysis.  
 
Establishing a department or a committee to monitor medicine quality was another 
strategy for ensuring quality assurance, which was discussed with the participants in 
this phase of the study. Almost all participants supported the establishment of such a 
department or committee, in order to monitor medicine quality problems, research 
patients’ satisfaction with medicines, educate staff about medicine quality problems and 
to act as a link between the MOI-MSD and SFDA to ensure rapid communication 
between the two organisations. Furthermore, the participants recommended that the 
department or committee should be centralised in Riyadh, have representatives in 
clinics, employ a sufficient number of staff, train their staff and use electronic means of 
communication in order to achieve the required objectives.    
 
The participants in this phase of the study discussed several potential factors affecting 
medicine supply. The majority of participants believed that medicine country of 
manufacture, medicine availability and medicine price were important factors affecting 
supply decisions. Country of manufacture was perceived as an important factor since 
different countries have a different capacity of monitoring medicines, importing 
medicine from distant countries could result in medicine shortages and political 
relationships between the supplying country and the importing country could be a major 
factor in the supply decisions. It has been previously reported that medicines from 
developed countries such as China and India were treated with some suspicion by 
healthcare providers in South Africa (Patel et al., 2012).  
 
Medicine availability was perceived as being preferred by healthcare professionals and 
patients since medicines are the core of the services provided by MOI-MSD primary 
clinics to patients: non-availability may raise suspicion and have other possible impacts 
on patients such as medicine non-adherence, health deterioration or patients using the 
wrong alternative medicine. Medicine price was viewed as an important factor in 
patients’ acceptance of the medicines: higher medicine prices would guarantee better 
quality, and medicine price is a major component of governmental regulations in tender 
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procurement. The WHO considers both medicine price and availability as essential 
indicators of medicine accessibility (WHO, 2008).  
 
In contrast, the participants in this phase of the study largely perceived other potential 
factors influencing medicine supply as not being important. The experience of a friend 
or a family member was believed to be unimportant since it is not based on reliable 
professional judgment and patient reactions and preferences for medicines differ 
considerably. Patient preference was also considered to be of minimal importance since 
it is not possible to please all patients. Perhaps these negative views about the 
importance of patient’s experience with the supply of medicines were influenced by 
limited perceptions of medicines within a socio-cultural context (Patel et a., 2010; Patel 
et al., 2012). The medicine information leaflet was not considered important since the 
majority of patients do not read them; they contain scientifically bias information, have 
unnecessary information about extremely rare diseases and are difficult to read due to 
small font size. Previous studies have shown that medicine information leaflets on 
branded medicines differed from generic alternatives in Saudi Arabia (Gebran & Al 
Haidari, 2006; Al-aqeel, 2012). Such differences could hinder the confidence of 
healthcare professionals in their content and therefore may not be considered as an 
attribute that could affect medicine supply decisions.    
 
Strengths and limitations of this phase of the study 
This phase of the study used telephone interviews as a means for data collection with 
the participants. The use of telephone interviews could have several advantages for the 
purpose of this phase of the study such as practicality when the researcher and the 
participants are located in different countries, cheaper costs for conducting interviews 
and may increase the comfort of the participants when interviews are conducted while 
they are in their homes, for example. In contrast, telephone interviews could limit the 
interviewer’s ability to observe the participant’s body language and technical 
difficulties may be encountered during the interview process. Technical difficulties 
during tape recording of the interviews were only encountered once and were 
immediately and simply resolved by terminating the call and restarting the interview 
from the point that had already been reached. This study had a limited sample size and 
 214 
did not seek data saturation since the objectives of this study were to clarify ambiguous 
responses and validate results from a previous survey phase of the study (Chapter 6 
phase 4). Only one female healthcare provider offered to participate in this study, which 
could be explained by cultural barriers between males and females in the country.  
 
Nevertheless, this phase of the study had several strengths, including being one of the 
few studies that explored issues around medicine quality and related issues from a social 
and qualitative approach worldwide and in Saudi Arabia. This phase of the study had 
also validated and explained some of the findings in a previous phase of the study. 
 
The following chapter triangulated the evidence collected from the different phases of 
this study and discussed the overall findings of the MOI-MSD stakeholders’ perceptions 
about medicine quality and any related issues.  
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7 Chapter 7: Overall results and discussion of stakeholders’ 
perceptions about medicine quality and related issues 
This chapter combines all results obtained from the previous chapter (Chapter 6) 
regarding the stakeholders’ perceptions about medicine quality and its related issues, 
which was followed by an overall discussion of the findings and a final conclusion to 
this chapter. The shared themes were identified among all MOI-MSD stakeholders 
through triangulation of the available data in addition to some individual themes and 
sub-themes to the patients, physicians and pharmacists in this study. 
7.1 Overall results of stakeholders’ perceptions  
The results obtained from the different phases of this study have identified five shared 
themes among the different stakeholders in MOI-MSD settings. These shared themes 
included beliefs about medicine quality, knowledge about medicine quality, experiences 
of and behaviour towards medicines with doubtful quality, challenges to medicine 
quality in the MOI-MSD and recommendations to improve medicine quality within 
these settings.  
 
Additionally, patients’ and healthcare providers' individual themes and sub-themes were 
identified from the findings of the different phases of the study. Patient’s individual 
themes and sub-themes included their knowledge and beliefs about medicines and their 
quality, the relationship between medicine price and disease severity, counterfeit 
medicines, challenges they encountered in MOI-MSD clinics and their trust in the 
healthcare providers. The pharmacists’ and physicians’ individual themes and sub-
themes included the pharmacist’s role in MOI-MSD, beliefs and views about medicine 
quality, the tender system for medicine procurement, medicine therapeutic classes and 
formulations of quality concern, reporting medicine quality issues, storage and 
transportation of medicines within the MOI-MSD, patients’ acceptance of their 
medicines and recommendations to enhance quality assurance.  
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7.1.1 Shared theme 1: Beliefs and views about medicines and their quality 
Most commissioners (5/6) and physicians (71%) in this study believed that the quality 
of medicines in Saudi Arabia was good or excellent. To a lower extent, more than half 
of the pharmacists (55%) and patients (58%) agreed with these views. However, the 
number of stakeholders that believed that the quality of medicines in MOI-MSD 
settings were good or excellent was found to be constantly lower, than what is available 
in the Saudi Arabian market in the opinion of commissioners (17%), physicians (52%) 
and pharmacists (36%) but not the patients (71%). 
 
More than half of the commissioners (4/6), physicians (83%), pharmacists (83%) and 
patients (62%) in this study believed that more than 10% of the global pharmaceutical 
supply chain was counterfeit. Similarly, the estimations about the prevalence rate of 
counterfeit medicines in Saudi Arabia were more than 10% of the local pharmaceutical 
supply chain in the opinion of commissioners (4/6), physicians (68%), pharmacists 
(57%) and patients (57%).  
 
All stakeholders in this study shared some common beliefs about medicines and their 
quality. Such beliefs included the conception that developed countries manufactured 
better quality medicines when compared with developing countries. Furthermore, the 
physicians, pharmacists and patients believed that the quality of medicines was different 
according to the manufacturer and the hospital that dispensed the medicine in Saudi 
Arabia. Moreover, all stakeholders reported that patients frequently demanded 
medicines by their brand name although medicines worked differently for various 
individuals.   
 
The stakeholders in this study identified several sources of information regarding the 
quality of their medicines. Their personal experience with regard to using a medicine, or 
the experience of a patient or healthcare staff, was considered a reliable source of 
information about medicine quality in the opinion of all stakeholder groups. The 
commissioners in this study have also identified circular letters they received from the 
SFDA as a source of information for medicine quality. Research studies and laboratory 
testing were only identified as being important by physicians and pharmacists in this 
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study. Further details regarding this theme can be found in Tables 7.1 and 7.2 in 
addition to Appendix 25.    
 
Table 7.1 Stakeholders’ opinions on quality of medicines 
Sub-theme Characteristics Commissioners Physicians Pharmacists Patients 
Medicine 
quality in  
Saudi Arabia 
Good/excellent 
Average 
Poor/unacceptable 
No answer 
 
5/6  
1/6  
- 
- 
45/63 (71%) 
14/63 (22%) 
4/63 (6%) 
- 
32/58 (55%) 
23/58 (38%) 
3/58 (5%) 
- 
31/53 (58%) 
15/53 (28%) 
5/53 (9%) 
2/53 (4%) 
Medicine 
quality in 
 MOI-MSD 
Good/excellent 
Average 
Poor/unacceptable 
No answer 
 
1/6  
4/6  
1/6  
- 
33/63 (52%) 
22/63 (35%) 
8/63 (13%) 
- 
21/58 (36%) 
19/58 (33%) 
18/58 (31%) 
- 
38/53 (71%) 
6/53 (11%) 
5/53 (9%) 
4/53 (8%) 
Percentage of 
counterfeit 
medicines 
globally 
0% to 10% 
20% to 50% 
60% or more 
No answer 
 
2/6  
2/6  
2/6  
- 
7/63 (11%) 
39/63 (62%) 
13/63 (21%) 
4/63 (6%) 
5/58 (9%) 
32/58 (55%) 
16/58 (28%) 
5/58 (9%) 
12/53 (23%) 
18/53 (34%) 
15/53 (28%) 
8/53 (15%) 
Percentage of 
counterfeit 
medicines in 
Saudi Arabia 
0% to 10% 
20% to 50% 
60% or more 
No answer 
 
2/6  
2/6  
2/6  
- 
16/63 (25%) 
27/63 (43%) 
16/63 (25%) 
4/63 (6%) 
20/58 (34%) 
19/58 (33%) 
14/58 (24%) 
5/58 (9%) 
17/53 (32%) 
19/53 (36%) 
11/53 (21%) 
6/53 (11%) 
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Table 7.2 Stakeholders’ beliefs and source of information about medicine quality 
Sub-theme Characteristics Commissioners Physicians Pharmacists Patients 
Beliefs about 
medicines 
and their 
quality 
Developed countries 
manufacture superior 
quality medicines 
        
 Medicine quality differs 
between manufacturers 
in Saudi Arabia 
        
 Medicine quality is 
different between 
hospitals in Saudi 
Arabia 
-       
 Patients frequently 
demand brand 
medicines 
        
 Medicines do not work 
similarly for all people 
 
        
Source of 
information 
about 
medicine 
quality 
Patient’s experience         
 Personal experience 
 
        
 Staff experience 
 
        
 Family/friend 
experience 
 
  - -   
 SFDA letters 
 
  - - - 
 Research studies 
 
-     - 
 Laboratory tests 
 
-     - 
 Manufacturer reputation 
 
-   - - 
 Visual check of 
medicine 
 
- -   - 
 Storage condition 
 
- -   - 
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7.1.2 Shared theme 2: Knowledge about medicine quality and their problems 
Members from all stakeholder groups identified a good quality medicine as a medicine 
with good effect and from a brand manufacturer. The reasonable medicine price was a 
characteristic of a good quality medicine in the opinion of commissioners, physicians 
and pharmacists but not the patients in this study. Furthermore, the physicians and 
pharmacists in this study highlighted medicine availability, safety and long expiry dates 
as important characteristics of a good quality medicine. 
 
A counterfeit medicine was believed to be a medicine with an effect problem by 
participants and respondents from all stakeholder groups in this study. Commissioners 
and pharmacists considered problems with the appearance of a medicine as a 
characteristic of a counterfeit medicine. Moreover, participants from the physician’ and 
patient’ groups believed that expired and generic medicines were counterfeit. Further 
details about this theme can be found in Table 7.3 and Appendix 26. 
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Table 7.3 Stakeholders’ knowledge about medicine quality  
Sub-theme Characteristics Commissioners Physicians Pharmacists Patients 
Characteristics of 
a good quality 
medicine 
Has good effect         
 From a brand 
company 
        
 Has good 
appearance 
  -   - 
 Has reasonable 
price 
      - 
 Is registered   -   - 
 Has good 
manufacturing 
-       
 Is accepted by 
patients 
    -   
 Is available -     - 
 Is safe -     - 
 Has good expiry 
dates 
 
-     - 
Characteristics of 
a counterfeit 
medicine 
Effect problem         
 Manufacturing 
problem 
-       
 Appearance 
problem 
  -   - 
 Content API 
problem 
      - 
 Fake copy of 
original 
-       
 From unreliable 
source 
-       
 Not registered in 
SFDA 
-       
 Is a generic 
medicine 
-   -   
 Is an expired 
medicine 
-   -   
 Has storage 
problem 
-   -   
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7.1.3 Shared theme 3: Experiences with and behaviour towards doubtful quality 
medicines 
Less than one-third of physicians (21%), pharmacists (36%) and patients (38%) 
reported having any previous experience with a doubtful quality medicine. However, 
this was not the case with commissioners, where two-thirds of them (4/6) have reported 
past experiences with such doubtful quality medicines. 
 
All stakeholders particularly from the commissioner group (4/6) described their 
experience with a doubtful quality medicine in terms of a medicine that did not have the 
desired effect. However, there were various other experiences with medicine quality 
concerns that were commonly described by the commissioners and pharmacists, in 
particular, a problem with medicine appearance, undesired odour or the presence of less 
than stated dosage numbers. A detailed account of the reported quality concerns and 
stakeholders’ experiences can be found in Table 7.4. 
 
The majority of physicians (56%) and some pharmacists (40%) indicated that they have 
not received reports about doubtful quality medicines on an annual basis. In contrast, 
one-half of the commissioners (3/6) indicated they routinely received one report every 
year regarding medicine quality concerns while the other half (3/6) highlighted that they 
received ten or more of these reports each year.  
 
All stakeholders in this study including the commissioners (3/6), physicians (22%), 
pharmacists (52%) and patients (8%) shared the same behaviour, reporting medicine 
quality concerns, but with various degrees, to the higher MOI-MSD administration 
and/or the SFDA. In particular, patients responded that they would probably stop using 
the medicine (70%) and/or inform their physician (42%) when they have such doubts 
about the quality of medicines. Further details can also be found in Table 7.4. 
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Table 7.4 Stakeholders’ experiences and behaviour about medicines with doubtful 
quality 
Sub-theme Characteristics Commissioners Physicians Pharmacists Patients 
Previous 
experience 
with doubtful 
quality 
medicines 
 
Yes 
No 
No answer 
4/6  
2/6  
- 
13/63 (21%) 
48/63 (76%) 
2/63 (3%) 
21/58 (36%) 
37/58 (64%) 
- 
20/53 (38%) 
23/53 (43%) 
10/53 (19%) 
 
Type of 
experience 
with doubtful 
quality 
medicines 
 
Medicine non-effective 
Medicine side effects 
SFDA failure letters 
Expired medicines 
Missing expiry date 
Medicine not registered 
Appearance problem 
Medicine had bad odour 
Less than stated doses 
Tablets did not dissolve 
 
4/6  
- 
2/6  
- 
- 
- 
1/6  
1/6  
- 
3/6  
 
4/63 (6%) 
- 
- 
1/63 (2%) 
- 
- 
- 
- 
- 
- 
 
2/58 (3%) 
- 
2/58 (3%) 
- 
1/58 (2%) 
2/58 (3%) 
5/58 (9%) 
1/58 (2%) 
1/58 (2%) 
- 
13/53 (25%) 
7/53 (13%) 
- 
- 
- 
- 
- 
- 
- 
- 
 
Number of 
annual 
reports about 
doubtful 
quality 
medicines 
 
None 
Once a year 
2 to 4 times a year 
5 to 10 times a year 
More than 10 times 
 
- 
3/6  
- 
- 
3/6  
35/63 (56%) 
14/63 (22%) 
6/63 (10%) 
1/63 (2%) 
5/63 (8%) 
23/58 (40%) 
12/58 (21%) 
12/58 (21%) 
7/58 (12%) 
4/58 (7%) 
Not applicable 
 
Behaviour 
when in 
doubt about 
medicine 
quality 
Report to authority 
Report to pharmacist 
Report to the Director of 
pharmacy 
Report to physician 
Find alternative 
medicines 
Stop medicine use 
Do not take action 
 
3/6  
- 
- 
 
- 
2/6  
 
- 
- 
14/63 (22%) 
25/63 (40%) 
31/63 (49%) 
 
11/63 (17%) 
1/63 (2%) 
 
35/63 (56%) 
4/63 (6%) 
30/58 (52%) 
12/58 (21%) 
35/58 (60%) 
 
16/58 (28%) 
2/58 (3%) 
 
15/58 (26%) 
2/58 (3%) 
4/53 (8%) 
3/53 (6%) 
- 
 
22/53 (42%) 
12/53 (23%) 
 
37/53 (70%) 
6/53 (11%) 
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7.1.4 Shared theme 4: Challenges to medicine quality in MOI-MSD 
All stakeholder groups in this study identified medicine procurement based solely on 
price differences, the difficulty in reporting medicine quality problems and medicine 
storage conditions as common challenges to medicine quality in MOI-MSD settings. 
Moreover, commissioners and healthcare providers (i.e. pharmacists and physicians) 
added the outdated medicine formulary and the limited budget available to procure 
medicines as additional challenges. Furthermore, patients and commissioners 
highlighted medicine non-availability as a challenge to medicine quality in these 
settings. Further details can be found in Table 7.5 and Appendix 27. 
 
Table 7.5 Stakeholders’ perceptions about challenges to medicine quality in MOI-MSD 
Sub-theme Commissioners Physicians Pharmacists Patients 
Tender procurement of 
medicines is based on 
price not quality 
        
Limited or difficulty in 
reporting medicine 
quality problems 
        
Medicine storage 
conditions 
        
Medicine transport 
conditions 
-     - 
Expired medicines 
 
-     - 
Nearly-expired 
medicines 
-     - 
Limited budget 
available to procure 
medicines 
      - 
Outdated medicine 
formulary 
      - 
Inadequate medicine 
monitoring 
-       
Patients do not accept 
their medicines 
-     - 
Medicine non-
availability 
  - -   
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7.1.5 Shared theme 5: Recommendations to improve medicine quality in MOI-
MSD 
Participants and respondents from all stakeholder groups have recommended improving 
medicine monitoring, medicine analysis, procurement of medicines, and conducting 
educational campaigns about medicines and their quality as a means to improve 
medicine quality in MOI-MSD settings. The physicians, pharmacists and patients have 
also suggested improvements to medicine storage conditions and communication 
between staff and patients. Furthermore, the healthcare providers in this study have 
suggested establishing a medicine quality department or committee within the MOI-
MSD in order to focus on medicine quality issues. A comprehensive list of all 
stakeholders’ recommendations can be found in Table 7.6 and Appendix 28.     
 
Table 7.6 Stakeholders’ recommendations to improve medicine quality in MOI-MSD 
Sub-theme Commissioners Physicians Pharmacists Patients 
Improve medicine 
monitoring 
        
Improve medicine 
analysis 
        
Improve medicine 
procurement system 
        
Educational campaigns 
about medicine quality 
        
Improve medicine 
storage conditions 
-       
Improve medicine 
transport conditions 
-     - 
Ensure medicine expiry 
dates 
-       
Improve 
communication among 
staff and with patients 
-       
Update the local 
medicine formulary 
  -   - 
Conduct further 
research on medicines 
  -   - 
Establish a department 
or a committee for 
medicine quality 
-     - 
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7.1.6 Individual stakeholders’ themes and sub-themes 
This study identified some themes and sub-themes, which were unique to the patients’ 
group of participants. It was found that more than one quarter of patients overall (26%) 
did not know the name of their medicines, particularly those from the chronic sub-group 
of patients (31%). Some patients have also expressed some beliefs about medicines that 
were not shared with other stakeholders in this study, such as the belief that increased 
severity of a disease would increase the related medicine price (8%) and that increased 
medicine strength would increase its quality (6%). Moreover, counterfeit medicines 
were believed to be increasing recently in Saudi Arabia (8%) and counterfeiting was 
mostly associated with herbal medicines or cosmetic products in the country rather than 
pharmaceutical products (8%).  The patients have also expressed concerns about several 
difficulties they encountered that are associated with MOI-MSD clinics, such as 
inconvenient locations and opening times (23%). Furthermore, patients have expressed 
their trust in their physicians (55%) more often than their pharmacists (8%). More 
details regarding patients’ specific themes and sub-themes are available in Table 7.7. 
 
Similarly, the follow-up interviews with pharmacists and physicians generated some 
unique themes and sub-themes, in addition to further details about previously identified 
themes and sub-themes from the survey questionnaire phase of the study. The role of 
the pharmacist in MOI-MSD settings was largely foreseen as educational regarding the 
medicine by both physicians (5/8) and pharmacists (6/8). Physicians (3/8) and 
pharmacists (4/8) have indicated that patients in MOI-MSD settings accepted the 
available medicines on most occasions. Moreover, the physicians and the pharmacists 
have provided further details to some of their recommendations to enhance the quality 
assurance of medicines in MOI-MSD settings. Such recommendations included 
improvement to medicine monitoring, medicine analysis, medicine supply practices, 
reporting of medicine quality problems and the establishment of a medicine quality 
department or committee within the MOI-MSD. Further details regarding the healthcare 
providers’ individual themes and sub-themes can be found in Table 7.7. 
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Table 7.7 Individual stakeholders’ themes and sub-themes 
Themes Sub-themes Patients Physicians Pharmacists 
Knowledge about 
medicines 
 
Do not know the name of their medicines 14/53 (26%)  
 
- - 
Beliefs about 
medicines 
 
Higher strength medicines have more quality 
Severe diseases medicines are more expensive 
3/53 (6%) 
4/53 (8%) 
- 
- 
- 
- 
Counterfeit 
medicines 
 
Increasing lately in Saudi Arabia 
Only exist in herbal medicines and cosmetics 
4/53 (8%) 
4/53 (8%) 
- 
- 
- 
- 
Challenges to 
patients in MOI-
MSD clinics 
 
Clinics inconvenient locations and times 
Hospital appointments take too long 
Excessive quantity of dispensed medicines  
12/53 (23%) 
3/53 (6%) 
2/53 (4%) 
- 
- 
- 
- 
- 
- 
Patient’s trust Patients completely trust their physicians 
Patients completely trust their pharmacists 
 
29/53 (55%) 
4/53 (8%) 
- 
- 
- 
- 
Perceptions about 
pharmacist’s role in 
MOI-MSD 
Educational role about medicines 
Dispense medicines appropriately 
Protect from medication errors 
Comprehensive role in medicine cycle 
Can be improved by education 
Can be improved by counselling patients 
Can be improved by becoming more active 
 
- 
- 
- 
- 
- 
- 
- 
5/8 (63%) 
4/8 (50%) 
2/8 (25%) 
1/8 (13%) 
5/8 (63%) 
- 
2/8 (25%) 
6/8 (75%) 
3/8 (38%) 
2/8 (25%) 
3/8 (38%) 
3/8 (38%) 
3/8 (38%) 
1/8 (13%) 
Patients’ acceptance 
of available 
medicines in the 
MOI-MSD 
Patients mostly accept their medicines 
Patients do not accept the available medicine 
Can be improved by selecting better medicines 
Can be improved by staff re-assurance about 
quality of available medicines 
 
- 
- 
- 
- 
3/8 (38%) 
1/8 (13%) 
4/8 (50%) 
2/8 (25%) 
 
4/8 (50%) 
2/8 (25%) 
3/8 (38%) 
1/8 (13%) 
 
Recommendations 
to enhance quality 
assurance in the 
MOI-MSD 
Establish a department to monitor medicine quality 
Improve communication with SFDA 
 Suppliers to include batch analysis certificates 
Provide incentives to staff to encourage reporting 
Establish an electronic reporting system 
Involve other departments in medicine procurement  
Procure the same medicines for chronic patients 
Add quality criterion in the selection process 
Learn from other hospital procurement experiences 
Establish warehouses up to international standards 
Collect statistical data of dispensed medicines 
Transport medicines via airplanes 
Transport medicines by a distributing company 
Include a thermometer in medicine consignments 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
4/8 (50%) 
1/8 (13%) 
- 
1/8 (13%) 
1/8 (13%) 
4/8 (50%) 
1/8 (13%) 
- 
1/8 (13%) 
3/8 (38%) 
1/8 (13%) 
2/8 (25%) 
- 
2/8 (25%) 
3/8 (38%) 
1/8 (13%) 
1/8 (13%) 
2/8 (25%) 
1/8 (13%) 
2/8 (25%) 
1/8 (13%) 
1/8 (13%) 
- 
2/8 (25%) 
4/8 (50%) 
1/8 (13%) 
3/8 (38%) 
- 
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 7.2 Overall discussion of stakeholders’ perception 
Stakeholders in this study commonly defined a good quality medicine in terms of 
achieving a desired therapeutic effect. Similar findings were identified in the literature 
among patients and healthcare providers in developing countries (Syhakhang et al., 
2004; Patel et al., 2010; Patel et al., 2012). Interestingly, only a limited number of 
stakeholders in this study have indicated that the registration status of a medicine would 
be a guarantee of a good quality medicine. This result is in contrast to the healthcare 
commissioners’ views in Sudan (Alfadl et al., 2013) and medicine wholesalers’ views in 
Cambodia (Khan et al., 2011), as reported in a previous studies. A possible explanation 
of this finding is that various stakeholders in this study could have limited trust in or 
knowledge about medicine registration processes; which would indicate a need for the 
regulatory agency in the country, the (SFDA), to increase awareness and share 
information about medicine registration and/or surveillance with various stakeholders. 
 
The most common definition of counterfeit medicines among all stakeholders in this 
study is that they have an effect problem, whether there was no effect or limited 
therapeutic effect. This finding did not mirror the results from previous studies with 
commissioners in Sudan (Alfadl et al., 2013) and managing executives in Cambodia 
(Khan et al., 2011). Only a limited number of stakeholders provided technical 
specifications regarding chemical analysis results, packaging appearance and medicine 
source to describe a counterfeit medicine despite the WHO emphasis on these elements 
(WHO, 1999a). This would suggest the need to raise stakeholders’ awareness, 
particularly from within the physicians’ and patients’ groups, about the nature of 
counterfeit medicines in order to minimise confusion with other medicine related issues 
such as expired or generic medicines that have been previously reported among patients 
in the literature (Sarradon-Eck et al., 2007; Håkonsen & Toverud, 2011). 
 
Most stakeholders believed that the quality of medicines in Saudi Arabia was good or 
excellent. However, there were some differences noted in their views about the quality 
of medicines within the MOI-MSD settings. Around one third of pharmacists rated the 
quality of medicines in the MOI-MSD as poor or unacceptable, more than physicians or 
commissioners. These views could be explained by the way that pharmacists consider 
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themselves as guardians of medicines (Alhamarnah, Rosenthal, McElnay & Tsuyuki, 
2011) and, therefore, could be over-protective about the quality of medicines in their 
own settings. Nevertheless, it should be noted that the differences between the 
pharmacists’ and physicians’ perceptions about medicine quality in both the MOI-MSD 
and in Saudi Arabia was found to be statistically insignificant as shown in Table 6.12. 
In contrast, almost three-quarters of patients believed that the quality of medicines in 
MOI-MSD settings was good or excellent. This surprising finding could be explained 
by the relative success of healthcare commissioners and providers in the protection of 
patients from receiving medicines with questionable quality. It is also possible that 
patients could be grateful for receiving medicines free of charge in the MOI-MSD 
settings and, therefore, do not attempt to question their quality. 
 
Around two-thirds of participants from all stakeholders groups in this study believed 
that the counterfeit medicines prevalence rate was more than 10% of the pharmaceutical 
supply chain both globally and in Saudi Arabia. These reported findings are more in line 
with media predictions of 30%-40% in Saudi Arabia (Saudi Gazette, 2011) than the 
figure the WHO estimates currently to be 10%  (Cockburn et al., 2005; Heyman et al., 
2011; Ziance, 2008) or what the SFDA predicts at 0.5% (Arabnews, 2010). However, 
the most likely explanation of these estimates are lack of knowledge within all 
stakeholder’ groups about counterfeit medicines rather than genuine concerns about 
their high incidence in the country as previously discussed. 
 
The sources of information regarding medicine quality varied considerably among the 
different stakeholders in this study. The healthcare commissioners and providers mostly 
used experience from the actual use of a medicine as a source of information about its 
quality. However, about half of the patients indicated that the physician’s 
recommendation was the only necessary source of information they needed regarding 
medicine quality. This result indicates the patients’ trust in their physicians and would 
suggest that any future educational programmes would probably be best delivered 
directly from the physician to the patient.  
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Past experiences with questionable quality medicines varied between different 
stakeholders. The majority of commissioners believed that they had encountered 
questionable quality medicines within MOI-MSD settings in the past. However, the 
majority of healthcare providers (i.e. pharmacists and physicians) did not believe that 
they had past experiences with questionable quality medicines. Patients’ opinions were 
split in half, where one half believed that they have previously encountered medicines 
with questionable quality, while the other half did not. The majority of these reported 
experiences cannot be confidently attributed to genuine experiences with questionable 
quality since they have been described as experiences with medicine effects. However, 
a number of experiences reported by pharmacists from both the commissioner’ and 
healthcare provider’ groups could be attributed to medicine quality problems, such as 
experiences with medicines that did not have an expiry date, a medicine with an 
appearance problem, a medicine with bad odour, a medicine that contained less than the 
stated dosage form and tablets that did not dissolve. The majority of these experiences 
have been reported in previous studies as shown in Chapter 3 of this thesis.  
 
The stakeholders in this study reported a range of behaviours, when in doubt about the 
quality of medicines. Reporting the concern about medicine quality to the higher 
authorities, including the SFDA, was reported by half of the pharmacists in the 
commissioner’ and healthcare provider’ groups but was less reported in the physicians’ 
and patients’ groups. This would indicate more knowledge among pharmacists about 
the significance of reporting medicine quality concerns on a national level. Furthermore, 
reporting these concerns internally to the Director of Pharmacy in the healthcare 
providers’ group and to the physician in the patient group was also documented. More 
than half of the physicians and patients in this study considered stopping prescribing or 
using the medicine, if they had doubts about a medicine’s quality, while only one 
quarter of the pharmacists in the healthcare provider’ group and none from the 
commissioner’ group considered stopping dispensing these medicines. It is possible that 
pharmacists did not feel they had the authority to stop dispensing medicines without 
clear instructions from their managers and/or physicians. Therefore, it is important to 
unify and communicate a clear plan of action to all stakeholders, when in doubt about 
the quality of medicines in these settings in order to clearly identify such concerns.  
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Reporting of medicine quality problems was a shared concern among all stakeholders in 
this study. It appears that some healthcare providers have limited knowledge of how to 
report, find paper-based documentation impractical and find that reporting such 
problems may not be rewarding for staff. These perceived barriers are not without 
support from the literature. Limited healthcare provider’ comprehension about the 
correct method of reporting medicine-related problems was found with community 
pharmacists in Saudi Arabia (Bawazir, 2006; Khan, 2013), community pharmacists in 
Turkey (Toklu & Uysal, 2008) and pharmacists in Jordan (Suyagh et al., 2015), for 
example. Another less prevalent, yet evident, barrier to reporting medicine-related 
problems in this study was the lack of incentives for the reporter. This finding is in 
agreement with other results from a systematic review of the literature about barriers to 
adverse drug reaction reports (Lopez-Gonzalez, Herdeiro & Figueiras, 2009). In Saudi 
Arabia, the SFDA has both options for the public to report medicine quality problems, 
medication errors or adverse drug reactions on one single form that can be completed on 
either an electronic reporting system or a paper-based system (SFDA, 2015b). Thus, it 
is imperative to educate the stakeholders about such reporting options. Multiple 
research studies have demonstrated that implementing educational tools had a positive 
impact on increasing the rate of medicine related problem reports to support this 
recommendation (Clarkson et al., 2001; Mehta et al., 2007; Figueiras, Herdeiro, Polónia 
& Gestal‐ Otero, 2006; Herdeiro et al., 2012). 
 
The stakeholders in this study believed that the medicine procurement system needed 
improvement and held the opinion that current tenders focused only on the price and not 
the quality of a manufacturer as determining supplier selection. It has been reported that 
different countries within the European Union use additional criterions in the selection 
of a supplier besides the best or cheapest offer, such as quality in Germany and impact 
on total healthcare budget in Slovenia (Dylst et al., 2011). Some pharmacists and 
physicians in this study have suggested the involvement of staff from other departments 
besides the Medical Supply Department in MOI-MSD settings. This recommendation is 
in line with the WHO recommendations for good procurement practices (GPP) that 
highlight the importance of dividing different steps of the procurement cycle between 
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different personnel or departments to minimise conflict of interest (WHO, 1999b). 
Another recommendation in this study was to provide specific consideration to chronic 
patients in the tender process, as it would result in frequent changes in the medicines 
supplied. This is in line with reported concerns about chronic patient adherence to their 
medicines in Germany, resulting from frequent changes in the medicines supplied 
through tender-based systems (Dylst et al., 2011).  
 
The healthcare providers, i.e. the pharmacists and physicians at the primary care clinics, 
reported concerns about medicine storage and transportation within MOI-MSD settings 
on more occasions than commissioners or patients. This finding was surprising since the 
commissioners are the individuals who initiate medicine storage and transportation in 
these setting for the healthcare providers in the primary clinics. The results could 
indicate a gap in communication between the healthcare providers and the 
commissioners in the medicine supply cycle. This issue is important since extreme hot 
weather conditions could play a major role in the degradation of some medicines and 
therefore they could become substandard (Crichton, 2004; Naidoo et al., 2006). 
Furthermore, it has been reported in the literature that community pharmacists in 
Riyadh in Saudi Arabia expressed similar concerns about medicine storage and 
transportation conditions in their settings (Khoja et al., 2013a). The same study 
contained an observational part that found that around 10% of community pharmacies 
visited in Riyadh had temperature readings of >25°C (Khoja et al., 2013a). Therefore, it 
is recommended that commissioners in the MOI-MSD become aware of these issues 
and that storage and transportations conditions would be explored and examined in 
comparison to international (WHO, 2003b; DELIVER, 2003; WHO, 2007) and national 
guidelines (SFDA, 2012). 
 
Several strategies have been proposed by the stakeholders in this study in order to 
enhance medicine quality assurance in these settings. All stakeholder groups’ in this 
study considered medicine monitoring as a key strategy but with minimal description of 
what it entails. However, international guidelines provided by the WHO illustrate points 
beyond those which the stakeholders in this study have reported and indicate that 
monitoring medicines is an ongoing activity which starts at the time of medicine 
 232 
manufacture, through procurement, storage, distribution, dispensing and monitoring 
complaints following use by the patient (WHO, 2007). The analysis of medicine 
samples is another strategy that has been reported by various stakeholders in this study 
in order to enhance quality assurance. There was a common belief held by healthcare 
providers, particularly from within the pharmacists’ group, that the performance of 
laboratory medicine analysis was the responsibility of the SFDA and that the MOI-
MSD responsibility was mainly to report and send medicine samples of questionable 
quality and then receive feed-back from the SFDA. This could be true since the WHO 
has indicated that one of the functions of a national regulatory agency in any country is 
the analysis of medicines during prequalification and registration stages (WHO, 2007). 
Moreover, the stakeholders have identified other strategies such as improvements to 
medicine procurement, storage, transportation and reporting of medicine quality 
problems that have been previously discussed. However, these strategies do not mirror 
the reported practices in South Africa (Patel et al., 2009) or Cambodia (Khan et al., 
2011).   
 
A number of medicine attributes that could affect medicine supply decisions have been 
identified in this study. The country of manufacturing was considered significant 
particularly from the pharmacists’ and physicians’ views. Previous research has 
suggested the medicine wholesalers in Cambodia considered the reputation of the 
manufacturer during their medicine procurement practices (Khan et al., 2011). The 
availability of medicines was considered an important factor in the supply of medicines 
according to the opinions of healthcare providers in this study. However, none of the 
healthcare providers and only one commissioner had identified medicine availability as 
a challenge in the MOI-MSD settings. In contrast, a significant number of patients, 
particularly those from Jeddah city, had complained of medicine non-availability. This 
would suggest a lack of knowledge or awareness about the patient-related issues with 
medicine use in these settings on both the commissioner and healthcare providers’ part. 
It is important to note that the WHO considered medicine accessibility, which largely 
depends on medicine price and availability, as a basic human right that needs to be 
preserved at all costs (WHO, 2008). Furthermore, medicine non-availability is a global 
problem that could be identified in many developing countries (Cameron, Ewen, Ross-
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Degnan, Ball, & Laing, 2008). Therefore, it is recommended that these findings be 
communicated to the healthcare commissioners and providers within the MOI-MSD to 
raise awareness about medicine non-availability in these settings. Furthermore, 
medicine prices were another factor that had been associated with supply decisions 
according to the physicians and pharmacists in this study. The Saudi Arabian 
governmental regulations regarding procurement in tenders support these perceptions 
with specific consideration of the selection of the least price of otherwise similar 
products (MOF, 2006). 
 
Overall strengths and limitations of the stakeholders’ perception study 
This study was among the few studies that explored the perceptions of stakeholders 
about medicine quality and related problems worldwide and the first in Saudi Arabia to 
the researcher’s knowledge. It had systematically explored the issue from the 
perspective of commissioners who make medicine supply decisions, physicians who 
prescribe the medicines, pharmacists who dispense medicine and patients who 
ultimately use the medicine within the MOI-MSD settings in Saudi Arabia. The 
common and specific themes and sub-themes were identified among the different 
stakeholder groups in this study. 
 
However, this study is not without its limitations. In the interview phases of the study, 
generalisability of results and data saturation was not achieved, as the purpose of the 
study was exploratory. Some questions were concerned with the participants’ previous 
experiences and therefore could be a subject of recall bias. Female participants were 
limited in the study particularly in the commissioners and healthcare provider groups 
due to cultural difficulties that would limit their presence in the MOI-MSD 
administration and the researcher’s access to them in primary care clinics. It was not 
possible to send the interview transcripts back to patients via e-mail as they have only 
provided their telephone numbers for future contact. The results were frequently 
displayed in numbers and percentages; however, caution is advised when interpreting 
such data from the small number of participants available in the commissioners’ group 
or interviews with pharmacists and physicians. Moreover, the questionnaire survey part 
of the study also had some limitations. The identity of respondents cannot be verified 
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since the questionnaire survey was anonymous. No further clarification of questions by 
the researcher was possible as the questionnaire was self-completed. Furthermore, there 
were other members of the healthcare staff at the MOI-MSD who did not participate in 
this study, such as nurses, technicians or other administrative staff in these settings.   
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7.3 Conclusion 
The majority of all stakeholders in this study (i.e. commissioners, physicians, 
pharmacists and patients) perceived the quality of medicines in Saudi Arabia as good or 
excellent. However, healthcare commissioners and providers (i.e. physicians and 
pharmacists) mostly perceived that the quality of medicines in the MOI-MSD was of a 
lower quality than that available elsewhere in Saudi Arabia, while patients mostly did 
not share these views. Thus, quality assurance strategies should target healthcare 
commissioners and providers in these settings.  
 
Most stakeholders estimated that counterfeit medicines are more prevalent than has 
been estimated by the local authorities (SFDA) or international organisations (WHO). 
This could be attributed to their understanding of what a good quality or a counterfeit 
medicine was, which was found to be mostly associated with medicine effect, with 
minimal regard to the medicine source or the technical attributes of the medicine such 
as packaging, source, chemical or physical analysis results. Therefore, an educational 
campaign is needed to increase the awareness of all stakeholders about the nature of 
counterfeit medicine and local or international prevalence estimations, to minimise 
unnecessary fear, which could impact medicine accessibility.  
 
Furthermore, there were common beliefs mostly shared among healthcare 
commissioners and providers, such as that a higher medicine price indicated a higher 
quality medicine; that developed countries manufactured better quality medicines than 
developing countries and that patients preferred to use brand medicines. However, the 
majority of patients did not agree with these views, particularly female and chronic 
patients. It is, therefore, suggested that encouragement is given to improve 
communication between healthcare commissioners/providers and patients, to assess 
their requirements and concerns. An example of such patient requirements or concerns 
was found in relation to medicine non-availability particularly in Jeddah city, which was 
not identified as a challenge by most healthcare commissioners or providers. Instead, 
healthcare providers and some commissioners highlighted other medicine challenges 
such as nearly expired medicines, procurement tenders that focus on price rather than 
quality and inadequate medicine storage and/or transportation conditions.  Furthermore, 
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all stakeholders agreed that the reporting of medicine quality problems within the MOI-
MSD was not clear and/or difficult. This would suggest that educating all stakeholders 
about procedures to report such problems and increasing the options for reporting 
medicine quality concerns such as electronic or telephone methods of reporting requires 
improvement.  
 
Moreover, nearly half of participants from all stakeholders groups believed that they 
had previous experiences with questionable quality medicines. However, details of such 
experiences rarely reflected reliable medicine quality concerns, with the exception of 
pharmacists in this study. Most of the reported medicine quality experiences involved 
the use of a medicine that had no or limited effect, which could be associated with a 
wide variety of issues, in addition to medicine quality problem. Therefore, it becomes 
imperative to educate the stakeholders, particularly physicians and patients, about 
medicine quality problems and how to detect them.  
 
All stakeholders in this study agreed that it was necessary to improve medicine 
monitoring, analysis, procurement and communication regarding the reporting of such 
problems, in order to improve the quality of medicines within the MOI-MSD settings as 
they were perceived as major challenges to medicine quality.      
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8 Chapter 8: Overall discussion of the research 
Medicines provided to patients should be ensured in terms of safety, efficacy and 
quality in all healthcare settings. Medicine quality problems, whether medicines are 
counterfeit or substandard, are increasing worldwide (Cockburn et al., 2005; Caudron et 
al., 2008; PSI, 2014a). This alarming increase in the prevalence rates should be 
considered together with the possibility of negligence, to consider medicine quality 
problems in cases of treatment failure, which is often associated with the disease 
progression rather than the medicine itself (deKieffer, 2006; Liang, 2006; Newton et al., 
2008; Feldschreiber, 2009; Davison, 2011). Nevertheless, evidence has been shown to 
associate medicine quality problems with mortality in severe cases (Cockburn et al., 
2005; Mackey & Liang, 2011; Kao et al, 2009). Furthermore, medicine quality 
problems could also have a negative impact on the patient in terms of morbidity, drug 
resistance, therapeutic failure or possible toxicity (Cockburn et al., 2005; Amin & 
Kokwaro, 2007; Jackson, 2009). Other dimensions of the negative impact of counterfeit 
and substandard medicines could be in the economic burden they may cause on the 
individuals involved and on societies as a wholes (Yankus & Marks, 2009; Wertheimer 
& Norris, 2009), as well as the impact on loss of trust in healthcare providers and 
healthcare settings (Cockburn et al., 2005; Amin & Kokwaro, 2007; Wertheimer & 
Norris, 2009; Mackey & Liang, 2011; Kyriacos et al., 2008). Therefore, the issue of 
substandard and counterfeit medicines was considered significant and needed to be 
addressed in this study.  
 
The quality of medicines has been traditionally determined in laboratory settings, by 
conducting chemical and physical testing of medicine samples, to test their conformity 
to various pharmacopoeial specifications (Patel et al., 2010). It is also important to 
authenticate the source and packaging information of a medicine sample in order to 
exclude the possibility of counterfeit medicines (WHO, 1999a; IMPACT, 2011).  
Another paradigm, possibly less explored, of medicine quality and related problems is 
through the social paradigm, by investigating the stakeholders’ perceptions. Therefore, 
chemical laboratory testing, authentication of source and packaging information, in 
addition to investigating the stakeholders’ perceptions including healthcare 
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commissioners, providers and patients was the approach of choice in this study. To the 
researcher’s knowledge, this was the first study with a pragmatic approach to consider 
the issue of medicine quality and related problems in terms of chemical laboratory 
testing, visual inspection of medicine source and packaging, in combination with the 
stakeholders' perceptions about medicine quality and any related problems.   
 
The first part of this study was concerned with conducting a systematic detail about the 
nature of evidence pertaining to counterfeit and substandard medicines in the published 
literature from a traditional laboratory based perspective. This study found that the 
majority of studies were conducted in certain parts of Asia and Africa, while only two 
studies were conducted in the Middle East (Kyriacos et al., 2008; Abdo-Rabbo et al., 
2005). The majority of studies were found to have investigated medicines for the 
treatment of infectious diseases, while extremely limited studies were reported on 
chronic disease medicines. Less than 10% of all identified studies have attempted to 
authenticate the source of the medicine and to inspect the medicine package information 
to account for the possibility of counterfeiting to supplement chemical analysis tests. 
The nature of problems found in this systematic review was found to relate more to 
substandard medicines rather than counterfeiting, which would agree with previous 
publications (Caudron et al., 2008). More specifically, the majority of problems 
identified in this study reported inadequate amounts of API concentrations and only a 
few studies reported the wrong API or absence of any API in the medicine samples. 
Furthermore, it was found that HPLC was the instrument of choice to conduct chemical 
analysis tests in most of the identified studies. Recent findings from the research studies 
since the publication of this systematic review were similar to the cited literature in the 
review (Khurelbat et al., 2014; Chikowe, Osei-Safo, Harrison, Konadu & Addae-
Mensa, 2015; Visser et al., 2015). Therefore, the findings from this study would call for 
the current knowledge gaps to be addressed by conducting studies that would consider 
the possibility of counterfeit and substandard medicines in areas of the world with 
limited scientific research published on the matter, such as the Middle East, the 
selection of non-communicable disease medicines as a therapeutic class for 
investigation and conducting chemical analysis test of the API, in addition to source 
authentication and package inspection.  
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The next part of this study addressed the issue of limited published scientific research 
pertaining to counterfeit and substandard medicines through laboratory testing of 
medicine samples in the Middle East and scarce evidence worldwide regarding 
medicine authentication of source and package inspection of non-communicable disease 
medicines. Glibenclamide, a popular antidiabetic medicine, was therefore selected on 
these bases, in addition to the high volume of consumption reported within the targeted 
healthcare setting within the MOI-MSD in Saudi Arabia (Table 6). Additional samples 
were also collected from community pharmacies in another city (Najran) in Saudi 
Arabia for comparison purposes. The chemical analysis of glibenclamide samples was 
performed using HPLC to confirm the API quantity of glibenclamide according to USP 
(36) pharmacopoeial specification. The authentication of glibenclamide source was 
performed by examining official reception documents with samples obtained only from 
the MOI-MSD (Appendix 8). Packaging inspection was performed by using a tool kit 
developed by WHPA and FIP for the visual inspection of medicines (FIP, 2013). The 
results of this study indicated that all glibenclamide samples were within the accepted 
USP (36) limits in terms of quantity. This finding is not in line with results from 
previous chemical analysis tests of amoxicillin samples in Saudi Arabia which found 
samples with unacceptable API limits (Kyriacos et al., 2008; Khoja et al., 2013a). 
However, these results were similar to a study conducted on another antidiabetic 
medicine (metformin) in Saudi Arabia that found the correct quantities of the API 
according to USP specifications (Afifi & Ahmadeen, 2012). Moreover, the source of 
glibenclamide samples from MOI-MSD settings was authenticated by comparison with 
official reception documents. Visual analysis of package information revealed no signs 
of errors or noticeable defects. It was, therefore, concluded that the MOI-MSD 
glibenclamide samples collected in this study were up to the required standards in terms 
of API quantity, were authentic in terms of source and had no visual defects by package 
inspection. Thus, it was necessary to examine the quality of medicines and any related 
problems from a social paradigm, by examining the MOI-MSD stakeholder’s 
perceptions about these issues in the next part of this study.             
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The following part of this study aimed at documenting published research on the topic 
of stakeholders’ perceptions about medicine quality and any related problems, such as 
counterfeit and substandard medicines. A detailed review of such evidence was not 
available and therefore this part of the study addressed this knowledge gap by 
conducting a systematic review of the literature regarding stakeholders’ perceptions 
about medicine quality and any related problems.  It was found that a good quality 
medicine was defined in terms of effect by patients (Syhakhang et al., 2004; Patel et al., 
2010; Patel et al., 2012), nurses (Syhakhang et al., 2004), pharmacists and physicians 
(Patel et al., 2012). Good quality medicines were also perceived as being expensive 
medicine from well-known manufacturers by some patients (Syhakhang et al., 2004). 
As for counterfeit medicines, commissioners in the public sector defined them as 
medicines that entered the country illegally and did not conform to the required 
specifications (Alfadl et al., 2013) while commissioners from the private wholesaler 
industry reported a wide range of characteristics of a counterfeit medicine including 
unregistered medicines, fraudulent manufacturing, had lower quantity of API and 
expired medicines (Khan et al., 2011). Perceptions about medicine quality were high in 
the opinion of patients (Syhakhang et al., 2004) and healthcare providers, including 
nurses, pharmacists and physicians (Syhakhang et al., 2004; Patel et al., 2012). This 
would indicate high trust by patients and healthcare providers in the quality of 
medicines in a country, regardless of the absence of scientific literature indicating 
medicine quality problems such as is the case with South Africa, or the presence of such 
evidence in Laos as noted in a previous part of the study (Chapter 3). It should also be 
noted that perceptions of generic medicines as being of poor quality have been found 
among physicians (García et al., 2011; Dunne et al, 2014a) and patients (Patel et al., 
2010; Patel et al., 2012; Dunne et al, 2014b). Such perceptions could also extend to 
perceiving generic medicines as being counterfeit on the part of some patients 
(Håkonsen & Toverud, 2011; Patel et al., 2012). Moreover, practices to ensure medicine 
quality were only identified in two studies (Patel et al., 2009, Khan et al., 2011). 
Commissioners in South Africa procured medicine from licensed suppliers, and used 
standard operating procedures and audits as strategies to ensure medicine quality in 
their settings (Patel et al., 2009). Executives from the wholesaler level in Cambodia 
used registration information, credibility of product and reputation of manufacturer as 
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key characteristics to ensure the quality of medicine at the procurement level and used 
visual analysis of medicine consignments to check for intactness and product 
information as key strategies to ensure quality of medicines at the reception level (Khan 
et al., 2011). However, none of the identified studies have explored the healthcare 
providers’ practices to ensure medicine quality and none have investigated practices to 
ensure medicine quality during the storage and transportation of medicines. In addition, 
several barriers to practices to ensure medicine quality were identified in some studies. 
Lack of communication regarding medicine quality problems by pharmacists and 
commissioners (Law & Youmans, 2011; Patel et al., 2009), lack of knowledge about the 
methods to report medicine quality concerns on the part of nurses, physicians and 
patients (Binkowska-Bury et al., 2012a; Binkowska-Bury et al., 2012b), low practice 
levels to ensure medicine quality on the part of pharmacists (Shahverdi et al., 2012), 
limited resources to track and lenient penalties for offenders in the opinion of 
pharmacists (Law & Youmans, 2011) were all identified as key barriers to ensuring 
medicine quality by healthcare commissioners and providers. Therefore, it was 
necessary to conduct a study that addresses the multiple knowledge gaps regarding 
medicine quality and any related problems from various stakeholders’ perspectives, in 
conjunction with considering a different setting from what has been already explored, in 
order to enhance knowledge about a topic where little has been established so far. The 
next part of this study addressed these issues from the perspectives of commissioners, 
physicians, pharmacists and patients in a previously unexplored country: Saudi Arabia. 
 
The final part of this study explored the perception of various stakeholders in MOI-
MSD settings in Saudi Arabia regarding medicine quality and any related issues. The 
results were triangulated in order to find common themes and/or differences in opinions 
regarding the topic among the healthcare commissioners, providers and patients in these 
settings.  
 
The definition of a good quality medicine was largely focused on its perceived effects, 
rather than the technical features of a medicine, in the opinion of commissioners, 
physicians, patients and, to a lesser extent, pharmacists. Such an understanding of 
medicine quality in terms of desired effects has been previously reported by different 
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stakeholders in previous studies (Syhakhang et al., 2004; Patel et al., 2010; Patel et al., 
2012). Surprisingly, many pharmacists from both the commissioner' and healthcare 
provider' groups defined a good quality medicine as a medicine from a reputable, 
innovative pharmaceutical company. This would suggest that pharmacists in this study 
associated brand medicines with better quality more than did other stakeholders in this 
study. It has been previously suggested in the Saudi Arabian media that patients have a 
tendency to prefer brand medicines (Abdullah, 2013), possibly because of the limited 
trust they have in generic medicines manufactured in developing countries. However, 
the results of this study suggest that pharmacists held these beliefs also and these were 
expressed on more occasions. A possible explanation of such findings can be found 
within the pharmacists’ views in this study, where commissioners associated generic 
medicines with quality defect warning letters received from the SFDA, while 
pharmacists in primary clinics associated generic medicines with previous medicine 
quality defects which had been visually noticed in their practice. Another surprising 
result was the limited reference to the registration status of a medicine with the SFDA 
as a characteristic of a good quality medicine among all stakeholders in this study. This 
result contrasts with previous studies which reported that commissioners from both 
public and private pharmaceutical sectors in other countries emphasised pharmaceutical 
product registration as a key determinant of a medicine's quality (Alfadl et al., 2013; 
Khan et al., 2011). Perhaps there is limited knowledge, awareness or trust among 
stakeholders in this study regarding the medicine registration processes performed by 
the SFDA in the country. It is also possible that current medicine registration processes 
failure in reducing the prevalence rates of counterfeit and substandard medicines 
according to the findings of a recent systematic review could have affected their opinion 
(El-Jardali et al., 2015). Moreover, it was surprising to find that only a few stakeholders, 
primarily from the pharmacists' group, have indicated visual characteristics of a 
medicine as a possible measure for medicine quality. Visual analysis of a medicine's 
appearance, packaging and information can be a tool to determine medicine quality 
problems, with limited or no resources required, as observed in a previous part of this 
study (Chapter 3).  
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Similarly, the stakeholders in this study also defined a counterfeit medicine as a 
medicine with no or little effect. This result was in contrast to previous studies, which 
suggested that commissioners in a developing country described a counterfeit medicine 
as an illegally sourced medicine (Alfadl et al., 2013). This also contrasts with the WHO 
definition of a counterfeit medicine, which emphasises the product identity and the 
source as key indicators of a counterfeit medicine (WHO, 1999a). Limited knowledge 
about counterfeit medicines could be associated with their confusion with generic 
medicines or expired medicines, as was shown by some patients and physicians in this 
study. The literature has reported supporting evidence of patients’ perceptions about 
generic or expired medicines being counterfeit (Sarradon-Eck et al., 2007; Håkonsen & 
Toverud, 2011).  
 
Furthermore, limited knowledge about medicine names was found among one-quarter 
of the patients who participated in this study. A previous study in Saudi Arabia has 
reported that community pharmacists in the Eastern part of the country had estimated 
that one-third of patients in their settings brought empty medicine bottles or boxes since 
they had no knowledge of their medicines' names (Khan & Ibrahim, 2012). This is 
particularly alarming with chronic patients in this study, where one-third of them did 
not know their medicines’ names, despite the fact that they should be using them 
regularly. A number of possibilities could explain this finding, such as the limited 
education they receive regarding their medicines, regular changes to the medicines they 
receive because of annual medicine tenders which makes remembering all the brand 
names difficult, or poly-pharmacy where patients co-administer many medicines due to 
multiple co-morbidities. Patients’ having no knowledge about their medicines' names, 
combined with other issues such as medicine non-availability, which has also been 
reported in this study, could increase the risk posed to patients in not administering the 
correct medicine or administrating two similar medicines for the same condition, and 
thereby increasing the risk of medicine-related toxicity. Patients co-administering two 
similar medicines due to lack of knowledge has been previously reported in some 
studies with Pakistani chronic patients in Norway (Håkonsen & Toverud, 2011). 
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A common belief among most members of all stakeholder’ groups was that the quality 
of medicines in Saudi Arabia was high. However, less confidence among MOI-MSD 
staff was shown in the quality of medicines available within MOI-MSD settings, 
particularly on the part of pharmacists in both the commissioner' and healthcare 
provider' groups. This result could be explained by the pharmacists’ protective views 
about their role as guardians of medicines (Alhamarnah et al., 2011), quality defect 
letters they receive from the SFDA concerning generic medicines or their negative 
experiences with the quality of some medicines based on previous visual inspections. 
Indeed, pharmacists’ low opinions on the quality of medicine within the MOI-MSD 
could have been associated with a negativity bias which favours remembering negative 
experiences rather than the positive experiences in their prolonged engagement with 
medicines (Rozin & Royzman, 2001). Surprisingly, patients in this study demonstrated 
more trust in the quality of medicines in the MOI-MSD when compared with other 
stakeholders. Possible explanations for this result could be successful healthcare 
professionals' interventions at the MOI-MSD to prevent questionable quality medicines 
from reaching patients or that patients may not question the quality of medicines which 
they receive free of charge, despite previous studies in South Africa which have 
suggested that some patients may perceive free medicine as being of inferior quality 
(Patel et al., 2010).  
 
Another common belief among all stakeholders, particularly pharmacists, was that 
higher priced medicines guaranteed a higher quality product. This belief could be 
associated with brand loyalty (Grabowski & Vernon, 1992; Costa-Font, Rudisill & Tan, 
2014), since innovator brand products are introduced earlier in the market and therefore 
any subsequent generic product would most likely have a cheaper price. This, in turn, 
would be related to negative experiences which pharmacists encountered with some 
generic medicines, as previously discussed, to develop such beliefs. It could also be 
possible that such beliefs were related to the assumption that developed countries 
manufactured better quality medicines than developing countries, as demonstrated by 
different members of the stakeholder’ groups. Such beliefs have been previously 
reported by patients in the Saudi Arabian media (Abdullah, 2013). However, the 
patients in this study were found to have a unique belief that the quality of medicines 
 245 
differs between hospitals in Saudi Arabia. This belief could have been associated with 
their visits to different hospitals, where they received different medicines for the same 
medical condition, due to different procurement practices among healthcare sectors 
within the country. This would suggest, however, that patients might question the 
quality of a medicine when the medicine brand names change frequently.   
 
All stakeholder groups in this study estimated counterfeit medicines to be widely 
prevalent worldwide as well as in Saudi Arabia. More than two-thirds of the members 
of each stakeholder group estimated that counterfeit medicines have more than a 10% 
prevalence rate on a global level and in Saudi Arabia. These estimations exceed 
regulatory agencies' estimation of 10% or less globally, issued by the WHO (Cockburn 
et al., 2005; Heyman et al., 2011; Ziance, 2008) and by the SFDA in Saudi Arabia 
(Arabnews, 2010). However, this estimation would more likely demonstrate a lack of 
knowledge about medicine counterfeiting rather than genuine concerns about medicine 
quality, which was generally perceived by stakeholders as being high in Saudi Arabia, 
as previously discussed. Therefore, caution is advised when asking stakeholders about 
their estimation of counterfeit medicine prevalence rates without establishing their 
knowledge about counterfeiting in advance.         
 
The source of information regarding medicine quality and any related issues could be a 
key factor in shaping beliefs about them. Within the context of this study, the 
stakeholders had different sources of information for knowledge about medicine quality 
and any problems. Commissioners emphasised SFDA warning letters about medicine 
quality defects, while healthcare providers focused on actual experiences with medicine 
use. On the other hand, patients generally sought the advice of the physician to provide 
them with the necessary information pertaining to medicine quality. Surprisingly, very 
few patients have identified the pharmacist, who is the dispenser of the medicine, as a 
source of information about medicine quality and any other related problems. This led 
the researcher to explore the healthcare providers’ views on the role of the pharmacist in 
MOI-MSD settings in the final part of this study. It was found that pharmacists’ roles 
were perceived mainly as dispensing medicines and providing information related to 
medicines to medical staff and patients. However, it was also found that certain barriers, 
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such as lack of space and time to counsel patients, could limit the pharmacists in MOI-
MSD settings from fulfilling their responsibility to educate patients about their 
medicines and, therefore, could have limited the strength of relationship between 
pharmacists and patients in MOI-MSD settings. On the other hand, equal emphasis 
should be given to increasing the pharmacist’s trust in the quality of medicines they 
dispense within the MOI-MSD, as well as strengthening the patient-pharmacist 
relationship in order to avoid the transfer of negative perceptions about medicine quality 
from the pharmacists to the patients, which could result in medicine non-adherence and 
the wasting of scarce resources.      
 
Most commissioners in this study believed they had encountered medicines of 
questionable quality in their practice in MOI-MSD settings. In contrast, healthcare 
providers largely did not report such encounters, particularly from within the physicians' 
group. It is possible that the nature of physicians’ work in diagnosing medical 
conditions and prescribing medicines could have limited their exposure to questionable 
quality medicines. Patients’ opinions resulted in half of them agreeing that they had 
previous experiences with questionable quality medicines while the other half did not 
report any such experiences. Most stakeholders’ experiences, except the pharmacists, 
reported incidents where medicines were not effective. Such experiences could have 
resulted from other issues besides medicine quality, such as incorrect diagnosis, 
antibiotic resistance or other reasons. On the other hand, pharmacists identified several 
experiences which could be related to medicine quality defects, such as appearance or 
odour problems, medicines with no stated expiry date or medicines with less than the 
stated dosage numbers. This result demonstrates that medicine quality problems do 
probably occur in the MOI-MSD settings and are likely to be accurately identified by 
pharmacists in primary clinics.   
 
Stakeholders’ behaviour when in doubt about medicine quality varied considerably 
between the different groups. Commissioners and pharmacists were more concerned 
about reporting such concerns to the higher authorities including the SFDA. In contrast, 
physicians and patients were more concerned with stopping prescribing/using the 
medicine with questionable quality. However, reporting such concerns about medicine 
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quality was a major barrier to practice as reported by members from all stakeholder' 
groups. It appears that a recognised mechanism to report such medicine quality 
concerns was not known by healthcare providers, despite the existence of such reporting 
forms within MOI-MSD settings (Appendix 24). Limited knowledge about the 
mechanism of reporting medicine-related problems, such as adverse drug reactions, 
have been previously reported in different cities in Saudi Arabia (Bawazir, 2006; Khan, 
2013; Al-Hazmi & Naylor, 2013; Abdel-Latif & Abdel-Wahab, 2015) and worldwide 
(Suyagh et al., 2015; Aziz, Siang & Badarudin, 2007). Another possible limitation to 
the reporting of medicine-related problems in this study was that reporting forms appear 
to be directed to the Pharmacy and Therapeutic Committee within the MOI-MSD. 
Committees, however, may not have adequate time and resources to increase knowledge 
about medicine quality and to improve the reporting of such issues, compared with a 
specific department which could implement such activities in their daily work.   
 
Stakeholders, particularly pharmacists and physicians, reported a wide degree of 
scepticism regarding the quality of medicine supply activities such as medicine 
selection, procurement, storage and transportation conditions. The medicines available 
within the MOI-MSD were often described as being outdated and in need of 
improvement. However, in such limited resource settings, guidance from international 
organisations, such as the WHO, could be beneficial in selecting the most cost-effective 
and essential medicines (WHO, 2015). Therefore, cross-checking the medicines 
available in the MOI-MSD formulary with the WHO essential list of medicines and then 
communicating these results to the physicians and pharmacists could improve their 
confidence in the medicine selection processes.  
 
The procurement of medicine was commonly described as being price-dependent rather 
than quality-dependent. This could be true of similar medicines which are registered 
with the SFDA and which would only compete based on price since the available Saudi 
Arabian governmental procurement regulations would favour the selection of local and 
cheaper products (MOF, 2006). Also, patients in this study, particularly from outside 
the capital, Riyadh, have reported problems with the availability of medicine in primary 
care clinics, which resulted in them acquiring the required medicines from elsewhere 
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and this was commonly described as expensive by the patients. This could indicate the 
need to improve the medicine procurement processes in these settings, as this would 
probably result in financial burdens for patients, in addition to exposing them to 
medicines from unknown sources. Possible improvements to the procurement practices 
could be achieved by implementing a system to collect data in order to evaluate 
suppliers’ performance, including delivery history and previous quality problems 
associated with their products (WHO, 2007). Such data could then be used, in addition 
to the governmental regulations regarding the price, in order to improve medicine 
procurement practices. Another possible improvement to procurement practices could 
be achieved by establishing a local MOI-MSD tender for medicines, which would focus 
on chronic medicines which are frequently demanded by regular patients, in order to 
avoid medicine non-availability issues which could be associated with joint 
procurement programmes because of their commitment to large quantities of medicine 
orders within different healthcare sectors. It has been previously suggested that hospital 
medicine tenders should focus on medicines which are most used by the patients and/or 
expensive items, in order to achieve immediate financial savings (Milovanovic, 
Pavlovic, Folic & Jankovic, 2004). 
 
Furthermore, the MOI-MSD medicine storage and transportation conditions were often 
described by healthcare providers as inadequate, particularly with regard to rural areas 
within the country. A future observational study would be needed to further explore this 
issue on site, since available evidence has shown the existence of medicine storage 
problems in community pharmacies in Riyadh (Khoja et al., 2013a). However, some 
cost-effective measures could be implemented immediately, in order to ensure the 
quality of these practices, such as including batch quality certificates for each medicine 
received by the MOI-MSD at the main warehouse, keeping records of warehouse 
temperatures regularly, regular pest control of all warehouses in the country, providing 
reliable vehicles to transport medicines, transporting medicines with thermometers to 
ensure appropriate temperature control in accordance with international guidelines and 
standards (WHO, 2003b; DELIVER, 2003; WHO, 2007).          
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The stakeholders, particularly from the healthcare provider group, raised concerns and 
recommended the improvement of medicine monitoring and medicine analysis in MOI-
MSD settings. They largely perceived that the task of medicine analysis should be 
performed by the SFDA and that the MOI-MSD should frequently send medicine 
samples for periodic analysis. This could be true, since the available evidence in this 
study does not support the notion of allocating scarce resources to establish laboratories 
in the MOI-MSD settings. On the other hand, this may require that a national 
framework would be developed and implemented in order for the SFDA to have legal 
authority to investigate and collect samples on site from all public healthcare 
organisations such as the MOI-MSD in addition to their current practices that focus on 
analysis of medicines in the country ports or from private healthcare organisations or 
pharmacies. Furthermore, international guidelines support conducting random sample 
checks where possible, in order to investigate the quality of medicines at the post-
procurement end of the medicine supply chain (WHO, 2007). However, the SFDA only 
has one laboratory to test medicine quality in the entire country. Therefore, a practical 
consideration needs to be taken into account, where only questionable quality 
medicines, based on observation or signals from patient’ or healthcare providers’ 
complaints, would be sent by the MOI-MSD to the SFDA for further investigation. It 
could also be possible for the MOI-MSD to use existing technologies such as handheld 
NIR or Raman instruments to screen the quality of medicine samples and address issues 
of temperature or humidity at the end of the supply chain cycle before they are 
dispensed to patients. A recent systematic review of the literature has found that both 
portable NIR and Raman devices are suitable for ensuring medicine quality in low-
resource settings in terms of cost, personnel training required and the diminished need 
for laboratory supplies, electricity power or designated facilities (Kovacs et al., 2014). 
 
Additionally, healthcare providers and patients had perceived inadequate medicine 
monitoring as a barrier to medicine quality within the MOI-MSD. Medicine monitoring 
is ideally relevant throughout all of the medicine supply cycle, including procurement, 
reception of medicines and medicine storage and/or transportation according to 
international guidelines (DELIVER, 2003). Based on these guidelines, several steps 
could be implemented in order to ensure medicine monitoring and, therefore, possibly 
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improve the stakeholders’ perceptions about them. At the procurement stage, 
monitoring could include previous patients' complaints about specific pharmaceutical 
products and/or suppliers through a reporting system, monitoring direct and indirect 
costs related to medicines, in addition to suppliers’ adherence to delivery schedules. At 
the reception stage, monitoring could include checking batch quality analysis 
certificates and the conformation of the received medicine with the purchase order. At 
the storage and transportation stage, monitoring could include measuring temperature 
and humidity regularly to ensure adequate conditions, according to the manufacturer's 
specifications, and keeping these records for future review.      
8.1 Summary 
What is already known about this topic: 
 Medicine quality problems such as counterfeit and substandard medicines are 
increasing worldwide and could affect health, the economy and patient' trust. 
 All stakeholders in developing countries could believe that a good quality 
medicine may be identified through its perceived effect. Patients also believed 
that higher priced medicines and reputable manufacturers represent a good 
quality medicine. Commissioners defined a good quality medicine in terms of 
good medicine manufacturing, storage and distribution conditions.  
 Commissioners in Sudan and Cambodia defined a counterfeit medicine as a 
medicine illegally entering a country with unacceptable specifications, 
unregistered, fraudulently manufactured, or with low API, as well as expired 
medicine. 
 Healthcare providers (i.e. nurses, pharmacists and physicians) and patients in 
developing countries perceived that the quality of medicines was high in their 
own settings.  
 Physicians, pharmacists and patients in developing and developed countries 
could have views that generic medicines are of poor quality. Patients in 
developing countries may also believe that generic medicines are counterfeit.  
 Commissioners’ practices to ensure medicine quality in Sudan and Cambodia 
included supply from licensed suppliers, using standard operating procedures, 
performing audits, ensuring medicine registration status, considering 
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manufacturer and product reputation at the procurement level. They would also 
conduct visual inspection of product intactness and information during 
reception of the medicine consignment.  
 Barriers to practices for medicine quality assurance could include lack of 
knowledge of the method to report medicine quality problems, in the opinion of 
healthcare providers (nurses and physicians) and patients in developing 
countries. Pharmacists and commissioners also reported lack of communication 
between healthcare staff, as being a barrier to ensuring medicine quality. The 
pharmacists have also identified low practice levels in addressing this issue, 
limited resources and lenient penalties for offenders, as possible barriers to the 
practices required to ensure medicine quality in developing and developed 
countries.  
 
What this study adds: 
 Systematically demonstrated that the majority of medicine quality problems 
reported in the field quality surveys in the literature were of substandard 
medicines, having out of specification API amounts, rather than being 
counterfeit.  
 The majority of laboratory-based medicine quality surveys in the literature were 
conducted on infectious disease medicines and not widely used chronic 
medicines or clinically significant narrow therapeutic medicines. 
 Only two studies investigating counterfeit and substandard medicines in 
laboratory settings were found in the Middle East and none in Saudi Arabia at 
the time of the systematic review of the literature. Since then, an additional 
study was performed to chemically analyse amoxicillin samples from private 
pharmacies in Saudi Arabia. 
 The systematic review of the literature identified that only 10% of included 
research articles had conducted chemical analysis of samples, authentication of 
medicine source and package inspection simultaneously to account for the 
possibility of counterfeiting in the selected samples. 
 The quality of glibenclamide collected from MOI-MSD settings in Saudi Arabia 
was found to be acceptable in terms of API quantity according to USP 
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specifications; source authentication was confirmed through official reception 
documents and packaging information revealed no signs of concern. 
 It was possible to use social media tools such as WhatsApp to distribute survey 
questionnaires in settings that use them as a mode of communication between 
administrations and staff, for example. 
 Commissioners, healthcare providers and patients in this study have also largely 
identified a good quality medicine in terms of effect, similar to previous studies 
conducted in medium or low-income countries. 
 Healthcare providers, commissioners and patients in this study mostly identified 
counterfeit medicines from their perceived effect. Laboratory specifications such 
as the presence of the correct API and medicine package information were 
predominantly identified by some pharmacists in this study. Only a few 
pharmacists and physicians from the healthcare provider' group specified that 
counterfeit medicines originate from an unreliable source. This result could 
explain why the majority of all stakeholders in this study estimated the 
prevalence of counterfeit medicines in Saudi Arabia and worldwide higher than 
any official estimation. 
 Some physicians shared the views of some patients in this study where a 
counterfeit medicine was identified as a cheaper generic medicine, an 
inadequately stored or expired medicine.   
 While the majority of stakeholders believed that the quality of medicines was 
good in Saudi Arabia, less confidence was shown in the quality of medicines in 
the MOI-MSD settings, particularly by pharmacists.  
 The majority of MOI-MSD stakeholders’ perceived experiences with 
questionable quality medicines were concerned with limited medicine effect, 
which cannot be related to medicine quality problems only. A few pharmacists 
reported experiences that could be related to medicine quality problems such as 
medicine appearance, taste or odour defects. 
 Commissioners have shown that SFDA warning letters could have a negative 
impact on their confidence about the quality of generic medicines. Patients, on 
the other hand, particularly chronic patients, appear to be influenced by their 
physicians’ opinion about medicine quality in MOI-MSD settings. 
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 The healthcare providers (pharmacists and physicians), commissioners and 
patients recommended improvement to medicine monitoring, medicine analysis, 
reporting of medicine quality problems, the medicine procurement system and 
medicine storage conditions, in order to ensure the quality of the available 
medicines within the MOI-MSD. The healthcare providers have also suggested 
improving medicine selection in the local formulary, medicine transportation 
conditions and establishing a medicine quality department or committee to 
ensure medicine quality.  
 This study has shown several difficulties which MOI-MSD patients’ encounter 
in their primary clinics, particularly patients located away from the capital, 
Riyadh. Such challenges included medicine non-availability, high medicine 
prices, limited knowledge about their medicine names, remote clinic locations 
and short opening times, which could lead to extra financial burdens on patients, 
place them in unnecessary threat from medicines with unknown sources or lead 
to patients’ non-adherence to their medicine regimens.       
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8.2 Conclusion 
The results of this study indicated that the quality of glibenclamide collected from MOI-
MSD settings and from community pharmacies were within API pharmacopoeial 
specifications and with no visual signs of defect in the tablets or their packaging. 
Furthermore, the glibenclamide samples collected from MOI-MSD settings were 
authenticated in terms of source by comparing them with official medicine reception 
documents. This would suggest that the SFDA prevalence estimation of counterfeit 
medicines in Saudi Arabia might be accurate, in contrast to media predictions. 
However, perceptions about medicine quality and any related issues were found to be a 
cause for concern. Most stakeholders believed that good quality and counterfeit 
medicines could be identified based on effect rather than laboratory testing, 
authentication of source or visual inspection. These beliefs demonstrated severe lack of 
knowledge about medicine quality and any related issues, when compared with existing 
evidence in the literature about counterfeit and substandard medicines. Although the 
majority of stakeholders expressed confidence in the quality of medicines in Saudi 
Arabia, this was not always the case with medicines in the MOI-MSD, particularly with 
pharmacists. The reasons for pharmacists’ scepticism about the quality of medicines in 
the MOI-MSD could be associated with their prolonged engagement with medicines in 
their role, previous negative experiences with generic medicines, SFDA warning letters 
predominantly about generic medicines or their belief that higher priced medicines 
would guarantee better quality. Behaviour, when in doubt about medicine quality, 
varied considerably among stakeholders, which would suggest the absence of an agreed 
and known method for reporting such concerns. Pharmacists, more than other 
stakeholders, recognised the importance of communicating such concerns to higher 
authorities, including the SFDA. The stakeholders identified medicine monitoring, 
medicine analysis, procurement practices, medicine storage conditions and reporting 
medicine quality problems as areas for improvement to ensure medicine quality in their 
settings. Furthermore, this study has identified several patient-related issues such as 
medicine non-availability, high medicine prices, the remote location of primary clinics 
and their short opening times, which could result in financial burdens on patients, make 
them vulnerable to medicines from unknown sources or lead to medicine non-
adherence.   
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8.3 Practice implication 
 The findings of this study suggest that medicine quality problems within the 
MOI-MSD in Saudi Arabia were associated with the social paradigm of 
perceptions about medicine quality and any related issues rather than the 
laboratory-based scientific analysis of medicine quality. This would suggest the 
need to develop appropriate intervention through educational programmes in 
these settings, in order to increase awareness about the definition and types of 
medicine quality problems. 
 Pharmacists from both the commissioner' and healthcare provider' groups 
demonstrated the lowest degree of confidence in medicine quality in their 
settings, when compared with other stakeholders’ perceptions. Thus, the 
implementation of quality assurance measures based on international guidelines 
in medicine selection, procurement, storage and transportation are needed in 
order to improve the confidence of pharmacists in medicines in their settings. 
 Patients in this study, particularly female and uneducated patients, had high 
opinions about the quality of medicines in Saudi Arabia and within the MOI-
MSD. They mostly based the information they had about medicines quality on 
their physician’s advice. Minimal confidence was shown by patients regarding 
the pharmacists’ advice about their medicines. This could be attributed to the 
pharmacists’ limited patient counselling in these settings. Therefore, allocating 
space and time for pharmacists to counsel patients regarding their medicines is 
significant to improve the pharmacists-patient relationship in order for patients 
to have immediate access to medicine-related information by a trusted 
healthcare professional, which may not always be possible with physicians, who 
could be engaged with other patients’ appointments.       
 This study has identified several barriers that some patients encounter in MOI-
MSD settings such as medicine non-availability, high medicine prices, limited 
knowledge of patients about their medicine names, distant locations of primary 
clinics and their short periods of opening. Such barriers could result in undesired 
outcomes for the patients, such as extra expenditure on procuring medicines 
from unknown sources or could negatively impact on their health due to 
medicine non-adherence. Thus, it is important that decision-makers in MOI-
 256 
MSD settings become aware of these patient-related issues, particularly 
healthcare providers, explore the reasons for some of these problems and design 
appropriate strategies to minimise or diminish such barriers.   
8.4 Strength and limitations of the research 
Strengths 
 The major strength of this study is integrating pharmacy practice approaches to 
explore stakeholders’ perceptions with pharmaceutical analysis of a selected 
high volume antidiabetic medicine (glibenclamide) to address the research 
question about medicine quality and any related issues in one setting. 
 The study that explored stakeholders’ perceptions about medicine quality and 
any related issues used a mixed method approach in addition to triangulation 
method to enhance the validity and reliability of the obtained results.    
  This study investigated different stakeholders’ perceptions about medicine 
quality and any related issues, such as counterfeit medicines, in one major 
governmental healthcare sector in Saudi Arabia, including commissioners 
(decision-makers), pharmacists and physicians (healthcare providers) and 
patients (users).  
 To the researcher’s knowledge, this study was the first to combine perceptions 
about medicine quality and counterfeit medicines. In addition, this study was the 
first to comprehensively explore the differences and similarities of medicine 
decision-makers, providers and users regarding the research issue in one setting 
in Saudi Arabia. 
 The systematic reviews in this study (Chapter 3 and 5) identified gaps in 
knowledge that were utilised to inform the aims and objectives in this study, as 
well as to encourage researchers worldwide to conduct research studies in the 
relevant fields accordingly.  
 
Limitations 
 The analysis of glibenclamide samples focused on API quantities based on the 
findings in the systematic review regarding the most common problems relating 
to medicine quality available in the literature and the types of analysis 
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performed (Chapter 3). Therefore, this study did not investigate the API identity, 
excipients in the samples, physical properties or use other analytical tools such 
as MS or NMR to identify the structure of the contents due to their complex 
nature and the limited time available. 
 The sample size in the laboratory phase and the stakeholders’ perception phase 
of the study could be considered small due to location constraints and time 
limitations. However, the sample size calculation in both phases was based on 
recognised methods and was comparable with many studies from both fields. 
 The study of the perception of stakeholders regarding medicine quality and any 
related issues was exploratory in nature and therefore focused on semi-
structured interviews, to shed light on the relevant issue where little is known, 
rather than to attempt to generalise findings. 
 The selection of stakeholders in this study was based on the medicine supply 
cycle within the MOI-MSD to involve medicine supply decision-makers, 
prescribers, dispensers and users. However, the perceptions of other 
stakeholders, such as nurses or healthcare technicians, for example, were not 
explored because they were beyond the scope of this study.  
8.5 Recommendations 
The threat of medicine quality problems such as counterfeit and substandard medicine is 
evident and could occur in any country regardless of the strength of their regulatory 
systems. On the other hand, negative perceptions about the quality of medicines without 
sufficient and scientific evidence to confirm them could lead to the wasting of scarce 
financial resources and inaccessibility to acceptable quality medicines which could, in 
turn, have harmful effects on the patient’s health. The findings suggest that the actual 
quality of medicines was acceptable and the majority of patients were satisfied with 
them. However, the medicine supply commissioners and healthcare providers, 
particularly pharmacists, were more sceptical about the quality of medicines in their 
own settings. Therefore, improving healthcare staff confidence about the quality of 
medicines available within the MOI-MSD through educational campaigns, ensuring 
quality in the different stages and processes of the medicine supply cycle and improving 
communication, would be the basis of the recommendations of this study as follows:   
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 The relationship between the MOI-MSD and the medicine regulatory agency in 
the country (SFDA) should be improved in order to ensure timely responses to 
medicine quality concerns and to expose healthcare commissioners and 
providers to the SFDA methods of ensuring medicine quality, in order to 
improve their confidence via site visits, if possible. 
 Reporting of medicine quality or other medicine-related concerns could be 
improved by designating the task of exchanging such information between the 
MOI-MSD and the SFDA to a specific department within the MOI-MSD rather 
than to a committee that cannot commit daily tasks to collect, follow-up and 
exchange such information. The reporting of such problems could also be 
improved by field visits of this designated department to primary care clinics 
and providing various methods to report medicine-related concerns to all 
stakeholders such as telephone, fax, e-mail or social media. 
 Medicine selection in the MOI-MSD formulary could be compared with what is 
available in the WHO essential medicine list or other treatment guidelines, such 
as The National Institute for Health and Care Excellence (NICE) guidelines, and 
the information would then be communicated back to healthcare commissioners 
and providers to increase their confidence.  
 Implementing a system to evaluate medicine suppliers' performance by 
collecting data about medicine direct and indirect costs, delivery date adherence 
and previous medicine quality complaints, and then implementing these data in 
the medicine procurement decisions, could further increase the confidence of 
stakeholders about the quality of medicines within the MOI-MSD. 
 Including a certificate of quality analysis for each batch of medicine delivered to 
the MOI-MSD by various suppliers could ensure the quality of each medicine 
consignment and improve perceptions about their quality. 
 Measuring and recording of temperatures during medicine storage and 
transportation in accordance with the manufacturer's specifications could also 
improve perceptions about medicine quality. 
 Allocating space for patient counselling in each MOI-MSD primary clinic could 
improve interaction with patients and, therefore, provide reliable information to 
patients and could increase the confidence of pharmacists in their role, which 
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could then be reflected towards their confidence in the medicines available in 
their settings.   
 Educational campaigns are needed to raise the awareness of all stakeholders 
about the evidence and nature of medicine quality problem worldwide. This 
could benefit them in identifying medicine quality concerns more accurately and 
possibly limit the degree of unnecessary concern regarding medicine quality, 
without sufficient reasons for doubt. 
 Extending the role of SFDA to investigate the quality of medicines in public 
health organisation settings in Saudi Arabia and the use of portable NIR or 
Raman devices could be essential to rapidly ensure the quality of medicines at 
different supply chain levels and possible issues associated with humidity and 
high temperatures in the country.  
8.6 Further research 
 The researchers are encouraged to examine the quality of medicines 
prospectively in terms of pharmacopoeial specifications, source authentication 
and package information, particularly in areas where little is known in terms of 
therapeutic category, such as chronic medicines and narrow therapeutic index 
medicines, or in terms of exploring the quality of medicines in pharmaceutical 
markets which have been rarely explored, such as the Middle East.  
 Perceptions of stakeholders about medicine quality and any related issues, such 
as counterfeit medicines have been rarely addressed within the literature and, 
therefore, future studies to examine these perceptions from different 
perspectives in different settings is encouraged in order to develop and validate 
tools for measuring such perceptions, as they could negatively affect 
accessibility to acceptable quality medicines and/or waste limited resources.  
 Studies exploring the perceptions of the SFDA, pharmaceutical companies 
and/or other healthcare sectors in Saudi Arabia, with the exception of the MOI-
MSD, does not exist and therefore the researchers in Saudi Arabia are 
encouraged to explore the perceptions of these stakeholders in order to generate 
a country-wide perception, which could be beneficial in constructing national 
policies to address common barriers. 
 260 
 Within the context of the MOI-MSD, observational studies are recommended to 
examine the medicine storage and transportation conditions in different primary 
clinics based on the results found in this study. It would also be important to 
examine prescribing and dispensing practices in order to explore possible 
association with complaints about limited medicine effects, as reported by 
stakeholders in this study. Furthermore, future research in these settings could 
examine patients' adherence to their medicines and rational use of medicines in 
order to generate knowledge about the complete medicine supply cycle within 
the MOI-MSD.    
8.7 Reflection on the research process 
Reflexivity can be an important part of conducting qualitative research. It entails 
critically examining the researcher's role and relationship with the research study and 
environment. Such examination could include previous preconceptions held by the 
researcher and how they shaped the research questions or the dynamics in the 
relationship between the researcher and the respondents.  
 
My educational background and personal work experience with the MOI-MSD had, no 
doubt, a major influence on the shaping of this study. I have had past experience with 
patients and healthcare professionals complaining about the medicine quality in these 
settings. This may have been the most important factor for myself: to find out if such 
negative perceptions could be warranted. My previous work experience could have 
helped me identify the key commissioners to interview and, as a result, their agreement 
to participate in this study. As for patient interviews, every attempt was made by myself 
not to influence their opinions, if they had a suspicion that I worked for the MOI-MSD. 
I introduced myself as a researcher for UH in the UK to all patients. Nevertheless, 
wearing my Saudi clothing could have been interpreted by some patients as being a 
person of authority in these settings, particularly where their own doctors would most 
probably be expatriates. In a later stage of interviews with pharmacists and physicians, 
it came to my attention that some participants might have thought that I would be upset 
if I heard negative comments from them, given my previous work experience. I 
reminded them that all comments are welcome and would be held in confidentiality.  
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The study started with a literature review and protocol development stage in the first 
year of study. This part was essential to gather information about medicine quality 
problems and perceptions about medicine quality from the relevant literature. It was 
very beneficial for me to increase my understanding about the subject of medicine 
quality problems such as counterfeit and substandard medicine and discover the 
controversy of such issues that starts from the very definition of these phenomena from 
the perspective of different countries and scholars. It was also noted that no systematic 
reviews on the subject were available, which would be of great importance to the 
subject at hand and had influenced my decision to conduct it by the end of my first year 
of study. Furthermore, this part of the study introduced me to literature examining the 
technical and laboratory analysis studies on counterfeit and substandard medicines, 
which I found new and exciting to read although sometimes challenging since I had no 
prior experience of this field. Nevertheless, by the end of the first year, I was able to 
gain sufficient knowledge to prepare a protocol for this PhD study and to prepare a draft 
for the systematic review. The protocol was sent to the relevant University of 
Hertfordshire Ethics Committee for their approval, which was granted at the end of the 
first year, and a similar letter of acceptance was granted by the Ministry of Interior 
Medical Services in Saudi Arabia to conduct the study at their settings. Consequently, 
the first phase of this study started with a focus group discussion with experienced 
Saudi Arabian pharmacists conducting their postgraduate studies at UH at that time to 
help develop questions for the upcoming interview and questionnaire studies. The focus 
group study was a great experience for myself to practice communication skills for later 
interview studies and had very useful information to be utilized in the question 
development for the later studies, in terms of experiences with poor quality medicines, 
emerging issues not covered in other literature and the accepted Arabic translation of 
technical terms, such as counterfeit medicines, to be used later when conducting 
interviews with patients in Arabic. However, the focus group study did demonstrate for 
me the difficulty of arranging convenient group meetings with different individuals 
since everyone has different commitments and preferred times. It also gave me some 
experience in moderating such group meeting to try to balance the meeting and give 
everyone a chance to express his or her opinion freely with minimal peer pressure. 
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The second year of the study had major phases of this study including data collection 
and the publication of my systematic review in a scientific journal and the focus group 
study findings in a poster at a UH conference. Glibenclamide medicine samples were 
collected from the MOI-MSD general warehouse and other samples were collected from 
community pharmacies in Najran city for comparison purposes. At the beginning of the 
second year, it was necessary for me to spend a three-month period in Saudi Arabia to 
conduct face-to-face interviews with MOI-MSD commissioners and patients, in 
addition to the distribution of questionnaires to pharmacists and physicians. My 
physical presence in Saudi Arabia for the purpose of conducting these studies could 
have greatly influenced the number of participants agreeing and may have also 
facilitated more rapid responses for the survey questionnaire. However, it could have 
also affected the opinions of some patients, particularly some female patients, during 
the interview process by the possibility of not speaking freely due to cultural barriers in 
these setting between male and female individuals. It is therefore possible that female 
researchers could obtain more information from some female patients, particularly the 
ones who did not agree for the interview to be tape-recorded. It was my observation that 
younger and more educated female participants were more open to sharing their views 
and also to their agreement for the interview to be tape-recorded.  
 
In the third and final year of the PhD study, the data collection of interviews with 
pharmacists and physicians in the MOI-MSD was conducted via telephone calls. This 
will be followed by transcription, translation and analysis of emerging themes from the 
interviews. In addition, ensuring the validity of translation through back translation was 
performed with the assistance of two native Arabic speaking members of staff at UH. 
Also, the write up for the final thesis was started in conjunction with this phase of the 
study. Between March and April 2015, my work was presented via poster presentations 
at UH and an International Pharmacy conference held in Germany in addition to an oral 
presentation at UH. This was a great opportunity to communicate my research findings 
to the wider research community and meet with other researchers who share similar 
interests in the field. The study was concluded by examining similarities and differences 
between emerging themes from the various phases of the study before a complete 
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understanding of the research problem and findings can be reached and 
recommendations can be given in the final stages of the thesis. 
 
The experience of conducting research towards a PhD qualification has been a life 
learning experience without a doubt. I have improved my communication skills through 
multiple interactions with participants while approaching and conducting interview 
studies. I have practiced the role of an independent researcher in research design, data 
collection, data analysis, data interpretation and communicating my findings to the 
wider community through presentations and publication of studies in scientific journals.  
For that, I am forever grateful to my sponsors, university, supervisors and colleagues for 
supporting me in achieving my objectives.  
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9 Research output 
Publications 
Alghannam AFA, Aslanpour Z, Evans S, Schifano F. OHP-024 Pharmacist focus group 
about quality of medicines and related issues. European journal of hospital pharmacy. 
2015;22(Suppl 1):A203-A204. 
 
Alghannam AFA, Aslanpour Z, Evans S, Schifano F. A systematic review of counterfeit 
and substandard medicines in field quality surveys. Integrated Pharmacy Research and 
Practice. 2014;3:71-88. 
 
Presentations 
Life and Medical Sciences Conference; University of Hertfordshire-14th April 2015. 
Survey with MOI-MSD pharmacists and physicians in Saudi Arabia regarding medicine 
quality and related issues. 
 
Department of Pharmacy evening sessions; University of Hertfordshire-11th June 2014. 
Evaluation of glibenclamide quality: analysis and perceptions of stakeholders’ about 
medicine quality in Ministry of Interior clinical settings. 
 
Department of Pharmacy evening sessions; University of Hertfordshire-10th July 2013. 
Suboptimal medicines in Saudi Arabia: Ministry of Interior perspective. 
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11 Appendices 
Appendix 1: Comparison between some chemical analysis methods 
Characteristic HPLC NIR NMR Raman 
Identification 
(API and excipient) 
API  All All All 
 
Quantification 
(API and excipient) 
Yes only API depending on 
detector 
Yes No Yes 
Time Slow Rapid Rapid Rapid 
Cost High cost in consumables and 
reagents 
Affordable. No ongoing 
cost of maintenance and 
sample 
Expensive Affordable. Might need change 
of laser 
Personnel Requirement Training and knowledge 
required 
Minimum training required Must be experts Minimum training required 
Destructive method Yes No Yes No 
Portable option No Yes No Yes 
Major Attributes Provide chemical information. 
Can detect impurities, 
adulterants or degraded 
substances 
 
Needs sample preparation 
 
 
Sensitive technique can reach 
Nano-gram level 
 
 
Can be automated to work 24 
hours daily 
 
 
 
Can be coupled with MS to 
identify unknown samples 
 
 
Provide chemical and 
physical properties 
information 
 
 
No or minimal sample 
preparation 
 
 
Sensitivity can reach 
micro-gram level (<5% 
m/m) 
 
Can be automated to work 
24 hours daily in NIR 
imaging 
 
 
Can identify different 
batches of same drug 
 
Mostly no need to remove 
sample from package 
 
Sensitive to humidity and 
temperature. Can 
differentiate water content 
(difference in storage 
conditions) 
Provide chemical structure 
and composition of unknown 
 
Needs sample preparation 
 
 
Sensitive technique can reach 
Nano-gram level 
 
 
Can detect mixtures 
simultaneously in a single 
run in DOSY NMR 
 
 
 
Provide chemical information. 
Can detect aromatic bonds such 
as S-S and C double bonds 
 
No or minimal sample 
preparation 
 
 
Sensitivity can reach micro-
gram level 
(<10% m/m) 
 
Can be automated to work 24 
hours daily 
 
 
 
Depending on the laser type 
you can detect excipients as 
well as APIs. 
1064 nm laser can identify 
excipients and API 
 
 
Major Problems Destructive 
 
 
Time consuming 
 
Use of chemometrics 
 
 
Low sensitivity in samples 
with less than 5% m/m 
concentration 
 
Need a reference library of 
batches 
Destructive 
 
 
Solvents are expensive 
Use of chemometrics for 
analysis is essential 
 
Weak Raman signal can be 
affected by samples with high 
fluorescence (can be used as an 
advantage) 
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Appendix 2: Population in Saudi Arabia based on 2010 census 
Region Province City Population/City Total Population 
Central Riyadh 
 
 
 
 
Qassim 
 
 
Hail 
Riyadh 
Alkharj, Aldawadmy 
Almajmaa, Algowaia and 
Wadi Aldawaser 
 
Buraidah 
Onaizah and Alras 
 
Hail 
5.25 million 
(100,000-500,000) 
 
 
 
600,000 
(100,000-500,000) 
 
(100,000-500,000) 
6.77 million 
 
 
 
 
1.2 million 
 
 
597,000 
Western Makkah 
 
 
 
 
Madinah 
Jeddah 
Makkah 
Taif 
Algonfotha and Alleth 
 
Madinah 
Yanbou 
3.4 million 
1.5 million 
980,000 
(100,000-500,000) 
 
1.1 million 
(100,000-500,000) 
6.9 million 
 
 
 
 
1.77 million 
Eastern Eastern Dammam 
Hafouf 
Alkhobar 
Alqatif 
Jubail, Dhahran and Hafr 
Albaten 
900,000 
660,000 
578,000 
528,000 
(100,000-500,000) 
 
4.1 million 
Southern Asir 
 
 
 
 
Jizan 
 
 
 
Najran 
 
Albaha 
Khamis Mushait 
Abha, Bisha, Mahail, 
Ahad Rofaidah, and 
Almjardah 
 
Jizan, Sabia, Abo Arish, 
Samta and Ahad 
Almasarha 
 
Najran 
 
Albaha 
512,000 
(100,000-500,000) 
 
 
 
(100,000-500,000) 
 
 
 
(100,000-500,000) 
 
(100,000-500,000) 
1.9 million 
 
 
 
 
1.36 million 
 
 
 
505,000 
 
411,000 
Northern Tabouk 
Northern 
Borders 
 
Aljouf 
Tabouk 
Araar 
 
 
Skaka and Alqoriat 
569,000 
(100,000-500,000) 
 
 
(100,000-500,000) 
791,000 
320,000 
 
 
440,000 
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Appendix 3: Geographical map of MOI PCC in Saudi Arabia 
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Appendix 4: Sample size used in some medicine quality surveys 
 
Reference 
Number of 
medicines 
Sample size 
Ratio 
(sample 
size/ 
number of 
medicines) 
Number of 
countries 
Kenyon et al. (1999) 1 13 13 1 
Shakoor et al. (1997) 5 96 19.2 2 
Taylor et al. (2001) 27 581 21.5 1 
Laserson et al. (2001) 3 71 23.6 6 
Dondorp et al. (2004) 8 303 37.8 5 
Schwertner & Storrow (2005) 5 29 5.8 2 
Abdo-rabbo, Bassili & Atta (2005) 3 50 16.6 1 
Gaudiano et al. (2007) 5 28 5.6 3 
Kaur et al. (2008) 7 304 43.4 1 
Bate, Coticelli, Tren & Attaran (2008) 7 210 30 6 
Tipke et al. (2008) 6 77 12.8 1 
Kyriacos, Mrouch, Chahine & Khouzam 
(2008) 
2 111 55.5 4 
Amanlou (2008) 2 23 11.5 1 
Sengaloundeth et al. (2009) 1 30 30 1 
Onwujekwe et al. (2009) 5 225 45 1 
Hadi et al. (2010) 5 104 20.8 1 
Khan et al. (2010) 3 203 67.6 1 
Bate and Hess (2010) 3 339 113 2 
Seear et al. (2011) 3 300 100 1 
Newton et al (2011) 10 59 5.9 9 
Karlage et al. (2012) 8 17 2.1 1 
Stanton et al. (2012) 2 101 50.5 1 
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Appendix 5: Photo of glibenclamide collection in MOI-MSD 
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Appendix 6: Glyburide (glibenclamide) monograph USP 36 
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Appendix 7: Selection of random blister pack numbers in 
glibenclamide samples collected from MOI-MSD warehouse 
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Appendix 8: Sample of glibenclamide official receiving record 
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Appendix 9: University of Hertfordshire ethical approval 
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Appendix 10: MOI-MSD initial approval letter for the study 
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Appendix 11: MOI-MSD approval letter for conducting interviews in 
the study 
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Appendix 12: Participant information sheet for the focus group phase 
of the study 
 
UNIVERSITY OF HERTFORDSHIRE 
 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS 
(‘ETHICS COMMITTEE’) 
 
FORM EC6: PARTICIPANT INFORMATION SHEET 
 
Title of Research 
 
Evaluation of quality of an oral anti-diabetic agent (glibenclamide) in Saudi Arabia: analysis and 
perceptions about medicine quality 
 
Introduction 
 
You are being invited to take part in a research study.  Before you decide whether to 
do so, it is important that you understand the research that is being done and what 
your involvement will include.  Please take the time to read the following information 
carefully and discuss it with others if you wish.  Do not hesitate to ask us anything that 
is not clear or for any further information you would like to help you make your 
decision.  Please do take your time to decide whether or not you wish to take part. 
Thank you for reading this. 
 
What is the purpose of this study? 
 
The purpose of this study is explore perceptions about medicines quality and related 
medicine quality issues from the perspective of the Ministry of Interior Medical Services 
Department (MOI MSD) healthcare professionals and patients. The research may also 
involve perceptions from other industries such as the Ministry of Health employees in 
Saudi Arabia particularly in the question design phase at the beginning of the project. 
 
Do I have to take part? 
 
It is completely up to you whether or not you decide to take part in this study.  If you do 
decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form.  Agreeing to join the study does not mean that you have to 
complete it.  You are free to withdraw at any stage without giving a reason.   
 
What will happen to me if I take part? 
 
If you decide to take part in this study, you will be involved in it for approximately three 
hours on one specified date. It is likely that the discussion would be video recorded for 
data analysis purposes where possible. 
 
The first thing to happen will be that the researcher will send you an invitation letter to 
participate in the study along with suggested dates for the discussion via electronic 
mail. Participants will then send a reply agreeing to participate if they wish along with 
their preferred times and dates. The researcher will then decide the most appropriate 
time, date and location for meeting with the participants and send an electronic mail to 
them to confirm it. The researcher will also attempt to contact all participants two days 
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prior to the discussion date as a reminder. On the specified date for the study, the 
researcher and his team will be waiting for participants to arrive at the study location 
and consent forms and demographic data will be collected before the start of the focus 
group discussion. 
 
What are the possible disadvantages, risks or side effects of taking part? 
 
We anticipate no major disadvantages, risks or side effects to your participation. We 
are interested in your perception regarding the subject of medicine quality. We aim not 
to disturb your daily life and every effort will be made to make your participation as 
convenient to you as possible. 
 
What are the possible benefits of taking part? 
 
Your involvement in this study is of paramount importance. You will be part of a study 
that will explore different perceptions about medicine quality issues from the 
perspective of both healthcare professionals and patients in Saudi Arabia. Outcomes 
from this study could result in highlighting new areas of concern about perceptions of 
medicine quality and could also lead to improvement on current policy/practice to better 
ensure and protect the quality of your medicines. Additionally, this study could be 
fundamental to other similar studies about medicine quality issues in Saudi Arabia or 
internationally. 
 
How will my taking part in this study be kept confidential? 
 
Participation in this study will be kept confidential and your involvement anonymous at 
all times. No names will be published in any report and all hard copy personal 
information will be kept with the researcher only at all times. Electronic material will be 
password protected and access to this information will be restricted to the research 
team only. The collected material will be available for a short period of time (2 years 
approximately) and then it will be destroyed. 
 
What will happen to the results of the research study? 
 
The results of this study will be used in academic publications by the researcher. 
However, no individuals will be named or identified at any point in time. 
 
Who has reviewed this study? 
 
The Ethics Committee at the University of Hertfordshire in the United Kingdom has 
reviewed this research study. 
 
Who can I contact if I have any questions? 
 
If you would like further information on the research project or would like to discuss any 
details personally, please get in touch with me by phone or by email:  
 
Abdulaziz Alghannam 
PhD student at the University of Hertfordshire, UK 
E-mail: Pharmafg@gmail.com 
Telephone in UK: 00447732142882. Telephone in Saudi: 0556560655 
 
Although we hope it is not the case, if you have any complaints or concerns about any aspect of the way you have been approached or treated 
during the course of this study, please write to the University Secretary and Registrar. 
 
Thank you very much for reading this information and giving consideration to taking part in this study. 
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Appendix 13: Participant information sheet for the questionnaire 
phase of the study 
 
UNIVERSITY OF HERTFORDSHIRE 
 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS 
(‘ETHICS COMMITTEE’) 
 
 
FORM EC6: PARTICIPANT INFORMATION SHEET 
(Questionnaire) 
 
 
Title of Research 
 
Evaluation of quality of an oral anti-diabetic agent (glibenclamide) in Saudi Arabia: analysis and 
perceptions about medicine quality 
 
Introduction 
 
You are being invited to take part in a questionnaire study.  Before you decide whether 
to do so, it is important that you understand the research that is being done and what 
your involvement will include.  Please take the time to read the following information 
carefully and discuss it with others if you wish.  Do not hesitate to ask us anything that 
is not clear or for any further information you would like to help you make your 
decision.  Please do take your time to decide whether or not you wish to take part. 
Thank you for reading this. 
 
What is the purpose of this study? 
 
The overall purpose of this project is to explore perceptions about medicines quality 
and related medicine quality issues from the perspective of the Ministry of Interior 
Medical Services Department (MOI MSD) healthcare professionals and patients. In this 
study, it is essential to broadly explore attitudes and behaviour regarding medicine 
quality from the perspective of pharmacists and physicians working in MOI MSD 
facilities in Saudi Arabia.  
 
Do I have to take part? 
 
It is completely up to you whether or not you decide to take part in this study. Agreeing 
to join the study does not mean that you have to complete it.  You are free to withdraw 
at any stage without giving a reason.   
 
What will happen to me if I take part? 
 
If you decide to take part in this study, you will be involved in it for no longer than 15 
minutes and completing the questionnaire will be required only once at a time and date 
of your convenience.   
 
The first thing to happen will be that the researcher will send you an e-mail invitation 
letter to participate in a self-completed questionnaire. You will be sent a web link to 
directly complete the questionnaire online. Alternatively, a Word document file of the 
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questionnaire will also be available attached to the invitation letter should you prefer 
not to enter the web link. Please remember to send back the completed questionnaire 
to the researcher if you have chosen to complete it on the Word document. You are 
only asked to complete one form of the questionnaire either through the web link or the 
Word file, please do not complete both forms of the questionnaire, as they are exactly 
the same. Please note the date for closing the questionnaire survey specified in the 
invitation letter as no responses can be recorded following this date. 
 
What are the possible disadvantages, risks or side effects of taking part? 
 
We anticipate no major disadvantages, risks or side effects to your participation. We 
are interested in your perception regarding the subject of medicine quality. We aim not 
to disturb your daily life and every effort will be made to make your participation as 
convenient to you as possible. 
 
What are the possible benefits of taking part? 
 
Your involvement in this study is of paramount importance. You will be part of a study 
that will explore different perceptions about medicine quality issues from the 
perspective of both healthcare professionals and patients in Saudi Arabia. Outcomes 
from this study could result in highlighting new areas of concern about perceptions of 
medicine quality and could also lead to improvement on current policy/practice to better 
ensure and protect the quality of your medicines. Additionally, this study could be 
fundamental to other similar studies about medicine quality issues in Saudi Arabia or 
internationally. 
 
How will my taking part in this study be kept confidential? 
 
Participation in this study will be kept confidential and your involvement anonymous at 
all times. You will not be asked for your name in the questionnaire and all hard copy 
personal information will be kept with the researcher only at all times. Electronic 
material will be password protected and access to this information will be restricted to 
the research team only. The collected material will be available for a short period of 
time (2 years approximately) and then it will be destroyed. 
 
 
What will happen to the results of the research study? 
 
The results of this study will be used in academic publications by the researcher.  
 
Who has reviewed this study? 
 
The Ethics committee at the University of Hertfordshire, Health and Human Sciences 
ECDA in the United Kingdom has reviewed and approved this study.  
Protocol number: c LMS/PG/UH/00155 
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Who can I contact if I have any questions? 
 
If you would like further information on the research project or would like to discuss any 
details personally, please get in touch with me by phone or by email:  
 
Abdulaziz Alghannam 
PhD student at the University of Hertfordshire, UK 
E-mail: Pharmafg@gmail.com 
Telephone in UK: 00447732142882 
Telephone in Saudi: 0556560655 
 
Alternatively, you can contact the principle supervisor of the project as follows: 
 
Dr. Zoe Aslanpour 
Head of Pharmacy and Public Health Practice 
University of Hertfordshire 
Hatfield 
AL10 9AB 
Tel - 01707 284563 
Email - Z.Aslanpour@herts.ac.uk 
 
 
Acknowledgment: 
 
We recognise that this study may raise fear of medicines with lower quality. If 
you have such concerns please feel free to share them with the researcher using 
one of his contact details mentioned above. Alternatively, you can also share 
these concerns with one of your trusted colleagues within MOI MSD clinics who 
will provide you with the necessary support that you may require. 
 
Although we hope it is not the case, if you have any complaints or concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, please write to the University Secretary and Registrar. 
 
 
Thank you very much for reading this information and giving consideration to 
taking part in this study. 
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Appendix 14: Participant information sheet for the interview phase of 
the study 
 
UNIVERSITY OF HERTFORDSHIRE 
 
ETHICS COMMITTEE FOR STUDIES INVOLVING THE USE OF HUMAN PARTICIPANTS 
(‘ETHICS COMMITTEE’) 
 
 
FORM EC6: PARTICIPANT INFORMATION SHEET (Interview) 
 
 
Title of Research 
 
Evaluation of quality of an oral anti-diabetic agent (glibenclamide) in Saudi Arabia: analysis and 
perceptions about medicine quality 
 
Introduction 
 
You are being invited to take part in an interview study.  Before you decide whether to 
do so, it is important that you understand the research that is being done and what 
your involvement will include.  Please take the time to read the following information 
carefully and discuss it with others if you wish.  Do not hesitate to ask us anything that 
is not clear or for any further information you would like to help you make your 
decision.  Please do take your time to decide whether or not you wish to take part. 
Thank you for reading this. 
 
What is the purpose of this study? 
 
The overall purpose of this project is to explore perceptions about medicines quality 
and related medicine quality issues from the perspective of the Ministry of Interior 
Medical Services Department (MOI MSD) healthcare professionals and patients. In this 
study, it is essential to obtain in-depth understanding of attitudes and behaviour 
regarding medicine quality from the perspective of commissioners and patients in MOI 
MSD facilities in Saudi Arabia. 
 
Do I have to take part? 
 
It is completely up to you whether or not you decide to take part in this study.  If you do 
decide to take part you will be given this information sheet to keep and be asked to 
sign a consent form.  Agreeing to join the study does not mean that you have to 
complete it.  You are free to withdraw at any stage without giving a reason.   
 
What will happen to me if I take part? 
 
If you decide to take part in this study, you will be involved in it for no longer than one 
hour on only one occasion at a time and date of your choice. 
 
The first thing to happen will be that the researcher will approach you personally with 
this participant information sheet and will answer all your questions if you require 
further information. An informed consent will then be required for your signature and 
arrangements will be made with the researcher for your preferred time and location for 
conducting the interview. The researcher will call you as a reminder two days before 
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the interview date if you decided not to do it on the same time/date you specified 
earlier. The interview will be tape-recorded for academic purposes unless you prefer it 
not to be recorded. In this case, the researcher will be taking notes during the 
conversation. You will not be identified or named in any following publication of this 
study at all times. Additionally, the interviews will most likely take place at a private 
room within MOI MSD facilities in order to maintain your confidentiality and no one 
besides the researcher and yourself will be present unless you specifically ask for the 
attendance of a particular person. 
 
What are the possible disadvantages, risks or side effects of taking part? 
 
We anticipate no major disadvantages, risks or side effects to your participation. We 
are interested in your perception regarding the subject of medicine quality. We aim not 
to disturb your daily life and every effort will be made to make your participation as 
convenient to you as possible. 
 
What are the possible benefits of taking part? 
 
Your involvement in this study is of paramount importance. You will be part of a study 
that will explore different perceptions about medicine quality issues from the 
perspective of both healthcare professionals and patients in Saudi Arabia. Outcomes 
from this study could result in highlighting new areas of concern about perceptions of 
medicine quality and could also lead to improvement on current policy/practice to better 
ensure and protect the quality of your medicines. Additionally, this study could be 
fundamental to other similar studies about medicine quality issues in Saudi Arabia or 
internationally. 
 
How will my taking part in this study be kept confidential? 
 
Participation in this study will be kept confidential at all times. No names will be 
published in any report and all hard copy personal information will be kept with the 
researcher only at all times. Electronic material will be password protected and access 
to this information will be restricted to the research team only. The collected material 
will be available for a short period of time (2 years approximately) and then it will be 
destroyed. 
 
 
What will happen to the results of the research study? 
 
The results of this study will be used in academic publications by the researcher. 
However, no individuals will be named or identified at any point in time. 
 
Who has reviewed this study? 
 
The Ethics committee at the University of Hertfordshire, Health and Human Sciences 
ECDA in the United Kingdom has reviewed and approved this study.  
Protocol number: c LMS/PG/UH/00155 
. 
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Who can I contact if I have any questions? 
 
If you would like further information on the research project or would like to discuss any 
details personally, please get in touch with me by phone or by email:  
 
Abdulaziz Alghannam 
PhD student at the University of Hertfordshire, UK 
E-mail: Pharmafg@gmail.com 
Telephone in UK: 00447732142882 
Telephone in Saudi: 0556560655 
 
Alternatively, you can contact the principle supervisor of the project as follows: 
 
Dr. Zoe Aslanpour 
Head of Pharmacy and Public Health Practice 
University of Hertfordshire 
Hatfield 
AL10 9AB 
Tel - 01707 284563 
Email - Z.Aslanpour@herts.ac.uk 
 
 
Acknowledgment: 
 
We recognise that this study may raise fear of medicines with lower quality. If 
you have such concerns please feel free to share them with the researcher using 
one of his contact details mentioned above. Alternatively, you can also share 
these concerns with your physician or one of your trusted colleagues within MOI 
MSD clinics who will provide you with the necessary support that you may 
require. 
 
Although we hope it is not the case, if you have any complaints or concerns 
about any aspect of the way you have been approached or treated during the 
course of this study, please write to the University Secretary and Registrar. 
 
 
Thank you very much for reading this information and giving consideration to 
taking part in this study. 
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Appendix 15: Consent form for participants in the focus group phase 
of the study 
 
CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS 
 
I, the undersigned [please give your name here, in BLOCK CAPITALS] 
 
…………………………………………………………………………………………………………………………. 
of  [please give contact details here, sufficient to enable the investigator to get in touch with you, such as 
mobile phone number or email address] 
 
…..…………………………………………………………………………………………………………………… .. 
hereby freely agree to take part in the study entitled 
 
Evaluation of quality of an oral anti-diabetic agent (glibenclamide) in Saudi Arabia: 
analysis and perceptions about medicine quality 
 
………………………………………………………………………………………………………………………….  
 
1  I confirm that I have been given a Participant Information Sheet (a copy of which is attached to this 
form) giving particulars of the study, including its aim(s), methods and design, the names and contact 
details of key people and, as appropriate, the risks and potential benefits, and any plans for follow-up 
studies that might involve further approaches to participants.   I have been given  details of my involvement 
in the study.  I have been told that in the event of any significant change to the aim(s) or design of the 
study I will be informed, and asked to renew my consent to participate in it.  
 
2  I have been assured that I may withdraw from the study at any time without disadvantage or having to 
give a reason. 
 
3  I have been given information about the risks of my suffering harm or adverse effects.   I have been told 
about the aftercare and support that will be offered to me in the event of this happening, and  I have been 
assured that all such aftercare or support  would be provided at no cost to myself.  
 
4  I have been told how information relating to me (data obtained in the course of  the study, and data 
provided by me about myself) will be handled: how it will be kept secure, who will have access to it, and 
how it will or may be used.   
 
5  I have been told what will be done if the study reveals that I have a medical condition which may have 
existed prior to the study, which I may or may not have been aware of, and which could affect the present 
or future health of myself or others. If this happens, I will be told about the condition in an appropriate 
manner and advised on follow-up action I should take.   Information about the condition will be passed to 
my GP, and I may no longer be allowed to take part in the study. 
    
6  I have been told that I may at some time in the future be contacted again in connection with this or 
another study. 
 
 
  
Signature of 
participant……………………………………………………………………………………Date…………………………. 
 
 
 
Signature of (principal) investigator……………………………………………………… Date………………………… 
 
Name of (principal) investigator [in BLOCK CAPITALS please] 
Abdulaziz Alghannam 
…………………………………………………………………………………………………………………………… 
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Appendix 16: Consent form for participants in the interview phase of 
the study 
 
                                             University of Hertfordshire 
 
 CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS 
Interview Phase 
 
I, the undersigned [please give your name here, in BLOCK CAPITALS] 
 
…………………………………………………………………………………………………………………………. 
of  [please give contact details here, sufficient to enable the investigator to get in touch with you, such as 
mobile phone number or email address] 
 
…..…………………………………………………………………………………………………………………… .. 
hereby freely agree to take part in the study entitled 
 
Evaluation of glibenclamide quality: analysis and perceptions of stakeholders’ 
about medicine quality in Ministry of Interior clinical settings 
………………………………………………………………………………………………………………………….  
 
1  I confirm that I have been given a Participant Information Sheet (a copy of which is attached to this 
form) giving particulars of the study, including its aim(s), methods and design, the names and contact 
details of key people and, as appropriate, the risks and potential benefits, and any plans for follow-up 
studies that might involve further approaches to participants.   I have been given  details of my involvement 
in the study.  I have been told that in the event of any significant change to the aim(s) or design of the 
study I will be informed, and asked to renew my consent to participate in it.  
 
2  I have been assured that I may withdraw from the study at any time without disadvantage or having to 
give a reason. 
 
3  I have been given information about the risks of my suffering harm or adverse effects.   I have been told 
about the aftercare and support that will be offered to me in the event of this happening, and  I have been 
assured that all such aftercare or support  would be provided at no cost to myself.  
 
4  I have been told how information relating to me (data obtained in the course of  the study, and data 
provided by me about myself) will be handled: how it will be kept secure, who will have access to it, and 
how it will or may be used.   
 
5  I have been told what will be done if the study reveals that I have a medical condition which may have 
existed prior to the study, which I may or may not have been aware of, and which could affect the present 
or future health of myself or others. If this happens, I will be told about the condition in an appropriate 
manner and advised on follow-up action I should take.   Information about the condition will be passed to 
my GP, and I may no longer be allowed to take part in the study. 
    
6  I have been told that I may at some time in the future be contacted again in connection with this or 
another study. 
 
7  I have been told that this interview will be audio taped and I agreed to that. 
 
Signature of 
participant……………………………………………………………………………………Date…………………………. 
 
Signature of (principal) investigator……………………………………………………… Date………………………… 
 
Name of (principal) investigator [in BLOCK CAPITALS please] 
Abdulaziz Alghannam 
………………………………………………………………………………………………………………………………... 
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Appendix 17: Focus group schedule 
 
Collect demographics and participants consent forms 
 
Moderator introduction 
 
Gratitude then explain research aim/objectives using slide presentation (2 minutes) 
 
Hello everyone. My name is Abdulaziz Alghannam and I am PhD student in Pharmacy 
here at the university of Hertfordshire.  I’d like to start off by thanking each of you for 
taking time to come today. We’ll be here for about two hours. The reason we’re here 
today is to get your opinions about issues related to medicines with quality problems.  
 
I’m going to lead our discussion today. I am the facilitator of this meeting and will 
appreciate your contributions. 
 
I also would like to introduce Dr. Zoe Aslanpour who will be helping me here today. 
 
Ground rules (2 minutes) 
 
To allow our conversation to flow more freely, I’d like to go over some ground rules. 
 
1. Only one person speaks at a time. 
 
2. Please avoid side conversations. 
 
3. Everyone doesn’t have to answer every single question, but I’d like to hear from each 
of you today as the discussion progresses. 
 
4. This is a confidential discussion in that I will not report your names or who said what 
to anyone. Names of participants will not even be included in the final report about this 
meeting.  
 
5. We stress confidentiality because we want an open discussion. We want all of you to 
feel free to comment on each other’s remarks without fear that your comments will be 
repeated later and possible taken out of context. 
 
6. There are no “wrong answers,” just different opinions. Say what is true for you, even 
if you’re the only one who feels that way. Don’t let the group influence you. But if you 
do change your mind, just let me know. 
 
 
Group Discussion 
 
Introduction of participants (2 minutes) 
 
Before we start, it would be good to do a round of introduction. Please tell us: 
1- your name 2- your previous pharmacy work experience 
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General questions (30-45 minutes) 
 
1- What is a good quality medicine in your opinion?  
2- What do you think about the quality of medicines in Saudi Arabia? Globally? 
3- Have you ever had an experience with a medicine with questionable quality? If 
yes when and how? 
4- In your opinion, what is the relationship between price and medicine quality? 
5- In your opinion, what is the relationship between a successful treatment and 
medicine quality? 
6- In your practice, what would you do to ensure supply of good quality medicines 
to your patients? 
7- In your practice, what would you do to protect the quality of medicines for your 
patients? 
8- If you had concerns about the quality of a medicine what would you do? 
 
 Specific questions (20-30 minutes) 
 
9- What is a counterfeit medicine in your opinion?  
10- What is a substandard medicine in your opinion?  
11- What type of medicines are you mostly concerned with in terms of quality and 
why? 
12- What is the possible impact of medicines with lower quality in your opinion? 
13- What are possible causes of medicines with lower quality in your opinion? 
 
Suggestion questions (5-10 minutes) 
 
14- What improvements would you suggest to current policies/procedures to ensure 
that medicines are of high quality in your settings? 
15- What advice would you give regarding the topic and to whom? 
 
Moderator presentation (2-3 minutes) 
 
Introduction to the issue and terminology used. 
Research aim/objectives and design 
 
Follow up questions (2-3 minutes) 
 
16-What word would you use in Arabic to describe counterfeit medicines? 
17-What word would you use in Arabic to describe substandard medicines? 
 
Closing (1 minute) 
 
Thanks for coming today and talking about these issues. I thank you for your time. 
 
We will use the information generated today in developing questionnaires where we 
will seek stakeholders’ perspectives in Saudi.  This is part of my PhD study.  If you 
wish to learn about my findings please let me know and I will endeavor to do so. 
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Appendix 18: Demographic information for focus group participants 
 
Demographic data of participants in focus group 
 
 
 Gender: ☐ male ☐female 
 
 Marital status: ☐single ☐married ☐divorced ☐widowed 
 
 Age group: ☐ 21-25 ☐26-30 ☐31-35 ☐36-40 ☐over 40 
 
 Working experience: ☐None ☐1-4 years ☐5-10 years ☐more than 10 years 
 
 Type of practice in work experience:  
          ☐private ☐public (MOH) ☐public (non-MOH) please specify-------- 
 
 Type of setting: ☐hospital ☐primary care clinics ☐community pharmacy 
 
 Location of current practice in Saudi Arabia:  
         ☐central region ☐northern region ☐western region ☐eastern region         
☐southern region  
 
 Role in current practice: 
☐dispensing ☐procurement ☐warehouse ☐management role ☐other please specify----- 
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Appendix 19: Number of physicians working in MOI-MSD PCC 
according to 2014 statistical report 
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Appendix 20: Number of pharmacists working in MOI-MSD PCC 
according to 2014 statistical report 
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Appendix 21: Physicians’ survey questionnaire 
 
Objective one: Establish knowledge and experience about medicine quality 
 
1. In your opinion what is a high quality medicine? 
 
 
2. In your opinion what is a counterfeit medicine? 
 
 
3. What in your opinion is the percentage of counterfeit medicines globally? 
 
 
 
 
 
4. What in your opinion is the percentage of counterfeit medicines in Saudi? 
 
 
 
 
 
5. Have you ever experienced a medicine with doubtful quality? If yes when and how? 
 
 
Objective two: Explore perception and behaviour towards medicine quality 
 
6. How would you rate the quality of medicines available in Saudi in general? 
 
Please rate 1-10 where 10 is the highest quality ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
7. How would you rate the quality of medicines available in MOI in general? 
 
Please rate 1-10 where 10 is the highest quality ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
8. How would you rate the quality of medicines you are prescribing now? 
 
Please rate 1-10 where 10 is the highest quality ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
9. When you are prescribing a medicine how important are these attributes to you? 
Please rate from 1-10 where 10 represent the highest importance 
 
Your confidence in the medicine’s quality of production ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 
☐9 ☐10 
 
Registration of the medicine in the Saudi FDA ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
0 10 20 30 40 50 60 70 80 90 100
0 
0 10 20 30 40 50 60 70 80 90 100
0 
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Lot and expiry date information on the medicine package ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 
☐9 ☐10 
 
Name of the manufacturing company ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Country of manufacturing ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Patient information leaflet ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Medicine’s price ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Your personal experience☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
The experiences of a friend or a family member ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
The availability of the medicine in the market ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
10. In your opinion, do you think that the more expensive medicines are of higher 
quality than the cheaper alternatives? 
 
Please rate 1-10 where 10 is the most likely ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
11. In your opinion, how likely would using an expensive medicine be related with 
better health outcomes? 
 
Please rate 1-10 where 10 is the most likely ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
12. Would concerns about the quality of a medicine influence your decision to prescribe 
a medicine? 
 
Please rate 1-10 where 10 is the most likely ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
13. If you had concerns about the quality of a medicine what would you do? Please 
select all that apply. 
 
☐ Report to a local doctor  
☐ Report to a local pharmacist  
☐ Report to the director of pharmacy 
☐ Stop prescribing the medicine  
☐ Report to the Saudi Food and Drug Authority (SFDA) 
☐ Report to the Ministry of Health (MOH)   
☐ Do not report it  
☐ Other action. Please specify------- 
 
14. How many times a year do you come across medicines with doubtful quality? Please 
select only one answer. 
 
☐Never 
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☐Once a year 
☐Two to four times a year 
☐Five to ten times a year 
☐More than ten times a year 
 
15. What medicine therapeutic class are you mostly concerned with in terms of quality? 
Please select only one answer. 
 
☐None of the therapeutic classes 
☐Medicines for treatment of infectious diseases such as antibiotics 
☐Medicines for treatment of chronic diseases such as diabetes and cardiovascular 
diseases 
☐Over the counter medicines such as analgesics  
☐All therapeutic classes 
☐Other therapeutic classes. Please specify-------- 
 
16. What type of medicine formulation are you mostly concerned with in terms of 
quality? Please select only one answer. 
 
☐None of the formulations 
☐Injections 
☐Tablets or capsules 
☐Syrups or suspensions 
☐eye/ear drops 
☐Creams or ointments 
☐Inhalers 
☐All formulations 
☐Other formulation. Please specify-------- 
 
17. What type of medicine issues are you mostly concerned with in your settings? 
Please select all that apply. 
 
☐No issues of concern 
☐Incorrect storage or transportation conditions  
☐Packaging is damaged 
☐Problems with the appearance of the medicine 
☐The medicine contains the wrong or no active ingredient 
☐The medicine contains the wrong amount of active ingredient 
☐The medicine does not dissolve in appropriate time 
☐Medicine is close or past the expiry date 
☐Medicine prescribing error 
☐Medicine dispensing error 
☐Medicine preparation error 
☐Limited number of available doses or dosage forms 
☐Patients do not accept the available medicines 
☐Other issues. Please specify-------- 
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18. How important are these considerations to you before you prescribe a medicine? 
Please rate 1-10 where 10 is the most important 
 
Clinical effectiveness ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Cost effectiveness to your organisation ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Quality of the medicine ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Affordability to the patient ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Patient safety ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Patient preference ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
19. Have you ever advised any patient to purchase medicines from a community 
pharmacy? If yes please give reasons. 
 
☐Yes. Reason --------------------------------- 
☐No  
 
 
Objective three: Investigate potential improvements to the existing policies and 
procedure to address the issue of suboptimal medicines in Saudi Arabia in context of 
global market 
 
20. What changes would you recommend to ensure the high quality of medicines? 
 
Demographics 
 
21. Age: _______ 
 
22. Gender: ☐Male ☐Female 
 
23. Location city: _________ 
 
24. Occupation: ☐Physician ☐Pharmacist  
 
25. Primary role in organisation: ☐GP ☐Registrar ☐Specialist ☐Consultant 
 
26. Education: ☐BSc ☐MSc ☐PhD 
 
27. Years of experience in MOI MSD: ☐less than one-year ☐1-4 years☐5-9 years ☐10-
14 years ☐More than 15 years 
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Contact details of research team 
 
 
If you would like further information on the research project or would like to discuss any 
details personally, please get in touch with me by phone or by email:  
 
Abdulaziz Alghannam 
PhD student at the University of Hertfordshire, UK 
E-mail: Pharmafg@gmail.com 
Telephone in UK: 00447732142882 
Telephone in Saudi: 0556560655 
 
Alternatively, you can contact the principle supervisor of the project as follows: 
 
Dr. Zoe Aslanpour 
Head of Pharmacy and Public Health Practice 
University of Hertfordshire 
Hatfield 
AL10 9AB 
Tel - 01707 284563 
Email - Z.Aslanpour@herts.ac.uk 
 
 
The Ethics committee at the University of Hertfordshire, Health and Human 
Sciences ECDA in the United Kingdom has reviewed and approved this study.  
Protocol number: c LMS/PG/UH/00155 
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Appendix 22: Pharmacists’ survey questionnaire 
 
Objective one: Establish knowledge and experiences about medicine quality 
 
1. In your opinion what is a high quality medicine? 
 
 
2. In your opinion what is a counterfeit medicine? 
 
 
3. What in your opinion is the percentage of counterfeit medicines globally? 
 
 
 
 
 
4. What in your opinion is the percentage of counterfeit medicines in Saudi? 
 
 
 
 
 
5. Have you ever experienced a medicine with doubtful quality? If yes when and how? 
 
 
Objective two: Explore perceptions and behaviour towards medicine quality 
 
6. How would you rate the quality of medicines available in Saudi in general? 
 
Please rate 1-10 where 10 is the highest quality ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
7. How would you rate the quality of medicines available in MOI in general? 
 
Please rate 1-10 where 10 is the highest quality ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
8. How would you rate the quality of medicines you are dispensing now? 
 
Please rate 1-10 where 10 is the highest quality ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
9. When you are dispensing a medicine how important are these attributes to you? 
Please rate from 1-10 where 10 represent the highest importance 
 
Your confidence in the medicine’s quality of production ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 
☐9 ☐10 
 
Registration of the medicine in the Saudi FDA ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
0 10 20 30 40 50 60 70 80 90 100
0 
0 10 20 30 40 50 60 70 80 90 100
0 
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Lot and expiry date information on the medicine package ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 
☐9 ☐10 
 
Name of the manufacturing company ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Country of manufacturing ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Patient information leaflet ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Medicine’s price ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
Your personal experience☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
The experiences of a friend or a family member ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
The availability of the medicine in the market ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
10. In your opinion, do you think that the more expensive medicines are of higher 
quality than the cheaper alternatives? 
 
Please rate 1-10 where 10 is the most likely ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
11. In your opinion, how likely would using an expensive medicine be related with 
better health outcomes? 
 
Please rate 1-10 where 10 is the most likely ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
12. Would concerns about the quality of a medicine influence your decision to dispense 
a medicine? 
 
Please rate 1-10 where 10 is the most likely ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
13. If you had concerns about the quality of a medicine what would you do? Please 
select all that apply. 
 
☐ Report to a local doctor  
☐ Report to a local pharmacist  
☐ Report to the director of pharmacy 
☐ Stop dispensing the medicine  
☐ Report to the Saudi Food and Drug Authority (SFDA) 
☐ Report to the Ministry of Health (MOH)   
☐ Do not report it  
☐ Other action. Please specify------- 
 
14. How many times a year do you come across medicines with doubtful quality? Please 
select only one answer. 
 
☐Never 
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☐Once a year 
☐Two to four times a year 
☐Five to ten times a year 
☐More than ten times a year 
 
15. What medicine therapeutic class are you mostly concerned with in terms of quality? 
Please select only one answer. 
 
☐None of the therapeutic classes 
☐Medicines for treatment of infectious diseases such as antibiotics 
☐Medicines for treatment of chronic diseases such as diabetes and cardiovascular 
☐Over the counter medicines such as analgesics  
☐All therapeutic classes 
☐Other therapeutic classes. Please specify-------- 
 
16. What type of medicine formulation are you mostly concerned with in terms of 
quality? Please select only one answer. 
 
☐None of the formulations 
☐Injections 
☐Tablets or capsules 
☐Syrups or suspensions 
☐eye/ear drops 
☐Creams or ointments 
☐Inhalers 
☐All formulations 
☐Other formulation. Please specify-------- 
 
17. What type of medicine issues are you mostly concerned with in your settings? 
Please select all that apply. 
 
☐No issues of concern 
☐Incorrect storage or transportation conditions  
☐Packaging is damaged 
☐Problems with the appearance of the medicine 
☐The medicine contains the wrong or no active ingredient 
☐The medicine contains the wrong amount of active ingredient 
☐The medicine does not dissolve in appropriate time 
☐Medicine is close or past the expiry date 
☐Medicine prescribing error 
☐Medicine dispensing error 
☐Medicine preparation error 
☐Limited number of available doses or dosage forms 
☐Patients do not accept the available medicines 
☐Other issues. Please specify-------- 
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18. How important are these considerations to you before you dispense a medicine? 
Please rate 1-10 where 10 is the most important 
 
Clinical effectiveness ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Cost effectiveness to your organisation ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Quality of the medicine ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Affordability to the patient ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Patient safety ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
Patient preference ☐1 ☐2 ☐3 ☐4 ☐5 ☐6 ☐7 ☐8 ☐9 ☐10 
 
19. Have you ever advised any patient to purchase medicines from a community 
pharmacy? If yes please give reasons. 
 
☐Yes. Reason --------------------------------- 
☐No  
 
Objective three: Investigate potential improvements to the existing policies and 
procedure to address the issue of suboptimal medicines in Saudi Arabia in context of 
global market 
 
20. What changes would you recommend to ensure the high quality of medicines? 
 
Demographics 
 
21. Age: _______ 
 
22. Gender: ☐Male ☐Female 
 
23. Location city: _________ 
 
24. Occupation: ☐Physician ☐Pharmacist  
 
25. Education: ☐BSc ☐MSc ☐PhD 
 
26. Years of experience in MOI MSD: ☐less than one-year ☐1-4 years☐5-9 years ☐10-
14 years ☐More than 15 years 
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Contact details of research team 
 
 
If you would like further information on the research project or would like to discuss any 
details personally, please get in touch with me by phone or by email:  
 
Abdulaziz Alghannam 
PhD student at the University of Hertfordshire, UK 
E-mail: Pharmafg@gmail.com 
Telephone in UK: 00447732142882 
Telephone in Saudi: 0556560655 
 
Alternatively, you can contact the principle supervisor of the project as follows: 
 
Dr. Zoe Aslanpour 
Head of Pharmacy and Public Health Practice 
University of Hertfordshire 
Hatfield 
AL10 9AB 
Tel - 01707 284563 
Email - Z.Aslanpour@herts.ac.uk 
 
 
The Ethics committee at the University of Hertfordshire, Health and Human 
Sciences ECDA in the United Kingdom has reviewed and approved this study.  
Protocol number: c LMS/PG/UH/00155 
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Appendix 23: Demographic information sheet for pharmacists and 
physicians interviews 
 
 
Demographic information for interview with physician and pharmacists participants 
 
 
1- Gender: ☐ Male ☐ Female 
 
2- Age: ____ 
 
3- City: ____ 
 
4- Occupation: ☐ Physician ☐ Pharmacist 
 
5- Education: ☐ BSc ☐ MSc ☐PhD ☐ other please specify ______ 
 
6- Experience at MOI-MSD: ☐ Less than one year ☐ 1-4 years ☐ 5-9 years  
                                               ☐ 10-14 years            ☐ 15 years or more 
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Appendix 24: MOI-MSD medical product quality reporting form 
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Appendix 25: Beliefs and views about medicine quality from the 
stakeholders’ views 
 
 Commissioners Physicians Pharmacists Patients 
Higher quality 
medicines 
provide better 
health 
outcomes 
Agree (5/6) 
Do not agree (1/6) 
Agree (31/63) 
Do not agree 
(12/63) 
Neutral (17/63) 
Agree (37/58) 
Do not agree (9/58) 
Neutral (9/58) 
Agree (35/53) 
Do not agree (5/53) 
No answer  (13/53) 
Developed 
countries 
manufacture 
superior quality 
medicines 
Agree (5/6) Agree * (7/8) Agree * (5/8) (7/53) 
Patients 
frequently 
demand brand 
medicines 
Agree (3/6) Agree * (3/8) Agree * (2/8) (2/53) 
Medicine 
quality is 
different 
between 
hospitals in 
Saudi  
0/6 *(2/8) *(3/8) (11/53) 
Medicine 
quality differs 
between 
manufacturers 
in Saudi  
5/6 *(2/8) *(2/8) (12/53) 
 
Medicines do 
not work 
similarly for all 
people  
1/6 *(2/8) *(2/8) (6/53) 
Source of 
information 
about medicine 
quality and 
issues 
Patient’s 
experience (1/6) 
Personal 
experience (1/6) 
Family/friend 
experience (1/6) 
Local staff 
experience (2/6) 
SFDA letters (3/6) 
Patient’s reported 
effect *(3/8) 
Patient’s 
acceptance *(2/8) 
Patient’s 
compliance *(1/8) 
Physician’s 
examination *(3/8) 
Physician’s 
Patient’s reported 
effect *(1/8) 
Patient’s 
acceptance *(3/8) 
Physician’s 
experience *(1/8) 
Pharmacist’s 
experience *(1/8) 
Research studies 
Physician’s advice 
(22/53) 
Pharmacist’s 
advice (2/53) 
Personal 
experience (5/53) 
Family/friend 
experience (4/53) 
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experience *(2/8) 
Pharmacist’s 
experience *(1/8) 
Research studies 
*(4/8) 
Laboratory analysis 
*(1/8) 
Manufacturer 
reputation *(3/8) 
*(1/8) 
Laboratory analysis 
*(3/8) 
Visual analysis 
*(2/8) 
Storage conditions 
*(1/8) 
Therapeutic 
classes of 
medicine 
quality 
concern 
Chronic disease 
medicines  
Infectious 
disease 
medicines  
All therapeutic 
classes  
Other 
therapeutic 
classes  
 
 
 
 
 
4/6 
3/6 
1/6 
1/6 
 
 
 
 
 
9/63 
21/63 
20/63 
7/63 
 
 
 
 
 
20/58 
15/58 
19/58 
2/58 
 
 
 
 
 
Not applicable 
Formulations 
of medicine 
quality 
concern 
Tablets or 
capsules   
Injections  
All 
formulations  
Other 
formulations  
 
 
 
 
3/6 
3/6 
2/6 
2/6 
 
 
 
 
22/63 
5/63 
22/63 
9/63 
 
 
 
 
12/58 
15/58 
23/58 
7/58 
 
 
 
 
Not applicable 
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Appendix 26: Knowledge about medicine quality 
 
 Commissioners Physicians Pharmacists Patients 
Definition of a good quality 
medicine 
Has good effect 
From a brand company 
Has good appearance/packaging 
Has reasonable price 
Is registered or authorised 
Is accepted by patients 
Has good manufacturing 
Is available 
Is safe 
Has good expiry dates 
 
 
6/6 
4/6 
2/6 
1/6 
1/6 
1/6 
0/6 
0/6 
0/6 
0/6 
 
 
30/63 
1/63 
0/63 
4/63 
0/63 
2/63 
1/63 
1/63 
4/63 
2/63 
 
 
22/58 
6/58 
4/58 
4/58 
2/58 
0/58 
8/58 
2/58 
4/58 
1/58 
 
 
29/53 
2/53 
0/53 
0/53 
0/53 
1/53 
7/53 
0/53 
0/53 
0/53 
Definition of a counterfeit 
medicine 
Has an effect problem 
Has a manufacturing problem 
Has no API 
Has wrong API 
Has wrong amount of API 
Has an appearance problem 
Is a fake copy of brand medicine 
Is from an unreliable source 
Is a non-registered medicine 
Is a cheaper generic medicine 
Is an expired medicine 
Is a medicine not stored in ideal 
conditions 
 
 
3/6 
0/6 
3/6 
0/6 
4/6 
3/6 
0/6 
0/6 
0/6 
0/6 
0/6 
0/6 
 
 
26/63 
1/63 
1/63 
2/63 
3/63 
0/63 
3/63 
4/63 
7/63 
1/63 
2/63 
1/63 
 
 
15/58 
6/58 
9/58 
3/58 
7/58 
3/58 
7/58 
3/58 
5/58 
0/58 
0/58 
0/58 
 
 
14/53 
10/53 
0/53 
0/53 
0/53 
0/53 
5/53 
3/53 
2/53 
4/53 
5/53 
2/53 
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Appendix 27: Challenges to medicine quality in MOI-MSD 
 
 Commissioners Physicians Pharmacists Patients 
Tender procurement of 
medicines is based on price 
not quality 
4/6 *(3/8) *(4/8) 
 
1/53 
 
Limited or difficulty in 
reporting medicine quality 
problems 
3/6 
 
*(4/8) 
 
 
*(3/8) 
 
8/53 
 
 
Medicine storage conditions 
in MOI-MSD 
1/6 32/63 30/58  
*(2/8) 
1/53 
Medicine transport conditions 
in MOI-MSD 
0/6 32/63 
*(1/8) 
30/58 
*(5/8) 
0/53 
Expired medicines 0/6 27/63 
*(5/8) 
29/58 
*(2/8) 
0/53 
Nearly-expired medicines 0/6 *(3/8) *(4/8) 0/53 
Limited budget available to 
procure medicines 
2/6 *(2/8) *(2/8) 0/53 
Outdated medicine formulary 1/6 *(2/8) *(1/8) 0/53 
Inadequate medicine 
monitoring 
0/6 *(1/8) *(2/8) 3/53 
Patients do not accept their 
medicines 
0/6 14/63 
*(1/8) 
21/58 
*(2/8) 
0/53 
Medicine non-availability 1/6 0/63 0/58 11/53 
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Appendix 28: Recommendations to improve medicine quality in MOI-
MSD 
 Commissioners Physicians Pharmacists Patients 
Improve medicine monitoring 2/6 9/63 6/58 
 
13/53 
 
Improve medicine analysis 2/6 
 
5/63 
 
 
4/58 
 
4/53 
 
 
Improve tender procurement 
system of medicines 
2/6 7/63 
*(4/8) 
10/58  
*(3/8) 
4/53 
Educational campaigns about 
medicine and their quality 
2/6 3/63 
*(5/8) 
3/58 
*(3/8) 
3/53 
Improve medicine storage 
conditions 
0/6 8/63 6/58 2/53 
Improve medicine 
transportation conditions 
0/6 5/63 3/58 0/53 
Ensure medicine expiry dates 0/6 2/63 1/58 2/53 
Improve communication 
among staff and with patients 
0/6 2/63 
*(3/8) 
0/53 
*(2/8) 
3/53 
Update medicine formulary in 
MOI-MSD 
1/6 0/63 1/58 0/53 
Conduct research on medicines 
in MOI-MSD 
1/6 0/63 1/58 0/53 
Establish a department or a 
committee for medicine quality  
0/6 3/63 
*(7/8) 
6/58 
*(3/8) 
0/53 
 
 
 
 
  
 334 
Appendix 29: SurveyMonkey copy of the questionnaire  
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